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1 Introduction to thioethers 
Sulfur is one of the main group elements on our planet with a natural abundance of 
(0.46±0.15)w%.[1] In its most common allotropic form sulfur is a yellow powder and exhibits a 
cyclic S8 structure. Apart of the cyclic S8 form, several smaller and larger ring allotropes of Sn 
with n = 6 to 20 have been isolated. Aside from its natural occurrence as the pure element, 
sulfur is also forming inorganic salts like sulfides, sulfates, or sulfites.[2] Moreover, sulfur plays 
an important role in the field of organic chemistry and biochemistry.[2] In this regard various 
sulfur-containing functional groups with different oxidation states of the sulfur atom, e.g. thiols 
(+II), disulfides (+I), sulfoxides (+IV) and sulfones (+VI) and thioethers (+II), are known (Figure 
1). 
 
Figure 1: Sulfur as a crucial element and its application as thioethers in various fields of research.[3] 
Especially aryl thioethers are predominantly important representatives of sulfur containing 
functional groups in organic chemistry because of their appearance in key scaffolds of 
pharmaceutical important compounds, natural products, in the field of material science as well 




Additionally, aryl thioethers, also known as aryl sulfides, are a versatile synthetic platforms 
because they can be easily converted in a variety of other functional groups and find also 
applications as directing groups in chemistry of C–H functionalization (see Chapter 1.3).  
Due to the significant importance of this compound class, this work will focus on the 
development of a transition metal free and highly modular protocol for the synthesis of a wide 
range of different unsymmetrically substituted aryl thioethers. Furthermore, the developed 





1.1 General structure of thioethers 
Thioethers are functional groups in which two carbon-based residues are bridged by a sulfur 
atom (Figure 2). The sulfur atom possesses two additional free electron pairs which causes an 
average bond angle (∢ (R1–S–R2)) of 103°.[4] Compared to ethers, the lower degree of 
hybridization of the sulfur atoms compared to the oxygen analogue results in a higher p-
character of the involved sulfur orbital of the R–S σ-bond. Therefore, the average ∢ (R1;S;R2) 
angle in thioethers with two aryl substituents is smaller than the ∢ (R1–O–R2 ) angle in the 
corresponding ethers (118°).[4] As the free electron pairs of thioethers are more diffuse and 
their highest occupied molecular orbital (HOMO) are above those of the corresponding ether 
electron pairs, they behave as weaker nucleophiles and can react as soft Lewis bases 
according to the HSAB concept.[5] 
 
Figure 2: General structure of thioethers. 
Due to its free electron pairs, thioethers can coordinate metals and act as potent directing 
groups in the field of catalysis (see Chapter 1.3.1.4). The rising number of applications of 
compounds with a thioether moiety in the fields of pharmaceutical chemistry and material 
science are leading to an increasing interest in the development of new synthetic protocols for 
the synthesis of this ubiquitous core structure. Starting from simple substitution reactions up 
to transition metal catalyzed cross-coupling reactions and versatile transition metal free 
protocols, a variety of synthetic strategies are already known (compare Chapter 1.4). 
The reactivity and application of thioethers and different approaches towards their preparation 





1.2 Relevance of aryl thioethers 
The structural motif of aryl thioethers is omnipresent in molecules with many different 
applications. Various aryl sulfides show useful biological activities and are applied in medicinal 
chemistry. Additionally, they are important building blocks in functional materials like 
transistors. For applications in the field of catalysis, aryl sulfides are reported as ligands in the 
catalysis of several reactions.  
1.2.1 Medicinal chemistry and natural products 
As recently reviewed by M. Feng et al., sulfur-containing molecules, represented by over 362 
sulfur compounds approved by the FDA in 2016,[6] are of extreme importance in medicinal 
chemistry. Apart from sulfonamides and sulfones which can be easily obtained by oxidation of 
sulfides (see Chapter 1.3.1.1), sulfides are one of the most dominant sulfur scaffold in this 
area.[7] 
One of the earliest approved drugs for the treatment of schizophrenia and major depressive 
disorder, bearing a diaryl sulfide scaffold in its dibenzothiazine backbone, is Prochlorperazine 
(1), which is commercially available since 1956 under the trade name Compazine (Figure 3).[6] 
It has been demonstrated, that derivatives of Prochlorperazine can also be used for the 
treatment of meningitis.[8] Several other Prochlorperazine-based anti-psychotic drugs were 
developed by modification of the N-attached alkyl chain or the substitution pattern on the 
internal diaryl sulfide core. For these derivatives, the risk of adverse drug reactions, such as 
dizziness, was dramatically reduced.[9] Besides the anti-psychotic activity of diaryl sulfide-
based molecules, also sulfides with the potential to treat neurodegenerative diseases like 
Alzheimer are known in literature. As presented by J. Dumas et al., diaryl sulfide 2 has a high 
activity for the inhibition of Cathepsin D (IC50 = 1.7 µM) (Figure 3).[10] This enzyme cleaves 
amyloid precursor proteins in neurons, and the obtained protein fragments are known to form 
amyloid plaques which are attached to neurons in Alzheimer affected brains. 
 
Figure 3: Pharmacologically relevant molecules bearing diaryl sulfide motifs like an anti-psychotic drug 
Prochlorperazine (1),[6] or Cathepson D-inhibitor 2, which can potentially prevent the formation of plaques in 




Additionally, arylthioindole derivatives (ATIs) are known to inhibit the polymerization of tubulin; 
this makes them potent candidates in the treatment of various cancer diseases.[11] Detailed 
analysis of the structure-activity relationship of ATIs and variation of the substitution pattern 
resulted in the synthesis of compound 3, which is one of the most efficient inhibitors of the 
tubulin polymerization (Figure 4). The potential of ATIs for the treatment of cancer was 
additionally substantiated by molecular docking studies as well as inhibition tests with human 
breast carcinoma cells.[11,12] Alternative potential application of ATIs lie in the field of asthma 
treatment, as some ATI derivatives are potent inhibitors of 5-lipoxygenase, which plays a key 
role in the allergy-induced asthma.[13] Also infection with Streptococcus pneumoniae could be 
potentially treated with ATI derivative 4, as demonstrated by the studies of S. S. Khandekar 
and coworkers.[14] The authors demonstrated the ability of indole derivative 4 to inhibit the 
important protein synthase III (FabH) of Streptococcus pneumoniae as well as of E. Coli and 
H. influenza. This shows the high antibiological potential of ATIs. Further ATIs may have 
therapeutic value for the curing of obesity.[15] 
 
Figure 4: 3-Arylthioindole derivatives which can potentially inhibit cancer growth by blocking the tubulin 
polymerization (3)[11] or which have antimicrobial properties (4).[14] 
The protein tyrosine phosphatase SHP2, which is an oncoprotein and associated with several 
different leukemia types, can be sufficiently inhibited with compounds containing thioether 
motifs like 5 and 6 (Figure 5). Even if the exact role of SHP2 is not fully understood yet, an 
interdisciplinary team around M. J. LaMarche and coworkers from Novartis Pharmaceutical 
has recently shown that 5 and 6 can efficiently inhibit SHP2. The exact pharmacokinetic was 
studied in mice models bearing subcutaneously implanted tumor cells and was accompanied 





Figure 5: Selective SHP2 inhibitors for the potential treatment of different cancer diseases as reported by M. J. 
LaMarche and coworkers.[16] 
Besides the previously presented fields of application diaryl, sulfides have also shown 
excellent anti-inflammatory behaviors, as shown by an extensive compound screening of G. 
Liu and coworkers.[17] Binding studies revealed the importance of the diaryl sulfide core with 
an anilino moiety in the structure of 7 to suppress a main pathway in the biochemical cascade 
of inflammations (Figure 6). 
Additionally, diaryl sulfides like 8 have a valuable impact for the potential treatment of parasitic 
infections (Figure 6). As evaluated by K. T. Douglas and coworkers, 2-amino-4-chlorophenyl 
phenyl sulfides like 8 are versatile molecules with anti-trypanosomal, anti-leishmanial, and anti-
malarial properties.[18] 
 
Figure 6: Diaryl sulfides derived drug targets with anti-inflammatory (7)[17] and anti-parasitic (8)[18] activity. 
Another family of compounds with high pharmacological significance are those containing a 
trifluoromethylthio group which has the highest Hansch constant of all functional groups (πR = 
1.44). The Hansch constant describes the contribution of a substituent to the lipophilicity of the 
molecule based on quantitative structure activity relationships (QSAR).[19] A high lipophilicity 
enables fast adsorption and increased bioavailability of medicinal target compounds. 
Examples for those relevant trifluoromethylthio ethers are Tiflorex (9) and Toltrazuril (10) 
(Figure 7). Tiflorex is a stimulant amphetamine derivative and is used as anorectic drug for the 
treatment of obesity.[20,21] Toltrazuril is a coccidiostatic (antiprotozoal) agent to cure animals of 





Figure 7: Examples of pharmaceutically relevant trifluoromethyl aryl thioethers: Tiflorex (9), an amphetamine 
derivative for the suppression of appetite,[20,21] and Toltrazuril (10), a drug for the treatment of coccidia 
infections.[22] 
 
Several natural products have an aryl thioether scaffold. Chuangxinmycin (11) is a cyclic aryl 
thioether which can be isolated from Actinoplanes tsinanensis n. sp. and exhibits antibiotic 
activity against several Gram-positive and Gram-negative bacteria like infections with 
Escherichia coli and Shigella dysenteriae (Figure 8).[23] The methyl aryl thioether Roseochelin 
B (12) is an algacidal regulator in the algal-bacterial symbiose of haptophyte Emiliania huxleyi 
and several marine Roseobacter clades. The compound regulates the growth of the algae 
(Figure 8).[24] 
A further natural product featuring a aryl thioether functionality is Collismycin A (13) which was 
initially isolated by S. Gomi and coworkers from the bacterium Streptomyces sp in 1994 (Figure 
8).[25] In addition to its originally reported activity against fungi, Gram-positive and Gram 
negative bacteria, Collismycin A shows protective properties against oxidative stress which 
makes it a potentially useful compound for the treatment of neurodegenerative diseases.[26] 
 





1.2.2 Material science 
Aryl sulfides are widely used in the field of material science especially as organic thin-film 
transistors (OTFTs) or in the polymer chemistry. 
Organic transistors have huge advantages compared to their inorganic counterparts, as they 
are employable in flexible electronic applications.[27] Examples of those functional materials 
are derivatives of benzothieno[3,2-b]benzothiophene (BTBT, 14) and dinaphtho[2,3-b:20,30-
f]thieno[3,2-b]thiophene (DNTT, 15) (Figure 9). In general, modified DDNTs have significantly 
smaller contact resistances and larger charge-carrier motilities than pentacene, which can also 
be used as an organic semiconductor.[28] BTBT derivatives with 2,7-diphenyl substitution 
pattern are of additional value for organic field-effect transistors (OFET) because of their high 
stability in operation as well as during storage.[29] The electronic properties of BTBTs can be 
modulated by substitution of the core with pentafluorophenyl groups to expand the optical band 
gap.[30] 
 
Figure 9: BTBT and DNTT as examples of benzothiophene-containing motifs which can be utilized as organic 
thin-film transistors. 
Apart from aryl sulfides with low molecular weight, compounds with a high molar mass can 
exhibit useful properties and are used as versatile materials in industrial contexts. An excellent 
example is polyphenylene sulfide (PPS, 16), a high-performance polymer with high thermal 
stability which also features a high chemical stability and was originally developed by Phillips 
Petroleum Company (Figure 10).[31] PPS is used for coating and for precision mechanical parts. 
Especially because of the high melting temperature (285 °C) and decomposition temperature 
of 450 °C PPS is known as a robust and useful material for manifold applications.[32]  
These supreme properties of PPS can be further boosted by the introduction of fluoro 
functionalities, as recently reported by the group of J. L. Hedrick.[33] Their presented synthesis 
of fluorinated poly(aryl thioethers), resulted in a series of different polymers like 17 (Figure 10). 
Latest trends in the synthesis and application of PPS have been summarized in a review by F. 
Bakir and coworkers.[34] 
A. Shockravi et al. demonstrated the applicability of diaryl backbones in the synthesis of 




are soluble in polar organic solvents and thermally stable. Additionally, diaryl sulfides-
containing polyamides, polyesters and polybenzimidazoles have been reported in literature.[36] 
A broad overview of sulfur compounds in polymer and material science can be found in a 
recently published review of P. Theato and coworkers.[37]  
 
Figure 10: Different diaryl thioethers-containing polymers like PPS (16), fluorinated PPS derivatives (17) and 
polyamide species 18. 
Also, the electronic properties of diaryl sulfides were used in the field of organic light-emitting 
diodes (OLEDs). As reported by L.-S. Liao, J. Fan and coworkers, the introduction of diaryl 
sulfide-containing substituents at the 3,3'-position of 9,9'-bicarbazoles resulted in improved 
photoelectrical properties like a low-lying energy level of the triplet state and appropriate 
HOMO/LUMO energy levels.[38] Compound 19 was tested as a host material in red- and green-
emitting OLEDs and exhibited good thermal stabilities and a strong absorption band at 292 nm 
(Figure 11). Finally, diaryl sulfides like the fluorine-substituted tetrakis(arylthio)benzene 20 can 
be used as organic luminophores. They have a unique singlet and triplet emission properties 
that can be controlled by deformation of their C–S bonds (Figure 11). The different degrees of 
deformation in the solid state of 20 depend on the nature of the solvent molecules incorporated 
in the crystal. This allows the synthesis of materials with distinct photoluminescence properties. 
A high conformational distortion of C–S bonds leads to an increased fluorescence of the 
compounds, whereas nearly undistorted C–S bonds resulted in dominant phosphorescence 





Figure 11: Functional diaryl sulfide-based materials with optical properties. 19 can be used as host materials in 
OLEDs,[38] and 20 exhibits strong fluorescence photoluminescence properties depending from the C–S bond 
distortion.[39] 
  
1.2.3 Use in ligand design and catalysis 
Several organocatalysts as well as ligands for transition metal catalysis possess an aryl sulfide 
unit in their core structure. One of the early examples of chiral thioethers-based ligands was 
reported by J. M. J. Williams and coworkers in 1993.[40] The authors presented a bidentate 
ligand 21 which combines a coordinating chiral oxazoline group with an auxiliary sulfur donor. 
Thus, catalyst 21 was employed in the enantioselective palladium-catalyzed allylic substitution 
in 1,3-diphenylprop-2-enyl acetate to give the nearly pure S-enantiomer (ee% > 96%) in 
excellent yield (Scheme 1). Additionally, the authors could demonstrate that the diaryl sulfide 
moiety in catalyst 21 plays a crucial role for the enantioselectivity of the reaction. This principle 
was further explored by L.-X. Dai et al. who presented the chiral (2-
phenyllthioferrocenyl)oxazoline 22 as a catalyst.[41] In comparison with 21, this catalyst was 
able to shorten the reaction time to 5 h with an equal loading of the palladium catalyst. 
 
Scheme 1: Palladium-catalyzed allylic substitution in 1,3-diphenylprop-2-enyl acetate utilizing chiral aryl sulfide-
based ligands 21 and 22.[40],[41] 
Another ferrocene-derived ligand with a sulfide functionality is the already well-established 
Fesulphos ligand (23), which was initially reported by J. C. Carretero and coworkers (Figure 
12).[42] Fesulphos can easily be prepared from ferrocene and commercially available (R)-S-
tert-butyl tert-butanethiosulfinate via a short four-step and high yielding synthesis and has 




palladium-catalyzed allylic substitution reaction[42], several other transformation were enabled 
by transition metal complexes of this sulfenylphosphinoferrocene derivative. In this regard, 
palladium-catalyzed alkylative ring opening reactions of oxabicyclic alkenes[43] or the copper-
catalyzed aza-Diels-Alder reaction between N-sulfonylaldimines and Danishefsky's-type 
dienes have to be mentioned.[44] 
 
Figure 12: Fesulphos (23), 1-sulfenyl-2-phosphinoferrocenes – versatile ligands presented by J. C. Carretero and 
coworkers.[42] 
In 2019, A. K. Singh et al. presented the novel palladium catalyst 24 for the transfer 
hydrogenation of aldehydes and ketones employing 2-propanol as a hydrogen source (heme 
2).[45] The utilization of the monoanionic [S,N,C]-tridentate ligand in the complex 24 enabled 
the hydrogenation of several electron-rich and electron-poor benzaldehyde derivatives, alkyl 
aldehydes and ketones in up to 85% yields. Most of the desired alcohols were even obtained 
with an extremely low catalyst loading of 0.05 mol%. Rhodium complexes of the same ligand 
were also employed in the N-alkylation of aniline with benzyl alcohol. 
 
heme 2: Pd-catalyzed transfer hydrogenation of carbonyl groups employing an aryl sulfide-containing ligand 
scaffold, as presented by A. K. Singh et al.[45] 
 
Aryl thioethers-derived [S,O]-bidentate ligands were also used in the C-H olefination of arenes 
(Scheme 3). As M. Á. Fernández-Ibáñez and coworkers demonstrated, the palladium complex 
of [S,O]-ligand 25 has unique properties and can be used for Fujiwara-Moritani olefination 
(dehydrogenative Heck reactions).[46] Usage of ligand 25 resulted in a high selectivity towards 
the olefination of substituted arenes. Furthermore, it enabled the late stage functionalization of 
pharmaceutically relevant compounds like Naproxen, a nonsteroidal anti-inflammatory drug. 




phenyliodine(III) diacetate (PIDA) as an oxidant and could additionally be utilized in the 
allylation reaction of arenes with allylbenzene. In the latter case, silver acetate acted as an 
oxidant. Recently, the substrate scope of the olefination protocol was extended to thiophene 
derivatives, as reported by the Fernández-Ibánez group as well.[47] 
 
Scheme 3: Aryl sulfide ligand 25 in Pd-catalyzed C-H functionalization reactions of arenes and thiophenes, as 
reported by M. Á. Fernández-Ibáñez and coworkers.[46,47] 
Diaryl sulfide-based ligands are also employed in the catalytical alkane transfer 
dehydrogenation, as was demonstrated by the group of A. S. Goldmann in 2019 (Scheme 
4).[48] The presented ruthenium pincher complex 26 featuring a [P,S,P]-tridentate ligand is able 
to catalyze the transfer dehydrogenation of cyclooctane with turnover frequencies up to ca. 1 
s−1 at 150 °C and 0.2 s−1 at 120 °C. This is more efficient than with a similar iridium [P,C,P]-
complex. Interestingly, in the solid state the complex 26 exhibits a bowl-like structure, whereas 
the corresponding [P,S,P] analog possess an approximately planar configuration. The authors 
suggested that this structural change is caused by the higher degree of sp2 hybridization of 
oxygen compared to sulfur. Presumably, the free electron pairs of the softer sulfur Lewis base 
coordinates the weak Lewis acid Ru(0) better than the harder oxygen donor. Additionally, the 
coordinative Ru–S bond is longer than the analogous Ru–O bond. 
 
Scheme 4: Alkane transfer dehydrogenation catalyzed by the complex 26 with a diaryl sulfide backbone, as 





Apart from the application of [S,N,C]- and [P,S,P]-tridentate pincer ligands discussed above, 
further catalytically active complexes with ligands possessing the aryl sulfide-containing 
scaffolds have been reported.[49] Their chemistry as well as the applications of aryl sulfide-
containing ligand, including the chiral ones, have been recently reviewed.[50]  
Thioesters themselves can act as chiral catalysts, as demonstrated unprecedentedly by X. 
Zhao and coworker (Scheme 5).[51] In the presented chlorination and desymmetrization 
protocol, benzyl-tethered diolefins were enantioselectively cyclized, resulting in the formation 
of two quaternary and one tertiary stereo centers. The induction of chirality resulted from the 
utilization of 27 as organocatalyst. It has been suggested that intermediate 28 is formed in situ 
from 27 by chlorination with 1,3-dichloro-5,5-dimethylhydantoin (DCDMH). As a result, 28 acts 
as an active chiral chlorinating reagent.  
 
 
Scheme 5: Action of the sulfide 27 as a chiral catalyst for desymmetrizing enantioselective chlorination via 





The cyclic aryl thioethers themselves can also be utilized as catalysts, as recently reported by 
the group of Y. Huang (Scheme 6).[52] The authors reported on the transition metal-free Suzuki 
coupling reaction of arylboronic acids with benzyl chlorides. The reaction mechanism involves 
the initial formation of a sulfonium salt from catalyst 29 and the benzyl chloride. This salt 
subsequently reacts with a base affording the corresponding sulfur ylide. The latter forms a 
boron “ate” complex with the boronic acid. Through the subsequent 1,2-aryllate shift, a new 
carbon-carbon bond is formed and the catalyst is regenerated. Under these conditions, the 
protodeboration results in the formation of the desired coupling product.  
 
Scheme 6: Employment of 29 as a catalyst in the transition metal-free Suzuki couplings of aryl boronic acids and 





1.3 Reactivity of aryl thioethers 
Aryl thioethers can be used for several chemical transformations, as they can be converted 
into other sulfur-containing functional groups such as sulfoxides and sulfones. Additionally, 
thioethers can also be applied as leaving or directing groups in the modern organic chemistry. 
Also they are precursors for the formation of sulfur-carbon bonds as well as carbon-E bonds 
(E = N, P, B, C) by transition metal catalysis (Figure 13). The chapter will highlight recent 
developments is this area and will give insights into the full synthetic potential of thioethers by 
discussing representative literature examples. 
 






The derivatization of thioethers 30 by oxidation gives access to racemic sulfoxides 31 and 
sulfones 32 (Scheme 7) and is one of the oldest transformations of thioethers, as already C. 
Märker described by the synthesis of dibenzyl sulfoxide from dibenzyl sulfide in 1865.[53] 
 
Scheme 7: Stepwise oxidation of thioethers 30 to sulfoxides 31 and sulfones 32. 
 
Traditionally, strong oxidants are employed in the synthesis of sulfones. Among them, for 
example, potassium permanganate,[54] elemental bromine,[55] sodium bromate,[56] ozone,[57] 
hydrogen persulfate,[58] and hydrogen peroxide combined with several catalysts e.g. tantalum 
carbide,[59] sodium tungstate,[60] Mo(IV) catalysts,[61] methyltrioxorhenium,[62] borax[63] and 
further polymer immobilized systems.[64] Organocatalytical approaches have also been 
published recently. Accordingly, the group of C. G. Kokotos studied the catalytic activity of 
2,2,2-trifluoroacetophenone in the oxidation of several different thioethers (Scheme 8).[65] On 
the other hand, M. Jereb showed that oxidation with aqueous hydrogen peroxide can proceed 
also without additional solvents and catalysts.[66] 
 
Scheme 8: Organocatalytic oxidation of thioethers to sulfones with hydrogen peroxide as an oxidant, as 
presented by C. G. Kokotos and coworkers. [65] 
 
The drawback of the most harsh oxidation conditions is their reduced tolerance towards 
numerous functional groups of the substrate molecules. Therefore, several other research 
groups have developed milder protocols which use m-chloroperbenzoic acid (mCPBA)[67] or 
periodic acid[68] as an oxidant. The mild conditions allow the late stage oxidation of sulfides in 
pharmaceutically relevant compounds, as described by R. J. Griffin, B. T. Golding et al.[67] 
The synthesis of sulfoxides can be achieved in most cases by using equimolar amounts or a 




usage of 1.5 instead of three equivalents hydrogen peroxide resulted in the selective formation 
of the sulfoxide.[65] Additionally, the utilization of triflic anhydride (0.5 equiv.) can prevent the 
overoxidation by an excess of oxidant, as reported by M. M. Khodaei, K. Bahrami et al.[69] An 
alternative approach to avoid the overoxidized side-products is the decreasing of the reaction 
temperature. In some other protocols the usage of a small excesses of bromine for the 
selective oxidation of thioethers have been reported.[70]  
In the borax-catalyzed oxidation of sulfides with hydrogen peroxide, the selective formation of 
sulfoxides can be enabled by adjusting the pH-value of the reaction mixture (Scheme 9).[63] 
Thus, under basic conditions the formation of diperoxoborates (HO)2B–(OOH)2 favors the 
formation of the sulfones, as proposed by the authors. In contrast to this, under neutral 
condition the less active peroxoboric acid (HO)2BOOH is formed predominantly and gives 
mainly the desired sulfoxide.  
 
 
Scheme 9: pH-Controlled selective oxidation of organic sulfides with hydrogen peroxide as an oxidant.[63] 
 
In recent years, special attention has been paid to the development of protocols for the 
stereoselective oxidation of sulfides due to the fundamental impact of enantiopure sulfoxides 
on several research areas. Chiral sulfoxides can be used as ligands for asymmetric catalysis 
as recently reviewed by B. M. Trost et al.[71]  
Also medicinal chemistry benefits from these efforts because of the high potential of chiral 
sulfoxides in the treatment of various diseases. In this respect, specialized protocols for the 
synthesis of proton pump inhibitors like esomeprazole (34) have been developed utilizing chiral 
Schiff bases for the stereoselective oxidation of thioethers (Scheme 10).[72] Additionally, 
approaches towards the biocatalytical enantioselective oxidation of pyrmetazole (33), the 






Scheme 10: Stereoselective synthesis of esomeprazole (34) from pyrmetazole (33) using chemical[72] or 
biochemical[73] oxidation protocols. 
 
Further methodologies for the oxidative synthesis of sulfoxides and sulfones have been 
recently reviewed by R. V. Kupwade.[74] 
 
1.3.1.2 Transformations based on transition metal insertion in CAr–SR bond 
In the recent decade, several transition metal-catalyzed conversions of thioethers into a variety 
of functional groups have been reported in literature. In this regard, the development of 
protocols for ipso-borylation, ipso-phosphorylation, ipso-amination and ipso-thioalkylation has 
expanded the range of synthetic tools for organic chemists. Furthermore, protocol for the 
arylation of thioethers, also known as Liebeskind-Strogl reaction, has been reported as well. 
The utilization of robust and stable thioether C–S bonds as levers for these reactions is 
desirable as a useful alternative to other cross-coupling reactions, in which aryl halides and 
pseudohalides are mainly used as precursors. 
i-Borylation of thioethers (C–S to C–B conversion) 
In 2016, the group of T. Hosoya reported the ipso-borylation of alkyl thioarenes via rhodium-
catalyzed cleavage of the sulfur-carbon bond (Scheme 11).[75] Their protocol allowed the 
synthesis of aryl pinacolboronates from alkyl and aryl sulfides in the presence of functional 
groups like acetates, tosylates and protected alcohols. Bis(pinacolato)diborane (Bpin)2 was 
used as a boron-containing precursor without an additional base. To achieve high yields, the 
catalyst has to be pre-activated by heating the rhodium precatalyst in the presence of the ligand 





Scheme 11: Rh-catalyzed ipso-borylation of thioethers, as reported by T. Hosoya and coworkers.[75] 
 
i-Phosphorylation of thioethers (C–SR to C–P conversion) 
Recently, the first ipso-phosphinylation of aryl thioethers was presented by the groups of T. 
Chen, S.-F. Yin and L.-B. Han (Scheme 12).[76] By utilization of a commercially available nickel 
catalyst the authors were able to synthesize triaryl and dialkyl aryl phosphine oxides from aryl 
thioethers and secondary phosphine oxides with low catalyst loading down to 0.1 mol%. 
Electron-rich as well as electron-withdrawing substituents were tolerated. This versatile 
protocol allowed the synthesis of several organophosphorus compounds in gram scale. The 
formation of the desired C–P bond was also possible by utilization of methylsulfoxide and 
methylsulfones as starting materials. 
 
Scheme 12: C–S/P–H cross-coupling of aryl sulfides with secondary phosphinoxides, as reported by T. Chen, S.-





i-Amination of thioethers (C–SR to C–N conversion) 
One of the first transition metal-catalyzed synthesis of diarylamines by replacing of C–S bonds 
with C-N ones was presented by K. Murakami, H. Yorimitsu and coworkers (Scheme 13).[77] 
The authors utilized a bulky NHC-derived palladium catalyst (SingaCycle-A3) with potassium 
hexamethyldisilazide (KHMDS) in the amination of aryl sulfides with substituted anilines. 
Previously, similar transformations were known only for the oxygen analogues upon cleavage 
of the C–O bonds.[78] The high reactivity of the used SingaCycle-A3 (35) complex also allowed 
the amination of bulky ortho-substituted aryl sulfides. The protocol enabled the conversion of 
several different alkyl and aryl thioethers into their aminated derivatives and was highly 
selective, as only secondary anilines were obtained by the transformation. 
 
Scheme 13: Pd-catalyzed amination of aryl thioethers with anilines, as reported by K. Murakami, H. Yorimitsu and 
coworkers.[77] 
In a consecutive publication, the group of H. Yorimitsu extended the protocol towards the 
amination of aryl sulfides with primary and secondary aliphatic amines.[79] The optimized 
reaction conditions utilizing the structurally similar catalyst SingaCycle-A1 (structure see below 
in Scheme 14) allowed also the amination with alkyl aryl amines, which was not reported in 





i-Thioalkylation of thioethers (C–S to C–S conversion): 
While alkene and alkyne metathesis are well established transformations in the field of organic 
synthesis and material science,[80,81] protocols for carbon-sulfur bond metathesis are rare in 
the literature. The first example in this nearly untapped area of research was presented by B. 
Morandi and coworkers in 2017 (Scheme 14).[82] They reported on the palladium-catalyzed 
carbon-sulfur bond metathesis by reversible arylation of several alkyl aryl sulfides, with a low 
catalyst loading of 0.4 mol%. Especially, methyl thioethers could be easily transferred into the 
envisaged alkyl aryl sulfides by reaction with thiolates, which were in situ generated by 
deprotonation of the thiol with an excess of lithium hexamethyldisilazane (LiHMDS). The 
driving force of the metathesis is the formation of nearly insoluble lithium methanethiolate. The 
authors examined a broad scope of arene- and heteroarene-derived methyl thioethers as 
substrates as well as different alkyl thiols as reactants. The reaction afforded the products in 
good to excellent yields and tolerated several functionalities, e.g. protected alcohols, 
aldehydes and nitrile groups. 
 
Scheme 14: Sulfur-carbon bond metathesis reaction for the synthesis of various alkyl aryl thioethers, as 




i-Alkylation/Arylation of thioethers (C–SR to C–C conversion) 
In 2002, L. S. Liebeskind and J. Srogl reported the first cross-coupling of boronic acid with 
heteroaromatic thioether for the formation of carbon-carbon bonds under mild conditions 
(Scheme 15).[83] The Pd-catalyzed, CuTC-mediated [copper(I) thiophene-2-carboxylate (37)] 
cross-coupling reaction allowed the synthesis of several variously functionalized diaryl 
substrates. However, the reaction was limited to application of electron-deficient thioethers. 
Apart from diaryl sulfides, also alkyl aryl sulfides were used as reactants. 
 
Scheme 15 Liebeskind-Srogl cross-coupling of aromatic thioethers with boronic acids using CuTC as a mediator 
and thiolate scavenger.[83] 
The reported protocol is based on their previously developed cross-coupling reaction with thiol 
esters as electrophilic reagents, also known as the first generation Liebeskind-Srogl cross-
coupling reaction. The latter can be used for the synthesis of unsymmetrical diaryl ketones.[84] 
In subsequently modified procedures, the boronic acid was replaced by aryl stannanes[85], 
siloxanes[86] and Grignard reagents[87] as well as organozincates[88] under transition metal 
catalysis. The orthogonality of the Liebeskind-Srogl-like cross-coupling compared to classical 
cross-coupling protocols was demonstrated by the group of M. C. Willis. They reported on the 
Rh-catalyzed coupling of boronic acids and aryl methyl sulfides in the presence of aryl halides 
and alkyl iodide residues.[89] 
The applications along with the detailed mechanistic evaluation of the Libeskind-Srogl reaction 
have been recently reviewed.[90] 
In 2019, J. Cornella and coworkers reported a protocol for the reductive Ni-catalyzed alkylation 
of heterocyclic aryl sulfides with primary and secondary alkyl bromides as well as aryl bromides 
(Scheme 16),[91] reminiscent to the Liebeskind-Srogl coupling. The use of electron-rich ligands 
like 1,1'-bis(diphenylphosphino)ferrocene (dppf) in the nickel-catalyzed activation of the strong 
thioether bond facilitated the formation of new C-C bonds. As a reducing agent, inexpensive 
elemental zinc was employed. The authors demonstrated the versatility of the presented 





Scheme 16: Ni-catalyzed alkylation of (hetero)cycles by reductive cleavage of methyl thioethers, as reported by J. 
Cornella and coworkers.[91] 
 
Apart from pre-functionalized arenes and alkanes like boronic acids or bromides, also un-
functionalized heteroarenes can be used in C-C coupling reactions with thioethers through a 
C–H bond activation step. Z.-X. Wang et al. demonstrated that electron-poor and -rich aryl 
thioethers react with unactivated azole and thiazole derivatives in a Pd-catalyzed coupling 
reaction (Scheme 17).[92] The authors extended the transformation to aryl selenides and 
demonstrated the broad functional group tolerance of their protocol. Other transition metal-
catalyzed C–C bond formations, which proceed via C–S bond cleavage, have been recently 
reviewed as well.[93] 
 
 
Scheme 17: Pd-catalyzed C-C bond formation via C-H/C-S activation of thioethers and hetero arenes, as 






1.3.1.3 Nucleophilic substitution (SN,Ar) 
Electron-poor aryl alkyl thioethers decorated with a nitrile substituent on the aryl moiety react 
with anilines or alkyl alcohols to form the corresponding diarylated aniline or ether derivatives. 
As presented by W. Zhao, X.-Q. Wang et al., such substitution of the alkyl thioethers allowed 
the transition metal-free synthesis with a broad scope of substrates, tolerating a plethora of 
functional groups (Scheme 18).[94] The protocol was further extended to secondary amines, 
thus providing access to tertiary substituted aniline derivatives. Mechanistic investigations 
showed that the reaction proceeded via a radical-free nucleophilic substitution pathway. 
Accordingly, the in situ generated alkylthiolate could be captured by addition of benzyl bromide 
after the reaction was completed. The methodology was used for the functionalization of 
several pharmaceutically relevant compounds and could be scaled up to 20 mmol.  
 
Scheme 18: The transition metal-free nucleophilic amination and etherification of cyanoaryl alkyl thioethers, as 
presented by W. Zhao, X.-Q. Wang et al.[94] 
 
The general mechanism and the kinetic of the nucleophilic attack of amines on electron-poor 
aryl thioethers with a special focus on the intermediate Meisenheimer complex was described 





1.3.1.4 Directing group 
Apart from substitutive and conversional transformations of thioethers groups, considerable 
attention was recently paid to their ability to act as a directing group in transition metal-
catalyzed C–H activation reactions of (hetero)arenes. 
In 2012, Y. Zhang and coworkers reported one of the first aryl thioethers-directed Fujiwara-
Moritani olefination[47b] (Scheme 19).[96] The reported palladium-catalyzed reaction gave 
access to a variety of substituted cinnamic esters 38. Furthermore, it was demonstrated that 
the presence of a thioether group is crucial for the C–H alkenylation, whereas the 
corresponding sulfoxide, sulfone and ether analogs were not reacting. The yield of the reaction 
was moderate to good and almost independent on the nature of the thioether (R2 = Alk, Ar, 
Bn). 
 
Scheme 19: Thioether-directed alkenylation of arenes, as presented by Y. Zhang and coworkers.[96] 
One year later, in 2013, this concept was utilized by Z.-J- Shi group in an optimized protocol 
using a rhodium catalyst instead of palladium acetate. With copper acetate as an additional 
oxidant it was also possible to conduct the alkenylation of arenes with acryl amides and styrene 
derivatives. Additionally, it has been shown that, depending on the choice of solvent, the 
reaction selectively lead to the mono- or dialkenylated products.[97]  
To enable the access to higher substituted alkene derivatives, E. P. Urriolabeitia et al. used 
microwave-assisted within 30 min hydroarylation of unsymmetrically substituted alkynes with 
thioether of the general structure 39 (Scheme 20, A).[98] 
Related thioether derivatives 40 can also be acylated with α-oxocarboxylic acids under 
palladium catalysis, as presented by C. Kuang et al. (Scheme 20, B).[99] The coordinating 
abilities of the thioethers enabled the palladium-catalyzed regioselective monoacylation of 40 





Scheme 20: A: Ru-catalyzed alkenylation of arenes with alkynes, as presented by E. P. Urriolabeitia et al.;[98]  
B: Thioether-directed ortho-acylation of thioethers.[99] 
 
An additional example of the directing ability of thioethers was presented by the group of M. 
Miura, who reported the rhodium-catalyzed selective C–H alkenylation of 3-
alkyl(aryl)thioindoles at C4 position with a commercially available Rh catalyst (Scheme 21).[100] 
The coordination of the catalyst enabled a regioselective trans-alkenylation of several different 
thioethers with electron-rich and electron-poor alkenes. Very recent the group of M. Miura 
reported the direct on C4-selective acylation catalyed by an iridium catalyst.[101] 
 
Scheme 21: Thioether-directed C–H functionalization of indole derivatives, as presented by M. Miura and 
coworkers.[100] 
In a subsequent publication, the authors expanded the scope of the thioethers-directed 
alkenylation towards naphthyl sulfides and were able to obtain higher substituted naphthyl 
alkenes by hydroarylation of internal alkynes (Scheme 22).[102] The presented peri-selective 




derivatives.[103] Additionally, the double C–H arylation of anthracenes by usage of two 
equivalents boronates was reported as well, however, in lower yield (19–43%). 
 
Scheme 22: Rhodium-catalyzed thioethers-directed peri-selective arylation[103] and alkenylation[102] reactions, as 
presented by the group of M. Miura.  
 
1.4 Synthesis of aryl thioethers 
Since aryl sulfide-containing core structures are of tremendous importance in several areas of 
organic synthesis (see previous Chapter), numerous synthetic protocols were developed for 
the design of this distinct structural motif.  
In addition to the classical Williamson-type thioether synthesis,[104] which consists in 
nucleophilic substitution on an alkyl halide with an aryl thiolate following a consecutive (SN1) 
or concerted (SN2) pathway (see Scheme 23), several new methodologies to sulfenylate 
arenes, with or without previous pre-functionalization, were elaborated over the past decades. 
 
 
Scheme 23: Classical Williamson-type thioether synthesis of alkyl aryl sulfides by nucleophilic substitution on a 




In general, these approaches can be divided into two general categories: transition metal-
based protocols and transition metal-free approaches. Traditional developments as well as 
recent results of both approaches will be discussed in this Chapter. 
1.4.1 Transition metal-based protocols 
The transition metal (TM)-catalyzed formation of C–S bonds has received significant attention 
in recent decades and changed the face of modern organic synthesis. Several different 3d-, 
4d- and 5d-metalcomplexes have shown significant reactivity in the preparation of aryl sulfides 
from pre-functionalized arenes with sulfur-containing precursors (Scheme 24, A). In these 
cases, the sulfur-containing moiety can be viewed as nucleophilic sulfur building block since it 
formally substitutes a negatively charged leaving group X.  
In recent years, various protocols have been reported for the formation of a C–S bond via C–
H functionalization, which allow a more atom economical synthesis of thioethers (Scheme 24, 
B). In most of these cases, the utilized sulfur-containing precursor shows an electrophilic 
character in the reaction mechanism. Additionally, sulfur-based radical reaction pathways have 
been elaborated, especially in the cases of photocatalytically- or electrochemically-induced 
transformations  
The following Chapter will discuss selected examples of the TM-catalyzed aryl sulfide 
synthesis. It is divided into Subchapters depending on the utilized metal. Various aspects of 
TM-catalyzed C–S bond formation reactions has been reviewed by several authors.[105] 
 
 
Scheme 24: Concept of transition metal-catalyzed synthesis of aryl sulfides by (A) cross-coupling of pre-





1.4.1.1 Palladium-based transformations 
One of the first palladium-catalyzed formations of aryl sulfides was reported by T. Migita et al. 
in 1978 (Scheme 25).[106,107] The authors demonstrated the ability of 
tetrakis(triphenylphosphine) palladium(0) to catalyze the cross-coupling reaction of aryl halides 
with aryl and alkyl thiolates which resulted in the formation of diaryl sulfides. Based on this 
initial result, the field of palladium-catalyzed aryl sulfide synthesis has been extended by 
several research groups.  
 
Scheme 25: Early example of palladium-catalyzed formation of diaryl sulfides, as reported by T. Migita et al.[106] 
The sequence of elementary steps in the classical cross-coupling of iodo-, bromo- and 
chloroarenes or arly triflates with thiols (Table 1, Entries 1–6) have been evaluated by detailed 
kinetic and mechanistic investigations by J. F. Hartwig and coworker[108] as well as by J. M. 
Campagne, A. Jutand et al.[109] Aryl hydrazines and aromatic carbonic acids (Table 1, Entries 
7&8) can also be transformed into the corresponding aryl sulfides by an oxidative cross-
coupling with oxygen or silver(I) salts as oxidizing reagents.[110–112] Apart of thiols, also further 
sulfur-containing substrates can be utilized in palladium-mediated C–S bond-forming 
reactions. (Table 1, Entries 9–13). Palladium-catalyzed cross-couplings of aryl halides with 
thiols can even proceed with extremely low catalyst loadings of down to 0.01 mol%, thus 





Table 1: Representative examples of palladium-catalyzed cross-coupling reactions for the synthesis of aryl 
sulfides. 
 
Entry X (S) R Reference 
1 I SH Alkyl [114] 
2 Br SH Alkyl, Aryl [115] 
3 Br SH Alkyl, Aryl, Silyl [116] 
4 Br SH Silyl [113] 
5 Cl SH Alkyl, Aryl, Silyl [117] 
6 OTf SH Alkyl [118] 
7 NHNH2 SH Aryl [110] 
8 COOH SH Alkyl, Aryl [111,112] 
9 I S-BBN Aryl [119] 
10 Br SSR Aryl [120] 
11 Si(OEt)3 SSO3Na Aryl [121] 
12 Br SBn Aryl [122] 
13 Br S-TIPS Aryl [123] 
 
Due to the high value of trifluoromethyl thioethers in medicinal chemistry (compare Chapter 
1.2.2), several synthetically oriented groups have invested great efforts to develop protocols 
for the trifluoromethylthiolation of arenes. In this regard, it has been reported that a series of 
palladium-catalyzed cross-couplings of aryl halides with trifluoromethyl thiolate provide access 
to a variety of different trifluoromethyl thioethers. Accordingly, different M–S–CF3 salts (like 
AgSCF3, Me4NSCF3) were employed.[124,125] A recent example of these protocols was 
published by F. Schoenebeck and coworkers, who presented the trifluoromethylthiolation of 
aryl iodides and bromides with a palladium(I) catalyst 41 (Scheme 26).[124] The recyclable and 
bench-stable catalyst 41 enabled the functionalization of aryl and heteroaryl halides and 






Scheme 26: Palladium-catalyzed synthesis of trifluoromethyl thioethers, as presented by the group of F. 
Schoenebeck.[124] 
 
In the past few years, special attention has been paid also to the development of palladium-
catalyzed C–H thiolation of arenes and heteroarenes bearing different directing groups, such 
as pyridine moieties.[126] In 2015, F. Glorius and coworkers reported on the C–H sulfenylation 
of several heteroarenes like thiophenes, pyrroles and furanes with diarylsulfides as 
sulfenylation reagent (Scheme 27, A).[127] This complemented the results of P. Anbarasan and 
colleague, who performed C–H thiolation of unactivated phenyl derivatives by usage of N-
(aryllthio)succinimides as electrophilic sulfur reagent (Scheme 27, B).[128] The both presented 
protocols did not require additional oxidants and allowed the synthesis of several diaryl 
sulfides.  
 
Scheme 27: Pd-catalyzed C-H sulfenylation protocols for the functionalization of unactivated (A) heteroarenes[127] 
and (B) arenes.[128] 
Additionally, the group of M. Beller demonstrated, that arylsulfonyl cyanides can be used as 






1.4.1.2 Nickel-based transformations 
Nickel is an abundant and inexpensive transition metal which is also known for the ability to 
enable the formation of aryl sulfides applying the general cross-coupling approach shown 
above in Scheme 24. The history of nickel-catalyzed aryl sulfide synthesis started in 1982 with 
a protocol of H. J. Cristau and coworkers, who reported the arylation of arenethiolates with aryl 
bromides in the presence of a nickel catalyst from NiBr2 and a bidentate [P,P]-ligand under 
very harsh reaction conditions (200 °C) (Scheme 28).[130]  
 
Scheme 28: Nickel-catalyzed thioarylation of aryl bromides at elevated temperatures, as reported by H. J. Cristau 
and coworkers.[130] 
Based on this result, several thiolations of halogenated arenes utilizing aryl thiols, thiolates and 
aryldisulfides as nucleophilic sulfur reagents have been reported in the literature. 
Representative examples of these reactions are given in Table 2. 
Table 2: Representative examples of nickel-catalyzed cross-coupling reactions for the synthesis of aryl sulfides. 
 
Entry X (S) R Reference 
1 I SSR Alkyl, Aryl [131] 
2 I SH Alkyl, (hetero) aryl [132] 
3 Br SH Alkyl, Aryl [133] 
4 Cl SH Alkyl, (hetero)aryl [134] 
5 OMs SNa Aryl [135] 
6 Cl, Br, I SH Alkyl, Aryl [136] 
 
In the case of disulfides as precursors, overstoichiometric amounts of zinc powder are 




into the sulfur-sulfur bond of the disulfide and enables the reductive elimination of the 
envisaged aryl sulfide with a formation of the new desired carbon-sulfur bond.[137]  
Almost all traditional nickel-catalyzed C–S-forming cross-couplings require harsh conditions 
like elevated temperatures (for an exceptional case see the work of N. D. Paul's team[138]). 
Therefore, the development of mild coupling conditions was targeted by several groups. Very 
recently, nickel-catalyzed electrochemical thiolations of aryl halides have been reported. This 
new approach enables the desired C–S bond formation at room temperature (Scheme 29). Y. 
Wang et al.[139] presented detailed electrochemical studies on the thioarylation of aryl iodide 
derivatives, whereas, the group of T.-S. Mei was able to utilize aryl bromides and chlorides as 
substrates with the same catalytic system.[140] Both protocols allowed the synthesis of 
heteroaryl sulfides and both groups proposed an initial anodic oxidation of the thiol as a key 
step of the catalytical cycle to generate a thiyl radical as the reactive species.  
 
Scheme 29: Electrocatalytical synthesis of aryl sulfides, as reported by Y. Wang et al.[139] 
Alkyl aryl sulfides can also be synthesized in a complementary fashion by utilization of aryl 
thiosulfonate and unactivated alkyl bromides. In this regard, a nickel-catalyzed reductive 
thiolation protocol has been reported in a collaborative publication of the L. Ackermann and 
S.-J. Ji groups, presenting an elegant and versatile catalytic method for the preparation of 
highly functionalized alkyl aryl sulfides under mild conditions (no base, 30 °C).[141] The authors 
were able to extend their newly elaborated protocol towards the synthesis of dialkyl sulfides as 
well as selenides. 
 
Scheme 30: Versatile nickel-catalyzed reductive chalcogenation of unactivated alkyl bromides with thiosulfonates, 





In contrast to the previously published protocols utilizing pre-functionalized arenes, L. 
Ackermann and colleagues circumvent this disadvantage by reporting the first Ni-catalyzed 
directed C–H chalcogenation of anilines with pyrimidyl as a directing group (Scheme 31).[142] 
The procedure did not require pre-functionalized substrates like halides and permited the 
selective ortho-thiolation with diaryldisulfides. By oxidation of the in situ generated aryl thiolate 
to aryl disulfide through addition of manganese oxide, the disulfide loading could be reduced 
to 1.2 equivalents. This new C–H activation protocol enables a more step-economical 
synthesis of the target molecules avoiding complex pre-functionalization of substrates. The 
catalytic cycle involves the formation of a sulfur-centered radical. 
 





1.4.1.3 Copper-based transformations 
Extensive work in the area of copper-catalyzed C–S bond-forming reactions has resulted in a 
significant progress in the synthesis of aryl sulfides. The use of copper catalysts is desirable 
due to the low price of the metal (~$0.01 per gram) and its relatively low toxicity. The general 
strategy relies upon the coupling of aryl iodides with thiols, which follows the concept of the 
copper-mediated Ullmann-type chemistry. In some cases (Entry 1, Table 3) expensive 
phosphazene-bases or high catalysts loading (up to 20 mol%) are required.[143] G. C. Fu, J. C. 
Peters and coworkers extended the reactant scope to aryl bromides by photoinduced, copper-
catalyzed cross-couplings via single electron transfer (SET) under mild conditions (0 °C) (Entry 
3, Table 3).[144,145] A few couplings of aryl chlorides with aryl thiols at elevated temperatures 
and long reaction times (135 °C, 24 h) are reported in the literature as well.[146] The mechanism 
of these Ullmann-type coupling reactions, either radical or via an oxidative addition, depends 
on the structure of a substrate and the reaction conditions and still remains a topic of current 
investigations.[147] 
Apart from aryl halides, also boronic acids and boronic esters can be arylthiolated by a variation 
of the Chan-Lam reaction with different sulfur precursors (Entries 5–14, Table 3).[148] While 
most of the Chan-Lam like protocols with thiols or disulfides (Entries 5–8, Table 3) as S-
reagents require elevated temperature, some processes for the S-arylation of boronic acids 
with thiols proceed at room temperature.[149] Also sulfothioates (Entry 9), thiosulfonates (Entries 
10 & 11), sulfonylhydrazines (Entry 12) and N-thioimides (Entry 13) can be utilized as 
precursors. The potential of copper-mediated cross-coupling reactions of Chan-Lam type was 
simultaneously demonstrated by the groups of Q. Shen and M. Rueping, who extended the 
methodology towards the synthesis of trifluoromethyl thioethers with N-
(trifluoromethylthio)phthalimide as a trifluoromethyl thiolating reagent (Entry 14, Table 3).[150,151]  
As reported by J. M. Hoover et al., (hetero)aromatic carboxylic acids can be used as starting 
materials in the copper-catalyzed synthesis of diaryl sulfides. This aerobic - decarboxylative 
thiolation uses molecular oxygen as an oxidant and (hetero)aryl thiols as reactants (Entry 15, 






Table 3: Representative examples of copper-catalyzed cross-coupling reactions for the synthesis of aryl sulfides. 
 
Entry X Ar (S) R Reference 
1 I Arene SH Aryl [143,153] 
2 I Arene SH Aryl, Alkyl [154] 
3 Br Arene SH Aryl [144] 
4 Cl Arene SH Aryl [146] 
5 B(OH)2 Arene SH Alkyl [155] 
6 B(OH)2 Arene SSR Alkyl, Alkenyl, Aryl [156] 
7 B(OH)2 Arene SSR (hetero)Aryl [157] 
8 Bpin (hetero-)arene SSR Aryl [158] 
9 B(OH)2 Arene SSO3Na (hetero)Aryl [159] 
10 B(OH)2 Arene SSO2R Alkyl, (hetero)Aryl [160] 
11 Bpin Alkenyl, 
(hetero-)arene 
SSO2R Alkyl, (hetero)Aryl [161] 
12 B(OH)2 Arene SO2NHNH2 Alkyl, Aryl [162] 
13 B(OH)2 Arene S-Suc Alkenyl, Aryl [163] 
14 B(OH)2 Arene S-Pht CF3 [150,151] 
15 COOH (hetero-)arene SH (hetero)Aryl [152] 
 
Additionally, a straightforward synthetic protocol for the copper-catalyzed electrophilic 
trifluoromethylthiolation of boronic acids with a benziodoxol reagent was reported by L. Lu, Q. 
Shen et al.[164] The presented methodology allowed the synthesis of several trifluoromethyl aryl 
sulfides in good to excellent yields.  
Apart from aryl halides, aryl boronic and carbonic acids as well as selected unfunctionalized 
aromatic systems can be arylthiolated in a copper-mediated fashion. Those C–H 
functionalization reactions use diaryldisulfides as sulfur-containing precursors and have been 
reported for arenes with[165] or without[166] additional directing groups as well as for hetero-cyclic 
systems.[167] These transformations need an additional oxidant like e.g. oxygen or persulfates 





1.4.1.4 Iron-based transformations 
In the last two decades, iron-catalyzed transformations have been elaborated to replace 
expensive and toxic transition metals in organic synthesis. As reviewed by H.-J. Knölker and 
coworker, iron catalysis is an fastly growing research topic with promising potential and 
versatile applications in laboratory as well as in chemistry on industrial scale.[168] Several 
sulfenylation protocols for pre- and un-functionalized arenes are reported in the field of iron-
mediated aryl sulfide synthesis. 
The cross-coupling reaction of aryl iodides with thiols is described for the synthesis of diaryl 
sulfides and alkyl aryl sulfides with different substitution patterns (Entries 1–2, Table 4). In a 
subsequent publication, the group of C. Bolm discussed the influence of transition metal 
contaminations [mainly copper(I)oxide] in iron(III)chloride on the yield of the diaryl sulfide and 
concluded that in certain cases Cu2O can significantly affect the result of the reaction.[169] 
Further procedures with simple iron(III)chloride as a pre-catalyst based on the initially reported 
protocol of C. Bolm and coworkers have been reported by C.-F. Lee and coworkers.[169] 
As demonstrated by T. G. Abi, G. Anilkumar et al., the substrate scope can be extended from 
aryl iodides to bromides and chlorides (Entry 3, Table 4). Nevertheless, iodides are substrate 
of choice for this kind of transformation.  
Table 4: Representative examples of iron-catalyzed cross-coupling reactions for the synthesis of aryl sulfides. 
 
Entry X Ar (S) R Reference 




2 I Arene SH Aryl, Alkyl [170] 






In contrast to pre-functionalized arenes, also unfunctionalized and electron-rich (hetero)arenes 
can be efficiently converted into the corresponding thioethers by iron-catalyzed 
transformations. Accordingly, the group of J. Yadav reported on iron(III)-catalyzed direct 
thiolation of indole derivatives with (hetero)aryl thiols at elevated temperature (Scheme 32).[172] 
 
Scheme 32: Iron-catalyzed sulfenylation of indole derivatives, as presented by J. Yadav and coworkers.[172] 
In 2014, X.-G. Zhang, J.-H. Li and coworkers extended the scope of the sulfenylation protocol 
to electron-rich aniline derivatives (Scheme 33).[173] In their procedure, equimolar amounts of 
diaryldisulfides and additional catalytical amounts of iodine (10 mol%) are used. Furthermore, 
iron (III)chloride has been replaced by iron(III)fluoride for the efficient synthesis of several 
diarylsulfides. The authors postulate the in situ formation of sulfenyl iodide as the reactive 
species but did not present any experimental support of this idea.  
 
Scheme 33: Synthesis of 4-chalcogensubstituted arylamines, as described by X.-G. Zhang, J.-H. Li and 
coworkers.[173] 
Since the yield of the reported iron-catalyzed transformations might be significantly affected by 






1.4.1.5 Miscellaneous transition metal-based transformations  
In addition to protocols based on palladium, copper, nickel, and iron, complexes of other 3d 
and 4d metals are also known to be useful catalysts in the synthesis of aryl sulfides.  
From the family of 3d metals, manganese-,[174]; cobalt-[175] and zinc-derived catalysts[176] have 
been applied for the synthesis of aryl sulfides. Further representatives of 4d metal derivatives 
with catalytic activity in the synthesis of diaryl sulfides are for example rhodium-based systems. 
As reported by various authors, rhodium(III) catalysts can be utilized for the sulfenylation of 
unactivated arenes with diaryldisulfides.[177,178] In such cases, the directed sulfenylation of 
arene C–H bonds requires the addition of an external oxidant like silver(I) salts to increase 
both the conversion and the yield. In some cases the over-stoichiometric use of the disulfide 
as well as high temperatures (130 °C) were necessary.[177] Remarkably, selective rhodium-
catalyzed substitution reactions of aryl fluorides with disulfides and the cross-coupling of 
boronic acids with S-aryl thiosulfonates have been reported.[179] Some other 4d metals like 
silver were utilized in the synthesis of aryl sulfides as well.[180]  
1.4.1.6 Photomediated approaches 
Recently, the utilization of photoredox catalysts for the preparation of aryl thioethers has 
become an emerging field in catalysis. Apart from organic photocatalysts (see mainly Chapter 
1.4.2.1), 4d and 5d transition metal complexes of ruthenium and iridium have been reported to 
be useful in the synthesis of aryl sulfides.  
In 2018, A. Polyzos et al. utilized Ir(ppy)3 for the photoredox-catalyzed thiolation of (hetero)aryl 
iodides at room temperature (Scheme 34).[181] The reaction tolerated several functional groups 
and provided the desired aryl thioethers in good to excellent yields. The reported 
transformation was compatible with a wide range of aryl, heteroaryl and vinyl iodides but was 
limited to dialkyl disulfides as precursors. Moreover, the latter must be used in a large excess. 
This makes this aryl radical-controlled protocol less economical for industrial purposes 
compared to previously reported procedures. 
 
Scheme 34: Application of visible light-induced photoredox catalysis for the synthesis of alkyl sulfides, as 




One year before, H. Fu et al. already reported on the similar synthesis of diaryl sulfides from 
aryl thiols.[182,183] The procedure allowed the selective sulfenylation of aryl iodides, bromides 
and chlorides and was even extendable to heteroaryl iodides and bromides as well as to aryl 
fluorides bearing electron-withdrawing groups.  
The authors propose a SET-based[181b] oxidation of the thiolate by the excited Ir(III) 
photocatalyst forming the sulfenyl radical and the reactive Ir(II) species, which can reduce the 
aryl halides substrate to the corresponding radical anion. The latter undergoes a nucleophilic 
substitution with a thiolate, whereby the desired carbon-sulfur bond is formed and the halide 
anion is released. The initially formed sulfur-centered radical oxidizes the finally obtained 
sulfur‐centered radical anion of the formed diaryl sulfide, and the desired product is obtained.  
 
Scheme 35: Photocatalytical synthesis of diaryl sulfides from aryl halides and thiols.[182] 
Additionally, examples of thioetherification via dual photoredox/nickel catalysis have been 
reported in literature.[184] 
The full potential of photocatalysts for the formation of sulfur–carbon bonds has been 




1.4.2 Transition metal-free protocols 
Apart from transition metal-catalyzed reactions, several transition metal-free approaches have 
been reported in the literature. These methodologies have the advantage, that they do not 
provoke the risk of toxic heavy metal contaminations of the desired products. This is of 
particular interest in the final steps of the synthesis of pharmaceutically active compounds.  
Regulatory standards of the Food and Drug Administration (FDA) as well as the ICH guidelines 
on elemental impurities of the European Medicine Agency (EMA) claim very low metal 
concentration, especially for elements like Co, Pd, Rh and Ru.[186] 
From a historical point of view, the transition metal-free synthesis of aryl sulfides has been 
already realized in the first half of the last century through nucleophilic aromatic substitution 
reactions (SNAr) of aryl thiolates with electron-poor arenes, like nitrobenzene derivatives 
(Scheme 36).[187] The mechanism of this reaction involves a two-step addition-elimination 
sequence with a non-aromatic intermediate Meisenheimer complex 42. By elimination of the 
leaving group (LG), the aromaticity of the system is regenerated and the final diaryl sulfide is 
released. Depending from the substitution pattern on the arenes, a concerted mechanism is 
proposed as well. Detailed studies on the influence of substituents have been recently reported 
by E. N. Jacobsen and coworkers.[188]  
 
 





An alternative, traditional transition metal-free protocol for the synthesis of diaryl sulfides is the 
Stadler-Ziegler reaction, which utilizes aniline-derived aryl diazonium salts 43 and thiolates 
(Scheme 37).[189] The desired C–S bond is formed under evolution of equimolar amounts of 
nitrogen and involves the formation of very active radical intermediates which can lead to the 
formation of by-products. The other drawbacks of this protocol are its multi-step synthetic chain 
starting from aniline precursors and, more importantly, the potentially explosive nature of the 
diazonium salts.  
 
Scheme 37: Stadler-Ziegler reaction for the synthesis of aryl sulfides following a radical mechanism. 
 
One strategy for reducing the risk of this transformation is to generate the diazonium species 
in situ and their subsequent reaction with the thiolate, as proposed by C.-F. Lee et al.[190] Due 
to the restrictive requirements for the nature of the substrates and the resulting limitation of the 
accessible structure motifs, the development of novel transition metal-free protocols is a 
desirable aim in modern organic synthesis. In recent decades, many groups have invested 
huge effort on the elaboration of general protocols for the metal-free synthesis of aryl sulfides 
because of their tremendous impact in different research fields (compare Chapter 1.2). In this 
Chapter, modern transition metal-free protocols for the synthesis of aryl sulfides will be 
discussed. Starting with new developments in the radical-controlled sulfenylation reaction, 
which demonstrate broader applicability than the historical Stadler-Ziegler reaction, new 
strategies for the sulfenylation of arenes with nucleophilic sulfur reagents will also be discussed 
in selected examples. 
Since the nucleophilic sulfenylation methodologies require the pre-functionalization of the 
arene before the sulfenylation step and most radical-driven approaches tend to form by-
products, alternative electrophilic sulfenylation reagents were developed in recent decades. In 
this way, the disadvantage of pre-functionalization could be overcome and a more atom-
economical synthesis of aryl sulfides could be made possible. This new strategy will be 





1.4.2.1 Radical sulfenylation reactions 
A. P. Antonchick and coworkers reported the ability of nitrosoniums ions to catalyze the 
carbon–sulfur bond formation via C–H/S–H cross-dehydrogenative coupling of thiols with 
phenol and indole derivatives (Scheme 38).[191] In this reaction ambient O2 serves as a terminal 
oxidant for the regeneration of the catalytically active nitrosonium ion. The reaction was carried 
out in hexafluoroisopropanol (HFIP) which enables a sufficient stabilization of the reactive thiyl 
radical intermediates. 
 
Scheme 38: Nitrosonium-catalyzed coupling of phenols or indoles with aryl thiols, as reported by A. P. Antonchick 
and coworkers.[191] 
 
Another radical-based sulfenylation has been presented by the group of A. Lei who utilized 
2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) as an oxidant for the radical-recombinative 
cross-coupling of electron-rich arenes and aryl thiols (Scheme 39).[192] The reaction of thiyl 
radicals 44 with an in situ generated arene radical resulted in the formation of several 
unsymmetrical aryl thioethers. The authors substantiated their proposed mechanism by 
identifying all postulated radical intermediates by means of radical trapping experiments and 
identified the SET-based formation of an aryl radical cation as the rate-determining step. 
 
Scheme 39: DDQ-controlled selective radical-radical cross-coupling of thiols with electron-rich arenes, as 





Recently, visible light-promoted radical-based transformations for the formation of 
diarylsulfides were published by several groups. 
X. Jiang et al. presented a protocol which allows the sulfenylation of diaryliodonium salts 45 
with organic thiosulfates. The reaction is promoted by blue LED radiation with Eosin Y (46) as 
a photatalyst (Scheme 40).[193] The procedure allowed the synthesis of several diaryl sulfides 
and alkylaryl sulfides in moderate to excellent yields in gram-scale from commercially available 
thiosulfate salts as staring materials. Mechanistic studies of X. Jiang et al. revealed that the 
first step of the reaction is a single electron transfer (SET)[181b] of the photoexcited Eosin Y to 
the aryliodonium species which subsequent formation of an aryl radical. Afterwards, the radical 
reacts with the thiosulfate to form the desired new sulfur-carbon bond and a sulfite as a leaving 
group. Finally, the obtained diaryl sulfide radical is reduced by the initially generated EY+∙ to 
regenerate the photocatalyst. 
 
Scheme 40: Eosin Y-promoted photocatalytic reaction of thiosulfate salts with diaryl iodonium salts for the 
synthesis of diaryl sulfides, as presented by X. Jiang et al.[193] 
An additional methodology for the photocatalytical formation of diarylsulfides was reported by 
A. Hajra et al.[194] The authors published a light-mediated oxidative coupling of arlylhydrazines 
with thiols. The transformation was photocatalyzed by rose bengal (47) and used air as an 
oxidant (Scheme 41). This allowed the synthesis of up to 33 unsymmetrical diaryl sulfides and 
aryl heteroaryl sulfides with electron-withdrawing as well as electron-donating substituents but 
did not tolerate proton-donating functional groups, e. g. alcohols and amines. In addition, the 
transformation was successfully extended towards selenides. The radical mechanism was 
proposed for the reaction: by stepwise oxidation of the arlylhydrazine, an arylradical is 
generated under evolution of gaseous N2. Based on radical-trapping experiments it was 
proposed that the aryl radical reacts with the in situ generated aryl disulfide under formation of 





Scheme 41: Rose bengal (47)-catalyzed oxidative coupling of phenyl hydrazines and thiols in the synthesis of 
unsymmetrical diarylsulfides presented by A. Hajra et al.[194] 
 
Recently, M. Miyake and coworkers designed a photo-catalyst-free protocol using simple aryl 
halides (X = I, Br, Cl) and thiols for the synthesis of unsymmetrical diarylsulfides (Scheme 42, 
A). Based on detailed DFT-studies the authors proposed a photoinduced intermolecular 
charge transfer process within the electron donor-acceptor (EDA) complex between the aryl 
halide and the thiolate (see Scheme 42 , B), followed by the radical combination of the aryl 
radical with the thiyl radical. This highly atom-economical reaction was scalable up to 50 mmol 
and allowed the late stage functionalization of pharmaceutically relevant compounds. Since 
the formation of a sufficient EDA complex with suitable geometry and energy of the HOMO of 
the thiolate and the LUMO of the aryl halide is crucial for the reaction to take place, neither 
arylheteroaryl sulfides, nor arylalkyl sulfides were accessible by this protocol. 
 
Scheme 42: Transition metal-free visible light-promoted synthesis of diarylsulfides presented by M. Miyake and 
coworkers.[195] 
 
The utilization of visible light as an energy source is a fundamental improvement of previously 
reported protocols, which used UV radiation and liquid ammonia as a solvent for the formation 
of the radicals. Due to the high energy radiation, the applicability of this methodology was 
limited to rather simple diarylsulfides.[196] 
Further applications of sulfur radicals in the area of organic chemistry have been recently 




1.4.2.2 Nucleophilic sulfenylation reactions 
As mentioned above (see Scheme 36), in a nucleophilic sulfenylation reaction, the sulfur in a 
sulfenylation reagent is formally negatively charged and reacts with a pre-functionalized 
electrophilic arene. Typical electrophiles for this purpose are, for example, aryl halides. 
Alternatively, diaryliodonium salts can also be sulfenylated in this fashion by thiols or alkyl 
thioethers. As reported by M. S. Sanford et al., several different diaryliodonium salts 48 form 
new sulfur-carbon bonds with alkyl/aryl thiols or alkyl thioethers (Scheme 43, A).[198] The 
authors proposed a mechanism based on the oxidative formation of sulfonium intermediate 49 
(Scheme 43, B). Subsequently, the intermediate undergoes a nucleophilic substitution with 
residual trifluoroacetate, and the desired aryl thioethers is formed under release of trifluroacetic 
acid (50, R = H). The disadvantage of this protocol is the formation of stoichiometric amounts 
of aryl iodides as a by-product. Furthermore, in cases where alkyl thioethers (R = Me or Bu) 
are used as sulfur-containing precursors, the desired aryl thioether is formed along with 
trifluroacetate ester (R = Alkyl) as a side product. 
   
Scheme 43: A: Diaryliodonium salt-promoted formation of aryl sulfides reported by M. S. Sanford et al.; B: 
Proposed mechanism of the transformation.[198]  
 
Electrophilic diaryliodonium salts can also be generated in situ, as presented by J. A. Campbell 
et al.[199] (Scheme 44). The authors activated electron-rich (hetero)arene substrates with 
phenyliodine(III) bis(trifluoroacetate) (PIFA) to generate a (hetero)diaryliodonium intermediate 
51 which undergoes C–S bond formation with thiols in the same fashion as described by M. S. 
Sanford et al.[198]. The reaction shows a high functional group tolerance, however, required an 





Scheme 44: Concept of the PIFA-mediated sulfenylation of electron-rich (hetero)arenes like indole derivatives.[199] 
 
1.4.2.3 Electrophilic sulfenylation reactions 
An efficient way to activate and functionalize electron-rich (hetero)arenes or carbanions is the 
usage of Lewis-acidic, electrophilic sulfenylation reagents. Such sulfur-based electrophilic 
reagents as 52 can be envisaged by attaching a strong electron-withdrawing group (EWG) 
onto the sulfur atom. This results in an inversion of its polarity (Figure 14).  
 
Figure 14: Concept of Umpolung to invert the electronic character of a thiol into an electrophilic sulfur reagent 
and the reaction with carbonucleophile (A) or an electron-rich arene (B). 
As a result of the Umpolung, the sulfur reagent 52 can either react with strong carbon 
nucleophiles e.g. a Grignard reagent (Figure 14, pathway A) or undergo an electrophilic 
aromatic substitution reaction (SEAr) with mainly electron-rich arenes to form a new carbon-
sulfur bond (Figure 14, pathway B).  
An example of the reaction of a carbon-nucleophiles with such an electrophilic sulfenylation 
reagent has been published by C.-F. Lee et al. (Scheme 45).[200] The transformation is based 
on the in situ generation of sulfenyl chloride 52 with EWG = Cl, which is formed in the reaction 
of the corresponding thiol with N-chlorosuccinimide (NCS). By subsequent reaction of 52 with 
a Grignard reagent a new carbon-sulfur bond is formed. The protocol gave access to a broad 
range of different aryl thioethers, but the functional group tolerance is limited due to the 





Scheme 45: One-pot synthesis of aryl sulfides by in situ formation of sulfenyl chloride its and subsequent reaction 
with a Grignard reagent, as presented by C.-F. Lee et al.[200] 
 
Apart from sulfenyl chlorides (52, EWG = Cl), sulfenyl thiocyanates (52, EWG = CN) can also 
react in similar fashion with these strong carbon nucleophiles. For example, sulfenyl pyrroles 
have been synthesized in this way from 2-(thiocyanato)pyrrole derivatives and Grignard 
reagents, albeit in low yields.[201] 
In this Subchapter further different electrophilic sulfur reagents for the electrophilic 
sulfenylation of (hetero)arenes will be discussed based on thenature of the sulfur-containing 
starting materials. Additionally, further versatile applications of these electrophilic sulfenylation 
reagents will be highlighted in selected examples. 
N-(Alkyl/arylthio)succinimides 
The succinimide group possesses suitable electron-withdrawing abilities for the Umpolung of 
thiols, as it was demonstrated by J. Cossy and coworkers (Scheme 46). The authors showed 
that N-(arylthio)- and N-(alkylthio)succinimides 53 can be used as sulfenylating reagents in the 
reaction with (hetero)arenes. By addition of an excess of trifluoroacetic acid (TFA) to N-
thiosuccinimides it was possible to convert several arenes[202] and indole derivatives[203] into 
the corresponding unsymmetrical thioethers. Due to the strong acidic conditions the functional 
group tolerance of this protocol was limited. Additionally, a general drawback of this 
methodology is that each N-(alkyl/arylthio)succinimide has to be synthesized separately from 
the corresponding thiol, sulfuryl chloride and succinimide.  
 
Scheme 46: Synthesis of unsymmetrical thioethers with N-(arylthio)- and N-(alkylthio)succinimides from 





Further studies on N-(arylthio)succinimides-based systems were conducted by J. L. Gustafson 
et al.[204] who could further improve the protocol by lowering the TFA loading to 10 mol% and 
using bis(p-methoxyphenyl) selenide (54) as an organocatalyst (Scheme 47). The authors 
proposed that the reaction reported by J. Cossy and coworkers proceeds by an autocatalytic 
mechanism whereby already formed thioethers 55 aggregated with residual protonated N-
(arylthio)succinimides. The obtained activated species 56 can easily react with arene 
substrates to give an additional molecule of the desired product 55. The formation of 56 is very 
slow and gives low yields in cases where the N-(arylthio)succinimides features an electron-
poor arene R1.  
In those cases (e.g. R1 = p-phenylazide), the addition of organocatalyst 54 can increase the 
yield of the desired unsymmetrically substituted thioethers by a factor up to 11, since the 
reaction pathway via intermediate 57 is favored. Due to the utilization of 54 J. L. Gustafson et 
al. could use an equimolar amount of TFA or 10 mol% of TfOH which makes the reaction more 
atom-economical compared to previous reaction conditions. Additionally, the authors 
expanded the scope of their elaborated protocol by using N-(trifluoromethylthio)saccharine to 





Scheme 47: Mechanistical and catalytical studies on the N-(arylthio)succinimides-based sulfenilation with 
additional improvements of the protocol by using organocatalyst 54.[204] 
Apart from selenide 54, J. L. Gustafson et al. showed that conjugate thiourea-based Lewis 
base-Brønsted acid catalysts 59 can facilitate the activation of N-(arylthio)succinimides for the 
sulfenylation of indole and pyrrole derivatives (Scheme 48).[205] Due to the high molecular 
weight and complicated synthesis of the thiourea the employment of this methodology on 
industrial scale is debatable.  
 
Scheme 48: Application of thiourea 59 as a catalyst for the formation of unsymmetrical thioethers in the 




Furthermore, catalyst- and acid-free protocols avoiding contaminations from transition metals 
have been reported by H. Fu et al. for the arylthiolation of aniline derivatives with N-
(arylthio)succinimides.[206] However, this reaction demands more harsh reaction conditions 
such as elevated temperature (100 °C) and longer reaction times (up to 30 h). This results in 
the formation of diarylthiolated side-products 
N-(alkyl/arylthio)phthalimides 
Besides N-(arylthio)- and N-(alkylthio)succinimides, the corresponding phthalimides can react 
in a similar fashion with electron-rich arenes and heteroarenes.  
As reported by A. Thompson et al., several pyrroles can be transformed into their 2-sulfenyl 
derivatives by reaction with different thiophthalimide reagents 60 (Scheme 49; R2 = alkyl, 
aryl).[207] The authors demonstrated that (semi)catalytic amounts of a Lewis acid like MgBr2 are 
crucial for the selective formation of the desired C-S bond in an electrophilic aromatic 
substitution reaction. 
 
Scheme 49: Reaction of pyrroles with N-(alkyl/aryl)succinimides presented by A. Thompson et al. [207]  
Apart from MgBr2 other Lewis acids like AlCl3[208], TiCl4[208] , BF3•Et2O[209], CeCl3 7•H2O[210] or 
anhydrous CeCl3[211] have been reported to catalyze the formation of unsymmetrical 
diarylsulfides from N-(alkyl/arylthio)succinimides or -phthalimides and (hetero)arenes. 
In 2015, F. Glorius and coworkers extended the phthalimide-based protocol towards the 
synthesis of trifluoromethylthioethers of pyrroles, indoles and further electron-rich N-hetero-
arenes (Scheme 50).[212] Additionally, the methodology allows the late-stage functionalization 
of pharmaceutically relevant compounds.  
 
Scheme 50: Extension of phthalimide-based protocol to trifluoromethylthiolation of (hetero)arenes, as presented 




In the same year, L. Lu, Q. Shen et al. reported a similar phthalimide-based reagent for 
difluorothiomethylation reactions. Its reaction with electron-rich (hetero)arenes proceeded at 
80–120 °C in DCE and required addition of overstoichiometric amounts of trimethylsilyl 
chloride, affording a variety of difluorothiomethylated compounds.[213]  
The conspicuous electrophilicity of N-(arylthio)succinimides and -phthalimides can also be 
used for the activation of alkenes in the process of aryl thioether formation. S. E. Denmark and 
coworkers reported an enantioselective sulfenocyclization of polyenes (Scheme 51).[214] The 
transformation proceeded with participation of selenocatalyst 61 and was extendable to 
geranylphenoles. The highest diasteriomeric ratio of up to 93:7 was obtained in 
hexafluoroisopropyl alcohol (HFIP) as a solvent. Additionally, the enantioselective syntheses 
of (+)-ferruginol (62) and (+)-hinokiol (63) along this path showed the value of the presented 
methodology.  
 
Scheme 51: Enantioselective sulfenocyclization with N-(arylthio)phthalimide (PhthSAryl) employing 
selenocatalyst 61.[214]   
 
Furthermore, N-(arylthio)succinimides and alcohols can be used for the oxysulfenylation of 
alkenes like styrenes. H. Fu et al. reported on the selective functionalization of activated and 
deactivated styrene derivatives (Scheme 52). The authors proposed the participation of 





Scheme 52: Oxysulfenylation of alkenes by N-(arylthio)succinimides in the presence of an alcohol, as reported by 
H. Fu et al.[215] 
 
In situ generation of sulfenyl chlorides and iodides from thiols  
Apart from thiosuccinimides and thiophthalimides, also sulfenyl halides can be used for the 
sulfenylation of arenes following an electrophilic aromatic substitution (SEAr) pathway due to 
the high electronegativity of halides, as mentioned in the beginning of the Chapter. In many 
cases the sulfenyl halides are generated in situ because of their high reactivity and instability.  
An example of the in situ formation of sulfenyl chloride was published by K. M. Schlosser et al. 
(Scheme 53).[216] In the protocol they presented, the activation of the thiol was achieved by N-
chlorosuccinimide (NCS). The obtained sulfenyl chloride (65) reacted under mild conditions 
with a wide range of indoles tolerating several other functionalities. The methodology was 
further expanded by S. Adimurthy and coworkers towards the regioselective sulfenylation of 
imidazoheterocycles at room temperature.[217] 
 
Scheme 53: Procedure for the 3-sulfenylation of indole elaborated by K. M. Schlosser et al.[216] 
One of the major disadvantages of the utilization of sulfenyl chlorides is their uncontrolled 
reactivity. Sulfenyl chlorides are known to undergo multifold addition reactions with electron-
rich heteroarenes. The mechanism of the twofold sulfenylation of indoles was studied in detail 





In contrast to this, in situ generated aryl sulfenyl iodides can overcome these limitations, as 
they exhibit much milder reaction behavior. As reported by R. K. Peddinti et al.,[219] the 
dehydrogenative coupling of in situ generated from thiols sulfenyl iodides with electron-rich 
arenes like aniline, methoxy- or hydroxyl-substituted arenes as well as hydroxylcoumarines 
gives only the desired monothiolated products (Scheme 54).[219] The authors proposed a 
catalytic cycle, in which the formed hydroiodic acid is oxidized by DMSO to regenerate iodine 
with the release of water and dimethylsulfide.  
 
Scheme 54: Iodine-catalyzed cross-coupling of thiols with electron-rich arenes presented by R. K. Peddinti et 
al.[219]  
In situ generation of sulfenyl iodides from diarylsulfides 
Very similar, but disulfide-based iodine-catalyzed sulfenylations of indoles via in situ 
generation of sulfenyl iodides and utilizing DMSO as a co-oxidant are described in the 
literature.[220][221] Although the latter protocol, reported by the group of A. L. Braga, allowed the 
sulfenylation of indole derivatives, it revealed poor functional group tolerance, essentially 
limited to methoxy- and bromoindoles (Scheme 55, A).[221] Again, in the proposed mechanism 
DMSO oxidizes the in situ generated hydroiodic acid to iodine (Scheme 55, B). 
 





Apart from the presented electrophilic sulfenylation pathways based on sulfenyl iodide, 
diaryldisulfides can also react with electron-rich hetero arenes to give access to various aryl 
sulfides. In this case iodate is the catalyst of choice, as reported by A. L. Braga and coworkers 
in a consecutive publication (Scheme 56, A).[222] The authors proposed the initial activation of 
heteroarene by the iodate anion furnishing intermediate 66 followed by intramolecular proton 
transfer and release of a hydroxide anion (Scheme 56, B). Subsequently, the nucleophilic 
attack on the disulfide liberates an aryl thiolate and leads to the formation of the desired C–S 
bond in the intermediate 67. Nucleophilic attack of hydroxide on the latter regenerates the 
iodate anion.  
The generated thiolate is oxidized by air to give disulfide RSSR which then can react again as 
discussed above. The methodology was furthermore extended to diaryldiselenides giving 
access to electron-rich seleno-ethers.  
 
 
Scheme 56: Direct C-H sulfenylation of indoles and imidazo-pyridines with disulfide in an iodate-catalyzed fashion 





In several previously published protocols, the same reaction was carried out with electron-rich 
(hetero)arenes applying one equivalent of disulfide and additional base at elevated 
temperature under an inert atmosphere (Scheme 57).[223,224] The drawback of this historical 




Scheme 57: General concept of former disulfide-based sulfenylation resulting in the release of equimolar 
amounts of thiolate as side-product.[223,224] 
In situ generation of sulfenyl chlorides from arylsulfonyl chlorides 
Apart from the already discussed approaches, sulfenyl chlorides can be generated in situ by 
reduction of arylsulfonyl chlorides with triphenylphosphine. This methodology allows the 
synthesis of di(hetero)aryl sulfides from electron-rich (hetero)arenes as indolizines, indoles 
and trimethoxybenzene (Scheme 58). Results of J. You et al. demonstrated that 
triphenylphosphine is superior to other reducing agents like TMSCl or P(OEt)3, as it led to the 
highest yields of the arylsulfide.[225] This protocol based on previous work by K. B Sharpless 
and coworker who showed, that more expensive trimethyl phosphite (MeO)3P can be used for 
the reduction of sulfonyl chlorides as well.[226] 
 
Scheme 58: Synthesis of diarylsulfides from arylsulfonyl chlorides via in situ reduction of the latter with PPh3, as 
presented by J. You et al.[225] 
On the other hand, the work of J. You et al. was inspired also by the studies of M. Raban et al. 
who performed detailed investigations on the reactions of arenesulfenyl chlorides with 
phosphines already in the early 1980.[227]  
Furthermore, A. T. Radosevich et al. designed a protocol for organophosphorus-catalyzed 
deoxygenation of sulfonyl chlorides which uses phenylsilane as a reducing agent (Scheme 
59).[228] Mechanistic investigations indicate that the phosphacyclic catalyst 68 is involved in the 
reaction of the in situ generated sulfenyl chloride with the electron-rich heteroarenes. The 




chloride. Unfortunately, the scope of this reaction was limited to indoles. Notwithstanding, the 
authors demonstrated that the methodology also enables the trifluoromethylthiolation, 
perfluoroalkylthiolation and alkylthiolation of indoles. 
 
Scheme 59: Organocatalytic sulfenylation of indole derivatives using sulfonyl chlorides as sulfur-containing 
precursor and phenylsilane as reductant.[228] 
 
In situ generation of sulfenyl iodides from sulfonyl hydrazines 
Several transition metal-free C-H thioarylations using sulfonyl hydrazines have been recently 
published. The majority of the reported procedures used iodine as a catalyst to generate the 
reactive species. Interestingly, S.-K. Tian et al. postulated the participation of intermediates 69 
and generated from this sulfenyl iodide 70: the both can react with such electron-rich 
heteroarenes as indole derivatives (Scheme 60).[229] In contrast, R. Yan, G. Huang and 
coworkers presented a mechanism mainly based on sulfenyl iodide 70 as a sole reactive 
species (Scheme 60).[230] In both protocols harsh conditions (THF, 100 °C[230] or EtOH, 
70 °C[229]) were required to transform indole derivatives[229,231] or naphthols/naphthylamines[230] 
into the desired thioethers. Additionally, these reactions were limited to a very narrow substrate 
scope but gave the desired products in good to excellent yields. On the other hand, electron-






Scheme 60: Iodine-catalyzed sulfenylation of indole derivatives[229] and naphthols/naphthylamines[230] (X = O, NH) 
using sulfonyl hydrazine as a precursor. 
The scope of arenes was further extended to benzo[b]furanes by X. Zhao, K. Lu and 
coworkers.[232] In their protocol, heating in 1,4-dioxane at 120 °C was necessary for the 
conversion of different furane derivatives into the corresponding thioethers.  
Sulfenyl iodides 70 are also capable to activate alkenes and alkynes. This was shown by S.-
K. Tian et al. who presented the oxysulfenylation of alkenes with sulfenyl hydrazine in the 
presence of catalytical amounts of iodine (Scheme 61).[233] The authors postulated nucleophilic 
ring opening of the thiiranium intermediate 71 with the participating alcohol as a key 
mechanistic step. This reaction gave access to several β-alkoxy aryl/alkyl sulfides starting from 
alkyl or aryl sulfenyl hydrazines. 
 
Scheme 61: Three-component oxysulfenylation reaction of alkenes presented by S.-K. Tian et al.[233] 
Furthermore, X. Zhao, K. Lu et al. activated the alkyne moieties upon electrophilic cyclization 
of 2-alkynylphenol derivatives with in situ generated thiodiazonium iodide 69.[232] The formation 




obtain the desired 3‑arylthio benzo[b]furans in moderate to good yield, and the reaction did 
not require inert conditions. 
 
Scheme 62: Oxysulfenylation of akynes with an internal alcohol and sulfenyl hydrazine as a sulfur precursor 
presented by X. Zhao, K. Lu et al.[232] 
 
In situ generation of sulfenyl iodides from S-arylthiosulfates: 
An alternative sulfur sources for the iodine-catalyzed synthesis of 3-thioindoles are S-
arylthiosulfates (Bunte salts). Bunte salts are commercially available and easy to handle. The 
protocol of T. Zhang, M. Luo et al. utilizes a catalytic amount of iodine for the in situ generation 
of sulfenyl iodides 70 which react with certain indole derivatives (Scheme 63).[234] The authors 
used DMSO as a solvent and also as an oxidizing agent for iodine regeneration the catalytic 
cycle.  
 
Scheme 63: Bunte salts as a sulfur source for the C3-sulfenylation of indole derivatives, as presented by T. 





In situ generation of sulfenyl iodides from sulfinates 
Under catalysis with iodine, sulfenyl iodides 70 can also be generated in situ from sulfinates, 
which are easy-to-handle salts. As presented by G.-J. Deng et al. (Scheme 64, A), upon 
treatment with the sulfinate/I2/DMSO system indoles were converted into the corresponding 3-
sulfenylated derivatives in 39–93% yield.[235] Diethyl phosphite was used as an additive in the 
initial step to generate diaryl disulfide, which then was converted with elemental iodine to form 
the reactive sulfenyl iodide. The subsequent reaction with indoles resulted in the formation of 
the desired sulfides. Due to the iodine-mediated in situ formation of sulfenyl iodide, the process 
resulted in selective monosulfenylation, whereas control experiments with disulfide as a 
starting material lead to the formation of twice sulfenylated by-products. Based on their initial 
observations, in the subsequent publication F. Xiao, Y. Liu, G.-J. Deng et al. described the 
chemoselective cross-coupling of thus generated sulfenyl iodides 70 with different phenols for 
the synthesis of alkylaryl sulfides and diaryl sulfides in water (Scheme 64, B).[236] In the case 
of electron-rich aryl sulfinates the products were obtained in lower yields. As for the reactions 
discussed above, the authors proposed a mechanism involving sulfenyl iodide 70 as the 
reactive intermediate.  
 
Scheme 64: Sulfenylation of indoles[235] (A) and of phenol derivatives[236] (B) using sulfinate salts as sulfur-
containing precursors and iodine at elevated temperatures. 
Furthermore, iodine/triphenylphosphine-mediated protocol for the sulfenylation of indols[237] as 







The unusual sulfenylation reagent 72, bearing a highly active quinone O,S-monoacetal moiety, 
was presented by Y. Kita et al. (Scheme 65).[239] In their communication, 72 was activated by 
TMSOTf and caused sulfenylation of different electron-rich arenes and heteroarenes like 
indols, dimethoxybenzene derivatives and 2-methoxynaphtalene as well as thiophenes and 
furans. As the methodology was limited to the transfer of pentafluorophenylthio groups, only 
corresponding thioethers were accessible. The authors suggested that the driving force of the 
reaction was the aromatization of the quinone.  
 





In situ generation of sulfonium salts from sulfoxides 
As reviewed by V. G. Nenaidenko et al.[240,241] and recently by M. Alcarazo et al.,[240,241] 
sulfonium salts are a valuable compound class with several new synthetic capabilities, which 
can be utilized as electrophilic sulfenation reagents. In 2016, D. J. Procter and coworkers 
reported the first protocol for the synthesis of electrophilic sulfenylation reagents starting from 
sulfoxides (Scheme 66).[242] Hereby, the direct C–H thioarylation of unfunctionalized arenes 
was achieved by activation of arylsulfoxide 73 with trifluoromethanesulfonic anhydride (Tf2O) 
to form the electrophilic sulfur species 74 which reacts with different arenes. The scope of the 
reaction included electron neutral benzene derivatives such as toluene as well as several 
hetero arenes. Due to the activation of the sulfoxide by Tf2O, protic functional groups like 
alcohols, thiols and primary amines were not tolerated by the protocol.  
 
Scheme 66: Sulfonium triflate 74-based protocol for the synthesis of diarylsulfides from aryl sulfoxides and 
arenes without any further pre-functionalization.[242] 
A similar reagent was recently used by H. Du, J. Xu, P. Li et al. for the electrophilic cyclization 
of aryl substituted internal alkynes (Scheme 67, A).[243] Similar to the protocol of D. J. Procter 
and coworkers,[242] H. Du, J. Xu, P. Li et al. used a nitrogen base for the nucleophilic 
substitution in intermediate 75 which resulted in release of the final sulfide (Scheme 67, B). 
 
Scheme 67: A: Electrophilic cyclization initialized by in situ generated sulfonium triflates presented by H. Du, J. 




2 Design of the project 
2.1 State of the art 
2.1.1 Thioimidazolium reagents from the Alcarazo group 
As recently published by M. Alcarazo and coworkers, imidazoline-2-thione derivatives are a 
powerful platform for the synthesis of new electrophilic group-transfer reagents. In 2015, M. 
Alcarazo, G. Talavera et al. reported the synthesis and application of imidazolium based 
reagents 76 and 77 for the electrophilic cyanation and alkynylation of several nucleophiles 
(Scheme 68).[244] The transfer of the [CN]+ to unfunctionalized (hetero)arenes was catalyzed 
by substoichiometric amounts of BF3∙Et2O. In case of S-, C- or N-centered nucleophiles 
equimolar amounts of Hünig base were required. The alkynylation of thiols or carbanions with 
a [C≡CR]+ synthon derived from reagent 77 illustrated the high potential of imidazolium 
sulfuranes for the Umpolung of functional groups. Additional work by M. Alcarazo, A. Barrado 
et al. reported on the chlorocyanation of alkynes with 76 in the presence of BCl3.[245] 
 
Scheme 68: Electrophilic cyanation (A) and alkynylation (B) utilizing imidazolium based reagent 76 and 77 as 





In a subsequent publication, M. Alcarazo and coworkers presented a series of distinct 
alkynylthioimidazolium salts 80 which can be utilized for the electrophilic thioalkynylation of C-
centered nucleophiles. The synthesis of this versatile reagents follows a two-step protocol. 
After initial bromination of imidazoline-2-thione 78 with elemental bromine, one bromide atom 
of the obtained dibromo(imidazolium)sulfurane 79 is substituted by an alkynyl residue upon 
treatment with organozincates (Scheme 69, A).[246] The authors reported that the well 
characterized salts 80 allow an easy access to dialkynyl sulfides and aryl alkynyl sulfides as 
well as alkyl alkynyl sulfides by reaction with Grignard reagents. During the electrophilic attack 
of the latter on the thioalkynyl moiety of the reagent, an imidazole carbene 81 is released as a 
leaving group and a formal RS+ synthon is transferred (Scheme 69, B). Additionally, Alcarazo 
et al. were able to extend the protocol towards alkynyl seleno ethers.  
 
 
Scheme 69: Electrophilic thioalkynylation of Grignard reagents with alkynylthioimidazolium salts recently 
presented by M. Alcarazo, J. Peňa et al.[246]; A: Synthesis of thioalkynylation reagent 80; B: Thiosulfenylation of 
C-centered nucleophiles. 
 
2.1.2 Thiourea derivatives as sulfur-containing precursors 
As recently reported by the group of W. Yi et al., the C–H activation of electron-rich 
(hetero)arenes by iodinated thiourea is a useful methodology for the formation of carbon-sulfur 
bonds in difluoromethylthiolation reactions.[247] The cationic sulfides 82 obtained from thiourea 
or imidazolium analogues can undergo hydrolysis or aminolysis upon heating with a base (e. 
g. NaOH/H2O, 90 °C; K2CO3/H2O, 80 °C or Na2CO3/wet PEG 200, 120 °C) to afford the 





Scheme 70: Thiolation of electron-rich (hetero)arenes with TMTU as sulfur-containing precursor 
Surprisingly, no study on the corresponding initial C–H activation of (hetero)arenes with 
halogenated imidazole-2-thiones has been reported to date, even if the electronic structure of 
those (dihalo)imidazothions has been already discussed in detail in the literature.[250] The only 
published methodologies for the synthesis of analogous to 82 arylthioimidazolium salts 83 are 
based on the alkylation of imidazole thioethers by strong alkylation reagents like alkyl 
iodides,[248,251] by reaction of a imidazole carbene with a diaryldisulfide[252] or by treatment of 2-
chlorimidazolium salts with thiolates (Scheme 71).[253] However, compounds 83 were never 
used for the synthesis of unsymmetrical thioethers. 
  
 





2.2 Project aim 
The aim of the project is the development of a modular and transition metal-free protocol for 
the straightforward synthesis of un-symmetrical aryl sulfides based on the reaction of two 
nucleophiles a sulfur-containing reagent (Scheme 72). These reagents can then be considered 
as a [S]2+ synthetic equivalents. This is of special interest, because nearly all previously 
reported C–H sulfenylation procedures require the synthesis of a new reagent for each 
electrophilic [R–S]+ transfer starting from a reactant already containing sulfur. Additionally, with 
most of the reported sulfenylation strategies only aryl sulfides of electron-rich arenes were 
accessible. Therefore, the development of a [S2+] synthon fills the gap in the toolbox of organic 
chemists.[254]  
 
Scheme 72: New approach for the synthesis of aryl sulfides. 
The first part of the project will focus on the synthesis towards an electrophilic S2+-containing 
sulfur reagent which can activate arenes and heteroarenes. Hereby the electrophilic character 
of the sulfur will be targeted by attaching a strong electron-withdrawing group (EWG) on the 
sulfur atom in analogy to the electrophilic sulfenylation protocols reviewed above (Scheme 73; 
compare Chapter 1.4.2.3). Ideally, the EWG in the reagent 84 also can act as an internal base 





Scheme 73: Proposed reactivity of thioimidazolium salts 85 as a potential intermediate in the modular synthesis 
of unsymmetrical diaryl sulfides. 
 
As presented in Chapter 2.1.2, the C–H activation of electron-rich heteroarenes with in situ 
oxidized thioureas is possible from the conceptual point of view. Afterwards, suitable conditions 
of the sulfenylation step will be examined and different sulfur containing precursors will be 
screened for the sulfenylating reagent synthesis, with a special focus on imidazole-2-thiones 
to get access to the general structure 85. In a second consecutive step, the ability of the 
obtained thioimidazolium salts 85 to form new carbon-sulfur bonds with carbon-centered 
nucleophiles like Grignard reagents will be investigated in continuation to former results of M. 
Alcarazo, J. Peňa et al. (Scheme 69, B). Additionally, the methodology will be extended 
towards the synthesis of unsymmetrical diaryl selenides and arylimidazole-containing 
thioethers.  
The synthetic utility of the developed protocols will be verified by the functionalization of 
pharmaceutically active compounds like the first-generation antihistamine Phenbenzamine 
(86). Additionally, the synthesis of the precursor 87 of an active tubulin inhibitor as well as the 
subsequent double sulfenylation of pyrrole derivatives 88 (Figure 15) will demonstrate the 





Figure 15: Potential targets for the desirable sulfenylation protocols.  
 
Due to the importance of sulfinimide in medical chemistry,[255] a later side project will focus on 
the synthesis of potential thiosulfinimide transfer reagents which can react e. g. with carbon-
centered nucleophiles. Therefore, representative compound of the general structure 89 will be 
synthesized, and the reactivity of these compounds will be further investigated (Scheme 74).  
 





3 Results and discussion 
The need for the elaboration of a selective electrophilic sulfenylation protocol by introduction 
of a general applicable S2+ synthon in organic frameworks as well as the state of the art 
sulfenylation approaches were discussed in the former Chapters. As explained, no protocol for 
the selective introduction of a general applicable S2+ synthon is known so far. Since multiple 
sulfenylation protocols require the sulfur atom to be already present in the [RS] + sulfenylating 
reagent, each of these sulfenylation reagent must be prepared separately in advance for each 
R. 
3.1 Synthesis of different thioimidazolium reagents 
Based on the experience of the Alcarazo group with thioimidazolium-based transfer reagents, 
a series of potential electrophilic sulfenylating reagents will be synthesized by attaching 
different electron withdrawing group on the sulfur of the imidazole-2-thione (Scheme 75). 
Since the electron-withdrawing group should act as an internal base in the sulfenylation step, 
N-basic residues like phthalimide (90), succinimide (91) and pyrrolidinone (92) were chosen 
as potential candidates for the EWG in 84. The strategy seems to be very promising because 
most of these groups have already been used in traditional sulfenylation approaches (compare 
Chapter 1.4.2.3). 
 





3.1.1 Synthesis of phthalimidylthioimidazolium bromide 
The phthalimide-containing potential sulfenylating reagent 90 was synthesized from the 
imidazolthione backbone 78 which was obtained in a condensation reaction of acetoin and 1,3-
diisopropylthiourea (Scheme 76). The bromination of 78 according to the published 
procedure[242] gave access to dibromide 79 in excellent yields. In a final step, the desired 
imidazolium reagent 90 was obtained by reaction of 79 with potassium phthalimide in 23% 
overall yield. 
 
Scheme 76: Synthesis of a new potential sulfenylating reagent 90. 
Single crystals of 90 suitable for X-ray diffraction analysis were obtained by slow diffusion of 
pentane into an acetonitrile solution of 90 under inert conditions since compound 90 hydrolyses 





Figure 16: Molecular structure of compound 90  MeCN. Thermal ellipsoids at 50% probability. Hydrogen atoms 
and MeCN molecules are omitted for clarity. Selected bond lengths, distances and angles: S1–C1 1.7584(15) Å, 
N1–S1 1.7137(13) Å, S1–Br1 3.177(8) Å, N1–S1–Br1 175.10(7)°, C1–S1–Br1 85.08(3)°, N1–S1–Br1 99.51(17)°. 
In the solid state 90 exhibits a slightly distorted T-shaped conformation with a nearly linear N1–
S1–Br1 axis (N1–S1–Br1 angle 175.1°) (Figure 16) which can be understood as a directed σ-
hole interaction of the bromide anion and the partly polarized sulfur atom. Due to the potential 
Coulomb attraction between the positively charged imidazolium moiety and the negatively 
charged bromide anion the N1–S1–Br1 axis is slightly tilted resulting in a large N1–S1–C1 
angle of 99.5° and a smaller C1–S1–Br1 angle of 85.1°. The C1–S1 bond is elongated by 
0.068 Å compared to the non-oxidized imidazole-2-thione 78 [1.690(5) Å] due to the partial 
loss of the double bond character.[256] This can be rationalized by a weaker π back-donation 
of the less electron-rich sulfur into the unpopulated p-orbital of the carbene-C in the reagent 
90 (Scheme 77).[257] 
 





As expected, the N1–S1 bond length of 1.7137(13) Å is in line with a typical sulfur-nitrogen 
single bond[258] whereas the short S1–Br1 distance of 3.177(4) Å is significantly less (15%) 
than the sum of the S–Br van-der-Waals radii (3.7 Å)[259].  
An explanation for this observation is the donation of electrons from the bromide anion into the 
anti-bonding S1–N1 orbital, commonly described in the literature as charge-assisted 
chalcogen bonds.[260] This observation is in accordance with the envisaged high electrophilic 
character of the sulfur atom in 90 and is frequently observed in other cationic sulfur reagents 
synthesized by the Alcarazo group.[261–263] 
3.1.2 Synthesis of succinylthioimidazolium chloride 91 
Compared to phthalimidylthioimidazolium bromide 90, the succinyl analogue was accessible 
directly from imidazole-2-thione 78 by treatment with N-chlorosuccinimide (NCS) in DCE at 
room temperature (Scheme 78). Succinylthioimidazolium chloride 91 was quantitatively 
obtained as a moisture-sensitive yellow powder which readily hydrolyses when exposed to 
ambient conditions furnishing a brown oil. 
 
Scheme 78: Synthesis of succinylthioimidazolium chloride 91. 
The structural identity of 91 was confirmed by X-ray diffraction (Figure 17). Appropriate single 
crystals were obtained by slow diffusion of pentane into a concentrated solution of 91 in 
dichloromethane at room temperature. Similar to 90, 91 also exhibits a slightly disturbed T-
shaped conformation with a nearly linear N1–S1–Cl1 axis. The N1–S1 [1.724(9) Å)] and C1–
S1 bond lengths of 91 [C1–S1: 1.7486(10) Å] are similar to those found in 90. 
In analogy to 90, the sulfur-halogen distance S1–Cl1 in 91 [ 3.024(4) Å] is significantly shorter 





Figure 17: Molecular structure of compound 91 in the crystal. Thermal ellipsoids at 50% probability, hydrogen 
atoms are omitted for clarity. Selected bond lengths, distances and angles: S1–C1 1.7486(10) Å, N1–S1 1.7181(9) 
Å, S1–Cl1 3.0311(4) Å, N1–S1–Cl1 177.99(3)°, C1–S1–Cl1 78.62(3)°, N1–S1–C1 100.0(4)°. 
It was assumed that the coordination of the chloride anion to the electrophilic sulfur atom could 
potentially reduce the reactivity of the reagent by blocking the electrophilic sulfur center. In the 
case of a reaction of 91 with nucleophiles like electron-rich arenes, the chloride may inhibit the 
reaction because it interacts significantly with the sulfur and must be displaced before the 
activation step of the arene. A weakly coordinating anion like hexafluoroantimonate would 
potentially be less competitive with the putative nucleophiles. Therefore, the 
hexafluoroantimonate 93 was synthesized by anion exchange of 91 with NaSbF6 (Scheme 79).  
 





3.1.3 Synthesis of pyrrolidinylthioimidazolium bromide 92 
Similar to 90, the pyrrolidinyl derivative 92 was accessible from dibromide 79 (Scheme 80). 
The reaction of 79 with trimethylsilyl-2-pyrrolidinone gave access to the desired reagent 92 in 
excellent yield. 
 
Scheme 80: Synthesis of pyrrolidinylthioimidazolium bromide 92. 
All diffusion-based attempts to grow suitable single crystals of compound 92 for X-ray 
diffraction experiments failed. After several unsuccessful attempts like the testing different 
solvent mixtures and temperature, the tetramethylimidazole-2-thione-derived analog 94 was 
synthesized, because the less sterically demanding methyl substituents on nitrogen atoms in 
the 95 backbone may favor the formation of more readily crystallizing solids (Scheme 81).  
 
 
Scheme 81: Synthesis of pyrrolidinylthioimidazolium bromide 94. 
 
After successful crystallization of 94 by slow diffusion of pentane into a saturated 
dichloromethane solution, X-ray diffraction analysis of the obtained single crystals confirmed 
the expected connectivity (Figure 18). Therefore, it is assumed that observed sulfur nitrogen 






Figure 18: Molecular structure of compound 94 in the crystal. Thermal ellipsoids at 50% probability, hydrogen 
atoms are omitted for clarity. Selected bond lengths, distances and angles: S1–C1 1.749(3) Å, N1–S1 1.699(3) Å, 
S1–Br1 3.476 Å, N1–S1–Br1 167.06°, C1–S1–Br1 66.88°, N1–S1–C1 100.77(14)°. 
Compared to 90 and 91, the anion C1–S1–Hal angle in 94 is smaller, most likely due to the 
lower steric demand of the methyl groups in comparison to iso-propyl substituents.  
This results into a weaker σ-hole interaction of the bromide with the sulfur. Therefore, the S–
Br distance is 0.299 Å longer than the corresponding one in reagent 90. Apparently, the lower 
electrophilicity of N1 in the pyrrolidinyl moiety, as compared to the phthalimide, results in a less 
accessible and possibly more diffuse anti-bonding (S1–N1) orbital. This might foreshadow a 





3.2 Comparison of the reagents and optimization of sulfenylation 
conditions 
To begin with, the reactivity of the synthesized thioimidazolium reagents was examined by 
electrophilic sulfenylation of phenyl pyrrole with 91, which led to the cationic sulfide 97 (Table 
5). Initial studies revealed the high impact of the workup protocol on the yield of the reaction.  
The initially attempted purification of the crude product applying repetitive column 
chromatography resulted in low yields (34%) of the highly hydroscopic chloride salt 97 ∙Cl. This 
purification problem could be overcome by anion exchange of the chloride anion before the 
column chromatography. Thus, after evaporation of the acetonitrile under reduced pressure, 
the residue was dissolved in DCM and washed with aqueous NaSbF6 solution. In this respect, 
replacing of the chloride with hexafluoroantimonate enabled the isolation of pure and non-
hydroscopic 97∙SbF6 in acceptable yields (66%) after flash column chromatography (fcc). 
Hexafluoroantimonate demonstrated superiority over other anions such as 
hexafluorophosphate which yielded the corresponding salt in a moderate 53% yield. The 
obtained 97∙SbF6 is air stable and could be stored for several weeks under ambient conditions 
without any observed decomposition.  
Table 5: Screening of different counteranions through the work up. 
 
Entry NaX Isolated 97∙X Comment 
1  34 % (X =Cl) Multiple fcc; impure, 
hydroscopic product 
2 NaPF6 53 % (X = PF6)  
3 NaSbF6 66 % (X = SbF6)  
 
Hereinafter, the influence of the electron-withdrawing group was investigated by the reaction 
of the reagents 90, 91 and 92 with a slight excess of N-phenylpyrrole (Table 6). In this regard, 




(30%), presumably due to the weaker electron-withdrawing character of the pyrrolidone moiety 
compared to the other reagents. Due to the more pronounced electron-withdrawing properties 
of the phthalimide residue than of pyrrolidine, reagent 90 demonstrated enhanced reactivity in 
the sulfenylation reaction (yield 50%, Entry 1).  
Unfortunately, purification of the desired product from the phthalimide by-product using flash 
column chromatography (fcc) was not possible. However, the pure antimonate salt was 
obtained after two subsequent fcc´s. 
As expected, the succinimide-based reagents gave the highest yields of compound 99 (Entries 
2&3). The predicted lower coordinating hexafluoroantimonate derivative reagent 93 showed a 
higher reactivity in comparison to the chloride analogue 91. Additionally, it could be 
demonstrated that the in situ formation of reagent 91 from 78 and NCS did not significantly 
reduce the yield (Entry 5). This enables the sulfenylation of electron-rich arenes in a one pot 
reaction from easy to handle starting materials.  
Table 6: Evaluation of reactivity for the synthesized reagents in the sulfenylation of N-phenylpyrrole. 
 
Entry reagent EWG X Isolated Yield 
1 90 Phthalimide Br 50%a 
2 91 Succinimide Cl 66% 
3 93 Succinimide SbF6 85% 
4 92 Pyrrolidinone Br 30% 
5 In situ formed 91 Succinimide Cl 65% 
                                             a: Isolated 99 was contaminated with phthalimide. 
In connection with the discovered possibility of obtaining sulfenylating reagent 91 by oxidation 
of 78 with NCS in situ, several other oxidants were also screened (Table 7). However, NCS 
turned out to be the only viable oxidant from the tested ones. N-Bromosuccinimide led to the 




was not reactive enough, as N-phenylpyrrole (98) was reisolated almost quantitatively. The 
higher reactivity of N-chlorosaccharine resulted in the formation of a complex mixture of 99 
with several unidentified side-products.  
Table 7: Screening of different oxidants for the in situ formation of succinimide-derived reagents. 
 
Entry Oxidant Isolated yield Comment 
1 N-Chlorosuccinimide 65%  
2 N-Bromosuccinimide n.d. Formation of regiomers 
3 N-Iodosuccinimide 0%  
4 N-Chlorosaccharine n.d. Complex mixture 
5 none 0%  
 
Further screening of the reaction conditions revealed no significant influence of polar solvent 
in the functionalization of 2-phenyl-1-methylindole, since the reaction gave high yields in both 
acetonitrile and DCE (Table 8, Entries 1 & 2). In toluene the reaction resulted in low yield, 
probably due to the low solubility of the reagent (Entry 3). As acetonitrile is known to be less 
toxic, more environmentally friendly and does not tend to undergo substitution reaction with 





Decreasing the reaction temperature resulted in very low yields of compound 100 (Entry 4). 
Instead, increasing the reaction concentration by factor eight resulted only in a slightly 
decreased yield (Entry 5). Furthermore, the transformation was sensitive to water, as the 
addition of small amounts of water significantly lowers the yield (Entry 6). To exclude a radical 
reaction pathway, equimolar amounts of TEMPO were added to the reaction mixture (Entry 7).  
Table 8: Screening of solvents, temperatures and additives. 
 
Entry Solvent T c /M Additives Yield 
1 DCE 70°C 0.1 - 71% 
2 MeCN 70°C 0.1 - 72% 
3 Tol 70°C 0.1 - 5% 
4 MeCN rt 0.1 - 15% 
5 MeCN 70°C 0.8 - 65% 
6 MeCN 70°C 0.1 2 equiv. H2O 47% 
7 MeCN 70°C 0.1 1 equiv. TEMPO 47% 
 
Since significant amounts of 100 (47%) were still isolated, although the yield dropped, an 
electrophilic aromatic substitution (SEAr) mechanism (see Scheme 82) is proposed for the 
reaction in analogy to the literature known electrophilic sulfenylation reagents (compare 
Chapter 1.4.2.3). 
 





3.3 Evaluation of backbone 
After appropriate reaction conditions for the imidazole-derived reagents (91) have been 
determined, the influence of the sulfur-containing backbone on the yield of the sulfenylation of 
N-phenylpyrrole was investigated by screening different thiourea derivatives. The latter were 
in situ oxidized with N-chlorosuccinimide and tested in the sulfenylation reaction of N-
phenylpyrrole affording the cationic sulfide of the general form 102 (Scheme 83).  
 
Scheme 83: Screening of different sulfur-containing backbones for the sulfenylation of N-phenylpyrrole resulting 
in cationic sulfides of the general structure 102. 
The reaction proceeded with different alkyl substituted imidazole-2-thione derivatives affording 




diisopropyl-4,5-dimethyl-imidazole-2-thione (78). The replacement of the methyl group at the 
nitrogen atom in the imidazolethione fragment by the ethoxycarbonyl group, as well as the 
oxidation of the imidazole-2-thione, did not lead to the formation of the desired cationic sulfides 
106 and 110, respectively.  
In contrast to this, acyclic thiourea derivatives were reactive enough for the sulfenylation of N-
phenylpyrrole. Unfortunately, the high reactivity, especially of tetramethylthiourea-derived 
sulfenylation reagent, led to a low selectivity of the sulfenylation, as a 75:4 mixture of the 2'- 
and 3'-sulfenylated regioisomers 107a and 107b was obtained. Both compounds could be 
separated by repetitive flash column chromatography affording the desired 2'-substituted 
product 107a in the yield of 46%. The connectivities in the regioisomers were confirmed by X-
ray crystallography of suitable single crystals obtained by slow evaporation of a DCM solution 
of the mixture of both compounds (Figure 19). 
 
Figure 19: Solid state structure of regio-isomers 107a and 107b. Thermal ellipsoids at 50% probability level; 
hydrogen atoms, anions and solvents are omitted for clarity. 
Other tested thiourea derivatives gave the corresponding cationic sulfide 109 and 108 in only 





The utilization of isoquinolinethione as a sulfur precursor resulted in formation of 111 in 
moderate yield; however, isolation of the product in acceptable purity appeared to be 
impossible after several attempts. With phthalazinethione as a starting material, only traces of 
the desired salt 112 were obtained. In general, the yields of the reaction may be affected by 
solubility effects during the isolation, as some cationic sulfides were highly polar and tend to 
stick on the silica gel during the flash column chromatography. Since the selectivity and 
reactivity were in an optimal agreement for the case of 1,3-diisopropyl-4,5-dimethylimidazole-
2-thione (78) as a sulfur-containing backbone, this sulfur precursor will be used in the next 
steps. In the solid state the corresponding cationic sulfide 99 shows a C1–S1–C2 bond angle 
of 100.5° and a dihedral angle φ(N1;C1;S1;C2) of 117.3° (Figure 20). As expected, the S1–C1 
bond was elongated from 1.690(5) Å in the imidazole-2-thione to 1.75495(9) Å in 99.[265]  
 
Figure 20: Solid state structure of 99 Thermal ellipsoids at 50% probability level, hydrogen atoms and anions are 
omitted for clarity. 
Furthermore, the connectivity in cationic sulfides 103 – 104, 92 and 111 was confirmed by X-
ray diffraction analysis (for crystal data see Chapter 5.8). As expected, the sulfur-carbon bond 
of all utilized backbones was elongated and ranged between 1.7868(16) Å and 1.7461(16) Å 
(see Scheme 84). This is a direct consequence of the reduction of the bonding order in the 
corresponding bond between sulfur and carbon and refers to the average length of these 





It can be assumed that long sulfur carbon bonds (e. g. in 111 & 108) tend to be weaker and 
can probably be partially hydrolyzed on the acidic silica gel upon the flash column 
chromatography, as the cationic sulfides were isolated in lower yields of 17% and 31%, 
respectively. 
  
Scheme 84: Bond length of the sulfur-carbon bonds in the cationic sulfides of the general structure 102. R equals 





3.4 Scope and limitation of reagent for the synthesis of thioimidazolium 
intermediates  
Having the optimized reaction conditions for the functionalization of N-phenylpyrrole and 
reagents 93 and 91 in hand, further heterocyclic arene derivatives were targeted by the 
sulfenylation reaction (Scheme 85). Apart of pyrrole derivatives 113 and 99, several other N-
heterocyclic arenes like indoles 114 to 118 and carbazole 119 derivatives were also obtained 
in good to excellent yields. In most cases, even the less reactive succinylthiolimidazolium 
chloride 91 gave products in excellent yields as well. Among less functionalized nucleophiles, 
the method tolerated several functionalities such as unprotected indole NH (products 115, 117, 
118), hydroxyl- (115), carboxylic (117) and ester groups (118). Upon sulfenylation of indole-2-
carboxylic acid, the cationic product 117 was obtained as the corresponding imidazolium 
chloride salt, which directly precipitated from the reaction mixture. Only electron-poor N-
heterocyclic arenes like pyrazole and imidazole[1,2-a]pyridine derivatives were not 
sulfenylated by this protocol.  
Additionally, some (benzo)thiazoles reacted with the more reactive reagent 93 in the expected 
fashion to give the corresponding cationic sulfides 122 and 123 in 61% and 90% yields, 
respectively. Unfortunately, O-heterocyclic systems were not reactive enough and could not 










To verify the connectivity in the cationic sulfides, single crystals suitable for X-Ray diffraction 
of selected representative products were obtained by slow diffusion of hexane, heptane or 
diethyl ether into saturated solutions in DCM. The solid state structures of various cationic 
sulfides are presented in Figure 21. All structural motives have a common angular geometry 
around the imidazole sulfur atom which varies between 102.59(8)° for 123 and 105.0(3)° for 
100. Additionally, no short contacts between the hexafluoroantimonate anion and the 
imidazolium sulfur atoms were observed, presumably because the antimonate is far less Lewis 
basic than the bromide or chloride anion. The S–Cimidazolium bond length varied between 
1.759(4) Å in 113 and 1.7463(8) Å in 116. The average bond length was slightly shorter than 
the S–Cheteroaryl bond with a length varying between 1.7712(15) Å in 123 and 1.750(5) Å in 113.  
 
Figure 21: Crystal structures of cationic sulfides of different indole, pyrrole and benzothiophene derivatives. 






Interestingly, apart from heterocyclic arenes, also electron-rich aromatics were sulfenylated by 
reagents 93 and 91 (Scheme 86). Especially, mono- and di-N-methylated methylanilines 
showed high reactivity furnishing compounds 130 and 129 in 43% and 91% yield, respectively. 
Furthermore, also unprotected and benzyl-protected anilines also gave the corresponding 
cationic sulfides 131 and 132 in up to 52% yield. Unfortunately, all attempts to sulfenylate N-
phenylacetamide failed, probably due to the deactivating effect of the attached acetylamide 
group and the resulting lower nucleophilicity of the arene core. 1,8-
Bis(dimethylamino)naphthalene was functionalized affording 136 in yield of 46%. Interestingly, 
apart from the desired para-functionalized product, also minor traces of the corresponding 
ortho-sulfenylated product crystalized from a saturated dichloromethane solution of the crude 
product (see chapter 5.8.3).  
Electron-donating substituents on the aniline core reduced the selectivity of the reaction, as 
meta-methylaniline was sulfenylated in both ortho and para position (ratio o:p = 28:72). The 
product distribution was determined by NMR spectroscopy and was in agreement with those 
observed in the solid state (compare crystal structure in Chapter 5.8.3). Attempts to increase 
the selectivity of the reaction employing lower temperature (40 °C) and elongating reaction 
times up to 24 h failed. 
Di- and trimethoxybenzene gave the corresponding sulfides 137 and 138 in good to excellent 
yields as well. In case of the less electron-rich dimethoxy benzene, the more active reagent 93 
has to be used, whereas the utilization of 91 gave only traces of the desired product 137. In 
contrast to that, additional electron-withdrawing functionalities in the substrate such as a nitrile 
group on the aniline core or the acetylation of the aniline amine group strongly inhibited the 






Scheme 86: Reaction scope of the sulfenylation reaction with different arene-based nucleophiles; For crystal 
structure of 136: Thermal ellipsoids at 50% probability level; hydrogen atoms, anions and solvents are omitted for 
clarity. 
As most of the obtained imidazolium salts are highly crystalline compounds, single crystal 
suitable for X-ray analysis of aniline derivatives 129 and 132 as well as methoxybenzenes 137 
and 138 were obtained to confirm the expected connectivity (see Figure 22). 
 
Figure 22: Crystal structure of cationic sulfides from arene derivatives. Thermal ellipsoids at 50% probability level; 




Unfortunately, all attempts to synthesize cationic sulfides from methoxybenzenes 140 – 145 
derivatives as well as from phenol 143 failed, as these arenes appeared to be not electron-rich 
enough (Scheme 87). This still remains the major limitation of the sulfenylation protocol and 
explains also, why triazole derivative 144 and ethynylbenzene (145) were not reactive applying 
the developed methodology.  
 
Scheme 87: Attempted synthesis of cationic sulfides from miscellaneous less electron-rich arenes.  
As indicator of the high chemical stability of the obtained air-stable cationic sulfides can be 
used the fact that in all cases no formation of symmetrical diarylsulfide was observed as a side 
product. Even the intended treatment of 137 with N,N-dimetylaniline under elevated conditions 
like extensive heating over elongated times in the presence of cesium carbonate as a base did 
not result in the formation of diaryl sulfides 146 (Scheme 88). Instead, 137 was nearly 
quantitatively reisolated. 
 
Scheme 88: Stability test of 137 under harsh conditions. 




To expand the scope of 93 for the functionalization of aniline derivatives, the core structure of 
the AZD4407 (147) was targeted (Scheme 89). The aryl thioether AZD4407 was of high 
pharmaceutical interest since it can inhibit the 5-lipoxygenase which makes it a potent 
candidate for the treatment of a variety of inflammatory conditions such as chronic obstructive 
pulmonary disease (COPD) and asthma.[267] The strategy to obtain core structure 148 based 
on the initial sulfenylation of 2-indolone (150). It was expected that the para to the nitrogen 
position is the most reactive one in 150, wherefore salt 149 should be the envisaged product. 
Surprisingly, the sulfenylation of 150 led to compound 151 in high yields of 84%. This can be 
rationalized by the keto-enol tautomerism of 150 giving also 1-hydroxyindole as a potential 
tautomer. To enable the sulfenylation of the arene ring, the introduction of a sterically 
demanding TBDMS-protecting group was envisaged. The silylation proceeded quantitatively 
following a modified protocol of E. Merifield and coworker.[267] Unfortunately, the sulfenylation 
of 152 gave a sluggish reaction and also resulted in the formation of 151 in low yields of 18%.  
 





3.5 Synthesis of arylsulfides 
3.5.1 Screening for appropriate nucleophiles 
Having established a selective protocol for the synthesis of the cationic imidazolium-derived 
intermediates 99, several different nucleophiles were screened for their ability to attack the 
sulfur atom under formation of a new sulfur-carbon bond and release of the imidazole N-
heterocyclic carbene (Scheme 90). Weak nucleophiles as enamines were not able to react in 
a desired manner to give access to iminium species 153. Also, deprotonated 1,3-dicarbonyl 
compounds, phosphorus ylides and TMS-protected enolates were not reactive enough to give 
the desired sulfides 154, 155 and 156, respectively. All attempts resulted in formations of 
complex reaction mixtures. Only unreacted starting material 99 was re-isolated in most cases. 
 
Scheme 90: Exploration for the identification of a suitable nucleophile for the formation of arylsulfides. 
Afterwards easy accessible harder nucleophiles like organometallic compounds were tested 




bromoanisol gave only traces of arylsulfide 157 (Table 9, Entry 1).[268] Also the corresponding 
zincate obtained by transmetallation of para-methoxyphenylmagnesium bromide with an 
excess of zinc bromide gave only minor yields of 157 (Table 9, Entry 2). 
As in the former thioalkynylation protocol of the Alcarazo group (see Chapter 2.1.1), Grignard 
reagents were found to be suitable nucleophiles enabling the synthesis of the desired 
unsymmetrical thioethers.[246] Luckily, from model substrate 99 the desired thioether 157 was 
obtained in excellent yields (94%).  
Table 9: Screening of different organometallic reagents. 
 
Entry MX Yield of 157 
1 CuBr (5.0 equiv.) Traces 
2 ZnBr (1.5 equiv.) 2% 
3 MgBr (1.5 equiv.) 94% 
 
Further screening of reaction conditions revealed that in other cases e.g. aniline adduct 129, 
bigger amounts of Grignard were needed to achieve high-yielding reactions (Table 10). The in 
situ formation of a turbo-Grignard by addition of LiCl did not result in increased yields (compare 
Table 10, Entries 2&4).[269] However, slow warming up the reaction mixture overnight resulted 
in better yields compared to immediately removing of the cooling bath after the addition of the 





Table 10: Optimization of reaction conditions for 129 
 
Entry RMgBr c /M Additives Conditions Yield of 158 
1 1.4 equiv. 0.1 - Fast warm up 25% 
2 1.5 equiv. 0.1 - Slow warm up 36% 
3 2.9 equiv. 0.1 - Slow warm up 75% 
4 1.5 equiv. 0.1 5 equiv. LiCl Slow warm up 43% 
 
To confirm the release of the carbene as a leaving group in the reaction, equimolar amounts 
of selenium powder were successively added after the reaction was finished (Scheme 91). The 
formation of selenium urea 159 was confirmed by detecting a mass of the corresponding 
selenourea with m/z of 260.0789 upon mass spectrometry. 
 
 
Scheme 91: Trapping of the liberated free imidazole carbene with selenium powder under formation of seleno 
urea 159. 
3.5.2 Scope, applications and limitations 
After Grignard reagents were found to be the best nucleophiles for the synthesis of diaryl 
sulfides from cationic imidazolium sulfides, as shown in the previous Chapter 3.5.1 for 99 and 
129, a library of 28 diaryl sulfides was synthesized (Scheme 92). The concentration of the 
utilized Grignard reagents was determined by titration before usage following established 
protocols.[270] For less reactive reagents and reactants, an excess of up to 2.9 equivalents of 




protic functional groups like carboxylic acids, additional equivalents of the organometallic 
nucleophile were added (e. g. 87). 
Studies revealed that more electron-rich und therefore more nucleophilic Grignard reagents 
gave higher yields of the desired aryl sulfides. Thus, para-methoxyphenylmagnesium bromide 
afforded arylsulfide 161 in 94% yield, whereas the utilization of corresponding fluoro- and 
cyano-containing Grignards resulted in formation of 162 and 163 in 67% and 78% yield, 
respectively. 
With the optimized reaction conditions in hand also more sophisticated diaryl sulfides with 
menthol (165 and 187) or sugar (169) motifs were accessible in yields of 89%, 51% and 53%, 
respectively. For the introduction of para-cyanophenyl (163) and bromopyridyl (172) motifs, 
the applied Grignard reagents were obtained by a LiCl-mediated Br/Mg exchange reaction, as 
reported by the group of Knochel and coworkers.[271]  
In other cases, e. g. for the synthesis of benzothiazole- (170), dichloropyridine- (173) and 
quinolone-containing (166) thioethers, Grignard reagents were prepared by deprotonation of 
the corresponding heterocycle with 2,2,6,6-tetramethylpiperidinylmagnesium chloride in the 
presence of lithium chloride (TMPMgCl LiCl) following the protocol of Knochel and 
coworkers.[272] In case of the furylpyrrolyl sulfide 167 it could be shown that also lithiumorganic 
reagents can be utilized as nucleophiles. In contrast to the observation of the group of N. Kuhn 
who reported the nucleophilic substitution of SMe- at the C2 atom of the imidazolium motif of 
2-(methylthio)imidazolium salts with methyl lithium, the utilized furyllithium organyl selectively 
substituted the NHC under formation of the desired aryl sulfide 167.[273] 
However, different metalalkynyl reagents (metal = Mg, Zn, Li) were not reactive enough to form 
alkyne sulfides 177, and sterically demanding Grignard reagents (e. g. mesitylmagnesium 
bromide) gave only traces of the desired product 178. Unfortunately, the utilization of 









In several cases (compounds 168, 87, 175, 170, 163 and 162) X-ray crystallography confirmed 
the expected connectivity of the obtained sulfides. The representative crystal structure of 168 
& 87 can be seen in Figure 23. 
 
 
Figure 23: Molecular structure of compound of 168 and 170 Non-acidic hydrogen atoms and solvent molecules 
are omitted for clarity. Thermal ellipsoids are drawn at 50% probability level. 
 
After several diaryl sulfides were successfully synthesized it could be shown, that alkyl aryl 
and alkenyl aryl sulfides were also accessible by the developed methodology with yields up to 
93% (Scheme 93). From the synthetic point of view, the introduction of alkenyl groups as in 
compounds 193, 195, 196 and 200 is of immense interest, because they are potential 
precursors for the formation of new C=C double bonds by alkene metathesis reaction.[80] 
Additionally, double bonds can be functionalized by bromination[274], epoxidation[275], 
aziridination[276] and other chemical transformations[277] to allow the selective introduction of 
new functional groups into a structure. As already discussed above in the case of diaryl sulfide 
synthesis, also lithiumorganic nucleophiles like sec- or tert-butyllithium can be utilized for the 






Scheme 93: Scope of alkyl and alkenyl aryl sulfides. 
In addition to the mono-sulfenylations of N-phenylpyrrole resulting in thioethers 161 to 164 
already described above (see Scheme 92), also the twofold sulfenylated species 88 was 
accessible by stepwise transformation of 161 with an overall yield of 61% (Scheme 94). 
 





Having the established protocol for the sulfenylation of arenes and heteroarenes in hand, the 
potential of the methodology was demonstrated in the synthesis of the compound 87, which is 
the precursor of the compound 151 (Scheme 95, A). Studies of R. Silvestri et al. have shown 
that 151 is a potent inhibitor of tubulin assembly and therefore a potential candidate for the 
treatment of cancer.[11,12] Upon sulfenylation of the indole derivative 203, the corresponding 
imidazolium chloride 117 precipitated from the reaction mixture and was obtained in good yield 
of 79%, as already shown in Scheme 85. Subsequent reaction of 117 with an excess of 
phenylmagnesium bromide gave access to precursor 87, whereas lowering the quantity of 
Grignard reagent to 3.5 equivalents decreased the yield significantly to 35% (Scheme 95, B).  
Attempts to obtain the tubulin inhibitor 151 starting from ethyl ester 204 failed, since the 
reaction of nearly quantitatively isolated intermediate 118 with Grignard reagent resulted in the 
formation of several by-products, most probably due to the reaction of the ester functionality 
with the Grignard reagent. Noteworthy, the sulfenylation of 190 with an overall yield of 49% 
starting is superior to the sulfenylation step in the work of R. Silvestri cited above, who reported 
a lower yield of 35% for the sulfenylation of 204 utilizing N-thiophenylsuccinimide and 
equimolar amounts of boron trifluoride diethyl etherate.[11] 
 
Scheme 95: A: Approach to potent inhibitor of tubulin assembly 151 by esterfication of precursor 87; B: 




The connectivity of the obtained imidazolium salts 117, 118 and of compound 87 was verified 
by X-ray diffraction of single crystals (Figure 24).
 
Figure 24: Molecular structure of imidazolium salts 117 and 118 and precursor 87 in the crystal. Non-acidic 






3.6 Investigations towards triazole-based reagents 
Since the release of the imidazole-derived NHC carbene is the key step in the formation of 
diaryl sulfides (compare Scheme 91), it was envisaged that changing from the imidazole- 
based backbone to the 1,3,4-triazole analogue might enable the utilization of softer 
nucleophiles like zincates. 
When the imidazolium cation 205 is considered as an adduct 206 of an imidazole NHC carbene 
and a +SR fragment, the utilization of a 1,3,4-triazole NHC carbene adduct 207 should led to a 
weaker sulfur-carbon bond (Scheme 96). This is assumed since 1,3,4-triazole carbenes exhibit 
weaker σ-donor abilities based on Huynh´s electronic parameter (HEP) than their imidazole-
derived counterparts.[278] 
 
Scheme 96: Mesomeric structures of imidazolium salt as covalent form (205) or adduct of σ-donating NHC 
carbene and cationic sulfide fragment +SR (206): comparison with envisaged 1,3,4-triazole carbene adduct 207. 
 
3.6.1 Synthesis of cationic triazolium intermediates 
As the activation of imidazole-2-thione 78 via in situ oxidation with NCS was a well-established 
protocol, triazole-3-thione 209 was also oxidized with equimolar amount of NCS in the 
presence of different (hetero)arenes in DCM at room temperature (Scheme 97). After a 
subsequent anion exchange with a sodium hexafluoroantimonate solution, the triazolium salts 
210 and 211 were purified by flash column chromatography. The yield of the sulfenylation of 
N-phenylpyrrole 98 (64%) was nearly equal to those of sulfenylation with the imidazolium 
chloride-based reagent 91 (60%).  
Interestingly, 1,3-dimethoxybenzene (208) is known as a weaker nucleophile than pyrrole 
derivatives, as reported by the group of H. Mayr and co-workers.[279] Despite this, the triazolium 
salt 211 was obtained in moderate yield even when the counterion in the in situ formed 
triazolium-derived sulfenylation reagent was a chloride anion. In contrast to this, the 
imidazolium chloride-derived reagent 91 gave only traces of the desired product, wherefore 




Nevertheless, the sulfenylation of very weak nucleophiles like 2,6-dimethylanisole (212) was 
not successful, as only traces of the corresponding triazolium salt 213 have been obtained.  
 
Scheme 97: Synthesis of triazolium salts 210 and 211. 
The expected structural connectivity of triazolium salt 210 was confirmed by X-Ray diffraction 
experiments of suitable single crystals (Figure 25). Similarly to the imidazolium salt 99, the 
structure of the triazolium salt 210 shows an angular geometry around the sulfur atom S1 and 




Therefore, a similar reactivity towards Grignard reagents of both imidazolium and triazolium 
salts 99 and 210 might be expected. 
 
Figure 25: Structures of imidazolium (99) and triazolium (210) salts in the crystals. Hydrogen atoms, anions and 
solvent molecules are omitted for clarity. Thermal ellipsoids are drawn at 50% probability level. 
 
3.6.2 Reactivity of triazolium intermediates 
With the adduct of N-phenylpyrrole 210 in hand, its ability to form aryl sulfides with Grignard 
reagents or zinc organyls was tested (Scheme 98). As expected, the reaction of triazolium salt 
210 with para-methoxyphenylmagnesium bromide resulted in the formation of the desired aryl 
sulfide 161 in comparable yield (83%) as reaction of the imidazolium analogue 99 (92%). 
Unfortunately, organozincates appeared to be still not strong enough as nucleophiles to 
release the 1,3,4-triazole carbene, as the reaction of 210 with (4-methoxyphenyl)zinc bromide 





Scheme 98: Comparison of the reactivities of imidazolium and triazolium salt 99 and 210 in the reaction with 
metalorganic reagents. 
In cases where less nucleophilic magnesium organyls like (4-fluorophenyl)magnesium 
bromide were used, the triazolium salt 210 did not show any advantage over the imidazolium 
analogue 99 (Scheme 99). 
 
Scheme 99: Synthesis of arylsulfide 162 from triazolium (210) and imidazolium (99) salts. 
All in all, the change from the imidazole backbone 78 to a 1,3,4-triazole-derived backbone 209 
in the sulfenylation reagent did not result in significant reactivity benefits of the corresponding 
salts, as they also require strong nucleophiles as Grignard reagents for the formation of 




Small advantages of the triazole-based sulfenylation protocol, like lowering the reaction 
temperature for the sulfenylation step of (hetero)arenes from 70 °C to rt, do not legitimate the 
change of the backbone, as the well-established imidazole-2-thione 78 is readily accessible by 
simple condensation of acetoine with diisopropylthiourea,[280] whereas triazole thione 209 
requires a multistep synthesis from cheap commercially available starting materials.[281] 
 
3.7 Extension of the synthetic protocol towards the preparation of 
unsymmetrical diarylselenides 
After the successful evaluation of the developed protocol for the synthesis of several aryl 
sulfides, it was envisaged to extend the method to the preparation of diaryl selenides. Diaryl 
selenides have attracted great attention in recent years, because they are known to catalyze 
important transformations like, for example, the chloroamidation of alkenes with nitriles utilizing 
N-chlorosuccinimide (NCS) as a halogen source.[282] Additionally, diaryl selenides have been 
employed in the functionalization of alkynes e. g. in trifluoromethylthiolation reactions.[283] 
Further diaryl selenides show antitubulin and anti-Alzheimer activities as well as they are active 
5-lipoxygenase inhibitors, too.[284] 
To obtain the selenium analogue of sulfenylation reagent 91, selenourea 159, prepared 
according to published by N. Kuhn et al.[285] protocol, was oxidized with NCS in acetonitrile 
(Scheme 100). The isolated reagent 214 was obtained quantitatively as light orange solid and 
could react with electron-rich (hetero)arenes to give access to the cationic selenides 215 to 
217 in good yields. In contrast to the cationic sulfide intermediates, compound 215 to 217 were 
only moderately stable at air and needed to be stored for longer times at –20°C. Presumably, 
the isolated cationic selenoether tend to get oxidized more rapidly, as they afford selenones 
faster than sulfones are formed from sulfides.[286] Fortunately, studies revealed that 
succinylselenoimidazolium chloride 214 does not need to be prepared and isolated in advance, 






Scheme 100: Synthesis of selenylation reagent 214 and scope of the electrophilic C-H sulfenylation of different 
electron-rich (hetero)arenes. 
To proof the expected connectivity in this completely new compound class, single crystals for 
X-ray analysis of 217 were obtained by slow diffusion of diethyl ether into a dichloromethane 
solution of the compound.  
As expected, the selenium-carbon bonds of 217 are significant longer [Se1–C1, 1.896(3) Å; 
Se1–C2, 1.914(4) Å] than the corresponding sulfur-carbon bonds [S1–C1, 1.751(3) Å; S1–C2, 
1.775(3) Å] of the isostructural 129 and are in agreement with typical single bond length 
between those elements (Se–C, 1.970 Å) (Figure 26).[266] The selenium-centered angle 
C2−Se1−C1 of 99.8(2)° is smaller than the observed sulfur-centered one C2−S1−C1 in 129 
[103.3(3)°]. This can be explained by the decreased tendency of heavier atoms towards 





Figure 26: Molecular structure of compound 217. Hydrogen atoms and solvent molecules (DCM) are omitted for 
clarity. Thermal ellipsoids are drawn at 50% probability level. 
The strong interaction between the hexafluoroantimonate and the cationic selenide in 217 can 
also be visualized with the Hirshfeld surfaces of 217 (See Figure 27, A).[287] The contact 
between the fluorine atom F1 of the hexafluoroantimonate and the Se1 in compound 217 is 
1.025 Å shorter than the shortest sulfur-fluorine contact in 129 where no significant interaction 
between S–F is observable (See Figure 27, B). In contrast to 217, the cationic sulfide in 129 
exhibits close contacts between the iso-propyl groups and the SbF6. Apart from crystal packing 
forces, the short Se–F contact can be rationalized as a chalcogenic interaction in which the F 
donates electron density into the sigma-hole of the cationic selenium center. This is in 
agreement with the nearly linear F1–Se1–C2 geometry of 165.6°.[257]  
The selenium center is more polarizable; therefore, it has a more pronounced sigma hole than 
in the sulfur compound. This might be the reason why the sulfur compound is not “electrophilic” 
enough to exhibit such interactions with the poor donor hexafluoroantimonate. Such kind of 
sigma hole interaction of selenium compounds have been recently discussed in literature for 
nitrogen donors.[288] A similar chalcogen-fluoride interaction is not observed in case of the sulfur 
analogue 129, hence the larger S–F distance. Considering the molecular orbitals, the σ* of the 
Se1–C2 is more diffuse than the S1–C2 bond which is in line with the observable reactivity of 





The stronger chalcogen-fluoride-interaction are also in line with the calculated Mulliken charge, 
calculated on B3LYP(6-311++g(d,p)) level, whereas the charge of the chalcogen atoms in 129 
(+0.33) is lower than in 217 (+0.42).  
 





Gratifyingly and as expected, the cationic selenides 215 to 217 undergo reactions with aryl and 
alkenyl Grignard reagents in the same fashion as the cationic sulfides (compare Chapter 3.5). 
This gives access to selenides 218–221 in good yields (Scheme 101). Compared to previously 
reported protocols of the group of A. L. Braga, no diselenide precursors and harsh conditions 
like elevated temperature (110 °C) or additional electrochemical equipment were necessary 
for the synthesis of these kind of electron-rich selenides.[289] 
 
Scheme 101: Scope of aryl selenides. 
Further attempts to expand the developed methodology to tellurides have not been attempted 





3.8 Investigation towards a one-step synthesis of imidazolyl thioethers 
After several diarylsulfides and selenides were successfully prepared, the synthesis of 
imidazole-containing aryl sulfides became a target of further research, since such sulfides 
show manifold applications in medicinal chemistry (Scheme 102). E. g. imidazolyl-sulfenylated 
aniline 222 shows a high pharmaceutical potential as a drug for the treatment of 
mycobacterium diseases,[291] and indole derivative 223 bearing an imidazolylsulfide moiety 
may have application in the treatment of prostaglandin D2-mediated diseases.[292]  
 
Scheme 102: Pharmaceutically active imidazolyl-sulfenylated arenes. 
Traditionally, these imidazolyl sulfides of general structure 226 are mainly prepared by 
nucleophilic aromatic substitution of 2-chloroimidazoles 224 with arylthiols 225 (Scheme 
103).[293] This can be challenging in cases of complex target molecules, as one building block 
has to be a free thiol 225.  
 
Scheme 103: Classical synthetic route to imidazolyl aryl sulfides 226. 
Following the procedure presented in Chapter 3.5, the synthesis of imidazolyl sulfide would 
require a two-step synthesis starting with the sulfenylation of arene 227 followed by utilization 
of imidazole Grignard reagent 229 to obtain the target structure 226 (Scheme 104). 
 




During the initial screening of different thiourea backbones (see Chapter 3.3, Scheme 83) it 
was found that Carbimazole 230, the prodrug for Thiamazole (an antithyroid agent to treat 
hyperthyroidism[294]), did not give the envisaged cationic sulfide intermediate 106. However, 
upon closer inspection, it turned out that the imidazolyl thioether 231 was formed in good yield 
of 82% (Scheme 105, A) as a white solid after purification (see Experimental Section). The 
formation of aryl sulfide 231 can be rationalized via the dealkoxycarbonylation of cationic 
sulfide intermediate 106 at elevated temperatures in the presence of residual water (see 
Scheme 105, B). The final decarboxylation step in the proposed mechanism might be 
accelerated due to the activation of the carboxyl group by the cationic imidazolium fragment. 
 
Scheme 105: A: Synthesis of imidazolyl sulfide 231; B: Proposed mechanism of the decarboxylation of 106 to 
231. 
 
In line with this observation, heating induced and silica gel-mediated dealkoxycarbonylation 
reactions of α-monosubstituted β-keto- and α-cyanoesters, have been recently reported by the 
group of M. Jaramillo-Gómez.[295] Since the unexpected reactivity of imidazole-2-thione 230 
gave access to 231, the generality of this methodology was tested with further arenes and 





3.8.1 Synthesis and characterization of reagent 232 
To investigate the mode of action of this serendipity-based observation and for the better 
understanding the mechanism of this transformation, the proposed intermediate reactive 
species 232 of the above discussed sulfenylation was synthesized by oxidizing carbamazole 
(230) with equimolar amounts of NCS in acetonitrile (Scheme 106). Since the obtained air 
sensitive yellow precipitate was insoluble in common solvents such as DCM, DCE and 
acetonitrile, the identity of reagent 232 was confirmed by X-ray crystallography. 
 
Scheme 106: Synthesis of sulfenylating reagent 232. 
Suitable single crystal for X-ray diffraction experiments of the poorly soluble sulfenylating 
reagent 232 were prepared by layering a solution of NCS in DCM over a Carbimazole 230 
solution. By slow diffusion twinned crystals of 232 were obtained. The interaction of the 
positively polarized sulfur atom S1 and the nearest chloride anion Cl1 results in an average 
S1–Cl1 distance of 3.084 Å which is shorter than the sum of the atomic van-der-Waals-radii 
(3.55 Å) (Figure 28).[296] Similarly to sulfenylation reagent 91, the structure of reagent 232 
shows a short N1–S1 distance of 1.7184(17) Å which correlates to a single bond and a C1-S1-
N1 angular of 98.26(8)°. 
 
Figure 28: Molecular structure of 232 in the crystal. Hydrogen atoms and solvent molecules (DCM) are omitted 




3.8.2 Scope, limitation and application 
The generality of this imidazolyl-drived sulfenylation was tested by the reaction with different 
electron-rich (hetero)arenes as nucleophiles (Scheme 107). N-Containing heterocycles like N-
phenylpyrrole, substituted indole derivatives as well as lilolidine were transformed into the 
corresponding imidazolyl sulfides 231, 233, 234 and 235, respectively, in moderate to good 
yields of up to 89%. Even the sulfenylation of ethyl 5,6-dimethoxyindole-2-carboxylate gave 
thioether 236 in good yield of 60%. Remarkably, also arenes with electron-donating 
substituents like aniline, N,N-dimethylaniline and trimethoxybenzene were sulfenylated 
affording 238, 237 and 239, respectively, in moderate to good yields. Additionally, the 
antipruritic and first-generation antihistamine Phenbenzamine, which is utilized in the treatment 
of hay fever, asthma and urticarial,[297] was functionalized affording 86 in moderate yields of 
31%. Contrary to this, the sulfenylation of methylaniline resulted in the formation an 
inseparable mixture of the desired thioether 240A and the corresponding cationic intermediate 
(240B). The 240A/240B ratio remained unchanged even after prolonged heating of the mixture 
in MeCN solution. Surprisingly, the sulfenylation of pyrrole gave solely the corresponding 





Scheme 107: Scope of the -sulfenylation with in situ generated reagent 232. 
The structural identity of selected products was verified by X-ray diffraction experiments. 
Suitable single crystals were grown by slow evaporation of saturated solutions of either the 
compounds or crude reaction products in DCM. The molecular structures are presented in 
Figure 29. The average C–S–C angle of the crystalized species ranged between 100.68(5)° 
for 237 and 103.89(9)° for 235 and is therefore bigger than the carbon-sulfur-nitrogen angle of 





Figure 29: Molecular structures of the imidazolyl sulfenylated derivatives 233, 235, 236, 237, 239 in the crystals. 
Hydrogen atoms and solvent molecules (DCM) are omitted for clarity. Thermal ellipsoids are drawn at 50% 
probability level. 
In contrast, the sulfenylated products from less activated arenes like dimethoxybenzene (242), 
less electron-rich heterocycles like benzothiophene derivative (245) and targets with carboxyl 
and hydroxyl functionalities (244 & 243) were not accessible by the protocol and only obtained 
in traces (Scheme 108). An insufficient electron density on the arenes remains still the main 





Scheme 108: Attempted sulfenylation reaction of highly functionalized and electron-poor targets. 
To verify the necessity of the carbamatester functionality in the Carbimazole-derived reagent 
232, a control experiment with Thiamazole 247 as a sulfur-containing reactant was conducted 
(Scheme 109). The observation that only traces of the desired product 237 were obtained by 
this reaction as well as the previously discussed formation of the cationic intermediate 240B 
and 241 support the hypothesis that 232 acts as the reactive reagent, even when the exact 
mode of the subsequent decarboxylation is still unknown.  
 





3.8.3 Investigation towards the extension of the protocol to benzimidazolyl-, 
triazolyl- and benzoxazolylthioether 
After the successful evaluation of the developed protocol for the synthesis of several imidazolyl 
arylsulfides with reagent 232, it was envisaged to extend the method to the preparation of 
further heterocyclic sulfides. For this purpose, benzoxazole-2-thione 250, benzimidazole-2-
thione 251and 1,2,4-triazole-3-thione 252 look to be suitable precursors for the synthesis of 
aryl sulfides of the general structure 249 (Scheme 110). 
 
Scheme 110: Envisaged sulfur-containing precursors 250 – 252 for the synthesis of aryl sulfides of general 
structure 249. 
Imidazole-2-thione- (251) and benzoxazole-2-thione-derived (250) precursors were accessible 
by reaction of the corresponding and commercially available benzimidazole-2-thione (253) and 
2-mercaptobenzoxazole (254), respectively, with ethyl chloroformate following a modified 
protocol of S. Dove et al. (Scheme 111).[298] The desired ethyl carbamates were obtained in 
moderate yields of 33% and 45%, respectively. Since the spectroscopical analysis of the 
obtained compounds did not allow the differentiation between the conceivable S- and the 
desired N-protection of the utilized starting materials, single crystals suitable for X-ray 
diffraction experiments of compound 250 were grown by slow evaporation of its saturated DCM 






Scheme 111: Synthesis of compound 251 and 250. Crystal structure of 250: Hydrogen atoms and solvent 
molecules are omitted for clarity and thermal ellipsoids are drawn at 50% probability level.  
4-Phenyl-1,2,4-triazole-3-thione (252) was synthesized according to a modified protocol of M. 
K. Bharty, N. K. Singh et. al.[299] starting with the formation of 1-formyl-4-phenyl-3-
thiosemicarbazide (257) from phenyl isothiocyanate (255) and formic acid hydrazide (256) 
(Scheme 112). The obtained semicarbazide 257 was cyclized under basic conditions to give 
4-phenyl-1,2,4-triazole-3-thione (258) in acceptable yield of 47% over two steps. Subsequent 
formation of the desired ethyl carbamate functionality by reaction of triazole 258 with ethyl 
chloroformate gave the desired 1,2,4-triazole-3-thione 252 in moderate yield of 57%.  
 





Having the sulfur-containing precursors 250 – 252 in hand, the sulfenylation of dimethylaniline 
was attempted to proof the transferability of the method from simple imidazolyl sulfides (see 
Chapter 3.8.2) to further heterocycles. In all cases, the sulfur-containing precursors were in 
situ oxidized with NCS.  
Unfortunately, only small amounts of the desired thioether 259 and 260 were obtained from 
complex reaction mixtures by purification with flash column chromatography (Scheme 113). 
Both compounds were strongly tailing on during the purification attempts, either because of 
low solubility or decomposition caused by silica gel. For analytical purposes, an additional 
HPLC separation was necessary. In the case of 1,2,4-triazole, only traces of aryl sulfide 261 
were detectable by mass spectrometry, but neither significant amounts of pure product nor 
residual starting materials were obtained. The sulfenylations of N-phenylpyrrole (98) gave only 
traces of benzoxazolyl thioether 262 and minor yields of triazolyl derivative 263. Due to 
disappointing initial results, no further sulfenylation attempts with other nucleophiles were 
performed. 
 






3.9 Investigation towards potential sulfonthioamidation reagents  
After the potential of imidazole-2-thione-based sulfenylation reagents was extensively studied 
and evaluated, reagents of the general structure 264 were synthesized and their reactivity 
towards the formation of different N-(alky/arylthio)sulfonamides 265 was investigated (Scheme 
114). As the known cationic intermediate 248 can be considered as a CS+ synthon, the general 
structure 264 is envisaged to act as a NS+ synthon.  
 
Scheme 114: Concept of a potential reagent 264 for the synthesis of N-(alky/arylthio)-p-tosylsulfonamides 265.  
These sulfonamides are of synthetic value. Thus, N‐trifluoromethylthiosulfonamide 266 can be 
used for the α‐trifluoromethylthiolation of simple ketones/aldehydes[300] and arenes[301] or for 
the chelation‐assisted palladium‐catalyzed trifluoromethylthiolation of C–H bonds[302] (Figure 
30). The cyclic sulfenamide 267 is a valuable reagent as well, as it can be used as highly 
reactive synthon possessing electrophilic sulfur and nucleophilic nitrogen atoms. It can be 
applied for the synthesis of different S,N-heterocyclic scaffolds which have various applications 
in medicinal chemistry.[303] Since only a small number of these N-
(alky/arylthio)toxylsulfonamides are known in literature they may hold distinct properties as 
pharmaceutical relevant compounds. 
 




3.9.1 Synthesis of imidazole-derived sulfonthioamidation reagent 269 
To start with, imidazole thione 78 was brominated with equimolar amounts of bromine resulting 
in the quantitative formation of dibromide 79 according to the published procedure[242] (Scheme 
115; see also Scheme 76). Afterwards, 79 was treated with p-toluenesulfonamide (268) in the 
presence of DIPEA. After washing the reaction mixture with water to remove the additionally 
formed ammonium bromide salt, the reagent 269 was obtained in good yield of 86%  
 
Scheme 115: Synthesis of the reagent 269. 
To get insights into the binding situation of compound 269 and to verify its identity, single 
crystals suitable for X-ray diffraction experiments were obtained by slow evaporation of a 
saturated DCM solution of 269. As expected, 269 exhibits an angular geometry in the solid 
state structure with an C1–S1–N1 angle of 107.43(4)°and a narrow dihedral angle 
Φ(N1;C1;S1;N3) of 59.5° (Figure 31), Noteworthy, the angle is significant smaller than the 
dihedral angle of the sulfenylation reagent 91 (81.8°). Apart of packing effects this can be 
rationalized by the attractive interaction between the negatively charged nitrogen N3 (Mulliken 
charge: –1.1), which is more negative compared to that one of free p-toluenesulfonamide (–
0.58), and the positively charged imidazolium nitrogen N1 (Mulliken charge: +0.68).[304] With 
the bond lengths of 1.7528(9) Å the for the S1–N3 bond and with 1.5944(8) Å for the S1–N3 
bond. Both N–S bonds exhibits typical characteristics of corresponding single bonds [S–N: 





Figure 31: Crystal structure of compound 269 (side view A and top view B). Hydrogen atoms and solvent 
molecules are omitted for clarity and thermal ellipsoids are drawn at 50% probability level. C: Mulliken charges of 
compound 269 after optimization with DFT on b3lyp/311-g(d,p) level. 
The significant negative charge on N3 resulted in highfield shifted 15N-signal of –283.4 ppm in 
compound 269. 
 
3.9.2 Investigation towards reaction of 269 with different nucleophiles 
Furthermore, the ability of different nucleophiles to release the imidazole NHC-carbene under 
the generation of N-[(hetero)arylthio]-p-tosylsulfonamides was investigated. No transfer of the 
thiosulfinimide or the p-toluenesulfonamide groups of 269 was observed in the initial attempts 
with electron-rich (hetero)arenes as nucleophiles (Scheme 116). Neither methylindole 270 nor 
dimethylaniline (272) led to the formation of the corresponding coupling products 271 and 273, 
respectively, whereas the utilized (hetero)arenes were nearly quantitatively reisolated. In both 
cases only traces of the already known cationic sulfide 114 and 129 were isolated (compare 
Chapter 3.4). 
 




The reaction with stronger nucleophiles like Grignards reagents may be more promising, as 
the latter gave good results with the previously discussed sulfenylation reagents (see Scheme 
92). Surprisingly, the reaction of 269 with cyclopentylmagnesium bromide (274) resulted in the 
formation of different products (Table 11). In addition to the desired N-
(cyclopentylthio)sulfonamide (275), p-toluenesulfonamide (268) and cationic sulfide 277 were 
formed. This indicates that compound 269 react via two different reaction pathways. In pathway 
A, the carbene acts as a leaving group leading to the formation of the envisaged product 275 
in 20% yield (Entry 1), whereas in pathway B the p-toluenesulfonamide (268, TosNH2) serves 
as leaving group furnishing species 277 as the product. Increasing the amount of Grignard 
reagent slightly favored the formation of toxylsulfonamide 275, while addition of over 
stoichiometric quantity of LiCl for the complexation of nitrogen in the tosyl moiety showed no 
effect on the formation of 275 (Entries 2 & 3). In contrast to this, lowering the concentration of 
the reagents by factor four was non-beneficial, as the yield of 275 dropped to 12% (Entry 4). 
Table 11: Optimization of the reaction conditions for the formation of 275. 
 
Entry Equiv. 269 c[269] /M 275 268 269 
1 1.5 0.13 20% 27% 11% 
2 3.0 0.13 31% 38% 19% 
3 3.0 + 6 equiv. LiCl 0.13 31% 50% 27% 
4 3.0 0.03 12% 54% 11% 
 
To investigate if the reaction pathway A can be favored by thermodynamic control, the reaction 




 –77 °C for two days and subsequently quenched with an aqueous ammonium chloride solution, 
275 was obtained in 25% yield. Additionally, unreacted 269 was isolated in 7% yield. Increasing 
the temperature to –35°C significantly affect the outcome of the reaction (Entry 2). When the 
reaction was run at room temperature, pathway B was strongly favored, as nearly the 
quantitative amounts of the released p-toluenesulfonamide (268) have been isolated. 
Table 12: Further optimization of the reaction conditions for the formation of 275.  
 
Entry T t 275 268 269 
1 –77°C 2 d 25% 10% 7% 
2 –35°C 2 d 39% 10% nb 
3 rt 1 d 0% 91% 0% 
 
As a preliminary conclusion, three equivalents of Grignard reagent and a reaction temperature 
of –78 °C to rt over 12 h turned out to be the best possible reaction conditions. 
To verify the structural identity of the previously unknown sulfonamide 275, crystals suitable 
for X-ray diffraction experiments were grown by slow evaporation of a saturated solution in 
DCM of either the compound or the crude reaction product. The solid state structure of 275 is 
depicted in Figure 32. 
 
Figure 32: Structure of compound 275 in the crystal. Hydrogen atoms are omitted for clarity and thermal 




After partial optimization of the reaction conditions for the sulfenylation reagent 269 using 
cyclopentylmagnesium bromide, 269 was treated with further strong nucleophiles to test the 
generality of the reaction (Scheme 117). Unfortunately, employment of neither para-
methoxybenzyl Grignard reagent (277) nor isopropylmagnesium bromide (280) nor 
phenylethynyl-derived Jocić-Normant reagent 283 resulted in formation of noteworthy amounts 
of the envisaged coupling products 278, 281 and 284, respectively (Scheme 117 A to C). 
Instead, major amounts of p-toluenesulfonamide (268) and cationic species 279 and 282 were 
obtained indicating that the reactions proceeded mainly along pathway B. When slightly over-
stoichiometric amounts of n-butyllithium (285) are utilized as nucleophiles, solely sulfonamide 
268 was isolated from a complex product mixture (Scheme 117 D). 
 




3.9.3 Synthesis and evaluation of triazole-derived sulfonthioamidation reagent  
As discussed above (compare Chapter 3.6), the change of the sulfur-containing backbone from 
an imidazole to a triazole motif led to slightly better sulfenylation abilities, triazole reagent 288 
was synthetically targeted. Therefore, the triazole-derived reagent 288 was obtained as a white 
foam from brominated 2,4-diisopropyl-1,2,4-triazole-3-thione 287 in the presence of p-
toluenesulfonamide (268) under basic conditions in good yields of 82% (Scheme 118).  
 
Scheme 118: Synthesis of 1,2,4-triazole-derived reagent 288.  
Unfortunately, only diaryl sulfide 289 was isolated in the reaction of 288 with magnesium 
organyl 277 (Scheme 119). Nevertheless, cyclopentylmagnesium bromide (274) gave the 
desired product 275 in moderate yield of 24%, only slightly reduced as compared to the efficacy 
of reagent 269 (25% yield, Table 12). 
 
Scheme 119: Reactivity of 1,2,4-triazole-derived reagent 288. 
Since the entire potential of the synthesized sulfonthioamidation reagents has not been fully 
investigated, yet further studies on the reactivity of the reagents 269 and 288 will be carried 
out in the nearest future. Potentially, the change of the sulfur-containing platform from an 
imidazoline-2-thione-based one towards a dibenzothiophene-derived backbone could 




dibenzothiophenes are extremely versatile platforms for transfer reagents, as recently 





4 Summary  
In the presented thesis, a highly modular protocol for the transition metal-free preparation of 
diaryl and alkyl aryl sulfides was accomplished as a significant contribution to the area of 
sulfide synthesis. For this purpose, the imidazole-2-thione-derived sulfenylation reagents 290 
X– were developed. It was shown that their versatile reactivity allowed the initial activation of 
several unfunctionalized (hetero)arenes. Additionally, the protocol demonstrated a high 
functional group tolerance (Scheme 120). Hereby, the influence of the sulfur-containing 
thiourea backbone as well as the effect of the electron-withdrawing N-succinimidyl moiety in 
the reagents was studied. In a consecutive step, metal organyls were identified as suitable 
nucleophiles for the synthesis of aryl sulfides from the cationic intermediate 291 which were 
isolated in moderate to excellent yields.  
The presented reagent can be considered as a synthetic equivalent of a [S]2 synthon which 
undergoes a double electrophilic attack. Noteworthy, the herein developed protocols allow the 
sequential twofold sulfenylation of electron-rich heterocycles like N-phenylpyrrole. In addition, 
several cationic intermediates 291 were crystallized and analyzed by X-ray crystallography to 
verify their molecular connectivity. The general methodology was further extended toward the 
synthesis of unsymmetrical aryl selenides.  
 





Based on these results, an efficient single step protocol for the synthesis of imidazolyl and 
further heterocyclic thioethers was elaborated. With this, further diheteroaryl sulfides were 
synthesized in yields of up to 82% from the in situ formed reagents 292 (Scheme 121). 
 
Scheme 121: Investigations towards the synthesis and application of (hetero)aryl-sulfenylating reagent 292. 
Additionally, different reagents of the general structure 293 were synthesized, and their 
connectivity was verified by X-ray crystallography experiments (Scheme 122). Furthermore, 
their reactivity with electro rich arenes was investigated. Finally, the reagents were 
successfully utilized in the reaction with metal organyl compounds in the formation of the 
scarce structure motif 265. 
 






5.1 General considerations 
All anhydrous solvents were obtained from a solvent purification system MBSPS7 from 
MBraun. All reactions were carried out under nitrogen atmosphere unless otherwise stated. 
IR: JASCO FT-4100 spectrometer, wavelengths in cm−1. Microwave: Biotage Initatior. MS 
(EI): AccuTOF (Jeol) (70 eV). ESIMS: ESI-HRMS: micrOTOF (Bruker) and maXis (Bruker). 
GC-MS: Reactions were monitored by GC-MS on Agilent Technologies 7820A gas 
chromatography system coupled with an Agilent Technologies5977 E MSD EI-MS detector. 
NMR: Spectra were recorded on Bruker AV 500, 400 or DPX 300 spectrometers; 1H and 
13C chemical shifts (δ) are given in ppm relative to TMS, coupling constants (J) in Hz. The 
solvent signals were used as references and the chemical shifts converted to the TMS scale. 
All flash column chromatography were performed using a Biotage One automated column 
chromatography system on CHROMABOND® Flash BT, 15g (or 25g) SiOH 40-63 µm from 
Macherey-Nagel. Thin-layer chromatography (TLC) analysis was performed using 
POLYGRAM® SIL G/UV254 TLC plates from Macherey-Nagel and visualized by UV 
irradiation and/or phosphomolybdic acid staining. All commercially available compounds 
(Acros, ABCR, Alfa Aesar, Aldrich, Fluorochem, TCI) were used as received; other 
compounds were prepared accordingly to the published procedures. The concentration of 
Grignard reagents and other metal organic compounds was determined before each 
experiment using the titration protocol of P. Knochel et al.1 
Crystal structure analysis: Data collection was performed on a Bruker D8 Venture four-circle-
diffractometer from Bruker AXS GmbH; used detector: Photon II from Bruker AXS GmbH; used 
X-ray sources: microfocus IµS Cu/Mo from Incoatec GmbH with mirror optics HELIOS and 
single-hole collimator from Bruker AXS GmbH.  
Used programs: APEX3 Suite (v2017.3-0) and therein integrated programs SAINT 










was done with SHELXT, refinement with SHELXS2; OLEX2 was used for data finalization.3 
Special Utilities: SMZ1270 stereomicroscope from Nikon Metrology GmbH was used for 
sample preparation; crystals were mounted on MicroMounts or MicroLoops from MiTeGen; for 
sensitive samples the X-TEMP 24 System was used for picking of crystals; crystals were 
cooled to given temperature with Cryostream 800 from Oxford Cryosystems. 
For clarity hydrogen atoms were removed from the Figures and Tables presented below. The 
numberings in the Figures do not follow that recommended by IUPAC. Ellipsoids are shown at 
50% probability level. 
 








2 Both: G. M. Sheldrick, Acta Cryst. 2008, A64, 112–122. 
3 O .V. Dolomanov, L. J. Bourhis, R. J Gildea, J. A. K. Howard, H. Puschmann, J. Appl. Cryst. 2009, 42, 339–341. 




5.2 Reactions towards the synthesis of sulfides 
5.2.1 Synthesis of backbones and reagents  
1,3-Dimethyl-1,3-dihydro-2H-imidazole-2-thione (294)5 
The reaction was carried out under ambient conditions. 1-Methyl-1H-
imidazole (5.40 g, 5.20 mL, 65.8 mmol, 1.00 equiv.) was dissolved in 
EtOAc (75 mL). Methyl iodide (9.34 g, 4.10 mL, 65.8 mmol, 1.00 equiv.) 
was added dropwise. The solution was stirred for 2 h at rt and the 
obtained white precipitate was filtered off and dried under reduced pressure to obtain 1,3-
dimethyl-1H-imidazol-3-ium iodide as a white powder (14.6 g, 65.2 mmol, 99%). The white 
powder was subsequently dissolved in dry MeOH (75 mL); sulfur (2.24 g, 70.0 mmol) and 
potassium carbonate (7.60 g, 55.0 mmol) were added, and the suspension was stirred at 65 
°C for 20 h. The hot brown solution was filtered through a Celite® pad. The pad was washed 
with MeOH (20 mL), and the combined organic phases were cooled to 4 °C for 17 h. The white 
crystals were filtered off and recrystallized from hot MeOH (75 mL) to give 294 as a white 
powder (2.33 g, 18.2 mmol, 28% over two steps 
1H NMR (300 MHz, d6-DMSO) δ = 3.45 (s, 6H), 7.11 (s, 2H). HRMS: m/z calcd. for C5H9N2S+ 







5 294 was synthesized applying a modified procedure of G. Roy et al.: M. Banerjee, R. Karri, K. Singh Rawat, K. 
Muthuvel, B. Pathak, G. Roy, Angew. Chem. Int. Ed. 2015, 54, 9323–9327. 





The reaction was carried out without Schlenk-techniques. To a stirred 
solution of 1,3-dimethyl-2-thiourea (8.28 g, 79.5 mmol, 1.00 equiv.) in 1-
hexanol (85 mL) was added acetoin (7.00 g, 6.9 mL, 79.5 mmol, 
1.00 equiv.). The reaction mixture was stirred at 160 °C for 16 h and cooled 
down to 4 °C for 18 h. The white solid was filtered off and washed with ice-cold ethanol (3  
20 mL). 957 was isolated as a white solid (4.00 g, 25.6 mmol, 32%).  
1H NMR (300 MHz, CDCl3 ppm) δ = 2.08 (d, J = 0.5 Hz, 6H), 3.55 (d, J = 0.5 Hz, 6H). HRMS: 
m/z calcd. for C7H12N2S+ [M]+ = 156.0721; found = 156.0724. The data are in line with the 
previously published ones.6,7 
1,3-Diisopropyl-4,5-dimethyl-2(3H)-imidazolethione (78)8 
The reaction was carried out without Schlenk-techniques. To a stirred 
solution of 1,3-di(isopropyl)-2-thiourea (38.0 g, 237.1 mmol, 1.00 equiv.) 
in 1-hexanol (150 mL) was added acetoin (20.9 g, 20.7 mL, 237.2 mmol, 
1.00 equiv.). The reaction mixture was stirred at 160 °C for 16 h and 
cooled down to 4°C for 18 h. The white solid was filtered off and washed 
with ice-cold ethanol (3  20 mL). After recrystallizing from hot 1-hexanol (50 mL), 78 was 
isolated as a white solid (22.9 g, 107.8 mmol, 45%).  
1H NMR (300 MHz, CDCl3 ppm) δ = 1.25 (d, J = 7.1 Hz, 12H), 2.00 (d, 6H), 5.49 (s, 6H). 
13C NMR (75 MHz, CDCl3, ppm) δ = 10.1, 20.4, 49.0, 121.2, 159.4. IR (neat, cm–1): 2974.3, 
2935.9, 1464.9, 1412.3, 1368.5, 1336.4, 1206.1, 1138.8, 1105.3, 1089.3, 980.1, 906.4, 806.6, 
759.1, 552.8. HRMS: m/z calcd. for C11H21N2S+ [M+H] + = 213.1420; found = 213.1426. The 






7 The protocol of M. Alcarazo et al. was applied: G. Talavera, J. Peña, M. Alcarazo, J. Am. Chem. Soc. 2015, 27, 
8704–8707. 




2-(Bromothio)-1,3,4,5-tetramethyl-1H-imidazol-3-ium Bromide (96) 
Thiourea 95 (2.00 g, 12.8 mmol, 1.00 equiv.) was dissolved in DCM 
(18 mL) and the obtained solution was cooled to 0°C. Bromine (2.05 g, 
656 µL, 12.8 mmol, 1.00 equiv.) was added dropwise, and the brown 
suspension was allowed to warm up to rt. After 3 h, all volatiles were removed in vacuo and 
969 was obtained as an orange solid (4.05 g, 12.8 mmol, 100%). 
1H NMR (300 MHz, CDCl3 ppm) δ = 2.28 (s, 6H), 3.82 (s, 6H). The data are in line with the 
previously published ones.6 
2-(Bromothio)-1,3-diisopropyl-4,5-dimethyl-1H-imidazol-3-ium Bromide (79) 
Thiourea 78 (8.63 g, 40.6 mmol, 1.00 equiv.) was dissolved in DCM 
(42 mL) and the obtained solution was cooled to 0°C. Bromine (6.49 g, 
2.08 mL, 40.6 mmol, 1.00 equiv.) was added dropwise, and the brown 
suspension was allowed to warm up to rt. After 3 h all volatiles were 
removed in vacuo and 7910 was obtained as an orange solid (15.1 g, 40.6 mmol, 100%). 
1H NMR (300 MHz, CDCl3 ppm) δ = 1.67 (d, J = 7.1 Hz, 12H), 2.37 (s, 6H), 5.66 (quint, J = 7.1 







9 The protocol of M. Alcarazo et al. was applied: G. Talavera, J. Peña, M. Alcarazo, J. Am. Chem. Soc. 2015, 27, 
8704–8707. 







Thiourea 78 (212 mg, 1.00 mmol, 1.00 equiv.) and N-chlorosuccinimide 
(134 mg, 1.00 mmol, 1.00 equiv.) were dissolved in 1,2-DCE (10 mL). The 
obtained yellow solution was stirred at rt for two hours. The solvent was 
removed in vacuo, and product 91 was isolated as a light yellow solid 
(346 mg, 1.00 mmol, 100%). 
1H NMR (300 MHz, CD2Cl2 ppm) δ = 1.62 (d, J = 7.0 Hz, 12H), 2.39 (s, 6H), 2.78 (s, 4H), 6.20 
(hept, J = 7.1 Hz, 2H). 13C NMR (75 MHz, CD2Cl2, ppm) δ = 11.2, 21.5, 29.3, 44.5, 54.6, 130.4, 
177.0. IR (neat, cm–1): 2971.8, 2941.9, 1773.2, 1714.4, 1610.3, 1470.5, 1445.4, 1422.2, 
1391.4, 1372.1, 1346.1, 1287.3, 1250.6, 1216.9, 1179.3, 1161.9, 1132.0, 1113.7, 1092.5, 
1010.5, 943.0, 906.4, 869.7, 820.6, 802.2, 752.1, 664.4, 644.1, 575.6, 544.8. HRMS: m/z calcd. 
for C15H24N3O2S+ [M–Cl]+ = 310.1584; found = 310.1584. 
2-[(2,5-Dioxopyrrolidin-1-yl)thio]-1,3-diisopropyl-4,5-dimethyl-1H-imidazol-3-ium 
Hexafluoroantimonate (93): 
Thiourea 78 (1.06 g, 5.00 mmol, 1.00 equiv.) and N-chlorosuccinimide 
(667 mg, 5.00 mmol, 1.00 equiv.) were dissolved in MeCN (50 mL). The 
obtained yellow solution was stirred at rt for 5 min. Sodium 
hexafluoroantimonate (1.94 g, 7.5 mmol, 1.50 equiv.) was added, and the 
yellow suspension was stirred at rt for 5 h. The solvent was removed in 
vacuo, and the residual yellow solid was extracted with DCM (4  50 mL). The organic phases 
were combined and the solvent was removed in vacuo. The title compound 93 was isolated as 
a yellow solid (2.51 g, 4.60 mmol, 92%). 
1H NMR (300 MHz, CD2Cl2 ppm) δ = 1.57 (d, J = 7.2 Hz, 12H), 2.41 (s, 6H), 2.85 (s, 6 H), 6.23 
(sept, J = 7.2 Hz, 2H). 13C NMR (126 MHz, CD2Cl2, ppm) δ = 11.2, 21.6, 29.3, 55.1, 132.9, 
133.5, 176.7.IR (neat, cm–1): 2993.9, 1736.6, 1597.7, 1458.9, 1421.3, 1397.2, 1376.0, 1291.1, 
1270.9, 1236.1, 1215.9, 1131.0, 1092.5, 1004.7, 819.6, 749.2, 568.9, 541.9, 516.8. HRMS: 







78 (21.2 mg, 100 µmol, 1.00 equiv.) and N-bromosuccinimide (17.8 mg, 
100 µmol, 1.00 equiv.) were dissolved in DCM (2 mL). The obtained yellow 
solution was stirred at rt for two hours. The solvent was removed in vacuo, 
and product 295 was isolated as a light yellow solid (39.0 mg, 100 µmol, 
100%). 
1H NMR (300 MHz, CD2Cl2 ppm) δ = 1.62 (d, J = 7.0 Hz, 12H), 2.39 (s, 6H), 2.82 (s, 4H), 6.17 
(hept, J = 7.0 Hz, 2H). 13C NMR (75 MHz, CD2Cl2, ppm) δ = 11.3, 21.5, 29.4, 54.7, 131.0, 
138.1, 176.9. IR (neat, cm–1): 2971.8, 2939.0, 1717.3, 1445.4, 1422.2, 1391.4, 1299.8, 1280.5, 
1246.8, 1232.3, 1219.8, 1159.0, 1139.7, 1132.0, 1092.5, 1009.6, 818.6, 729.9, 696.2, 649.9, 
574.7, 502.4. HRMS: m/z calcd. for C15H24N3O2S+ [M–Br]+ = 310.1584; found = 310.1583. 
2-[(1,3-Dioxoisoindolin-2-yl)thio]-1,3-diisopropyl-4,5-dimethyl-1H-imidazol-3-ium Bro-
mide (90) 
Compound 79 (1.42 g, 3.82 mmol, 1.00 equiv.) and potassium 
phthalimide (742 mg, 4.01 mmol, 1.05 equiv.) were dissolved in 
MeCN (50 mL). The orange solution became yellow. The reaction 
mixture was stirred at rt for two hours, the white precipitate was 
filtered off and the MeCN was removed in vacuo. Product 90 was isolated as a yellow solid 
(800 mg, 1.82 mmol, 48%). 
1H NMR (300 MHz, CDCl3 ppm) δ = 1.51 – 1.82 (bs, 12H), 2.35 (s, 6H), 6.34 (d, J = 7.1 Hz, 
2H), 7.75 – 7.81 (m, 2H), 7.80 – 7.89 (m, 2H). 13C NMR (101 MHz, CDCl3, ppm) δ = 2.0, 10.9, 
54.3, 124.3, 129.9, 131.4, 135.3, 139.6, 167.3. IR (neat, cm–1): 1719, 1584, 1448, 1406, 1370, 
1338, 1282, 1268, 1252, 1213, 1173, 1140, 1089, 1054, 1011, 952, 904, 865, 800, 751, 709, 
698, 626, 547, 501. HRMS: m/z calcd. for C19H24N3O2S+ [M–Br]+ = 358.1584; found = 
358.1579. 
1,3,4,5-Tetramethyl-2-[(2-oxopyrrolidin-1-yl)thio]-1H-imidazol-3-ium Bromide (94) 
Dibromide 96 (458 mg, 1.45 mmol, 1.00 equiv.) was dissolved in MeCN 
(80 mL). A solution of 1-(trimethylsilyl)pyrrolidin-2-one (342 mg, 348 µL, 
2.17 mmol, 1.50 equiv.) in MeCN (5 mL) was added dropwise over a 




concentrated under reduced pressure to a volume of ca 3 mL. Under vigorous stirring, Et2O 
(20 mL) was added, and the resulting white suspension was sonicated in an ultrasonic bath 
for 2 min. Solvents were removed by filtration, and the obtained white powder was washed 
with Et2O (20 mL). After removing the solvent by filtration, the product was dried in vacuo. 94 
was isolated as a grey solid (428 mg, 1.34 mmol, 92%). 
1H NMR (300 MHz, CDCl3 ppm) δ = 2.05 – 2.22 (m, 2H), 2.35 (s, 6H), 2.40 (dd, J = 8.6, 7.4 
Hz, 2H), 3.85 (t, J = 7.0 Hz, 2H), 4.11 (s, 6H). 13C NMR (101 MHz, CDCl3, ppm) δ = 10.1, 19.2, 
29.3, 35.2, 52.3, 130.4, 138.5, 177.8. IR (neat, cm–1): 3403.7, 2949.6, 1707.7, 1623.8, 1497.5, 
1433.8, 1366.3, 1283.4, 1243.9, 1213.0, 1120.4, 1105.0, 1011.5, 947.8, 854.3, 778.1, 638.3, 
546.7. HRMS: m/z calcd. for C11H18N3OS+ [M–Br]+ = 240.1165; found = 240.1163. 
1,3-Diisopropyl-4,5-dimethyl-2-[(2-oxopyrrolidin-1-yl)thio]-1H-imidazol-3-ium Bromide 
(92) 
Dibromide 79 (934 mg, 2.51 mmol, 1.00 equiv.) was dissolved in 
MeCN (90 mL). A solution of 1-(trimethylsilyl)pyrrolidin-2-one (592 mg, 
602 µL, 3.76 mmol, 1.50 equiv.) in MeCN (5 mL) was added dropwise 
over a period of 10 min. The obtained yellow solution was stirred at rt 
for 1.5 h. All volatiles were removed under reduced pressure, and the obtained yellow foam 
was washed with Et2O (3  15 mL) under sonication in an ultrasonic for 2 min each time until 
a fine powder was obtained. After removing the solvent by filtration, the product was dried in 
vacuo. Product 92 was isolated as a grey solid (901 mg, 2.39 mmol, 95%). 
1H NMR (300 MHz, CD3CN ppm) δ = 1.56 (d, J = 7.1 Hz, 12H), 1.98 – 2.09 (m, 2H), 2.24 – 
2.33 (m, 2H), 2.40 (s, 6H), 3.54 – 3.67 (m, 2H), 5.77 (hept, J = 7.1 Hz, 2H). 13C NMR (75 MHz, 
CD3CN, ppm) δ = 11.0, 19.6, 21.2, 29.8, 52.3, 54.4, 131.7, 137.6, 178.2. IR (neat, cm–1): 
2967.9, 1691.3, 1618.0, 1424.2, 1369.2, 1244.8, 1220.7, 1118.5, 1025.9, 942.1, 907.3, 805.1, 







imidazol-3-ium Chloride (296) 
Compound 78 (21.2 mg, 100 µmol, 1.00 equiv.) and N-
chlorosaccharin (21.8 mg, 100 µmol, 1.00 equiv.) were dissolved 
in DCM (2 mL). The obtained yellow orange solution was stirred at 
rt for 1.5 h. All volatiles were removed under reduced pressure, and 
the product 296 was obtained as a light yellow powder (43.0 mg, 
100 µmol, 100%). 
1H NMR (400 MHz, CD2Cl2 ppm) δ = 1.65 (d, J = 7.0 Hz, 12H), 2.40 (s, 6H), 5.88 (hept, J = 7.0 
Hz, 2H), 7.76 – 7.86 (m, 3H), 7.96 – 7.99 (m, 1H). 13C NMR (101 MHz, CD2Cl2, ppm) δ = 11.1, 
21.2, 54.4, 54.5, 121.3, 125.6, 129.3, 130.1, 134.5, 135.2, 140.2, 162.4.IR (neat, cm–1): 2982.4, 
2938.0, 2553.3, 1727.9, 1607.4, 1448.3, 1425.1, 1393.3, 1373.1, 1322.0, 1283.4, 1241.0, 
1218.8, 1175.4, 1159.0, 1110.8, 1047.2, 975.8, 943.0, 892.9, 793.6, 753.1, 729.9, 702.0, 
675.0, 624.8, 590.1, 562.1, 534.2, 511.0. HRMS: m/z calcd. for C18H24N3O3S2+ [M–Cl]+ = 





5.2.2 Screening of different backbones 
General protocol GP1 
 
Scheme 123: Preliminary screening of different backbones 297. 
Backbone 297 (1.00 mmol, 1.00 equiv.), N-chlorosuccinimide (147 mg, 1.10 mmol, 
1.10 equiv.) and phenylpyrrole (158 mg, 1.10 mmol, 1.10 equiv.) were dissolved in MeCN 
(10 mL). The yellow solution was stirred for 10 min at rt and then at 70 °C for 16 h. The 
resulting orange brown reaction mixture was allowed to cool down to rt, and all volatiles were 
removed under reduced pressure. The residual orange oil was dissolved in DCM (10 mL) and 
washed with sat. aq. NaSbF6 (10 mL) for 3 min. The organic layer was dried over MgSO4 and 
concentrated in vacuo.  
2-Isopropyl-1-[(1-phenyl-1H-pyrrol-2-yl)thio]isoquinolin-2-ium Hexafluoroantimonate 
(111): 
After threefold column chromatography (DCM:MeOH), product 111 was 
obtained as an orange solid (99.1 mg, 171 µmol, 17%) according to GP1; 
however, with a purity of 80%. Fortunately, the identity of compound was 
confirmed by X-Ray crystal structure analysis.  
1H NMR (300 MHz, CD2Cl2 ppm) δ = 1.41 (d, J = 6.7 Hz, 6H), 5.97 (hept, J = 6.7 Hz, 1H), 6.44 
(dd, J = 3.9, 3.0 Hz, 1H), 6.86 – 6.95 (m, 3H), 7.02 (dd, J = 3.0, 1.8 Hz, 1H), 7.04 – 7.11 (m, 
2H), 7.30 – 7.39 (m, 1H), 7.82 (ddd, J = 8.4, 6.1, 2.1 Hz, 1H), 8.00 – 8.09 (m, 2H), 8.26 (q, J = 
7.0 Hz, 2H), 8.65 (dd, J = 8.8, 0.9 Hz, 1H). 13C NMR (101 MHz, CD2Cl2, ppm) δ = 23.3, 62.6, 
111.7, 121.5, 121.9, 127.0, 127.6, 128.5, 129.2, 129.4, 130.0, 130.5, 130.6, 131.1, 132.4, 
132.5, 137.4, 137.5, 138.3. IR (neat, cm–1): 1711.5, 1644.0, 1620.9, 1595.8, 1550.6, 1497.5, 
1458.9, 1431.9, 1374.0, 1321.0, 1265.1, 1230.4, 1172.5, 1155.2, 1133.9, 1086.7, 1055.8, 
1037.5, 1009.6, 877.5,  823.5,  755.0, 735.7, 697.1, 649.9, 567.9, 514.9. HRMS: m/z calcd. for 







In our hands, it was not possible to isolate pure 112.  




In our hands, it was not possible to isolate 105.  




antimonate (108):  
After threefold column chromatography (DCM:MeOH), 108  was 
obtained as an orange solid (180.7 mg, 306.1 µmol, 31%) according to 
GP1 with a purity of 90%. However, the identity of compound was 
confirmed by X-ray crystal structure analysis.  
1H NMR (300 MHz, CD2Cl2 ppm) δ = 1.43 – 1.51 (m, 8H), 1.58 – 1.67 (m, 2H), 1.75 – 1.81 (m, 
2H), 3.38 – 3.44 (m, 8H), 6.48 (dd, J = 3.9, 2.9 Hz, 1H), 6.82 (dd, J = 3.9, 1.7 Hz, 1H), 7.20 
(dd, J = 2.9, 1.7 Hz, 1H), 7.27 – 7.33 (m, 2H), 7.49 – 7.61 (m, 3H). 13C NMR (126 MHz, CD2Cl2, 
ppm) δ = 23.6, 26.5, 54.7, 111.7, 112.0, 123.1, 126.8, 129.1, 129.6, 130.3, 138.4, 173.3. IR 
(neat, cm–1): 2947.7, 1596.8, 1571.7, 1497.5, 1443.5, 1428.0, 1395.2, 1364.4, 1320.0, 1285.3, 
1270.9, 1252.5, 1210.1, 1164.8, 1133.9, 1114.7, 1090.5, 1039.4, 1005.7,  950.7,  912.2, 853.3, 
789.7, 768.5, 742.5, 696.2, 649.9, 564.1, 509.1. HRMS: m/z calcd. for C21H28N3S+ [M–SbF6]+ 







Compound 104 was prepared according to GP1, purified by column 
chromatography (DCM:MeOH) and obtained as a white solid (321.1 mg, 
634.4 µmol, 63%).  
1H NMR (300 MHz, CD2Cl2 ppm) δ = 3.45 (s, 6H), 6.41 (dd, J = 3.9, 3.0 Hz, 1H), 6.96 (dd, J = 
3.9, 1.7 Hz, 1H), 7.11 (dd, J = 3.9, 1.7 Hz, 1H), 7.17 – 7.22 (m, 2H), 7.24 (s, 2H), 7.49 – 7.61 
(m, 3H). 13C NMR (126 MHz, CD2Cl2, ppm) δ = 36.8, 109.7, 111.0, 123.7, 125.1, 127.6, 130.0, 
130.1, 130.4, 138.7. IR (neat, cm–1): 3144.4, 1596.8, 1566.9, 1509.0, 1499.4, 1458.9, 1433.8, 
1412.6, 1328.7, 1237.1, 1164.8, 1088.6, 1045.2, 931.5, 799.4, 757.9, 742.5, 725.1, 699.1, 




Compound 109 was prepared according to GP1, purified by column 
chromatography (DCM:MeOH) and obtained as a white solid (200.5 mg, 
373.3 µmol, 37%).  
1H NMR (600 MHz, CD2Cl2 ppm) δ = 1.13 (d, J = 6.4 Hz, 6H), 1.23 (d, J = 
6.5 Hz, 6H), 3.80 – 3.99 (m, 2H), 5.28 – 5.32 (m, 1H), 6.60 (dd, J = 3.9, 2.9 Hz, 1H), 6.90 (d, 
J = 8.3 Hz, 1H), 7.04 (dd, J = 3.9, 1.7 Hz, 1H), 7.23 (dd, J = 7.9, 1.7 Hz, 2H), 7.41 (dd, J = 3.0, 
1.7 Hz, 1H), 7.50 – 7.57 (m, 3H). 13C NMR (126 MHz, CD2Cl2, ppm) δ = 22.1, 22.3, 47.5, 50.2, 
106.1, 112.5, 126.6, 126.7, 129.8, 130.1, 132.2, 137.8, 164.5. IR (neat, cm–1): 1708.6, 1618.0, 
1513.8, 1497.5, 1466.6, 1432.9, 1392.4, 1375.0, 1319.1, 1159.0, 1039.4, 745.4, 694.2, 653.8, 
549.6. HRMS: m/z calcd. for C17H24N3S+ [M–SbF6]+ = 302.1685; found = 302.1680. 
1,3,4,5-Tetramethyl-2-[(1-phenyl-1H-pyrrol-2-yl)thio]-1H-imidazol-3-ium hexafluoroanti-
monate (103): 
Compound 109 was prepared according to GP1, purified by column 
chromatography (DCM:MeOH) and obtained as a white solid (128.6 mg, 
240.7 µmol, 24%).  
1H NMR (300 MHz, CD2Cl2 ppm) δ = 2.16 (s, 6H), 3.33 (s, 6H), 6.38 (dd, J = 3.9, 3.0 Hz, 1H), 




7.50 – 7.58 (m, 3H). 13C NMR (126 MHz, CD2Cl2, ppm) δ = 9.6, 33.5, 110.8, 111.4, 122.9, 
127.7, 129.6, 129.7, 129.8, 130.2, 136.3, 138.9. HRMS: m/z calcd. for C17H20N3S+ [M–SbF6]+ 
= 298.1372; found = 298.1373. 
1,3-Diisopropyl-4,5-dimethyl-2-[(1-phenyl-1H-pyrrol-2-yl)thio]-1H-imidazol-3-ium Hexa-
fluoroantimonate (99):  
Compound 99 was prepared according to GP1, purified by column 
chromatography (DCM:MeOH) and obtained as a white solid 
(383 mg, 648.8 µmol, 65%).  
1H NMR (300 MHz, CD2Cl2 ppm) δ = 1.34 (d, J = 7.1 Hz, 12H), 2.29 
(s, 6H), 5.00 (hept, J = 7.1 Hz, 2H), 6.40 (dd, J = 3.9, 3.0 Hz, 1H), 6.68 (dd, J = 3.9, 1.7 Hz, 
1H), 7.13 (dd, J = 3.0, 1.8 Hz, 1H), 7.33 – 7.39 (m, 2H), 7.49 – 7.62 (m, 3H). 13C NMR (101 
MHz, CD2Cl2, ppm) δ = 10.8, 21.3, 53.8, 111.7, 112.6, 121.9, 126.5, 128.9, 129.4, 130.4, 130.5, 
135.8, 138.7. IR (neat, cm–): 2993.9, 1495.5, 1455.0, 1436.7, 1413.6, 1376.9, 1319.1, 1207.2, 
1136.8, 1109.8, 1086.7, 1038.5, 767.5, 725.1, 700.0, 654.7, 615.2, 602.6, 571.8, 559.3. 
HRMS: m/z calcd. for C21H28N3S+ [M–SbF6]+ = 354.1998; found = 354.2000; calcd. for SbF6– 






(107a) and 1,1,3,3-tetramethyl-2-(1-phenyl-1H-pyrrol-3-yl)isothiouronium hexafluoro-
antimonate (107b): 
After column chromatography (DCM:MeOH) of a crude 
product prepared according to GP1, a mixture of 107a 
(380 mg, 744.8 µmol, 75%)11 and 107b (21 mg, 4.1 µmol, 
4%) was obtained as a pale yellow solid. 
For 107: 1H NMR (300 MHz, CD2Cl2 ppm) δ = 2.95 (s, 
12H), 6.46 (dd, J = 3.0, 3.9 Hz, 1H), 6.84 (dd, J = 1.9, 3.9 
Hz, 1H), 7.19 (dd, J = 1.9, 3.0 Hz, 1H), 7.29 (dd, J = 1.9, 8.5 Hz, 2H), 7.51 – 7.61 (m, 3H). 
13C NMR (75 MHz, CDCl3, ppm) δ = 43.9, 111.3, 111.5, 122.6, 126.8, 129.1, 129.8, 130.3, 
138.4, 175.6. IR (neat, cm–1): 1596, 1497, 1457, 1436, 1390, 1320, 1255, 1166, 1111, 868, 
773, 738, 703, 649, 616, 605. HRMS: m/z calcd. for C15H20N3S+ [M–SbF6]+ = 274.1372; found 
= 274.1372; calcd. for SbF6– [M]– = 234.8948; found = 234.8950. 
For 107: 1H NMR (300 MHz, CD2Cl2 ppm) δ = 3.22 (s, 12H), 6.41 (dd, J = 1.8, 3.1 Hz, 1H), 







11 To remove residual traces of 107b, the main product was purified by column chromatography 
(DCM:MeOH) for the second time affording 107a as a yellow solid (235 mg, 460.1 µmol, 46%). Crystals 




5.2.3 Synthesis of arylthioimidazolium salts 
Optimization of the synthesis of arylthioimidazolium salts 
1. Effect of the counterion on the reactivity of 91 and 93 
 
 
Scheme 124: Effect of the counterion on the reactivity of 91 and 93. 
General protocol GP2 
A dry Schlenk flask was charged with 91 or 93, (1.65 mmol, 1.20 equiv.) and 1,3-
dimethoxybenzene (190 mg, 181 µL, 1.37 mmol, 1.00 equiv.). 1,2-DCE (0.1 M) was added, 
and the mixture was stirred at the indicated temperature for the indicated time. The reaction 
mixture was allowed to reach rt and then washed with sat. aq. NaSbF6 (10 mL) for 5 min. The 
organic layer was dried over MgSO4 and concentrated in vacuo. The crude product was 





2. Effect of solvents, concentrations and additives on the formation of arylthioimidazolium salt 
100 
 
Scheme 125: Formation of arylthioimidazolium salt 100 applying in situ generated 91. 
General protocol GP3 
A dry Schlenk flask was charged with imidazolthione 78 (127 mg, 600 µmol, 1.20 equiv.), N-
chlorosuccinimide (80.1 mg, 600 µmol, 1.20 equiv.) and 1-methyl-2-phenylindole (104 mg, 
500 µmol, 1.00 equiv.). MeCN (6 mL) was added, and the solution was stirred for 10 min at rt. 
and then at the indicated temperature for the indicated time. The orange brown solution was 
allowed to cool down to rt and all volatiles were removed under reduced pressure. The 
obtained orange oil was dissolved in DCM (5 mL) and washed with sat. aq. NaSbF6 solution 
(5 mL) for 4 min. In case of 1,2-DCE as a solvent, the reaction mixture was directly washed 
with aq. NaSbF6 solution without evaporation of DCE. The organic layer was dried over MgSO4 
and concentrated in vacuo. After column chromatography (DCM:MeOH), the 
arylthioimidazolium salt 100 was obtained as a yellow foam. 
Table 13: Effect of solvents, concentrations and additives on the formation of arylthioimidazolium salt 100. 
Entry Solvent T c /M Additives Yield 
1 1,2-DCE 70°C 0.1 - 71% 
2 MeCN 70°C 0.1 - 72% 
3 MeCN rt 0.1 - 15% 
4 MeCN 70°C 0.8 - 65% 
5 MeCN 70°C 0.1 2 equiv. H2O 47% 







- In Entry 6, 3-chloro-1-methyl-2-phenylindole was isolated as a side product (yield: 29%). 
- There was no difference in yields if 91 was prepared either in situ from imidazolthione 78 and 
N-chlorosuccinimide or synthesized beforehand. 
- In cases of high reactivity of the (hetero)arenes towards  91, the latter was not used to 
maintain the maximum possible stepwise efficiency of the protocol. 
- In case of DCE as a solvent (Table 13, Entry 1), activation of DCE was observed to give 2-
[(2-chloroethyl)thio]-1,3-diisopropyl-4,5-dimethyl-1H-imidazol-3-ium hexafluoroantimonate as 
a side-product, 1H NMR spectrum of which is presented below in Figure 33. 
 
 








Product 113 was prepared according to modified GP2. A solution of 
compound 93 (262 mg, 480 µmol, 1.19 equiv.) in MeCN (4 mL) was 
stirred for 10 min at rt. Pyrrole (27 mg, 402 µmol, 1.00 equiv.) was 
added, and the yellow solution was stirred at 70 °C for 16 h. The 
reaction mixture was allowed to cool down to rt, and all volatiles were removed under reduced 
pressure. The obtained orange oil was dissolved in DCM (4 mL) and washed with sat. aq. 
NaSbF6 (4 mL) for 5 min. The organic layer was dried over MgSO4 and concentrated in vacuo. 
After column chromatography (DCM:MeOH), compound 113 was obtained as a yellow foam 
(175 mg, 340 µmol, 85%). 
1H NMR (300 MHz, CD2Cl2 ppm) δ = 1.54 (d, J = 7.2 Hz, 12H), 2.34 (s, 6H), 5.50 (hept, J = 7.2 
Hz, 2H), 6.20 – 6.26 (m, 1H), 6.46 – 6.52 (m, 1H), 6.95 – 7.03 (m, 1H), 9.37 (s, 1H). 13C NMR 
(126 MHz, CD2Cl2, ppm) δ = 10.9, 21.4, 109.3, 111.4, 118.9, 124.8, 130.3, 136.2. IR (neat, 
cm–1): 3181.0, 2716.2, 1772.3, 1715.4, 1620.9, 1602.6, 1376.9, 1070.3, 1051.0, 713.5, 648.9, 
607.5, 547.7, 533.2, 506.2. HRMS: m/z calcd. for C15H24N3S+ [M–SbF6]+ = 278.1685; found = 
278.1686; calcd. for SbF6– [M]– = 234.8948; found = 234.8951. 
1,3-Diisopropyl-4,5-dimethyl-2-[(1-methyl-1H-indol-3-yl)thio]-1H-imidazol-3-ium Hexa-
fluoroantimonate (114): 
According to GP3, compound 78 (212 mg, 1.00 mmol, 1.20 equiv.) and 
N-chlorosuccinimide (134 mg, 1.00 mmol, 1.20 equiv.) were dissolved 
in MeCN (10 mL) and stirred for 10 min at rt. 1-Methylindole (107 µL, 
109 mg, 831 µmol, 1.00 equiv.) was added, and the yellow solution was 
stirred at 70 °C for 16 h. The orange brown reaction mixture was 
allowed to cool down to rt, and all volatiles were removed under reduced pressure. The 
obtained orange oil was dissolved in DCM (10 mL) and washed with sat. aq. NaSbF6 (10 mL) 
for 3 min. The organic layer was dried over MgSO4 and concentrated in vacuo. After column 
chromatography (DCM:MeOH), compound 114 was obtained as a yellow foam (361 mg, 
624 µmol, 75%). 
1H NMR (300 MHz, CD2Cl2 ppm) δ = 1.48 (d, J = 7.1 Hz, 12H), 2.33 (s, 6H), 3.84 (s, 3H), 5.54 
– 5.66 (m, 2H), 7.27 – 7.39 (m, 2H), 7.40 (s, 1H), 7.43 – 7.47 (m, 1H), 7.61 – 7.66 (m, 1H). 
13C NMR (75 MHz, CD2Cl2, ppm) δ = 10.8, 21.3, 33.9, 53.6, 95.6, 111.4, 118.3, 122.2, 123.9, 




1376.0, 1243.9, 1112.7, 737.6, 656.6, 630.6, 541.9. HRMS: m/z calcd. for C20H28N3S+ [M–
SbF6]+ = 342.1998; found = 342.1999; calcd. for SbF6– [M]– = 234.8948; found = 234.8952. 
1,3-Diisopropyl-4,5-dimethyl-2-[(1-methyl-2-phenyl-1H-indol-3-yl)thio]-1H-imidazol-3-
ium Hexafluoroantimonate (100): 
According to GP3, compound 78 (255 mg, 1.20 mmol, 1.20 equiv.) 
and N-chlorosuccinimide (160 mg, 1.20 mmol, 1.20 equiv.) were 
dissolved in MeCN (10 mL) and stirred for 10 min at rt. 1-Methyl-2-
phenylindole (207 mg, 1.00 mmol, 1.00 equiv.) was added, and the 
yellow solution was stirred at 70 °C for 16 h. The orange brown 
reaction mixture was allowed to cool down to rt, and all volatiles were removed under reduced 
pressure. The residual orange oil was dissolved in DCM (10 mL) and washed with sat. aq. 
NaSbF6 (10 mL) for 4 min. The organic layer was dried over MgSO4 and concentrated in vacuo. 
After column chromatography (DCM:MeOH), compound 100 was obtained as a yellow foam 
(471 mg, 720 µmol, 72%). 
1H NMR (400 MHz, CD2Cl2 ppm) δ = 1.22 (d, J = 7.1 Hz, 12H), 2.26 (s, 6H), 3.68 (s, 3H), 5.12 
(hept, J = 7.1 Hz, 2H), 7.34 (t, J = 7.6 Hz, 1H), 7.38 – 7.45 (m, 3H), 7.54 (dd, J = 18.7, 8.0 Hz, 
2H), 7.60 – 7.66 (m, 3H). 13C NMR (126 MHz, CD2Cl2, ppm) δ = 11.0, 21.2, 32.5, 53.7, 94.8, 
111.6, 118.1, 122.8, 124.4, 128.7, 129.6, 129.7, 129.9, 130.8, 131.1, 137.9, 138.2, 146.9. IR 
(neat, cm–1): 2993.9, 2941.9, 1693.2, 1621.8, 1464.7, 1445.4, 1427.1, 1396.2, 1377.9, 1338.4, 
1294.0, 1236.1, 1217.8, 1157.1, 1134.9, 1111.8, 1020.2, 803.2, 745.4, 709.7, 649.9, 550.6. 
HRMS: m/z calcd. for C26H32N3S+ [M–SbF6]+ = 418.2311; found = 418.2310; calcd. for 
SbF6–  [M]– = 234.8948; found = 234.8952. 
2-{[2-(Hydroxymethyl)-1H-indol-3-yl]thio}-1,3-diisopropyl-4,5-dimethyl-1H-imidazol-3-
ium Hexafluoroantimonate (115): 
According to GP3, compound 78 (212 mg, 1.00 mmol, 1.20 equiv.), N-
chlorosuccinimide (134 mg, 1.00 mmol, 1.20 equiv.) and (1H-indol-2-
yl)methanol (123 mg, 836 µmol, 1.00 equiv.) were dissolved in MeCN 
(10 mL). The clear red solution was stirred for 16 h at 70 °C. The dark 
red reaction mixture was allowed to cool down to rt, and all volatiles were 
removed under reduced pressure. The obtained red solid was dissolved in DCM (10 mL) and 
washed with sat. aq. NaSbF6 (10 mL) for 5 min. The organic layer was dried over MgSO4 and 
concentrated in vacuo. After column chromatography (DCM:MeOH), compound 115 was 




1H NMR (600 MHz, CD2Cl2 ppm) δ = 1.38 (d, J = 7.1 Hz, 12H), 2.31 (s, 6H), 4.91 (s, 2H), 5.39 
– 5.46 (m, 2H), 7.23 – 7.31 (m, 2H), 7.46 – 7.48 (m, 1H), 7.50 (d, J = 8.1 Hz, 2H), 9.45 (s, 1H). 
13C NMR (126 MHz, CD2Cl2, ppm) δ = 11.0, 21.2, 53.7, 56.8, 93.7, 113.2, 117.5, 122.4, 124.1, 
128.9, 129.9, 135.7, 137.9, 144.0. IR (neat, cm–1): 3392.2, 2983.3, 1708.6, 1618.9, 1448.3, 
1422.2, 1395.2, 1376.0, 1344.1, 1326.8, 1293.0, 1268.9, 1230.4, 1215.9, 1190.8, 1173.5, 
1151.3, 1138.8, 1112.7, 1074.2, 1029.8, 1009.6, 749.2, 651.8, 589.1, 567.0, 546.7. HRMS: 
m/z calcd. for C20H28N3OS+ [M–SbF6]+ = 358.1948; found = 358.1953; calcd. for SbF6– [M] – = 
234.8948; found = 234.8951. 
3-[(1,3-Diisopropyl-4,5-dimethyl-1H-imidazol-3-ium-2-yl)thio]-5,6-dimethoxy-1H-indol-1-
ium-2-carboxylate Chloride (117): 
According to GP3, compound 78 (140 mg, 659 µmol, 1.10 equiv.), 
N-chlorosuccinimide (88.1 mg, 660 µmol, 1.10 equiv.) and 5,6-
dimethoxy-1H-indole-2-carboxylic acid (133 mg, 601 µmol, 
1.00 equiv.) were dissolved in MeCN (7.5 mL) and stirred for 24 h 
at rt. The formed grey precipitate was washed with MeCN 
(3  2 mL) and dried in vacuo. Compound 117 was obtained as a white powder (223 mg, 
476 µmol, 79%). 
1H NMR (400 MHz, CD2Cl2 ppm) δ = 1.35 (d, J = 7.1 Hz, 12H), 2.34 (s, 6H), 3.21 (s, 2H), 3.85 
(d, J = 1.3 Hz, 3H), 3.91 (d, J = 1.0 Hz, 3H), 5.32 – 5.39 (m, 2H), 6.75 (s, 1H), 7.05 (d, J = 1.8 
Hz, 1H). 13C NMR (126 MHz, CD2Cl2, ppm) δ = 11.1, 21.3, 56.6, 56.8, 95.9, 98.9, 102.5, 121.9, 
127.7, 129.7, 131.5, 138.4, 148.4, 151.4, 161.3. IR (neat, cm–1): 3255.3, 1667.2, 1632.4, 
1620.9, 1513.8, 1447.3, 1425.1, 1403.9, 1394.3, 1375.0, 1272.8, 1251.6, 1206.3, 1178.3, 
1153.2, 1111.8, 1004.7, 849.5, 719.3, 582.4, 564.1. HRMS: m/z calcd. for C22H30N3O4S+ [M–






1H-imidazol-3-ium Hexafluoroantimonate (118): 
According to GP3, compound 78 (153 mg, 720 µmol, 1.20 equiv.), 
N-chlorosuccinimide (96.1 mg, 720 µmol, 1.20 equiv.) and ethyl 
5,6-dimethoxy-1H-indole-2-carboxylate (150 mg, 602 µmol, 
1.00 equiv.) were dissolved in MeCN (7.5 mL) and stirred for 24 h 
at rt. All volatiles were removed under reduced pressure. The 
obtained brown solid was dissolved in DCM (7.5 mL) and washed 
with sat. aq. NaSbF6 (7.5 mL) for 5 min. The organic layer was dried over MgSO4 and 
concentrated in vacuo. After column chromatography (DCM:MeOH), compound 118 was 
obtained as a brown foam (392 mg, 563 µmol, 94%). 
1H NMR (400 MHz, CD2Cl2 ppm) δ = 1.36 – 1.41 (m, 16H), 2.37 (s, 6H), 3.83 (s, 3H), 3.89 (s, 
3H), 4.35 (q, J = 7.2 Hz, 2H), 5.33 – 5.39 (m, 2H), 6.56 (s, 1H), 7.05 (s, 1H). 13C NMR (101 
MHz, CD2Cl2, ppm) δ = 11.0, 14.6, 21.3, 54.1, 56.6, 56.7, 62.2, 95.6, 98.8, 104.6, 121.4, 126.0, 
130.1, 131.3, 137.4, 148.7, 152.0, 159.7. IR (neat, cm–1): 3415.3, 2357.6, 1696.1, 1514.8, 
1454.1, 1341.2, 1263.1, 1241.0, 1209.1, 1180.2, 1157.1, 1112.7, 1032.7, 1019.2, 1003.8, 
832.1, 652.8, 593.0, 564.1. HRMS: m/z calcd. for C24H34N3O4S+ [M–SbF6]+ = 460.2265; found 
= 460.2266; calcd. for SbF6– [M]– = 234.8948; found = 234.8950. 
2-[(5,6-Dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)thio]-1,3-diisopropyl-4,5-dimethyl-1H-
imidazol-3-ium Hexafluoroantimonate (116): 
According to GP3, 78 (255 mg, 1.20 mmol, 1.20 equiv.) and N-
chlorosuccinimide (160 mg, 1.20 mmol, 1.20 equiv.) were dissolved in 
MeCN (5 mL) and stirred for 10 min at rt. Lilolidine (157 mg, 1.00 mmol, 
1.00 equiv.) was added, and the purple solution was stirred at 70 °C for 
16 h. The orange reaction mixture was allowed to cool down to rt and 
all volatiles were removed under reduced pressure. The obtained orange oil was dissolved in 
DCM (9.0 mL) and washed with sat. aq. NaSbF6 (10 mL) for 3 min. The organic layer was dried 
over MgSO4 and concentrated in vacuo. After column chromatography (DCM:MeOH), 
compound 116 was obtained as a yellow foam (361 mg, 597 µmol, 60%). 
1H NMR (300 MHz, CD2Cl2 ppm) δ = 1.49 (d, J = 7.1 Hz, 12H), 2.15 – 2.27 (m, 2H), 2.33 (s, 
6H), 2.99 (t, J = 6.1 Hz, 2H), 4.15 – 4.24 (m, 2H), 5.53 – 5.76 (m, 2H), 7.03 (dd, J = 7.2, 1.0 
Hz, 1H), 7.18 (dd, J = 8.0, 7.1 Hz, 1H), 7.41 (dd, J = 8.1, 0.9 Hz, 1H), 7.43 (s, 1H). 13C NMR 




126.6, 129.9, 133.1, 134.8, 138.2. IR (neat, cm–1): 2940.9, 1619.9, 1505.2, 1466.6, 1448.3, 
1382.7, 1324.9, 1246.8, 1218.8, 1167.7, 1134.9, 1109.8, 1033.7, 906.4, 827.3, 785.9, 750.2, 
652.8, 600.7, 567.9. HRMS: m/z calcd. for C22H30N3S+ [M–SbF6]+ = 368.2155; found = 
368.2160; calcd. for SbF6– [M]– = 234.8948; found = 234.8951. 
1,3-Diisopropyl-2-{[6-methoxy-2-(4-methoxyphenyl)benzo[b]thiophen-3-yl]thio}-4,5-
dimethyl-1H-imidazol-3-ium Hexafluoroantimonate (123): 
Product 123 was prepared according to modified GP2. 
Compound 93 (255 mg, 467 µmol, 1.20 equiv.) was dissolved 
in MeCN (10 mL) and stirred for 10 min at rt. 6-Methoxy-2-(4-
methoxyphenyl)benzo[b]thiophene (105 mg, 388 µmol, 
1.00 equiv.) was added, and the yellow solution was stirred at 
70 °C for 16 h. The yellow reaction mixture was allowed to cool down to rt and all volatiles 
were removed under reduced pressure. The residual orange oil was dissolved in DCM (5 mL) 
and washed with sat. aq. NaSbF6 (10 mL) for 5 min. The organic layer was dried over MgSO4 
and concentrated in vacuo. After column chromatography (DCM:MeOH), 123 was obtained as 
a yellow foam (250 mg, 350 µmol, 90%). 
1H NMR (300 MHz, CD2Cl2 ppm) δ = 1.28 (d, J = 7.1 Hz, 12H), 2.27 (s, 6H), 3.88 (s, 3H), 3.89 
(s, 3H), 5.06 (hept, J = 7.1 Hz, 2H), 7.05 – 7.11 (m, 2H), 7.11 – 7.15 (m, 1H), 7.37 (d, J = 2.3 
Hz, 1H), 7.45 (d, J = 8.9 Hz, 1H), 7.49 – 7.54 (m, 2H). 13C NMR (75 MHz, CD2Cl2, ppm) δ = 
10.9, 21.0, 53.9, 56.1, 56.3, 106.2, 112.1, 115.2, 116.3, 122.4, 124.4, 130.7, 131.7, 133.2, 
135.9, 140.1, 149.2, 159.0, 161.7. IR (neat, cm–1): 2939.0, 1604.5, 1529.3, 1477.2, 1461.8, 
1439.6, 1421.3, 1397.2, 1377.9, 1299.8, 1290.1, 1247.7, 1214.9, 1176.4, 1111.8, 1062.6, 
1029.8, 957.5, 849.5, 837.9, 805.1, 766.6, 734.7, 710.6, 651.8, 606.5, 586.3, 562.1, 546.7, 
536.1. HRMS: m/z calcd. for C27H33N2O2S2+ [M–SbF6]+ = 481.1978; found = 481.1980; calcd. 
for SbF6– [M]– = 234.8948; found = 234.8950. 
1,3-Diisopropyl-4,5-dimethyl-2-[(5-methylthiophen-2-yl)thio]-1H-imidazol-3-ium 
Hexafluoroantimonate (122): 
According to modified GP2, compound 93 (120 mg, 220 µmol, 
1.20 equiv.) was dissolved in MeCN (1.5 mL) and stirred for 10 min 
at rt. 2-Methylthiophene (18 mg, 17.6 µL, 183 µmol, 1.0 equiv.) was 
added, and the yellow solution was stirred at 70 °C for 16 h. The 
dark brown reaction mixture was allowed to cool down to rt and all 




(2 mL) and washed with sat. aq. NaSbF6 (3 mL) for 5 min. The organic layer was dried over 
MgSO4 and concentrated in vacuo. After column chromatography (DCM:MeOH), compound 
122 was obtained as a yellow foam (61.2 mg, 112 µmol, 61%). 
1H NMR (300 MHz, CD2Cl2 ppm) δ = 1.58 (d, J = 7.1 Hz, 12H), 2.39 (s, 6H), 2.47 (d, J = 1.1 
Hz, 3H), 5.48 (hept, J = 7.1 Hz, 2H), 6.76 – 6.79 (m, 1H), 7.23 (d, J = 3.7 Hz, 1H). 13C NMR 
(75 MHz, CD2Cl2, ppm) δ = 10.9, 16.1, 21.4, 54.1, 121.7, 127.4, 131.0, 137.2, 149.2. IR (neat, 
cm–1): 1422.2, 1396.2, 1376.9, 1217.8, 1137.8, 1112.7, 1092.5, 1070.3, 953.6, 803.2, 711.6, 
652.8, 603.6, 567.9, 518.8. HRMS: m/z calcd. for C16H25N2S2+ [M–SbF6]+ = 309.1454; found = 
309.1454; calcd. for SbF6– [M]– = 234.8948; found = 234.8950. 
2-{[4-(Dimethylamino)phenyl]thio}-1,3-diisopropyl-4,5-dimethyl-1H-imidazol-3-ium 
Hexafluoroantimonate (129): 
According to modified GP2, compound 93 (157 mg, 287 µmol, 
1.20 equiv.) was dissolved in MeCN (3 mL) and stirred for 
10 min at rt. Dimetylaniline (272, 30.3 µL, 29 mg, 239 µmol, 
1.00 equiv.) was added, and the yellow solution was stirred at 
70 °C for 16 h. The dark blue reaction mixture was allowed to cool down to rt, and all volatiles 
were removed under reduced pressure. The residual dark blue oil was dissolved in DCM 
(3 mL) and washed with sat. aq. NaSbF6 (3 mL) for 5 min. The organic layer was dried over 
MgSO4 and concentrated in vacuo. After column chromatography (DCM:MeOH), compound 
129 was obtained as a blue foam (123 mg, 216 µmol, 90%). 
1H NMR (300 MHz, CD2Cl2 ppm) δ = 1.51 (d, J = 7.1 Hz, 12H), 2.38 (s, 6H), 2.96 (s, 6H), 5.35 
– 5.50 (m, 2H), 6.64 – 6.70 (m, 2H), 7.15 – 7.22 (m, 2H). 13C NMR (126 MHz, CD2Cl2, ppm) δ 
= 10.9, 21.5, 40.5, 53.9, 112.4, 113.9, 130.4, 133.4, 137.6, 152.0. IR (neat, cm–1): 2939.9, 
1595.8, 1505.2, 1469.5, 1444.4, 1426.1, 1393.3, 1373.1, 1359.6, 1218.8, 1197.6, 1171.5, 
1140.7, 1112.7, 946.9, 809.0, 653.8, 607.5, 516.8. HRMS: m/z calcd. for C19H30N3S+ [M–SbF6]+ 
= 332.2155; found = 332.2155; calcd. for SbF6– [M]– = 234.8948; found = 234.8950. 
2-{[4,5-Bis(dimethylamino)naphthalen-1-yl]thio}-1,3-diisopropyl-4,5-dimethyl-1H-imid-
azol-3-ium Hexafluoroantimonate (136): 
According to modified GP2, compound 93 (600.8 mg, 
1.1 mmol, 1.10 equiv.) and 1,8-bis(dimethylamino)-
naphthalene (214.3 mg, 1.00 mmol, 1.00 equiv.) were 
dissolved in MeCN (10 mL), and the deep red solution was 




oil was dissolved in DCM (10 mL) and washed with sat. aq. NaSbF6 (10 mL) for 5 min. The 
organic layer was dried over MgSO4 and concentrated in vacuo. After column chromatography 
(DCM:MeOH), 136 was obtained as a yellow solid (301.2 mg, 455.3 µmol, 46%). 
1H NMR (300 MHz, CD2Cl2 ppm) δ = 1.55 (d, J = 7.1 Hz, 12H), 2.50 (s, 6H), 3.14 (d, J = 2.7 
Hz, 6H), 3.18 (d, J = 2.5 Hz, 6H), 5.11 (hept, J = 7.0 Hz, 2H), 6.93 (d, J = 8.2 Hz, 1H), 7.80 – 
8.01 (m, 3H), 8.35 (dd, J = 7.8, 1.8 Hz, 1H). 13C NMR (101 MHz, CD2Cl2, ppm) δ = 11.1, 21.5, 
27.3, 47.0, 47.0, 120.2, 122.7, 123.5, 125.2, 126.5, 129.5, 132.1, 132.2, 133.4, 144.2, 145.4. 
IR (neat, cm–1): 1462.7, 1403.9, 1377.9. 1262.2. 1214.9. 1196.6. 1170.6. 1136.8. 1109.8. 
1015.3. 837.9. 807.1. 766.6. 652.8. 588.2. HRMS: m/z calcd. for C25H37N4S+ [M–SbF6]+ = 
425.2733; found = 425.2734; calcd. for SbF6– [M]– = 234.8948; found = 234.8952. 
2-[(4-Aminophenyl)thio]-1,3-diisopropyl-4,5-dimethyl-1H-imidazol-3-ium Hexafluoro-
antimonate (131):  
 
According to modified GP2, compound 93 (150 mg, 275 µmol, 
1.22 equiv.) was dissolved in MeCN (5 mL) and stirred for 10 min 
at rt. Aniline (21 µL, 21 mg, 225 µmol, 1.00 equiv.) was added, 
and the yellow solution was stirred at 70 °C for 16 h. The yellow reaction mixture was allowed 
to cool down to rt and all volatiles were removed under reduced pressure. The residual yellow 
oil was dissolved in DCM (3 mL) and washed with sat. aq. NaSbF6 (3 mL) for 5 min. The 
organic layer was dried over MgSO4 and concentrated in vacuo. After twofold column 
chromatography (DCM:MeOH), compound 137 was obtained as a yellow oil (63.7 mg, 






12 After the first chromatographic purification, the yield was approximated 81%. Unfortunately, the isolated 





1H NMR (300 MHz, CD2Cl2 ppm) δ = 1.49 (d, J = 7.1 Hz, 12H), 2.37 (s, 6H), 4.12 (s, 2H), 5.35 
(sept, J = 7.1 Hz, 2 H), 6.69 (m, 2H), 7.09 (m, 2H). 13C NMR (75 MHz, CD2Cl2, ppm) δ = 10.8, 
21.3, 53.8, 115.2, 116.8, 130.5, 133.4, 137.1, 149.6. IR (neat, cm–1): 3506, 3407, 2984, 2945, 
1620, 1595, 1500, 1415, 1305, 835, 655, 530. HRMS: m/z calcd. for C17H26N3S+ [M–SbF6]+ = 




According to GP3, compound 78 (255 mg, 1.20 mmol, 
1.20 equiv.), N-chlorosuccinimide (160 mg, 1.20 mmol, 
1.20 equiv.) and N-methylaniline (107 mg, 108 µL, 1.00 mmol, 
1.00 equiv.) were dissolved in MeCN (10 mL). The yellow 
solution was stirred at rt for 16 h. All volatiles were removed under reduced pressure. The 
residual yellow oil was dissolved in DCM (10 mL) and washed with sat. aq. NaSbF6 (10 mL) 
for 5 min. The organic layer was dried over MgSO4 and concentrated in vacuo. After column 
chromatography (DCM:MeOH), compound 130 was obtained as a white foam (240 mg, 
433 µmol, 43%). 
1H NMR (300 MHz, CD2Cl2 ppm) δ = 1.50 (d, J = 7.1 Hz, 12H), 2.37 (s, 6H), 2.80 (s, 3H), 4.29 
(s, 1H), 5.33 – 5.46 (m, 2H), 6.57 – 6.64 (m, 2H), 7.10 – 7.17 (m, 2H). 13C NMR (101 MHz, 
CD2Cl2, ppm) δ = 10.7, 21.3, 30.5, 53.7, 114.1, 130.4, 133.7, 151.6. IR (neat, cm–1): 3437.5, 
2988.2, 1596.8, 1509.0, 1448.3, 1421.3, 1397.2, 1376.9, 1326.8, 1215.9, 1186.0, 1111.8, 
822.5, 752.1, 570.8, 545.8, 523.6. HRMS: m/z calcd. for C18H28N3S+ [M–SbF6]+ = 318.1998; 
found = 318.2003; calcd. for SbF6– [M]– = 234.8948; found = 234.8948. 
2-[(2,4-Dimethoxyphenyl)thio]-1,3-diisopropyl-4,5-dimethyl-1H-imidazol-3-ium Hexa-
fluoroantimonate (137): 
According to modified GP2, compound 93 (901 mg, 1.65 mmol, 
1.20 equiv.) was dissolved in MeCN (12 mL) and stirred for 
10 min at rt. 1,3-Dimethoxybenzene (190 mg, 180.1 µL, 
1.375 mmol, 1.00 equiv.) was added, and the yellow solution was 
stirred at 70 °C for 16 h. The yellow solution was allowed to cool down to rt and all volatiles 
were removed under reduced pressure. The residual yellow oil was dissolved in DCM (15 mL) 
and washed with sat. aq. NaSbF6 (15 mL) for 5 min. The organic layer was dried over MgSO4 
and concentrated in vacuo. After column chromatography (DCM:MeOH), compound 137 was 




1H NMR (300 MHz, CD2Cl2 ppm) δ = 1.48 (d, J = 7.1 Hz, 12H), 2.38 (s, 6H), 3.82 (s, 3H), 3.83 
(s, 3H), 5.39 (hept, J = 7.1 Hz, 2H), 6.52 – 6.61 (m, 2H), 7.24 (d, J = 8.6 Hz, 1H). 13C NMR 
(126 MHz, CD2Cl2, ppm) δ = 11.0, 21.5, 54.0, 56.4, 57.0, 100.5, 107.5, 130.6, 134.4, 136.6, 
159.9, 163.8. IR (neat, cm–1): 2944.8, 2357.6, 1602.6, 1590.0, 1487.8, 1454.1, 1436.7, 1415.5, 
1314.3, 1286.3, 1210.1, 1159.0, 1115.6, 1074.2, 1033.7, 828.3, 798.4, 653.8. HRMS: m/z 
calcd. for C19H29N2O2S+ [M–SbF6]+ = 349.1944; found = 349.1947; calcd. for SbF6–  [M]– = 
234.8948; found = 234.8948. 
1,3-Diisopropyl-4,5-dimethyl-2-[(2,4,6-trimethoxyphenyl)thio]-1H-imidazol-3-ium Hexa-
fluoroantimonate (138): 
According to GP3, compound 78 (510 mg, 2.40 mmol, 1.20 equiv.), N-
chlorosuccinimide (320 mg, 2.40 mmol, 1.20 equiv.) and 1,3,5-
trimethoxybenzene (336 mg, 2.00 mmol, 1.00 equiv.) were dissolved in 
dry MeCN (20 mL). The red solution was stirred at 70 °C for 16 h. The 
dark red reaction mixture was allowed to cool down to rt and all volatiles 
were removed under reduced pressure. The residual yellow oil was dissolved in DCM (20 mL) 
and washed with sat. aq. NaSbF6 (20 mL) for 5 min. The organic layer was dried over MgSO4 
and concentrated in vacuo. After column chromatography (DCM:MeOH), compound 138 was 
obtained as a yellow solid (1.09 g, 1.77 mmol, 89%). 
1H NMR (400 MHz, CD2Cl2 ppm) δ = 1.44 (d, J = 7.1 Hz, 12H), 2.34 (s, 6H), 3.84 (s, 3H), 3.86 
(s, 6H), 5.50 (hept, J = 7.1 Hz, 2H), 6.21 (s, 2H). 13C NMR (101 MHz, CD2Cl2, ppm) δ = 10.9, 
21.4, 53.4, 56.3, 57.1, 92.2, 94.5, 129.8, 138.3, 161.7, 164.8. IR (neat, cm–1): 2978.5, 2942.8, 
1582.3, 1455.0, 1412.6, 1374.0, 1339.3, 1231.3, 1204.3, 1187.0, 1160.9, 1122.4, 1092.5, 
1026.9, 949.8, 915.1, 808.0, 756.0, 651.8, 633.5, 546.7, 518.8. HRMS: m/z calcd. for 
C20H31N2O3S+ [M–SbF6]+ = 379.2050; found = 379.2051; calcd. for SbF6– [M]– = 234.8948; 
found = 234.8950. 
1,3-Diisopropyl-2-[{5-[(4-methoxyphenyl)thio]-1-phenyl-1H-pyrrol-2-yl}thio]-4,5-dime-
thyl-1H-imidazol-3-ium Hexafluoroantimonate (201): 
According to GP3, compound 78 (219 mg, 1.03 mmol, 
1.00 equiv.), N-chlorosuccinimide (138 mg, 1.03 mmol, 
1.00 equiv.) and 2-[(4-methoxyphenyl)thio]-1-phenyl-1H-
pyrrole (290 mg, 1.03 mmol, 1.00 equiv.) were dissolved 
in dry MeCN (10 mL). The yellow solution was stirred at 




to cool down to rt and all volatiles were removed under reduced pressure. The residual yellow 
oil was dissolved in DCM (10 mL) and washed with sat. aq. NaSbF6 (10 mL) for 5 min. The 
organic layer was dried over MgSO4 and concentrated in vacuo. The almost pure crude product 
of 201 was obtained as a yellow solid (560 mg, 769 mmol, 75%). An analytical sample was 
obtained by column chromatography (DCM:MeOH) of a small aliquot of the crude product. 
1H NMR (300 MHz, CD3CN ppm) δ = 1.32 (d, J = 7.1 Hz, 12H), 2.28 (s, 6H), 3.73 (s, 3H), 4.89 
(hept, J = 7.0 Hz, 2H), 6.56 (d, J = 4.0 Hz, 1H), 6.70 (d, J = 3.9 Hz, 1H), 6.76 (d, J = 8.8 Hz, 
2H), 6.89 (d, J = 8.9 Hz, 2H), 7.05 – 7.11 (m, 2H), 7.43 – 7.59 (m, 3H). 13C NMR (101 MHz, 
CD2Cl2, ppm) δ = 10.7, 21.1, 54.0, 56.0, 115.7, 120.5, 127.2, 127.6, 128.9, 129.7, 130.2, 130.6, 
131.1, 131.6, 137.3, 160.1. IR (neat, cm–1): 2992.0, 2942.8, 1615.1, 1599.7, 1568.8, 1519.6, 
1461.8, 1422.2, 1403.0, 1377.9, 1342.2, 1320.0, 1266.0, 1216.9, 1196.6, 1170.6, 1139.7, 
1109.8, 1054.9, 1014.4, 986.4, 898.7, 838.9, 828.3, 810.0, 766.6, 742.5, 651.8, 588.2, 569.9, 
526.5, 517.8, 507.2. HRMS: m/z calcd. for C28H34N3OS2+ [M–SbF6]+ = 492.2138; found = 
492.2141. 
2-[(4-Amino-3-methylphenyl)thio]-1,3-diisopropyl-4,5-dimethyl-1H-imidazol-3-ium He-
xafluoroantimonate (134A) and 2-[(2-Amino-3-methylphenyl)thio]-1,3-diisopropyl-4,5-
dimethyl-1H-imidazol-3-ium Hexafluoroantimonate (134B): 
According to GP3, compound 78 (234 mg, 1.10 mmol, 1.10 equiv.), 
N-chlorosuccinimide (147 mg, 1.10 mmol, 1.10 equiv.) and o-
toluidine (106.6 µL, 107 mg, 1.00 mmol, 1.00 equiv.) were 
dissolved in dry MeCN (10 mL). The orange solution was stirred at 
70 °C for 16 h. The orange reaction mixture was allowed to cool 
down to rt and all volatiles were removed under reduced pressure. 
The residual yellow oil was dissolved in DCM (10 mL) and washed 
with sat. aq. NaSbF6 (10 mL) for 5 min. The organic layer was dried over MgSO4 and 
concentrated in vacuo. After column chromatography (DCM:MeOH), product 134 was obtained 
as a white solid (470 mg, 848 µmol, 85%) as a mixture of regiomers. The ratio of 134A : 134A 
B was 72 : 28, as determined by the integration of the methyl groups in the methylaniline 
moiety of 134. Repetitive chromatography (DCM:MeOH) as well as further attempts to 
separate regiomers by HPLC were not successful. Decreasing the reaction temperature to 
ambient resulted in a lower yield of 63% after 24 h stirring with a similar ratio of the regiomers 
A and B. However, the identity of the compound 134A and 134B was confirmed by X-Ray 
structure analysis of a single crystal. The ratio A:B in the solid state was essentially identical 




1H NMR (300 MHz, CD2Cl2 ppm) δ = 1.43 – 1.54 (m, A&B, 12H), 2.13 (s, A, 2.28H), 2.21 (s, 
B, 0.77H), 2.38 (s, A&B, 6H), 4.01 (s, A, 1.38H), 4.41 (s, B, 0.47H), 5.23 (hept, B, J = 7.1 Hz, 
0.52H), 5.34 – 5.47 (hept, A, J = 7.1 Hz, 1.20H), 6.66 – 6.75 (m, A&B, 1.28H), 6.95 – 7.04 (m, 
A&B, 1.49H), 7.11 (d, B, J = 7.0 Hz, 0.24H). IR (neat, cm–1): 1699.0, 1587.1, 1376.9, 1343.2, 
1237.1, 1167.7, 1107.9, 1025.0, 907.3, 807.1, 755.0, 652.8. HRMS: m/z calcd. for C18H28N3S2+ 
[M–SbF6]+ = 318.1998; found = 318.1997; calcd. for SbF6– [M]– = 234.8948; found = 234.8950. 
2-{[4-(Benzylamino)phenyl]thio}-1,3-diisopropyl-4,5-dimethyl-1H-imidazol-3-ium Hexa-
fluoroantimonate (132): 
According to modified GP3, compound 78 (1.06 g, 5.00 mmol, 
1.00 equiv.), N-chlorosuccinimide (668 mg, 5.00 mmol, 
1.00 equiv.) and N-benzylaniline (1.01 g, 5.50 mmol, 
1.10 equiv.) were dissolved in DCE (40 mL). The yellow 
solution was stirred at 70 °C for 16 h. After the yellow reaction mixture was cooled to rt, it was 
washed with sat. aq. NaSbF6 (50 mL) for 1 min. The organic layer was dried over MgSO4 and 
concentrated in vacuo. After twofold repetitive column chromatography (DCM:MeOH), 132 was 
obtained as a yellow solid (1,14 g, 1.82 µmol, 33%)13.  
1H NMR (300 MHz, CD2Cl2 ppm) δ = 1.50 (d, J = 7.4 Hz, 12H), 2.37 (s, 6H), 4.35 (d, J = 6.6 
Hz, 2H), 4.72 (bs, 1H), 5.35 (sept, J = 7.4 Hz, 2H), 6.65 (m, 2H), 7.12 (m, 2H), 7.23-7.39 (m, 
5H). 13C NMR (75 MHz, CD2Cl2, ppm) δ = 10.7, 21.3, 47.9, 53.7, 114.0, 114.8, 127.7, 127.8, 
129.1, 130.4, 133.6, 137.3, 139.1, 150.2. IR (neat, cm–1): 3423, 2985, 1594, 1441, 1420, 1107, 
821, 737, 648, 522. HRMS: m/z calcd. for C24H32N3S+ [M–SbF6]+ = 394.2311; found = 394.2316; 








13 After the first chromatographic purification, the NMR yield was 82% (based on 1H NMR spectrum), but some 






According to GP2, compound 93 (131 mg, 240 µmol, 
1.20 equiv.) and 9-methylcarbazole (36.1 mg, 199 µmol, 
1.00 equiv.) were dissolved in anhydrous DCE (2.5 mL), and 
the obtained green solution was stirred at 70 °C for 16 h until 
complete conversion. The reaction mixture was cooled to rt and washed with sat. aq. NaSbF6 
(6 mL) for one minute. The aq. phase was re-extracted with DCM (3  10 mL). Combined 
organic phases were dried over magnesium sulfate, and the solvents were removed in vacuo. 
After column chromatography (DCM:MeOH), 119 was obtained as a blue solid (58.0 mg, 
92.3 µmol, 46%).14 
1H NMR (300 MHz, CD2Cl2 ppm) δ = 1.53 (d, J = 7.1 Hz, 12H), 2.44 (s, 6H), 3.87 (s, 3 H), 5.51 
(s, 2H), 7.30 (td, J = 1.0, 8.0 Hz, 1H), 7.38 (dd, J = 1.9, 8.6 Hz, 1H), 7.47 (dt, J = 0.9, 8.2 Hz, 
1H), 7.51 (d, J = 8.6 Hz, 1H), 7.55 (td, J = 1.2, 8.3 Hz, 1H), 8.09 (dt, J = 1.2, 8.0 Hz, 1H), 8.12 
(d, J = 1.9 Hz, 1H). 13C NMR (75 MHz, CD2Cl2, ppm) δ = 11.1, 21.5, 29.9, 44.8, 109.8, 111.4, 
113.8, 117.9, 120.5, 121.0, 121.9, 124.0, 124.8, 127.7, 128.6, 130.7, 141.8, 142.2. IR (neat, 
cm–1): 3404, 2971, 2926, 2856, 1616, 1598, 1458, 1418, 1373, 1249, 1111, 744, 658, 626. 
HRMS: m/z calcd. for C24H30N3S+ [M–SbF6]+ = 392.2155; found = 392.2165; calcd. for SbF6– 







14  Due to an essential amount of residual succinimide (0.2 equiv.) in the product, its purification by 







According to modified GP3, N-chlorosuccinimide (133.5 mg, 
1.00 mmol, 1.20 equiv.) and compound 95 (156 mg, 1.00 mmol, 
1.20 equiv.) were dissolved in anhydrous DCE (10 mL). Aniline 
(75.3 μL, 77.6 mg, 833 μmol, 1.00 equiv.) was added dropwise. 
The obtained yellow solution was stirred at 70 °C for 18 h. The brown reaction mixture was 
cooled to rt and washed with sat. aq. NaSbF6 solution. The aq. phase was re-extracted with 
DCM (3  20 mL). The combined organic phases were dried over magnesium sulfate, and the 
solvents were removed in vacuo. The residual brown oily liquid was purified by column 
chromatography with DCM as the eluent with a 0–10 %-MeOH gradient. The desired 
compound was obtained as a brown solid (218 mg, 450 µmol, 54%). 
1H NMR (300 MHz, CD2Cl2, ppm) δ  = 2.28 (s, 6H), 3.82 (s, 6H), 4.11 (bs, 2H), 6.69 (d, 
J = 8.7 Hz, 2H), 7.12 (d, J = 8.7 Hz, 2H). 13C NMR (75 MHz, CD2Cl2, ppm) δ = 9.8, 34.3, 113.5, 
116.7, 130.1, 134.47, 138.6, 149.7. IR (neat, cm–1) = 3494, 3402, 3391, 1627, 1618, 1595, 
1498, 1303, 1183, 834, 648, 523. MS (ESI): m/z (negative mode, %): calculated: 234.9 (100) 
[121SbF6]–, 236.9 (75) [123SbF6]–, found: 234.9 (100) [121SbF6]–, 236.9 (75) [123SbF6]–. HRMS 




According to modified GP2, compound 93 (65.5 mg, 120 µmol, 
1.00 equiv.) and N-methylindolin-2-one (17.7 mg, 120 µmol, 
1.00 equiv.) were dissolved in anhydrous MeCN (2.0 mL) and the 
obtained yellow solution was stirred at 70 °C for 16 h until full 
conversion. The reaction mixture was cooled to rt and was washed with sat. aq. NaSbF6 (6 mL) 
for one minute. The aq. phase was re-extracted with DCM (3  10 mL). The combined organic 
phases were dried over magnesium sulfate, and the solvents were removed in vacuo. After 
column chromatography (DCM:MeOH), 151 was obtained as a red solid (60.0 mg, 101 µmol, 
84%). 
1H NMR (400 MHz, CD2Cl2 ppm) δ = 1.59 (t, J = 6.6 Hz, 12H),  2.44 (s, 6H),  3.19 (s, 3H),  4.74 
(s, 1H),  5.35 (sept, J = 7.4 Hz, 2H),  6.98 (d, J = 7.9 Hz, 1H),  7.21 (td, J = 7.6, 1.0 Hz, 1H), 
7.47 (tt, J = 7.4, 1.0 Hz, 2H). 13C NMR (75 MHz, CD2Cl2, ppm) δ = 11.2, 21.5, 21.5, 27.1, 48.3, 




1611.6, 1492.3, 1470.9, 1418.5, 1372.1, 1344.0, 1295.2, 1191.1, 1122.7, 1091.6, 819.1, 766.3, 
653.5. HRMS: m/z calcd. for C20H28N3OS+ [M–SbF6]+ = 358,1948; found = 358.1977; calcd. for 
SbF6– [M]– = 234.8948; found = 234.8950. 
5.2.4 Synthesis of aryltriazolium salts 
5-{[2-(Ethoxycarbonyl)-5,6-dimethoxy-1H-indol-3-yl]thio}-1,4-diisopropyl-1H-1,2,4-
triazol-4-ium Hexafluoroantimonate (300): 
According to GP2, triazole-3-thione 209 (92.6 mg, 500 µmol, 
1.00 equiv.), N-chlorosuccinimide (66.8 mg, 500 µmol, 
1.00 equiv.) and ethyl 5,6-dimethoxy-1H-indole-2-carboxylate 
(131 mg, 525 µmol, 1.05 equiv.) were dissolved in DCM (5.0 mL) 
and stirred at rt for 17 h. The orange reaction mixture was 
washed with sat. aq. NaSbF6 (3.5 mL) for 5 min. The organic layer was dried over MgSO4 and 
concentrated in vacuo. After column chromatography (DCM:MeOH), 300 was obtained as a 
brown foam (222 mg, 332 µmol, 66%). 
1H NMR (400 MHz, CD2Cl2 ppm) δ = 1.31 – 1.38 (m, 9H), 1.47 (d, J = 6.8 Hz, 6H), 3.93 (s, 
3H), 3.95 (s, 3H), 4.31 (q, J = 7.1 Hz, 2H), 4.93 (d, J = 7.0 Hz, 2H), 7.06 (s, 1H), 7.13 (s, 1H), 
8.49 (s, 1H), 9.76 (s, 1H). 13C NMR (126 MHz, CD2Cl2, ppm) δ = 14.5, 21.7, 22.8, 56.3, 56.7, 
56.9, 62.5, 95.6, 98.8, 99.5, 122.9, 127.0, 130.9, 141.8, 147.7, 149.4, 152.4, 159.4. IR (neat, 
cm–1): 3349.7, 2968.9, 1714.4, 1518.7, 1490.7, 1458.9, 1444.4, 1405.9, 1374.0, 1344.1, 
1332.6, 1269.9, 1246.8, 1206.3, 1192.8, 1179.3, 1158.0, 1115.6, 1054.9, 1024.0, 1011.5, 
1000.9, 857.2, 830.2, 773.3, 740.5, 658.6, 642.2, 581.4, 558.3. HRMS: m/z calcd. for 
C21H29N4O4S+ [M–SbF6]+ = 433.1904; found = 433.1904. 
1,4-Diisopropyl-5-[(1-phenyl-1H-pyrrol-2-yl)thio]-1H-1,2,4-triazol-4-ium Hexafluoroanti-
monate (210):  
According to GP2, triazole-3-thione 209 (185 mg, 1.00 mmol, 1.00 equiv.), 
N-chlorosuccinimide (133.5 mg, 1.00 mmol, 1.00 equiv.) and phenyl 
pyrrole (150 mg, 1.05 mmol, 1.05 equiv.) were dissolved in DCM (5.0 mL) 
and stirred at rt for 17 h. The yellow reaction mixture was washed with sat. 
aq. NaSbF6 (7.0 mL) for 5 min. The organic layer was dried over MgSO4 
and concentrated in vacuo. After column chromatography (DCM:MeOH), 210 was obtained as 
a white solid (362 mg, 643 µmol, 63%). 




(hept, J = 6.7 Hz, 1H), 4.69 (hept, J = 6.7 Hz, 1H), 6.48 (dd, J = 4.0, 3.0 Hz, 1H), 7.03 (dd, J = 
3.9, 1.7 Hz, 1H), 7.19 (dd, J = 2.9, 1.7 Hz, 1H), 7.22 – 7.26 (m, 2H), 7.52 – 7.57 (m, 3H), 8.42 
(s, 1H). 13C NMR (126 MHz, CD2Cl2, ppm) δ = 22.0, 22.8, 53.4, 56.3, 107.6, 112.0, 124.9, 
127.1, 130.0, 130.5, 130.9, 138.3, 142.3, 145.3. IR (neat, cm–1): 3154.0, 2988.2, 2360.4, 
1709.6, 1597.7, 1524.5, 1499.4, 1460.8, 1438.6, 1405.9, 1392.4, 1380.8, 1372.1, 1346.1, 
1326.8, 1299.8, 1203.4, 1178.3, 1147.4, 1136.8, 1094.4, 1079.9, 1054.9, 1042.3, 1013.4, 
883.2, 858.2, 777.2, 730.9, 702.9, 684.6, 675.0, 651.8, 617.1, 605.5, 583.4, 571.8, 561.2, 
504.3. HRMS: m/z calcd. for C18H23N4S+ [M–SbF6]+ = 327.1638; found = 327.1643; calcd. for 
SbF6– [M]– = 234.8948; found = 234.8956. 
5-[(2,4-Dimethoxyphenyl)thio]-1,4-diisopropyl-1H-1,2,4-triazol-4-ium Hexafluoroanti-
monate (211): 
According to GP3, triazole-3-thione 209 (92.6 mg, 500 µmol, 1.00 
equiv.), N-chlorosuccinimide (66.8 mg, 500 µmol, 1.00 equiv.) and 
1,3-dimethoxybenzene (65.4 µL, 69 mg, 500 µmol, 1.00 equiv.) 
were dissolved in MeCN (5.0 mL) and stirred for 17 h at 70 °C. All 
volatiles were removed under reduced pressure, and the residual yellow solid was dissolved 
in DCM (5 mL) and washed with sat. aq. NaSbF6 (3.0 mL) for 5 min. The organic layer was 
dried over MgSO4 and concentrated in vacuo. After column chromatography (DCM:MeOH), 
211 was obtained as a colourless oil (110 mg, 197 µmol, 39%). 
1H NMR (600 MHz, CD2Cl2 ppm) δ = 1.43 (d, J = 6.7 Hz, 6H), 1.52 (d, J = 6.9 Hz, 6H), 3.77 (s, 
3H), 3.85 (s, 3H), 4.96 (d, J = 6.9 Hz, 1H), 5.14 (d, J = 6.7 Hz, 1H), 6.54 (d, J = 2.6 Hz, 1H), 
6.66 (dd, J = 8.7, 2.6 Hz, 1H), 7.64 (d, J = 8.7 Hz, 1H), 8.59 (s, 1H). 13C NMR (126 MHz, 
CD2Cl2, ppm) δ = 21.9, 22.8, 30.3, 56.3, 56.5, 57.2, 100.7, 102.6, 108.0, 137.1, 142.5, 147.0, 
160.7, 165.2. IR (neat, cm–1): 1599.7, 1577.5, 1526.4, 1487.8, 1459.8, 1403.0, 1376.0, 1304.6, 
1288.2, 1208.2, 1182.2, 1161.9, 1144.5, 1068.4, 1023.1, 829.2, 656.6, 591.1, 530.3. HRMS: 





5.2.5 Synthesis of unymmetrical sulfides 
Optimization of the synthesis of unsymmetrical sulfides 
 
Scheme 126: Formation of unsymmetrical sulfides from thioimidazolium salts and Grignard reagents. 
General protocol GP4 
A dry Schlenk flask was charged with thioimidazolium intermediate 129 (49.0 mg, 86.3 µmol, 
1.00 equiv.) was dissolved in anhydrous THF (1.5 mL) and cooled to -78 °C, if not otherwise 
indicated. Pre-titrated p-tolylmagnesium-bromide solution was added dropwise to the violet 
suspension, and the reaction mixture was allowed to warm up under indicated conditions. The 
dark brown suspension was quenched with sat. NH4Cl (5 mL), stirred for 5 min and extracted 
with DCM (4  20 mL). The combined organic phases were dried over MgSO4, concentrated 
in vacuo and purified by column chromatography (DCM:MeOH) to obtain 158 as a colorless 
oil. 
Table 14: Screening of conditions for synthesis of 158. 
Entry RMgBr c /M Additives Conditions Yield 
1 1.4 equiv. 0.1 - Fast warm up 25% 
2 1.5 equiv. 0.1 - Slow warm up 36% 
3 2.9 equiv. 0.1 - Slow warm up 75% 
4 1.5 equiv. 0.8 5 equiv. LiCl Slow warm up 43% 
5 2.9 equiv. 0.1 5 equiv. LiCl Slow warm up 71% 
6 2.9 equiv. 0.5 5 equiv. LiCl Slow warm up 66% 
Note: 
- The addition of LiCl (Entries 4–6), the concentration (Entries 4 vs.5) as well as the duration 
of the warm-up phase (Entries 1 vs.3) have a strong influence on the yield of the reactions.  
- The amount of Grignard used in the reaction (Entries 2 vs.3) did affect the yield. For 




In cases of less reactive Grignard´s even higher amounts were used. On the other hand, 
already 1.5 equiv. of Grignard gave acceptable yields with compound 99.  
Capture of the free carbene by selenium 
 
 
Scheme 127: Formation of 2-selenoimidazoline 159 from thioimidazolium intermediate 129. 
General protocol GP5 
A dry Schlenk flask was charged with thioimidazolium intermediate 129 (212 mg, 373 µmol) 
was dissolved in THF (2.0 mL) and cooled to -78 °C. para-Methoxyphenylmagnesium bromide 
solution (0.5M in THF, 597 µL, 294 µmol, 0.79 equiv.) was added dropwise to the violet 
suspension and the solution was allowed to warm up overnight. Selenium (29.5 mg, 
0.373 mmol) was added to the white suspension, and the mixture was stirred for at rt for 2 h. 
GC-MS & HRMS confirmed the formation of 2-selenoimidazoline 159 (Figure 34). HRMS: m/z 










Synthesis of substrates for Grignard preparation 
1-Bromo-4-[{[(1R,2S,5R)-2-isopropyl-5-methylcyclohexyl]oxy}methyl]benzene (301):15 
A solution of L-menthol (8.78 g, 56.2 mmol, 1.49 equiv.) in anhydrous THF 
(40 mL) and added dropwise to a stirred suspension of NaH (1.52 g, 
63,3 mmol, 1.68 equiv.) in THF (90 mL). After cessation of the gas evolution, 
4-bromobenzyl bromide (9.39 g, 37.6 mmol, 1.00 equiv.) was added dropwise, 
and the suspension was heated under reflux for 90 min. Afterwards, the 
suspension was allow to reach rt, and the reaction was carefully quenched with water 
(100 mL). The mixture was extracted with Et2O (3  90 mL); the combined ethereal extracts 
were dried over MgSO4 and concentrated in vacuo. The obtained oil was purified by column 
chromatography (hexane:EtOAc). Compound 301 was obtained as a white solid (9.30 g, 
28.6 mmol, 76%). 
1H NMR (400 MHz, CDCl3 ppm) δ = 0.74 (d, J = 6.9 Hz, 3H), 0.85 – 1.01 (m, 9H), 1.26 – 1.44 
(m, 2H), 1.61 – 1.71 (m, 2H), 2.14 – 2.21 (m, 1H), 2.28 (heptd, J = 7.0, 2.9 Hz, 1H), 3.17 (td, J 
= 10.6, 4.2 Hz, 1H), 4.35 (d, J = 11.7 Hz, 1H), 4.61 (d, J = 11.8 Hz, 1H), 7.20 – 7.25 (m, 2H), 
7.44 – 7.48 (m, 2H). 13C NMR (101 MHz, CDCl3, ppm) δ = 16.3, 21.1, 22.5, 23.4, 25.7, 31.7, 
34.7, 40.4, 48.4, 69.7, 79.1, 121.3, 129.5, 131.5, 138.3. IR (neat, cm–1): 2955.4, 2946.7, 
2919.7, 2867.6, 2843.5, 1486.8, 1456.0, 1447.3, 1386.6, 1342.2, 1109.8, 1095.4, 1086.7, 
1075.1, 1052.9, 1043.3, 1010.5, 994.1, 804.2, 559.3. HRMS: m/z calcd. for C17H25BrO+ [M]+ = 








15 Compound 301 was synthesis according a modified protocol of E. Nakamura et al.: K. Harano, R. M. Gorgoll, 






A solution of diacetone-D-glucose (3.12 g, 12.0 mmol, 1.50 equiv.) in anhydrous THF (35 mL) 
was added dropwise to a stirred suspension of NaH (336 mg, 
14.0 mmol, 1.75 equiv.) in THF (15 mL). After the gas evolution 
ceased, n-BuN4I (3.25 g, 8.80 mmol, 1.10 equiv.) was added. 
Afterwards, 4-bromobenzyl bromide (2.00 g, 8.00 mmol, 1.00 
equiv.) was added dropwise. The suspension stirred for an 
additional 12 h, the reaction was carefully quenched with water (50 mL). The reaction mixture 
was extracted with EtOAc (4  100 mL); the combined extracts were dried over MgSO4 and 
concentrated in vacuo. The residual oil was purified by column chromatography on (100 g of 
silica gel, hexane:EtOAc). Compound 302 was obtained as a colorless oil (2.00 g, 4.66 mmol, 
58%).  
1H NMR (400 MHz, CDCl3 ppm) δ = 1.31 (s, 3H), 1.37 (s, 3H), 1.42 (s, 3H), 1.49 (s, 3H), 3.97 
– 4.03 (m, 2H), 4.09 – 4.14 (m, 2H), 4.30 – 4.37 (m, 1H), 4.55 – 4.68 (m, 3H), 5.89 (d, J = 3.7 
Hz, 1H), 7.21 – 7.25 (m, 2H), 7.44 – 7.49 (m, 2H). 13C NMR (75 MHz, CDCl3, ppm) δ = 25.6, 
26.4, 27.0, 67.7, 71.8, 72.6, 81.5, 82.0, 82.8, 105.4, 109.2, 112.0, 121.9, 129.4, 131.7, 136.8. 
IR (neat, cm–1): 2964.1, 1384.6, 1376.9, 1370.2, 1256.4, 1233.3, 1213.0, 1165.8, 1153.2, 
1122.4, 1084.8, 1062.6, 1046.2, 1036.6, 1007.6, 973.9, 967.1, 945.9, 886.1, 862.0, 843.7, 











2-[(tert-Butyldimethylsilyl)oxy]-1-methyl-1H-indole (152):17  
1-Methylindolin-2-one (750 mg, 5.10 mmol, 1.00 equiv.) was 
dissolved in DCM (52 mL) and cooled to 0°C. Dry trimethylamine 
(1.86 g, 2.56 mL, 18.4 mmol, 3.60 equiv.) was added dropwise to the 
light yellow solution, and the reaction mixture became dark orange. After stirring for 15 min, 
tert-butyldimethylsilyl trifluoromethanesulfonate (2.09 g, 1.82 mL, 9.17 mmol, 1.80 equiv.) was 
added dropwise. The solution was allowed to warm up to rt and stirred for an additional 2.5 h. 
After quenching the reaction with MeOH (2.5 mL), all volatiles were removed in vacuo and the 
obtained brown oil was extracted with dry pentane (4  10 mL). Extracts were combined, and 
the solvent was removed in vacuo to give pure 152 as a light brown solid (1.12 g, 4.28 mmol, 
84%). 
1H NMR (400 MHz, CD2Cl2 ppm) δ = 0.32 (s, 6H), 1.04 (s, 9H), 3.53 (s, 3H), 5.55 (s, 1H), 6.95 
– 7.06 (m, 2H), 7.13 (d, J = 7.2 Hz, 1H), 7.32 – 7.37 (m, 1H). 13C NMR (126 MHz, CD2Cl2, 
ppm) δ = –3.2, 26.0, 26.5, 36.3, 108.4, 122.5, 124.6, 125.2, 128.2, 145.9, 175.1. IR (neat, cm–
1): 3058.5, 2950.6, 2928.4, 2883.1, 2856.1, 1717.3, 1614.1, 1577.5, 1550.5, 1468.5, 1459.8, 
1437.7, 1397.2, 1364.4, 1333.5, 1312.3, 1254.5, 1235.2, 1193.7, 1160.9, 1143.6, 1126.2, 
1091.5, 1013.4, 935.3, 913.1, 879.4, 837.9, 824.4, 810.9, 783.9, 768.5, 752.1, 733.8, 709.7, 
679.8, 650.9, 617.1, 591.1. HRMS: m/z calcd. for C15H23NOSi+ [M]+ = 261.1549; found = 







17 Compound 152 was synthesis according a modified protocol of E. Merifield et al.: M.-L. Alcaraz, S. Atkinson, P. 
Cornwall, A. C. Foster, D. M. Gill, L. A. Humphries, P. S. Keegan, R. Kemp, E. Merifield, R. A. Nixon, A. J. Noble, D. 
O'Beirne, Z. M. Patel, J. Perkins, P. Rowan, P. Sadler, J. T. Singleton, J. Tornos, A. J. Watts, I. A. Woodland, Org. 





(Furan-2-yl)trimethylsilane (303):18  
n-BuLi (17.2 mL, 1.6 M in hexane, 27.5 mmol, 1.00 equiv.) was added 
dropwise to a stirred solution of furane (2.00 mL, 1.87 g, 27.5 mmol, 
1.00 equiv.) in dry diethylether (9 mL) at 0 °C within 10 min. The cooling bath was removed 
and the mixture was stirred for 4 h at rt. After cooling the reaction micture to 0 °C, TMSCl 
(3.8 mL, 3.26 g, 30.0 mmol, 1.09 equiv.) was dropwise added and the mixture was stirred at 
0 °C for 1 h. The reaction was quenched with water (20 mL), phases were separated and the 
aq. layer was extracted with diethylether (20 mL). The combined organic phases were dried 
over MgSO4 and the solvents were slowly removed under reduced pressure. 303 could be 
isolated as a colorless oil (2.56 g, 18.3 mmol, 66%) by careful distillation (b. p. 65 
°C/110 mbar).  
1H NMR (600 MHz, CDCl3 ppm) δ = 0.27 (s, 9H), 6.38 (dd, J = 3.2, 1.6 Hz, 1H), 6.62 (dd, J = 
3.2, 0.6 Hz, 1H), 7.65 (dd, J = 1.7, 0.6 Hz, 1H). 13C NMR (126 MHz, CD2Cl2, ppm) δ = –1.3, 
109.4, 119.5, 146.6, 160.3. IR (neat, cm–1): 1552.4, 1456.0, 1249.6, 1202.4, 1106.0, 1004.7, 
901.6, 836.0, 755.0, 740.5, 697.1, 629.6, 594.9. HRMS: m/z calcd. for C7H12OSi+ [M]+ = 







18 Compound 303 was synthesis according to the modified protocol of G. Lefèvre, T. Cantat et al.: X. Frogneux, 




Synthesis of aryl sulfides with for Grignard reagents 
2-[(4-Methoxyphenyl)thio]-1-phenyl-1H-pyrrole (161): 
According to GP4, imidazolium salt 99 (60.2 mg, 102.0 µmol, 
1.00 equiv.) was dissolved in anhydrous THF (1.0 mL) and 
cooled to -70 °C. Methoxyphenylmagnesium bromide (0.5M in 
THF, 306 µL, 153 µmol, 1.50 equiv.) was added dropwise, and 
the reaction mixture was allowed to warm up to 10 °C over a period of 14 h affording the orange 
solution. The reaction was quenched with sat. NH4Cl (5 mL), stirred for 5 min and extracted 
with DCM (3  20 mL). The combined organic phases were dried over MgSO4, concentrated 
in vacuo and purified by column chromatography (hexane:EtOAc) affording 161 as a white 
solid (26.9 mg,  95.6 µmol, 94%).  
The similar reaction with the triazole salt 210 gave 161 in a yield of 83% on a 120 µmol reaction 
scale.  
1H NMR (300 MHz, CDCl3, ppm) δ = 3.74 (s, 3H), 6.35 (dd, J = 3.6, 3.0 Hz, 1H), 6.69 – 6.72 
(m, 1H), 6.71 (d, J = 8.9 Hz, 2H), 6.92 (d, J = 8.9 Hz, 2H), 7.03 (dd, J = 3.0, 1.8 Hz, 1H), 
7.20 – 7.25 (m, 2H), 7.30 – 7.38 (m, 3H). 13C NMR (75 MHz, CDCl3, ppm) δ = 55.5, 109.5, 
114.6, 120.5, 126.2, 126.7, 127.5, 128.7, 129.3, 129.4, 139.7, 158.3. IR (neat, cm–1): 2958.3, 
2828.1, 2359.5, 1596.8, 1487.8, 1455.0, 1449.2, 1433.8, 1393.3, 1322.0, 1291.1, 1240.0, 
1204.3, 1180.2, 1171.5, 1161.9, 1137.8, 1105.0, 1087.7, 1074.2, 1029.8, 1002.8, 962.3, 820.6, 
808.0, 795.5, 761.7, 724.1, 692.3, 650.9, 636.4, 619.0, 604.6, 562.1. HRMS: m/z calcd. for 
C17H15NOS+ [M]+ = 281.0874; found = 281.0871. 
2-[(4-Fluorophenyl)thio]-1-phenyl-1H-pyrrole (162): 
According to GP4, imidazolium salt 99 (94.4 mg, 160 µmol, 1.00 equiv.) 
was dissolved in THF (1.0 mL) and cooled to -78 °C. 4-
Fluorophenylmagnesium bromide solution (1.0M in THF, 240 µL, 
240 µmol, 1.50 equiv.) was added dropwise to the colorless solution, and the reaction mixture 
was allowed to warm up overnight furnishing the yellowish white suspension. The reaction was 
quenched with sat. NH4Cl (5 mL), stirred for 5 min and extracted with DCM (3  20 mL). The 
combined organic phases were dried over MgSO4, concentrated in vacuo and purified by 






1H NMR (300 MHz, CDCl3, ppm) δ = 6.39 (dd, J = 3.6, 3.0 Hz, 1H), 6.74 (dd, J = 3.6, 1.8 Hz, 
1H), 6.82 – 6.95 (m, 5H), 7.07 (dd, J = 3.0, 1.8 Hz, 1H), 7.19 – 7.24 (m, 2H), 7.31 – 7.35 (m, 
2H). 13C NMR (126 MHz, CDCl3, ppm) δ = 109.6, 115.9 (d, JC-F = 22.0 Hz), 119.2, 121.1, 126.5, 
126.6, 127.6, 128.6 (d, JC-F = 7.9 Hz), 128.7, 133.9, 133.9, 139.4, 161.2 (d, JC-F = 244.5 Hz). 
19F NMR (282 MHz, CDCl3, ppm) δ = –117.3. IR (neat, cm–1): 3047.9, 2360.4, 1586.2, 1486.8, 
1433.8, 1394.3, 1317.1, 1215.9, 1156.1, 1133.9, 1087.7, 1033.7, 1009.6, 821.5, 806.1, 
762.7,749.2, 729.9, 722.2, 692.3, 648.9, 617.1, 603.6, 561.2, 507.2. HRMS: m/z calcd. for 
C16H12FNS+ [M]+ = 269.0674; found = 269.0671. 
4-[1-Phenyl-1H-pyrrol-2-yl)thio]benzonitrile (163): 
According to GP4, imidazolium salt 99 (45.5 mg, 77.0 µmol, 1.00 
equiv.) was dissolved in THF (1.0 mL) and cooled to -40 °C. 
Nitrilphenylmagnesium chloride•LiCl solution 19  (1.20M in THF, 
97 µL, 116 µmol, 1.50 equiv.) was added dropwise to the stirred white suspension, and the 
reaction mixture was allowed to warm up overnight affording the dark red solution. The reaction 
was quenched with sat. NH4Cl (5 mL), stirred for 5 min and extracted with DCM (3  20 mL). 
The combined organic phases were dried over MgSO4, concentrated in vacuo and purified by 
column chromatography (hexane:DCM) affording compound 163 as a colorless oil (16.5 mg, 
59.7 µmol, 78%). 
1H NMR (300 MHz, CDCl3, ppm) δ = 6.44 (dd, J = 3.7, 3.0 Hz, 1H), 6.76 (dd, J = 3.7, 1.8 Hz, 
1H), 6.92 – 6.96 (m, 2H), 7.15 (dd, J = 3.0, 1.8 Hz, 1H), 7.17 – 7.21 (m, 2H), 7.30 – 7.36 (m, 
3H), 7.38 – 7.42 (m, 2H). 13C NMR (126 MHz, CDCl3, ppm) δ = 108.4, 110.2, 115.8, 118.9, 
122.3, 125.5, 126.3, 127.5, 127.9, 128.9, 132.3, 139.0, 147.1. IR (neat, cm–1): 3047.9, 2224.5, 
1590.0, 1497.5, 1482.0, 1455.0, 1433.8, 1394.3, 1319.1, 1138.8, 1077.0, 1035.6, 1014.4, 
961.3, 912.2, 819.6, 762.7, 728.0, 692.3, 645.1, 620.0, 606.5, 582.4, 560.2, 541.9. HRMS: m/z 






19 The nitrilphenylmagnesium chlorid • LiCl solution was prepared following the well-elaborated protocol of P. 




tert-Butyl 4-[(1-Phenyl-1H-pyrrol-2-yl)thio]benzoate (164): 
According to GP4, imidazolium salt 99 (72.6 mg, 123 µmol, 1.00 
equiv.) was dissolved in THF (1.0 mL) and cooled to -60 °C. 4-
(tert-butoxycarbonyl)phenylmagnesium bromide solution 20 
(0.164M in THF, 2.18 mL, 357 µmol, 2.90 equiv.) was added 
dropwise to the clear solution and the reaction mixture was allowed to warm up overnight 
furnishing the dark orange solution. The reaction was quenched with sat. NH4Cl (5 mL), stirred 
for 5 min and extracted with DCM (3  20 mL). The combined organic phases were dried over 
MgSO4, concentrated in vacuo and purified by two subsequent column chromatographies 
(hexane:DCM) affording sulfide 164 as a colorless oil (11.4 mg, 32.4 µmol, 26%). 
1H NMR (600 MHz, CDCl3, ppm) δ = 1.56 (s, 9H), 6.42 (dd, J = 3.7, 3.0 Hz, 1H), 6.76 (dd, J = 
3.7, 1.8 Hz, 1H), 6.90 – 6.95 (m, 2H), 7.13 (dd, J = 3.0, 1.8 Hz, 1H), 7.20 – 7.22 (m, 2H), 7.28 
– 7.34 (m, 3H), 7.75 – 7.79 (m, 2H). 13C NMR (126 MHz, CDCl3, ppm) δ = 28.4, 81.0, 110.0, 
117.0, 122.0, 124.8, 126.3, 127.1, 127.7, 128.8, 129.8, 139.3, 145.8, 165.5. IR (neat, cm–1): 
2977.6, 2928.4, 1706.7, 1590.0, 1498.4, 1456.0, 1434.8, 1392.4, 1366.3, 1318.1, 1305.6, 
1290.1, 1254.5, 1161.9, 1138.8, 1117.5, 1106.9, 1089.6, 1034.6, 1012.4, 960.4, 846.6, 758.9, 
724.1, 690.4, 620.0, 509.1. HRMS: m/z calcd. for C21H22NO2S+ [M+H]+ = 352.1366; found = 
352.1364. 
4-[(4-Methoxyphenyl)thio]-N-methylaniline (188): 
According to GP4, imidazolium salt 130 (89.8 mg, 162 µmol, 1.00 
equiv.) was dissolved in THF (1.0 mL) and cooled to -78 °C. 
Methoxyphenylmagnesium bromide (0.50M in THF, 939 µL, 
470 µmol, 2.90 equiv.) was added dropwise to the stirred white suspension, and the reaction 






20  4-(tert-butoxycarbonyl)phenylmagnesium bromide solution was prepared following the TMPMgCl 
deprotonation protocol of P. Knochel et al.: A. Krasovskiy, V. Krasovskaya, P. Knochel, Angew. Chem. Int. Ed. 




quenched with sat. NH4Cl (5 mL), stirred for 5 min and extracted with DCM (3  20 mL). The 
combined organic phases were dried over MgSO4, concentrated in vacuo and purified by 
column chromatography (hexane:DCM) affording sulfide 188 as a white solid (18.8 mg, 76.6 
µmol, 47%). 
1H NMR (300 MHz, CDCl3, ppm) δ = 2.84 (s, 3H), 3.77 (s, 3H), 6.56 – 6.62 (m, 2H), 6.77 – 
6.84 (m, 2H), 7.17 – 7.22 (m, 2H), 7.24 – 7.30 (m, 3H). 13C NMR (75 MHz, CDCl3, ppm) δ = 
31.0, 55.5, 113.6, 114.8, 131.2, 134.4. IR (neat, cm–1): 1604.5, 1496.5, 1437.7, 1273.8, 1246.8, 
1182.2, 1039.4, 1011.5, 823.5, 809.0, 781.0, 551.5, 514.9. HRMS: m/z calcd. for C14H15NOS+ 
[M]+ = 245.0874; found = 245.0877. 
 
4-[(4-Methoxyphenyl)thio]aniline (189): 
According to GP4, imidazolium salt 131 (118.9 mg, 220 µmol, 1.00 
equiv.) was dissolved in THF (1.0 mL) and cooled to -78 °C. 
Methoxyphenylmagnesium bromide (0.50M in THF, 1.28 mL, 640 µmol, 2.90 equiv.) was 
added dropwise to the stirred white suspension, and the reaction mixture was allowed to warm 
up overnight affording the brown solution. The reaction was quenched with sat. NH4Cl (5 mL), 
stirred for 5 min and extracted with DCM (3  20 mL). The combined organic phases were 
dried over MgSO4, concentrated in vacuo and purified by column chromatography 
(hexane:DCM) furnishing sulfide 189 as a white solid (3.9 mg, 17 µmol, 8%). 
1H NMR (300 MHz, CD2Cl2, ppm) δ = 3.76 (s, 3H), 3.80 (s, 2H), 6.59 – 6.65 (m, 2H), 6.78 – 
6.84 (m, 2H), 7.16 – 7.23 (m, 4H). 13C NMR (128 MHz, CD2Cl2, ppm) δ = 55.9, 115.1, 116.0, 
123.6, 129.4, 131.9, 134.5, 147.2, 159.1. IR (neat, cm–1): 3372.9, 3312.1, 3205.1, 2921.6, 
1631.5, 1589.1, 1571.7, 1488.8, 1461.8, 1452.1, 1438.6, 1425.1, 1278.6, 1260.3, 1245.8, 
1171.5, 1119.5, 1100.2, 1083.8, 1025.0, 1005.7, 818.6, 795.5, 754.0, 723.2, 695.2, 646.0, 








According to GP4, imidazolium salt 99 (94.4 mg, 160 µmol, 1.00 
equiv.) was dissolved in THF (1.0 mL) and cooled to -78 °C. 4-
(Mentholoxymethyl)phenylmagnesium bromide (0.36M, 667 µL, 
240 µmol, 1.50 equiv.) 21  was added dropwise, and the was 
allowed to warm up overnight affording the orange solution. The 
reaction was quenched with sat. NH4Cl (5 mL), stirred for 5 min and extracted with DCM (3  
20 mL). The combined organic phases were dried over MgSO4, concentrated in vacuo and 
purified by column chromatography (Hexane:DCM) furnishing sulfide 165 as a colourless oil 
(60.1 mg, 143 µmol, 89%). 
1H NMR (400 MHz, CDCl3, ppm) δ = 0.69 (d, J = 6.9 Hz, 3H), 0.82 – 1.01 (m, 9H), 1.22 – 1.40 
(m, 2H), 1.56 – 1.70 (m, 2H), 2.12 – 2.19 (m, 1H), 2.20 – 2.31 (m, 1H), 3.13 (td, J = 10.5, 4.1 
Hz, 1H), 4.30 (d, J = 11.4 Hz, 1H), 4.56 (d, J = 11.4 Hz, 1H), 6.39 (t, J = 3.3 Hz, 1H), 6.71 – 
6.76 (m, 1H), 6.90 – 6.95 (m, 2H), 7.06 – 7.12 (m, 1H), 7.16 (d, J = 8.2 Hz, 2H), 7.20 – 7.25 
(m, 2H), 7.27 – 7.36 (m, 3H). 13C NMR (101 MHz, CDCl3, ppm) δ = 16.2, 21.1, 22.5, 23.4, 25.6, 
31.7, 34.7, 40.4, 48.4, 70.1, 78.8, 109.7, 118.5, 121.6, 126.1, 126.4, 126.6, 127.5, 128.6, 
128.8, 136.4, 138.6, 139.6. IR (neat, cm–1): 2951.5, 2917.8, 2865.7, 1597.7, 1498.4, 1455.0, 
1433.8, 1319.1, 1105.0, 1085.7, 1073.2, 1052.9, 1035.6, 1015.3, 834.1, 804.2, 759.8, 721.2, 







21 Prepared from 301 in accordance with procedure published by H. Ess, L. Kürti et al.: H. Gao, Z. Zhou, D.-H. 
Kwon, J. Coombs, S. Jones, N. E. Behnke, D. H. Ess, L. Kürti, Nat. Chem. 2017, 9, 681–688. BrCH2CH2Br was used 





According to GP4, imidazolium salt 119 (38.5 mg, 61.2 µmol, 1.00 
equiv.) was dissolved in THF (1.0 mL) and cooled to -78 °C. 
Methoxyphenylmagnesium bromide (0.5M in THF, 354 µL, 177 µmol, 
2.89 equiv.) was added dropwise, and the reaction mixture was 
allowed to warm up overnight affording the brown solution. The reaction was quenched with 
sat. NH4Cl (5 mL), stirred for 5 min and extracted with DCM (3  20 mL). The combined organic 
phases were dried over MgSO4, concentrated in vacuo and purified by column chromatography 
(hexane:DCM) to obtain sulfide 185 as a white solid (5.3 mg, 16.5 µmol, 27%).  
1H NMR (400 MHz, CD2Cl2, ppm) δ = 3.77 (s, 3H), 3.78 (s, 3H), 6.81 – 6.84 (m, 2H), 6.86 – 
6.90 (m, 2H), 7.26 – 7.35 (m, 4H), 7.37 (d, J = 8.6 Hz, 1H), 7.52 (dd, J = 8.5, 1.8 Hz, 1H), 8.08 
(dd, J = 1.8, 0.6 Hz, 1H). 13C NMR (126 MHz, CD2Cl2, ppm) δ = 55.6, 55.9, 110.1, 115.0, 115.1, 
115.2, 123.4, 124.9, 126.1, 128.9, 129.6, 130.9, 132.6, 137.1, 137.7, 141.2, 159.4, 160.6. IR 
(neat, cm–1): 1591.0, 1571.7, 1512.9, 1487.8, 1457.9, 1428.0, 1389.5, 1319.1, 1285.3, 1241.0, 
1199.5, 1171.5, 1123.3, 1101.2, 1085.7, 1072.2, 1029.8, 1003.8, 949.8, 819.6, 789.7, 760.8, 
720.3, 692.3, 630.6, 617.1, 594.9,  546.7, 513.0. HRMS: m/z calcd. for C20H17NOS+ [M]+ = 
319.1031; found = 319.1020. 
2-(Furan-2-ylthio)-1-phenyl-1H-pyrrole (167): 
According to modified GP4, imidazolium salt 99 (177 mg, 300 µmol, 
1.00 equiv.) was dissolved in THF (1.5 mL) and cooled to -78 °C. Furan-2-
yllithium22 (0.35M in Et2O/THF, 1.29 mL, 452 µmol, 1.50 equiv.) was added 
dropwise to the clear solution, and the reaction mixture was allowed to warm up overnight 
furnishing an orange suspension. The reaction was quenched with sat. NH4Cl (5 mL), stirred 






22 Prepared according to the protocol of G. Lefèvre, T. Cantat et al.: X. Frogneux, N. von Wolff, P. Thuéry, G. 




MgSO4, concentrated in vacuo and purified by repeated twofold column chromatography 
(DCM:MeOH & hexane:DCM) affording sulfide 167 as a light yellow oil (52.0 mg, 215.4 µmol, 
72%). 
1H NMR (500 MHz, CD2Cl2, ppm) δ = 6.07 (dd, J = 3.3, 0.9 Hz, 1H), 6.23 – 6.28 (m, 2H), 6.63 
(dd, J = 3.7, 1.8 Hz, 1H), 6.97 (dd, J = 3.0, 1.8 Hz, 1H), 7.33 – 7.37 (m, 3H), 7.39 – 7.49 (m, 
3H). 13C NMR (126 MHz, CD2Cl2, ppm) δ = 109.7, 111.9, 115.5, 119.6, 119.7, 126.5, 127.4, 
128.1, 129.3, 140.0, 145.4, 146.0. IR (neat, cm–1): 1715.4, 1596.8, 1497.5, 1456.0, 1434.8, 
1391.4, 1367.3, 1319.1, 1213.0, 1205.3, 1151.3, 1135.9, 1110.8, 1086.7, 1073.2, 1058.7, 
1034.6, 1003.8, 957.5, 905.4, 880.3, 761.7, 720.3, 692.3, 655.7, 633.5, 615.2, 595.9, 557.3. 
HRMS: m/z calcd. for C14H11NNaOS+ [M+Na]+ = 264.0454; found = 264.0462. 
2-{[4-({[(3aR,5R,6R,6aR)-5-[(R)-2,2-Dimethyl-1,3-dioxolan-4-yl]-2,2-dimethyltetrahydro-
furo[2,3-d][1,3]dioxol-6-yl]oxy}methyl)phenyl]thio}-1-phenyl-1H-pyrrole (169): 
According to modified GP4, imidazolium salt 99 (183 mg, 
310 µmol, 1.00 equiv.) was dissolved in THF (1.3 mL) and 
cooled to -78 °C. The linked fructose-derived Grignard 
reagent23 solution (0.70M in THF, 1.28 mL, 896 µmol, 2.89 
equiv.) was added dropwise to the clear solution, and the 
reaction mixture was allowed to warm up overnight affording 
the brown solution. The reaction was quenched with sat. 
NH4Cl (5 mL), stirred for 5 min and extracted with DCM (3  20 mL). The combined organic 
phases were dried over MgSO4, concentrated in vacuo and purified by repetitive twofold 
column chromatography (DCM:MeOH) affording sulfide 169 as a white solid (86.9 mg, 







23 The linked fructose-derived magnesium bromide solution was prepared from the corresponding arylbromide 
302 and Mg tuning following the protocol of H. Ess, L. Kürti et al.: H. Gao, Z. Zhou, D.-H. Kwon, J. Coombs, S. 




1H NMR (300 MHz, CDCl3, ppm) δ = 1.30 (s, 3H), 1.34 – 1.36 (m, 3H), 1.41 – 1.42 (m, 3H), 
1.49 (s, 3H), 3.95 – 4.01 (m, 2H), 4.09 (s, 2H), 4.28 – 4.35 (m, 1H), 4.50 – 4.57 (m, 3H), 5.87 
(d, J = 3.7 Hz, 1H), 6.40 (dd, J = 3.6, 3.0 Hz, 1H), 6.73 (dd, J = 3.6, 1.8 Hz, 1H), 6.89 – 6.93 
(m, 2H), 7.09 (dd, J = 3.0, 1.8 Hz, 1H), 7.12 – 7.16 (m, 2H), 7.20 – 7.25 (m, 2H), 7.26 (s, 3H). 
13C NMR (126 MHz, CDCl3, ppm) δ = 25.7, 26.5, 27.0, 27.1, 67.6, 72.1, 72.6, 81.3, 81.4, 81.7, 
105.4, 109.1, 109.7, 111.9, 118.4, 121.4, 126.1, 126.4, 126.6, 127.5, 128.3, 128.7, 134.8, 
139.1, 139.4. IR (neat, cm–1): 2985.3, 2934.2, 2890.8, 1498.4, 1455.0, 1435.7, 1379.8, 1371.1, 
1349.0, 1320.0, 1251.6, 1211.1, 1163.8, 1121.4, 1069.3, 1014.4, 960.4, 942.1, 884.2, 845.6, 
802.2, 763.7, 733.8, 696.2, 636.4, 605.5, 535.2, 510.1. HRMS: m/z calcd. for C29H34NO6S+ 
[M+H]+ = 524.2101; found = 524.2085. 
3-Bromo-2-[(1-phenyl-1H-pyrrol-2-yl)thio]quinoline (166): 
According to GP4, imidazolium salt 99 (116.9 mg, 198 µmol, 1.00 equiv.) 
was dissolved in THF (1.0 mL) and cooled to -30 °C. 3-(Bromoquinolin-2-
yl)magnesium bromide solution 24  (0.36M in THF, 1.52 mL, 547 µmol, 
2.76 equiv.) was added dropwise to the clear solution, and the reaction mixture was allowed 
to warm up overnight furnishing the dark brown solution. The reaction was quenched with sat. 
NH4Cl (5 mL), stirred for 5 min and extracted with DCM (3  20 mL). The combined organic 
phases were dried over MgSO4, concentrated in vacuo and purified by column chromatography 
(hexane:DCM) affording sulfide 166 as a white solid (40.8 mg, 107 µmol, 54%). 
1H NMR (600 MHz, CDCl3, ppm) δ = 6.48 (dd, J = 3.6, 3.0 Hz, 1H), 6.76 (dd, J = 3.7, 1.8 Hz, 
1H), 7.16 – 7.26 (m, 3H), 7.39 – 7.44 (m, 3H), 7.56 – 7.61 (m, 2H), 7.71 – 7.74 (m, 1H), 8.06 
(s, 1H). 13C NMR (126 MHz, CDCl3, ppm) δ = 109.8, 114.9, 116.5, 121.2, 126.1, 126.4, 126.5, 
127.1, 127.2, 127.3, 128.4, 128.6, 129.7, 137.9, 139.9, 146.7, 159.2. IR (neat, cm–1): 3053.7, 






24  3-Bromoquinolin-2-yl magnesium bromide solution was prepared following the TMPMgCl deprotonation 





877.5, 863.0, 768.5, 748.2, 719.3, 693.3, 688.5, 675.9, 648.9, 600.7, 522.6. HRMS: m/z calcd. 
for C19H13BrN2S+ [M]+ = 379.9983; found = 379.9983. 
2-({4-[(4-Methoxyphenyl)ethynyl]phenyl}thio)-1-phenyl-1H-pyrrole (168): 
According to GP4, imidazolium salt 99 (183 mg, 
310 µmol, 1.00 equiv.) was dissolved in THF (1.5 mL) 
and cooled to -78 °C. 4-[(4-Methoxy-
phenyl)ethynyl]phenyl-magnesium bromide solution 25  (0.45M in THF, 1.03 mL, 464 µmol, 
1.50 equiv.) was added dropwise to the clear solution, and the reaction mixture was allowed 
to warm up overnight furnishing the brown solution. The reaction was quenched with sat. NH4Cl 
(5 mL), stirred for 5 min and extracted with DCM (3  20 mL). The combined organic phases 
were dried over MgSO4, concentrated in vacuo and purified by column chromatography 
(hexane:DCM) affording sulfide 168 as a white solid (86.9 mg, 228 µmol, 74%). 
1H NMR (600 MHz, CDCl3, ppm) δ = 3.82 (s, 3H), 6.43 (dd, J = 3.7, 2.9 Hz, 1H), 6.78 (dd, J = 
3.7, 1.8 Hz, 1H), 6.86 – 6.92 (m, 4H), 7.12 (dd, J = 3.0, 1.8 Hz, 1H), 7.21 – 7.24 (m, 2H), 7.30 
– 7.35 (m, 5H), 7.42 – 7.48 (m, 2H). 13C NMR (126 MHz, CDCl3, ppm) δ = 55.5, 87.9, 89.6, 
109.8, 114.1, 115.4, 117.7, 120.4, 121.7, 125.7, 126.4, 126.8, 127.6, 128.7, 131.8, 133.0, 
139.4, 139.8, 159.6. IR (neat, cm–1): 1603.5, 1509.0, 1497.5, 1456.0, 1435.7, 1396.2, 1319.1, 
1286.3, 1243.9, 1179.3, 1171.5, 1137.8, 1106.0, 1030.8, 1010.5, 819.6, 762.7, 728.0, 694.2, 








25  The aryl magnesium bromide solution was prepared starting from 1-bromo-4-(4-methoxyphenyl) 
ethynylbenzene following the Br-Mg-exchange protocol published by P. Knochel et al.: A. Krasovskiy, P. Knochel, 





According to GP4, imidazolium salt 99 (99.2 mg, 168 µmol, 
1.00 equiv.) was dissolved in THF (1.3 mL) and cooled to -78 °C. 
(Benzo[d]thiazol-2-yl)-magnesium bromide solution (0.318M in THF, 
1.54 mL, 487 µmol, 2.90 equiv.) was added dropwise to the clear solution, and the reaction 
mixture was allowed to warm up overnight furnishing the dark brown solution. The reaction 
was quenched with sat. NH4Cl (5 mL), stirred for 5 min and extracted with DCM (3  20 mL). 
The combined organic phases were dried over MgSO4, concentrated in vacuo and purified by 
column chromatographiy (hexane:DCM) affording sulfide 170 as a white solid (40,9 mg, 
132.6 µmol, 79%). 
1H NMR (300 MHz, CD3CN ppm) δ = 6.50 (dd, J = 3.8, 3.0 Hz, 1H), 6.93 (dd, J = 3.8, 1.8 Hz, 
1H), 7.24 – 7.34 (m, 2H), 7.35 – 7.44 (m, 7H), 7.70 – 7.75 (m, 1H), 7.76 – 7.80 (m, 1H). 
13C NMR (126 MHz, CD3CN, ppm) δ = 111.3, 116.0, 122.3, 122.5, 123.8, 125.3, 127.2, 127.5, 
129.1, 129.6, 129.9, 136.3, 139.7, 155.1, 173.2. IR (neat, cm–1): 3053.7, 2924.5, 1591.0, 
1494.6, 1463.7, 1454.1, 1428.0, 1389.5, 1319.1, 1237.1, 1140.7, 1078.0, 1068.4, 1000.9, 
958.4, 916.0, 764.6, 754.0, 726.1, 720.3, 691.4, 672.1, 617.1. HRMS: m/z calcd. for 






According to GP4, imidazolium salt 99 (79.7 mg, 135 µmol, 1.00 equiv.) 
was dissolved in THF (1.0 mL) and cooled to -78 °C. 2,6-
Dichloropyridin-4-yl magnesium bromide solution26 (0.43M in THF, 908 
µL, 390 µmol, 2.90 equiv.) was added dropwise to the stirred clear 
solution, and the reaction mixture was allowed to warm up overnight furnishing the dark brown 
solution. The reaction was quenched with sat. NH4Cl (5 mL), stirred for 5 min and extracted 
with DCM (3  20 mL). The combined organic phases were dried over MgSO4, concentrated 
in vacuo and purified by column chromatography (hexane:DCM) affording sulfide 173 as a 
white solid (5.1 mg, 15.8 µmol, 12%).  
1H NMR (400 MHz, CDCl3, ppm) δ = 6.47 (dd, J = 3.7, 3.0 Hz, 1H), 6.68 (s, 2H), 6.78 (dd, J = 
3.7, 1.8 Hz, 1H), 7.19 (dd, J = 3.0, 1.8 Hz, 1H), 7.20 – 7.24 (m, 2H), 7.33 – 7.41 (m, 3H). 
13C NMR (101 MHz, CDCl3, ppm) δ = 110.7, 113.1, 118.2, 122.9, 126.3, 128.3, 128.3, 129.2, 
138.8, 150.5, 157.7. IR (neat, cm–1): 3059.5, 1716.3, 1596.8, 1551.5, 1521.6, 1495.5, 1455.0, 
1433.8, 1392.4, 1355.7, 1318.1, 1260.3, 1233.3, 1208.2, 1161.9, 1139.7, 1079.9, 1035.6, 
1002.8, 979.7, 961.3, 844.7, 804.2, 760.8, 727.0, 692.3, 620.0, 606.5, 553.5, 513.9. HRMS: 
m/z calcd. for C15H10Cl2N2S+ [M]+ = 319.9942; found = 319.9944. 
 
3-Bromo-5-[(1-phenyl-1H-pyrrol-2-yl)thio]pyridine (172): 
According to GP4, imidazolium salt 99 (105.7 mg, 179 µmol, 1.00 equiv.) 
was dissolved in THF (1.3 mL) and cooled to -78 °C. 5-Bromopyridin-3-
yl-magnesium bromide (1.23M in THF, 420 µL, 517 µmol, 2.90 equiv.) 






26 2,6-Dichloropyridin-4-yl magnesium bromide solution was prepared following the TMPMgCl deprotonation 





up overnight furnishing the dark brown solution. The reaction was quenched with sat. NH4Cl 
(5 mL), stirred for 5 min and extracted with DCM (3  20 mL). The combined organic phases 
were dried over MgSO4, concentrated in vacuo and purified by column chromatography 
(hexane:DCM) affording sulfide 172 as a colorless oil (38.0 mg, 114,6 µmol, 64%). 
1H NMR (300 MHz, CDCl3, ppm) δ = 6.39 – 6.43 (m, 1H), 6.77 (ddd, J = 3.7, 1.8, 0.3 Hz, 1H), 
7.12 (ddd, J = 3.0, 1.8, 0.3 Hz, 1H), 7.19 – 7.23 (m, 2H), 7.29 (td, J = 2.0, 0.3 Hz, 1H), 7.32 – 
7.40 (m, 3H), 8.02 (s, 1H), 8.32 (s, 1H). 13C NMR (126 MHz, CDCl3, ppm) δ = 110.2, 115.6, 
122.0, 126.5, 127.5, 128.0, 128.9, 136.2, 139.0, 144.9, 147.1. IR (neat, cm–1): 3006.5, 2950.6, 
2843.5, 1540.8, 1408.7, 1369.2, 1311.4, 1106.0, 1084.8, 1060.7, 1004.7, 982.6, 950.7, 874.6, 
752.1, 685.6, 645.1. HRMS: m/z calcd. for C15H11BrN2S+ [M]+ = 329.9826; found = 329.9821. 
2-[(4-Methoxyphenyl)thio]-1H-pyrrole (171): 
According to GP4, imidazolium salt 113 (90.0 mg, 175 µmol, 1.00 equiv.) 
was suspended in THF (1.0 mL) and cooled to -78 °C. 
Methoxyphenylmagnesium bromide (0.50M solution in THF, 1.02 mL, 
510 µmol, 2.91 equiv.) was added dropwise to the stirred white suspension, and the reaction 
mixture was allowed to warm up overnight furnishing the brown suspension. The reaction was 
quenched with sat. NH4Cl (5 mL), stirred for 5 min and extracted with DCM (3  20 mL). The 
combined organic phases were dried over MgSO4, concentrated in vacuo and purified by 
column chromatography (hexane:DCM) affording sulfide 171 as a white solid (23.2 mg, 113 
µmol, 65%). 
1H NMR (300 MHz, CDCl3, ppm) δ = 3.76 (s, 3H), 6.28 (ddd, J = 3.4, 2.5 Hz, 1H), 6.54 (ddd, J 
= 3.4, 2.5, 1.5 Hz, 1H), 6.76 – 6.85 (m, 2H), 6.86 – 6.93 (m, 1H), 7.05 – 7.12 (m, 2H), 8.26 (s, 
1H). 13C NMR (75 MHz, CDCl3, ppm) δ = 55.5, 110.4, 114.8, 117.7, 117.8, 121.5, 128.9, 129.3, 
158.4. IR (neat, cm–1): 3366.1, 2939.0, 2835.8, 1590.0, 1573.6, 1489.7, 1460.8, 1439.6, 
1404.9, 1284.4, 1236.1, 1173.5, 1107.9, 1087.7, 1074.2, 1024.0, 1006.7, 928.6, 819.6, 794.5, 







According to GP4, imidazolium salt 114 (37.0 mg, 63.9 µmol, 1.00 
equiv.) was dissolved in THF (1.0 mL) and cooled to -80 °C. 
Methoxyphenylmagnesium bromide (0.5M solution in THF, 371 µL, 
185.5 µmol, 2.90 equiv.) was added dropwise, and the reaction mixture was allowed to warm 
up to 10 °C over a period of 14 h furnishing the dark brown solution. The reaction was 
quenched with sat. NH4Cl (5 mL), stirred for 5 min and extracted with DCM (3  20 mL). The 
combined organic phases were dried over MgSO4, concentrated in vacuo and purified by 
column chromatography (hexane:EtOAc) affording sulfide 157 as a white solid (15.0 mg, 
55.6 µmol, 87%).  
1H NMR (400 MHz, CDCl3, ppm) δ = 3.73 (s, 3H), 3.83 (s, 3H), 6.69 – 6.78 (m, 2H), 7.09 – 
7.17 (m, 2H), 7.13 – 7.20 (m, 1H), 7.25 – 7.33 (m, 1H), 7.32 (s, 1H), 7.36 (d, J = 8.1 Hz, 1H), 
7.63 (d, J = 8.0 Hz, 1H). 13C NMR (126 MHz, CDCl3, ppm) δ = 33.3, 55.5, 102.6, 109.7, 114.5, 
119.8, 120.4, 122.5, 128.5, 129.8, 130.1, 134.5, 137.5, 157.8. IR (neat, cm–1): 2934.2, 2831.0, 
1591.9, 1571.7, 1509.0, 1488.8, 1457.9, 1439.6, 1420.3, 1353.8, 1332.6, 1315.2, 1284.4, 
1237.1, 1171.5, 1154.2, 1125.3, 1110.8, 1088.6, 1027.9, 1007.6, 819.6, 795.5, 765.6, 738.6, 
637.4, 623.9, 610.4, 513.0. HRMS: m/z calcd. for C16H15NOS+ [M]+ = 269.0869; found = 
269.0873.  
3-[(4-Methoxyphenyl)thio]-1-methyl-2-phenyl-1H-indole (175): 
According to GP4, imidazolium salt 100 (45.8 mg, 70.0 µmol, 1.00 
equiv.) was suspended in THF (1.0 mL) and cooled to -70 °C. 
Methoxyphenylmagnesium bromide (0.5M solution in THF, 406 µL, 
203 µmol, 2.90 equiv.) was added dropwise, and the reaction mixture 
was allowed to warm up to 10 °C over a period of 14 h furnishing the 
orange solution. The reaction was quenched with sat. NH4Cl (5 mL), 
stirred for 5 min and extracted with DCM (3  20 mL). The combined organic phases were 
dried over MgSO4, concentrated in vacuo and purified by column chromatography 
(hexane:EtOAc) to obtain 175 as a white solid (8.0 mg, 23.2 µmol, 33%).  
1H NMR (600 MHz, CDCl3, ppm) δ = 3.72 (s, 3H), 3.72 (s, 3H), 6.69 – 6.73 (m, 2H), 6.99 – 
7.03 (m, 2H), 7.15 – 7.22 (m, 1H), 7.28 – 7.33 (m, 1H), 7.39 – 7.49 (m, 6H), 7.66 – 7.69 (m, 
1H). 13C NMR (126 MHz, CDCl3, ppm) δ = 31.9, 55.5, 101.5, 109.8, 114.3, 114.5, 119.9, 120.9, 
122.8, 127.8, 128.1, 128.3, 128.7, 129.9, 130.8, 137.6, 145.5, 157.5. IR (neat, cm–1): 2921.6, 




1010.5, 824.4, 814.8, 797.4, 737.6, 697.1, 620.0, 550.6, 506.2. HRMS: m/z calcd. for 
C22H19NOS+ [M]+ = 345.1182; found = 345.1187. 
5,6-Dimethoxy-3-(phenylthio)-1H-indole-2-carboxylic acid (87): 
According to GP4, imidazolium salt 117 (98.2 mg, 209.8 µmol, 1.00 
equiv.) was suspended in THF (1.0 mL) and cooled to -78 °C. 
Phenylmagnesium bromide (0.84M solution in THF, 1.25 mL, 
1.05 mmol, 5.00 equiv.) was added dropwise to the stirred white 
suspension, and the reaction mixture was allowed to warm up overnight affording the yellow 
solution. The reaction was quenched with sat. NH4Cl (5 mL), stirred for 5 min and extracted 
with DCM (3  20 mL). The combined organic phases were dried over MgSO4, concentrated 
in vacuo and purified by column chromatography (DCM:MeOH) furnishing sulfide 87 as a white 
solid (42.2 mg, 128 µmol, 61%). 
1H NMR (400 MHz, CD2Cl2, ppm) δ = 3.77 (s, 3H), 3.89 (s, 3H), 6.92 (d, J = 2.6 Hz, 2H), 7.16 
– 7.29 (m, 5H), 9.53 (s, 2H). 13C NMR (126 MHz, CDCl3, ppm) δ = 56.3, 56.4, 94.5, 100.9, 
108.0, 123.0, 126.7, 127.5, 128.5, 129.4, 131.7, 135.4, 147.8, 151.6, 161.5. IR (neat, cm–1): 
2920.7, 1671.0, 1632.4, 1579.4, 1508.1, 1476.2, 1461.8, 1437.7, 1258.3, 1227.5, 1205.3, 
1172.5, 1149.4, 1085.7, 1049.1, 1021.1, 1003.8, 913.1, 836.0, 797.4, 734.7, 688.5, 663.4, 
561.2. HRMS: m/z calcd. for C17H15NNaO4S+ [M+Na]+ = 352.0614; found = 352.0610. 
1-[(4-Methoxyphenyl)thio]-5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinoline (176): 
According to GP4, imidazolium salt 116 (175 mg, 290 µmol, 
1.00 equiv.) was dissolved in THF (3.0 mL) and cooled to -78 °C. 
Methoxyphenylmagnesium bromide solution (0.50M in THF, 
1.68 mL, 840 µmol, 4.80 equiv.) was added dropwise to the stirred clear solution, and the 
obtained orange reaction mixture was allowed to warm up overnight furnishing the red solution. 
The reaction was quenched with sat. NH4Cl (5 mL), stirred for 5 min and extracted with DCM 
(3  20 mL). The combined organic phases were dried over MgSO4, concentrated in vacuo 
and purified by column chromatography (hexane:DCM) affording sulfide 176 as a white solid 
(65.1 mg, 220 µmol, 76%). 
1H NMR (300 MHz, CD2Cl2 ppm) δ 2.20 – 2.31 (m, 2H), 3.00 (dd, J = 6.7, 5.5 Hz, 2H), 3.72 (s, 
3H), 4.13 – 4.27 (m, 2H), 6.72 – 6.75 (m, 2H), 6.93 – 7.04 (m, 2H), 7.11 – 7.15 (m, 2H), 7.30 
– 7.36 (m, 2H). 13C NMR (126 MHz, CD2Cl2, ppm) δ = 23.5, 25.1, 45.0, 55.8, 102.5, 114.8, 




1591.0, 1489.7, 1459.8, 1438.6, 1378.9, 1362.5, 1322.9, 1284.4, 1240.0, 1173.5, 1162.9, 
1153.2, 1103.1, 1029.8, 957.5, 821.5, 777.2, 748.2, 608.4, 517.8. HRMS: m/z calcd. for 
C18H18NOS+ [M+H]+ = 296.1104; found = 296.1094. 
2-[(4-Methoxyphenyl)thio]-5-methylthiophene (186): 
According to GP4, imidazolium salt 122 (66.0 mg, 121 µmol, 
1.00 equiv.) was dissolved in THF (1.0 mL) and cooled 
to -78 °C. Methoxyphenylmagnesium bromide (0.5M solution in 
THF, 363 µL, 181.5 µmol, 1.50 equiv.) was added dropwise to the brown suspension, and the 
reaction mixture was allowed to warm up overnight furnishing the orange solution. The reaction 
was quenched with sat. NH4Cl (5 mL), stirred for 5 min and extracted with DCM (3  20 mL). 
The combined organic phases were dried over MgSO4, concentrated in vacuo and purified by 
column chromatography (DCM:MeOH) affording sulfide 186 as a colorless oil (24.3 mg, 102.8 
µmol, 85%). 
1H NMR (400 MHz, CDCl3, ppm) δ = 2.46 (d, J = 1.1 Hz, 3H), 3.77 (s, 3H), 6.67 (dt, J = 3.5, 
1.1 Hz, 1H), 6.79 – 6.85 (m, 2H), 7.05 (d, J = 3.5 Hz, 1H), 7.24 – 7.28 (m, 2H). 13C NMR (126 
MHz, CDCl3, ppm) δ = 15.9, 55.5, 114.7, 125.9, 129.1, 130.6, 130.7, 134.9, 145.3, 158.8. IR 
(neat, cm–1): 2916.8, 2831.0, 1591.9, 1572.7, 1489.7, 1458.9, 1438.6, 1285.3, 1241.0, 1212.0, 
1171.5, 1160.0, 1104.0, 1064.5, 1029.8, 1005.7, 952.7, 821.5, 793.6, 637.4, 624.8, 566.0, 
528.4. HRMS: m/z calcd. for C12H12OS2+ [M]+ = 236.0324; found = 236.0324. 
6-Methoxy-2-(4-methoxyphenyl)-3-[(4-methoxyphenyl)thio]benzo[b]thiophene (190): 
According to GP4, imidazolium salt 123 (50.2 mg, 69.9 µmol, 
1.00 equiv.) was dissolved in THF (1.0 mL) and cooled 
to -78 °C. Methoxyphenylmagnesium bromide (0.5M solution 
in THF, 210 µL, 105 µmol, 1.50 equiv.) was added dropwise to 
the light yellow suspension, and the reaction mixture was 
allowed to warm up overnight affording the white suspension. The reaction was quenched with 
sat. NH4Cl (5 mL), stirred for 5 min and extracted with DCM (3  20 mL). The combined organic 
phases were dried over MgSO4, concentrated in vacuo and purified by column chromatography 
(hexane:DCM) furnishing sulfide 190 as a white solid (11.7 mg, 28.6 µmol, 41%). 
1H NMR (300 MHz, CDCl3, ppm) δ = 3.72 (s, 3H), 3.84 (s, 3H), 3.87 (s, 3H), 6.71 – 6.76 (m, 
2H), 6.93 – 7.05 (m, 5H), 7.29 – 7.32 (m, 1H), 7.61 – 7.70 (m, 3H). 13C NMR (126 MHz, CDCl3, 
ppm) δ = 55.5, 55.5, 55.8, 105.0, 114.0, 114.8, 114.8, 118.4, 124.5, 126.2, 128.2, 128.5, 131.0, 




1557.2, 1523.5, 1489.7, 1470.5, 1435.7, 1402.0, 1298.8, 1285.3, 1112.7, 1061.6, 985.4, 904.5, 
819.6, 803.2, 765.6, 730.9, 647.0, 636.4, 621.0, 584.3, 560.2, 511.0. HRMS: m/z calcd. for 
C23H20O3S2+ [M]+ = 408.0848; found = 408.0854. 
N,N-Dimethyl-4-(phenylthio)aniline (179): 
According to GP4, imidazolium salt 129 (55.0 mg, 96.7 µmol, 1.00 
equiv.) was dissolved in THF (1.5 mL) and cooled to -78 °C. 
Phenylmagnesium bromide solution (0.92M in THF, 300 µL, 
276 µmol, 2.85 equiv.) was added dropwise to the violet suspension, 
and the reaction mixture was allowed to warm up overnight affording the dark brown 
suspension. The reaction was quenched with sat. NH4Cl (5 mL), stirred for 5 min and extracted 
with DCM (3  20 mL). The combined organic phases were dried over MgSO4, concentrated 
in vacuo and purified by column chromatography (DCM:MeOH) furnishing sulfide 179 as a 
colorless oil (14.2 mg, 61.9 µmol, 64%). 
1H NMR (300 MHz, CDCl3, ppm) δ = 3.00 (s, 6H), 6.69 – 6.75 (m, 2H), 7.05 – 7.13 (m, 3H), 
7.14 – 7.25 (m, 2H), 7.38 – 7.42 (m, 2H). 13C NMR (75 MHz, CDCl3, ppm) δ = 40.5, 113.1, 
117.6, 125.1, 127.0, 128.9, 136.3, 140.4, 150.8. IR (neat, cm–1): 2885.0, 1677.8, 1591.9, 
1550.5, 1504.2, 1475.3, 1438.6, 1354.7, 1314.3, 1260.3, 1223.6, 1192.8, 1167.7, 1129.1, 
1100.2, 1084.8, 1062.6, 1023.1, 998.0, 944.0, 906.4, 810.9, 764.6, 735.7, 688.5, 644.1, 621.0, 
610.4, 594.0, 527.4. HRMS: m/z calcd. for C14H16NS+ [M+H]+ = 230.0998; found = 230.0999. 
N,N-Dimethyl-4-(p-tolylthio)aniline (158): 
According to GP4, imidazolium salt 129 (49.0 mg, 86.2 µmol, 
1.00 equiv.) was dissolved in THF (1.5 mL) and cooled 
to -78 °C. p-Tolylmagnesium bromide solution (0.92M in THF, 
272 µL, 250 µmol, 2.90 equiv.) was added dropwise to the 
violet suspension, and the reaction mixture was allowed to warm up overnight giving the dark 
brown suspension. The reaction was quenched with sat. NH4Cl (5 mL), stirred for 5 min and 
extracted with DCM (4  20 mL). The combined organic phases were dried over MgSO4, 
concentrated in vacuo and purified by column chromatography (DCM:MeOH) affording sulfide 
158 as a colorless oil (15.8 mg, 64.9 µmol, 75%) 




7.09 (m, 4H), 7.34 – 7.40 (m, 2H).27 
4-[(4-Methoxyphenyl)thio]-N,N-dimethylaniline (160): 
According to GP4, imidazolium salt 129 (104.6 mg, 184 µmol, 
1.00 equiv.) and LiCl (39.0 mg, 920 µmol, 5.00 equiv.) were 
dissolved in THF (1.5 mL) and cooled to -78 °C. 4-
Methoxyphenylmagnesium bromide solution (0.50M in THF, 
1.07 mL, 535 µmol, 2.91 equiv.) was added dropwise to the violet suspension, and the reaction 
mixture was allowed to warm up overnight affording the yellow suspension. The reaction was 
quenched with sat. NH4Cl (5 mL), stirred for 5 min and extracted with DCM (3  20 mL). The 
combined organic phases were dried over MgSO4, concentrated in vacuo and purified by 
column chromatography (DCM:MeOH) furnishing sulfide 160 as a white solid (43.1 mg, 
166 µmol, 90%). 
1H NMR (300 MHz, CDCl3, ppm) δ = 2.86 (s, 6H), 3.67 (s, 3H), 6.53 – 6.61 (m, 2H), 6.67 – 
6.73 (m, 2H), 7.06 – 7.13 (m, 2H), 7.18 – 7.27 (m, 2H). 13C NMR (75 MHz, CDCl3, ppm) δ = 
40.5, 55.4, 113.1, 114.7, 120.6, 129.7, 131.0, 134.4, 137.4, 150.2, 158.4. IR (neat, cm–1): 
2855.1, 1590.0, 1487.8, 1453.1, 1356.7, 1280.5, 1230.4, 1193.7, 1028.8, 808.0, 628.7, 523.6, 
504.3. HRMS: m/z calcd. for C15H17NOS+ [M]+ = 259.1025; found = 259.1024. 
4-{[4-({[(1R,2S,5R)-2-Isopropyl-5-methylcyclohexyl]oxy}methyl)phenyl]thio}-N,N-dime-
thylaniline (187): 
According to GP4, imidazolium salt 129 (75.0 mg, 131.9 µmol, 
1.00 equiv.) was dissolved in THF (1.0 mL) and cooled 






27 1H NMR spectrum was in agreement with the data published by R. K. Peddinti et al.: S. K. R. Parumala, R. K. 
Peddinti, Green Chem. 2015, 17, 4068–4073. 
28 Prepared from 301 in accordance with the procedure published by H. Ess, L. Kürti et al.: H. Gao, Z. Zhou, D.-H. 
Kwon, J. Coombs, S. Jones, N. E. Behnke, D. H. Ess, L. Kürti, Nat. Chem. 2017, 9, 681–689. BrCH2CH2Br was used 




solution (0.404M in THF, 948 µL, 382.9 µmol, 2.90 equiv.) was added dropwise to the violet 
solution, and the reaction mixture was allowed to warm up overnight furnishing the orange 
suspension. The reaction was quenched with sat. NH4Cl (5 mL), stirred for 5 min and extracted 
with DCM (3  20 mL). The combined organic phases were dried over MgSO4, concentrated 
in vacuo and purified by column chromatography (hexane:DCM) affording sulfide 187 as a 
white solid (26.8 mg, 67.4 µmol, 51%). 
1H NMR (300 MHz, CDCl3, ppm) δ = 0.71 (d, J = 6.9 Hz, 3H), 0.86 – 1.01 (m, 9H), 1.22 – 1.44 
(m, 2H), 1.64 (ddt, J = 12.6, 9.7, 3.2 Hz, 2H), 2.17 (dtd, J = 12.2, 3.8, 1.9 Hz, 1H), 2.27 (hd, J 
= 7.0, 2.8 Hz, 1H), 2.99 (s, 6H), 3.14 (td, J = 10.6, 4.2 Hz, 1H), 4.32 (d, J = 11.4 Hz, 1H), 4.58 
(d, J = 11.4 Hz, 1H), 6.67 – 6.73 (m, 2H), 7.08 – 7.13 (m, 2H), 7.17 – 7.22 (m, 2H), 7.34 – 7.40 
(m, 2H). 13C NMR (126 MHz, CDCl3, ppm) δ = 16.3, 21.2, 22.6, 23.5, 25.7, 31.8, 34.8, 40.5, 
40.5, 48.5, 77.2, 78.8, 113.1, 118.1, 127.3, 128.4, 135.8, 136.2, 139.1, 150.6. IR (neat, cm–1): 
2949.6, 2916.8, 2864.7, 1592.9, 1505.2, 1490.7, 1444.4, 1355.7, 1223.6, 1192.8, 1168.7, 
1103.1, 1081.9, 1066.4, 1014.4, 944.9, 806.1, 655.7, 528.4. HRMS: m/z calcd. for C25H35NOS+ 
[M]+ = 397.2434; found = 397.2436. 
(2,4-Dimethoxyphenyl)(4-methoxyphenyl)sulfane (184): 
According to GP4, imidazolium salt 137 (70.2 mg, 119.9 µmol, 1.00 
equiv.) was dissolved in THF (1.0 mL) and cooled to -78 °C. 
Methoxyphenylmagnesium bromide (0.50M in THF, 360 µL, 
180 µmol, 1.50 equiv.) was added dropwise to the stirred white suspension, and the reaction 
mixture was allowed to warm up overnight giving the brown suspension. The reaction was 
quenched with sat. NH4Cl (5 mL), stirred for 5 min and extracted with DCM (3  20 mL). The 
combined organic phases were dried over MgSO4, concentrated in vacuo and purified by 
column chromatography (hexane:DCM) affording sulfide 184 as a white solid (16.5 mg, 59.7 
µmol, 50%). 
1H NMR (400 MHz, CDCl3, ppm) δ = 3.79 (s, 3H), 3.80 (s, 3H), 3.84 (s, 3H), 6.40 – 6.46 (m, 
1H), 6.49 (d, J = 2.6 Hz, 1H), 6.82 – 6.86 (m, 2H), 7.08 (dd, J = 8.5, 1.0 Hz, 1H), 7.25 – 7.30 
(m, 2H). 13C NMR (126 MHz, CDCl3, ppm) δ = 55.5, 55.6, 56.1, 99.2, 105.3, 114.8, 115.9, 
126.4, 132.7, 133.4, 158.8, 158.9, 160.7. IR (neat, cm–1): 2937.1, 2832.9, 1589.1, 1572.7, 
1489.7, 1458.9, 1435.7, 1409.7, 1299.8, 1279.5, 1240.0, 1206.3, 1170.6, 1159.0, 1102.1, 
1007.6, 933.4, 917.0, 820.6, 793.6, 634.5, 621.9, 518.8. HRMS: m/z calcd. for C15H16O3S+ [M]+ 






According to GP4, imidazolium salt 99 (135.7 mg, 230 µmol, 1.00 equiv.) was 
dissolved in THF (1.0 mL) and cooled to -78 °C. Isopropylmagnesium chloride 
solution (1.30M in THF, 513 µL, 667 µmol, 2.90 equiv.) was added dropwise to 
the clear solution, and the reaction mixture was allowed to warm up overnight 
furnishing the yellow solution. The reaction was quenched with sat. NH4Cl (5 mL), stirred for 5 
min and extracted with DCM (3  20 mL). The combined organic phases were dried over 
MgSO4, concentrated in vacuo and purified by column chromatography (hexane:DCM) 
affording sulfide 191 as a colorless oil (32.0 mg, 147 µmol, 64%). 
1H NMR (300 MHz, CDCl3, ppm) δ = 1.02 (d, J = 6.7 Hz, 6H), 2.72 (hept, J = 6.7 Hz, 1H), 6.29 
(dd, J = 3.5, 2.9 Hz, 1H), 6.54 (dd, J = 3.6, 1.8 Hz, 1H), 7.00 (dd, J = 2.9, 1.8 Hz, 1H), 7.32 – 
7.49 (m, 5H). 13C NMR (126 MHz, CDCl3, ppm) δ = 23.1, 40.5, 108.9, 120.1, 121.6, 125.6, 
126.8, 127.2, 128.7, 140.1. IR (neat, cm–1): 2958.3, 2920.7, 2858.0, 1596.8, 1497.5, 1455.0, 
1431.9, 1363.4, 1319.1, 1237.1, 1153.2, 1133.0, 1088.6, 1073.2, 1050.1, 1033.7, 959.4, 760.8, 
718.4, 616.1, 606.5, 559.3, 505.3. HRMS: m/z calcd. for C13H15NS+ [M]+ = 217.0920; found = 
217.0923. 
2-(2-Butylthio)-1-phenyl-1H-pyrrole (192): 
According to modified GP4, imidazolium salt 99 (218.4 mg, 370 µmol, 
1.00 equiv.) was dissolved in THF (1.5 mL) and cooled to -78 °C. sec-
Buthyllithium (1.50M in cyclohexane, 396 µL, 594 µmol, 1.61 equiv.) was 
added dropwise to the clear solution, and the reaction mixture was allowed 
to warm up overnight furnishing the dark brown solution. The reaction was 
quenched with sat. NH4Cl (5 mL), stirred for 5 min and extracted with DCM (3  20 mL). The 
combined organic phases were dried over MgSO4, concentrated in vacuo and purified by 
column chromatography (hexane:DCM) affording sulfide 192 as a light yellow oil (57.2 mg, 
247.2 µmol, 67%). 
1H NMR (600 MHz, CDCl3, ppm) δ = 0.75 (t, J = 7.4 Hz, 3H), 0.99 (d, J = 6.8 Hz, 3H), 1.22 – 
1.29 (m, 1H), 1.30 – 1.40 (m, 1H), 2.43 – 2.51 (m, 1H), 6.28 (dd, J = 3.6, 2.9 Hz, 1H), 6.54 (dd, 
J = 3.6, 1.8 Hz, 1H), 7.00 (dd, J = 3.0, 1.8 Hz, 1H), 7.34 – 7.41 (m, 3H), 7.42 – 7.46 (m, 2H). 
13C NMR (126 MHz, CDCl3, ppm) δ = 11.5, 20.6, 29.4, 47.3, 108.9, 120.2, 121.3, 125.5, 126.9, 
127.2, 128.6, 140.1. IR (neat, cm–1): 2961.2, 2919.7, 1596.8, 1514.8, 1497.5, 1455.0, 1431.9, 
1374.0, 1319.1, 1133.0, 1088.6, 1072.2, 1034.6, 958.4, 796.5, 760.8, 717.4, 692.3, 621.0, 





According to GP4, imidazolium salt 99 (76.7 mg, 130 µmol, 
1.00 equiv.) was dissolved in THF (1.3 mL) and cooled to -78 °C. 4-
Pentenylmagnesium bromide solution (1.80M in Et2O, 209 µL, 
376 µmol, 2.89 equiv.) was added dropwise to the clear solution, and 
the reaction mixture was allowed to warm up overnight furnishing the grey suspension. The 
reaction was quenched with sat. NH4Cl (5 mL), stirred for 5 min and extracted with DCM 
(3  20 mL). The combined organic phases were dried over MgSO4, concentrated in vacuo 
and purified by column chromatography (hexane:DCM) affording sulfide 193 as a colorless oil 
(26.3 mg, 108 µmol, 83%). 
1H NMR (300 MHz, CD2Cl2 ppm) δ = 1.44 (p, J = 7.3 Hz, 2H), 1.92 – 2.02 (m, 2H), 2.38 (d, J 
= 7.1 Hz, 2H), 4.87 – 4.89 (m, 1H), 4.91 – 4.95 (m, 1H), 5.67 (ddt, J = 15.9, 10.7, 6.7 Hz, 1H), 
6.26 (dd, J = 3.6, 3.0 Hz, 1H), 6.49 (dd, J = 3.6, 1.8 Hz, 1H), 6.98 (dd, J = 3.0, 1.8 Hz, 1H), 
7.34 – 7.51 (m, 5H). 13C NMR (126 MHz, CD2Cl2, ppm) δ = 28.9, 32.8, 37.2, 109.4, 115.2, 
119.2, 122.5, 125.7, 127.0, 127.7, 129.1, 138.3, 140.4. IR (neat, cm–1): 2926.4, 1718.3, 1639.2, 
1596.8, 1515.8, 1497.5, 1455.0, 1432.9, 1393.3, 1319.1, 1295.0, 1272.8, 1257.4, 1205.3, 
1173.5, 1133.0, 1088.6, 1073.2, 1033.7, 999.9, 990.3, 957.5, 910.2, 879.4, 823.5,796.5, 760.8, 
717.4, 692.3, 660.5, 641.2, 619.0, 605.5, 575.6, 556.4, 533.2. HRMS: m/z calcd. for C15H18NS+ 
[M+H]+ = 244.1154; found = 244.1157. 
1-Phenyl-2-(prop-1-en-2-ylthio)-1H-pyrrole (195): 
According to GP4, imidazolium salt 99 (79.1 mg, 134 µmol, 1.00 equiv.) was 
dissolved in THF (1.0 mL) and cooled to -78 °C. Isopropenylmagnesium 
bromide solution (0.5M in THF, 772 µL, 386 µmol, 2.88 equiv.) was added 
dropwise to the colorless solution, and the reaction mixture was allowed to warm up overnight 
furnishing the orange solution. The reaction was quenched with sat. NH4Cl (5 mL), stirred for 
5 min and extracted with DCM (3  20 mL). The combined organic phases were dried over 
MgSO4, concentrated in vacuo and purified by column chromatography (DCM:MeOH) affording 
sulfide 195 as a colorless oil (26.2 mg, 121.6 µmol, 91%). 
1H NMR (300 MHz, CDCl3, ppm) δ = 1.77 – 1.81 (m, 3H), 4.47 – 4.49 (m, 1H), 4.87 – 4.90 (m, 
1H), 6.34 (dd, J = 3.6, 2.9 Hz, 1H), 6.63 (dd, J = 3.6, 1.8 Hz, 1H), 7.06 (dd, J = 3.0, 1.8 Hz, 
1H), 7.32 – 7.45 (m, 5H). 13C NMR (126 MHz, CDCl3, ppm) δ = 22.2, 108.7, 109.5, 118.7, 
121.1, 126.1, 127.4, 128.7, 139.7, 143.3. IR (neat, cm–1): 2955.4, 1595.8, 1488.8, 1456.0, 




1105.0, 1086.7, 1028.8, 1002.8, 820.6, 808.0, 794.5, 760.8, 725.1, 691.4, 649.9, 635.4, 619.0, 
561.2, 509.1. HRMS: m/z calcd. for C13H13NS+ [M]+ = 215.0763; found = 215.0767. 
2-[(2-Methylprop-1-en-1-yl)thio]-1-phenyl-1H-pyrrole (196): 
According to GP4, imidazolium salt 99 (96.8 mg, 163.9 µmol, 1.00 equiv.) 
was dissolved in THF (1.0 mL) and cooled to -78 °C. 2-Methyl-1-
propenylmagnesium bromide solution (0.5M in THF, 951 µL, 475.5 µmol, 
2.90 equiv.) was added dropwise to the colorless solution, and the 
reaction mixture was allowed to warm up overnight furnishing the yellow solution. The reaction 
was quenched with sat. NH4Cl (5 mL), stirred for 5 min and extracted with DCM (3  20 mL). 
The combined organic phases were dried over MgSO4, concentrated in vacuo and purified by 
column chromatography (hexane:DCM) affording sulfide 196 as a colorless oil (33.2 mg, 144.7 
µmol, 88%). 
1H NMR (400 MHz, CDCl3, ppm) δ = 1.64 (dd, J = 1.2, 0.5 Hz, 3H), 1.66 – 1.69 (m, 3H), 5.55 
– 5.58 (m, 1H), 6.30 (dd, J = 3.6, 3.0 Hz, 1H), 6.53 (dd, J = 3.6, 1.8 Hz, 1H), 6.98 (dd, J = 2.9, 
1.8 Hz, 1H), 7.33 – 7.48 (m, 5H). 13C NMR (126 MHz, CDCl3, ppm) δ = 19.3, 25.1, 109.2, 
117.4, 119.4, 122.3, 125.1, 126.6, 127.2, 128.7, 134.9, 139.8. IR (neat, cm–1): 2909.1, 1596.8, 
1498.4, 1454.1, 1433.8, 1371.1, 1319.1, 1298.8, 1133.0, 1087.7, 1072.2, 1059.7, 1033.7, 
959.4, 798.4, 759.8, 716.4, 692.3, 664.4, 619.0, 605.5, 558.3, 504.3. HRMS: m/z calcd. for 
C14H16NS+ [M+H]+ = 230.0998; found = 230.0995. 
3-(n-Butylthio)-1-methyl-1H-indole (197): 
According to modified GP4, imidazolium salt 114 (49.2 mg, 85.1 µmol, 
1.00 equiv.) was dissolved in THF (1.3 mL) and cooled to -78 °C. n-
Buthyllithium (1.23M in hexane, 104 µL, 127.9 µmol, 1.50 equiv.) was added 
dropwise to the clear solution, and the reaction mixture was allowed to warm 
up overnight furnishing the orange solution. The reaction was quenched with sat. NH4Cl 
(5 mL), stirred for 5 min and extracted with DCM (3  20 mL). The combined organic phases 
were dried over MgSO4, concentrated in vacuo and purified by column chromatography 
(hexane:DCM) affording sulfide 197 as a colorless oil (12.0 mg, 54.7 µmol, 64%). 
1H NMR (300 MHz, CD2Cl2 ppm) δ = 0.79 (t, 3H), 1.25 – 1.34 (m, 2H), 1.45 – 1.57 (m, 2H), 
2.59 – 2.69 (m, 2H), 3.34 (s, 3H), 7.13 – 7.37 (m, 4H), 7.71 (ddd, J = 7.6, 1.5, 0.8 Hz, 1H). 
13C NMR (126 MHz, CD2Cl2, ppm) δ = 14.1, 22.3, 32.6, 33.4, 37.0, 104.4, 110.1, 119.7, 120.2, 




1419.4, 1328.7, 1315.2, 1241.0, 1204.3, 1152.3, 1133.0, 1100.2, 1077.0, 1012.4, 883.2, 761.7, 
734.7, 709.7, 572.8. HRMS: m/z calcd. for C13H18NS+ [M+H]+ = 220.1154; found = 220.1151. 
4-(Isopropylthio)-N,N-dimethylaniline (198): 
According to GP4, imidazolium salt 129 (45.4 mg, 79.9 µmol, 1.00 
equiv.) was dissolved in THF (1.0 mL) and cooled to -78 °C. 
Isopropylmagnesium chloride solution (1.3M in THF, 178 µL, 
231.4 µmol, 2.90 equiv.) was added dropwise to the stirred violet suspension, and the reaction 
mixture was allowed to warm up overnight furnishing the colorless solution. The reaction was 
quenched with sat. NH4Cl (5 mL), stirred for 5 min and extracted with DCM (3  20 mL). The 
combined organic phases were dried over MgSO4, concentrated in vacuo and purified by 
column chromatography (hexane:DCM) affording sulfide 198 as a colorless oil (14.6 mg, 
74.7 µmol, 93%). 
1H NMR (400 MHz, CDCl3, ppm) δ = 1.23 (d, J = 6.7 Hz, 6H), 2.96 (s, 6H), 3.11 (hept, J = 6.7 
Hz, 1H), 6.60 – 6.72 (m, 2H), 7.30 – 7.42 (m, 2H). 13C NMR (126 MHz, CDCl3, ppm) δ = 23.4, 
40.0, 40.6, 112.6, 119.8, 136.1, 150.2. IR (neat, cm–1): 2956.3, 2921.6, 2859.9, 1591.9, 1502.3, 
1442.5, 1349.9, 1223.6, 1192.8, 1166.7, 1153.2, 1130.1, 1100.2, 1059.7, 1049.1, 944.9, 810.9, 
524.5. HRMS: m/z calcd. for C11H17NS+ [M]+ = 195.1076; found = 195.1089. 
4-(Cyclopentylthio)-N,N-dimethylaniline (182): 
According to modified GP4, imidazolium salt 129 (76.7 mg, 134.9 µmol, 
1.00 equiv.) and LiCl (28.6 mg, 676 µmol, 5.00 equiv.) were dissolved in 
THF (1.5 mL) and cooled to -78 °C. Cyclopentyl-magnesium bromide 
solution (2.0M in THF, 196 µL, 392 µmol, 2.90 equiv.) was added dropwise to the stirred violet 
suspension, and the reaction mixture was allowed to warm up overnight furnishing the brown 
suspension. The reaction was quenched with sat. NH4Cl (5 mL), stirred for 5 min and extracted 
with DCM (4  20 mL). The combined organic phases were dried over MgSO4, concentrated 
in vacuo and purified by column chromatography (DCM:MeOH) affording sulfide 182 as a 
colorless oil (18.5 mg, 83.5 µmol, 62%). 
1H NMR (300 MHz, CDCl3, ppm) δ = 1.50 – 1.64 (m, 4H), 1.69 – 1.81 (m, 2H), 1.84 – 2.01 (m, 
2H), 2.95 (s, 6H), 3.29 – 3.41 (m, 1H), 6.60 – 6.70 (m, 2H), 7.32 – 7.39 (m, 2H). 13C NMR (75 
MHz, CDCl3, ppm) δ = 24.7, 33.5, 40.6, 48.8, 112.8, 121.3, 135.1, 150.1. IR (neat, cm–1): 
2951.5, 2799,2, 1592,9, 1502,3, 1442,5, 1349,9, 1222,6, 1191,8, 1166,7, 944,9, 810, 524,5. 




4-[(4-Fluorophenyl)thio]-N,N-dimethylaniline (182):  
According to GP4, imidazolium salt, 129 (108 mg, 190 µmol, 1.00 
equiv.) was dissolved in THF (1.0 mL) and cooled to -78 °C. 4-
Fluorophenylmagnesium-bromide solution (1.0M in THF, 551 µL, 
551 µmol, 2.90 equiv.) was added dropwise to the stirred violet suspension, and the reaction 
mixture was allowed to warm up overnight furnishing the white suspension. The reaction was 
quenched with sat. NH4Cl (5 mL), stirred for 5 min and extracted with DCM (3  20 mL). The 
combined organic phases were dried over MgSO4, concentrated in vacuo and purified by 
column chromatography (hexane:DCM) affording sulfide 182 as a white solid (12.2 mg, 
49.3 µmol, 26%). 
1H NMR (300 MHz, CDCl3, ppm) δ = 2.99 (s, 6H), 6.65 – 6.74 (m, 2H), 6.88 – 6.96 (m, 2H), 
7.07 – 7.18 (m, 2H), 7.30 – 7.41 (m, 2H). 13C NMR (126 MHz, CDCl3, ppm) δ = 40.5, 113.1, 
115.9 (d, JC-F = 21.9 Hz), 118.4, 129.5 (d, JC-F = 7.7 Hz), 135.0, 135.6, 150.6, 161.2 (d, JC-F = 
244.1 Hz). 19F NMR (282 MHz, CDCl3, ppm) δ = –117.3. IR (neat, cm–1): 2892.7, 1587.1, 
1552.4, 1503.2, 1484.9, 1443.5, 1393.3, 1349.0, 1261.2, 1208.2, 1196.6, 1169.6, 1154.2, 
1091.5, 1080.9, 1063.6, 1010.5, 943.0, 825.4, 814.8, 802.2, 765.6, 637.4, 623.9, 612.3, 526.5.  
HRMS: m/z calcd. for C14H14NFS+ [M]+ = 247.0825; found = 247.0835. 
N,N-Dimethyl-4-(prop-1-en-2-ylthio)aniline (200): 
According to GP4, imidazolium salt 129 (108.5 mg, 190.9 µmol, 1.00 
equiv.) was dissolved in THF (1.0 mL) and cooled to -78 °C. 
Isopropenylmagnesium bromide solution (0.50M in THF, 1.11 mL, 
555 µmol, 2.91 equiv.) was added dropwise to the violet suspension, and the reaction mixture 
was allowed to warm up overnight furnishing the yellowish white suspension. The reaction 
suspension was quenched with sat. NH4Cl (5 mL), stirred for 5 min and extracted with DCM 
(3  20 mL). The combined organic phases were dried over MgSO4, concentrated in vacuo 
and purified by column chromatography (hexane:DCM) affording sulfide 200 as a white solid 
(32.9 mg, 170.1 µmol, 89%). 
1H NMR (300 MHz, CDCl3, ppm) δ = 1.96 (dd, J = 1.4, 0.8 Hz, 3H), 2.98 (s, 6H), 4.57 (s, 1H), 
4.93 (q, J = 1.4 Hz, 1H), 6.63 – 6.73 (m, 2H), 7.31 – 7.39 (m, 2H). 13C NMR (75 MHz, CDCl3, 
ppm) δ = 22.8, 40.4, 108.4, 112.8, 117.3, 136.4, 144.0, 150.8. IR (neat, cm–1): 2913.9, 1593.9, 
1550.5, 1505.2, 1481.1, 1443.5, 1355.7, 1315.2, 1288.2, 1224.6, 1188.9, 1168.7, 1129.1, 




m/z calcd. for C11H15NS+ [M]+ = 193.0920; found = 193.0920. 
2-{[(1s,3s)-Adamantan-1-yl]thio}-1-phenyl-1H-pyrrole (194): 
According to GP4, imidazolium salt 99 (207 mg, 350.6 µmol, 1.00 equiv.) 
was dissolved in THF (1.0 mL) and cooled to -78 °C. Under stirring, 
adamantylmagnesium bromide solution (2.0M in THF, 510 µL, 
1.02 mmol, 2.91 equiv.) was added dropwise to the colourless solution, and the reaction 
mixture was allowed to warm up overnight furnishing the yellow solution. The reaction was 
quenched with sat. NH4Cl (5 mL), stirred for 5 min and extracted with DCM (3  20 mL). The 
combined organic phases were dried over MgSO4, concentrated in vacuo and purified first by 
column chromatography (hexane:DCM), then by preparative HPLC (YMX PVA-Sil, 4.6  250 
mm, 5µm; gradient hexane:DCM from 100:0 to 60:40) affording sulfide 194 as a white solid 
(5.4 mg, 17.5 µmol, 5%). 
1H NMR (400 MHz, CDCl3, ppm) δ = 1.45 – 1.60 (m, 12H), 1.85 – 1.90 (m, 3H), 6.28 (dd, J = 
3.6, 3.0 Hz, 1H), 6.51 (dd, J = 3.6, 1.8 Hz, 1H), 7.04 (dd, J = 3.0, 1.8 Hz, 1H), 7.32 – 7.37 (m, 
3H), 7.39 – 7.47 (m, 2H). 13C NMR (126 MHz, CD2Cl2, ppm) δ = 30.7, 36.6, 43.9, 50.0, 105.2, 
109.1, 122.2, 126.5, 127.3, 127.6, 128.8. IR (neat, cm–1): 2925.5, 1591.0, 1489.7, 1458.9, 
1438.6, 1378.9, 1338.4, 1322.9, 1284.4, 1239.0, 1161.9, 1102.1, 1028.8, 955.6, 818.6, 776.2, 
746.3, 635.4, 621.9, 607.5, 513.0. HRMS: m/z calcd. for C20H24NS+ [M+H]+ = 310.1624; found 
= 310.1623. 
(4-Methoxyphenyl)(2,4,6-trimethoxyphenyl)sulfane (184): 
According to GP4, imidazolium salt 138 (949 mg, 1.54 mmol, 1.00 
equiv.) was dissolved in THF (8.0 mL) and cooled to -78 °C. 
Methoxyphenylmagnesium bromide (0.35M in THF, 6.61 mL, 
2.31 mmol, 1.50 equiv.) was added dropwise to the stirred white 
suspension, and the reaction mixture was allowed to warm up overnight furnishing the brown 
solution. The reaction was quenched with sat. NH4Cl (15 mL), stirred for 5 min and extracted 
with DCM (2  25 mL). The combined organic phases were dried over MgSO4, concentrated 
in vacuo and purified by column chromatography (hexane:DCM) furnishing sulfide 184 as a 
white solid (200 mg, 652.7 µmol, 42%). 
1H NMR (300 MHz, CD2Cl2, ppm) δ = 3.73 (s, 3H), 3.80 (s, 6H), 3.85 (s, 3H), 6.22 (s, 2H), 6.66 
– 6.82 (m, 2H), 7.03 (d, J = 8.9 Hz, 2H). 13C NMR (101 MHz, CD2Cl2, ppm) δ = 55.8, 55.9, 




1580.4, 1491.7, 1468.5, 1449.2, 1409.7, 1334.5, 1285.3, 1242.9, 1222.6, 1205.3, 1178.3, 
1160.9, 1116.6, 1027.9, 953.6, 916.0, 812.8, 782.0, 679.8, 660.5, 633.5, 621.9, 520.7. HRMS: 
m/z calcd. for C16H18NaO4S+ [M+Na]+ = 329.0818; found = 329.0823. 
 
2-[(4-Methoxyphenyl)thio]-1-phenyl-5-(prop-1-en-2-ylthio)-1H-pyrrole (88): 
According to GP4, imidazolium salt 201 (200 mg, 274.5 µmol, 1.00 
equiv.) was dissolved in THF (6.0 mL) and cooled to -78 °C. Under 
stirring, isopropenylmagnesium bromide solution (0.50M in THF, 
1.59 mL, 795 µmol, 2.90 equiv.) was added dropwise to the 
suspension, and the reaction mixture was allowed to warm up 
overnight furnishing the yellow suspension solution. The reaction was quenched with sat. 
NH4Cl (5 mL), stirred for 5 min and extracted with DCM (3  20 mL). The combined organic 
phases were dried over MgSO4, concentrated in vacuo and purified by column chromatography 
(hexane:DCM) giving sulfide 88 as a white solid (78.1 mg, 221 µmol, 81%). 
1H NMR (300 MHz, CDCl3, ppm) δ =  1.76 (s, 3H), 3.75 (s, 3H), 4.50 (d, J = 0.8 Hz, 1H), 4.84 
– 4.90 (m, 1H), 6.65 (d, J = 3.7 Hz, 1H), 6.68 – 6.75 (m, 3H), 6.87 – 6.95 (m, 2H), 7.00 – 7.06 
(m, 2H), 7.26 – 7.42 (m, 3H). 13C NMR (126 MHz, CD3Cl, ppm) δ = 22.3, 55.4, 109.3, 114.5, 
118.6, 119.7, 123.3, 126.0, 127.8, 128.0, 128.2, 128.9, 130.3, 137.5, 142.4, 158.5. IR (neat, 
cm–1): 1706.7, 1618.9, 1450.2, 1423.2, 1376.0, 1326.8, 1293.0, 1215.9, 1175.4, 1111.8, 
1074.2, 1029.8, 906.4, 822.5, 749.2, 652.8, 545.8. HRMS: m/z calcd. for C20H20NOS2+ [M+H]+ 





5.3 Reactions towards the synthesis of selenides 
5.3.1 Synthesis of arylselenoimidazolium salts 
2-[(2,5-Dioxopyrrolidin-1-yl)selanyl]-1,3-diisopropyl-4,5-dimethyl-1H-imidazol-3-ium 
Chloride (214): 
2-Selenoimidazoline (159) (75.0 mg, 0.289 mmol, 1.00 equiv.) and N-
chlorosuccinimide (38.6 mg, 0.289 mmol, 1.00 equiv.) were dissolved 
in MeCN (2 mL) and the mixture was stirred for 5 min at r.t. Removal 
of the solvents in vacuo afforded 214 as a light yellow solid (114 mg, 
0.290 mmol, quantitative). 
1H NMR (400 MHz, CD2Cl2 ppm) δ = 1.48 – 1.70 (m, 12 H), 2.36 (s, 6H), 2.61 (s, 4H), 6.03 
(hept, J = 7.0 Hz, 2H). 13C NMR (101 MHz, CD2Cl2, ppm) δ = 10.9, 21.3, 30.1, 56.1, 129.0, 
142.8, 180.6. IR (neat, cm–1): 2176.4, 2037.9, 2029.8, 1983.1, 1969.1, 1707.6, 1594.4, 1511.3, 
1360.4, 1178.3, 670.9, 658.5, 634.7, 624.1. HRMS: m/z calcd. for C15H24N3O2Se+ [M–Cl]+ = 




According to GP3, 2-selenoimidazoline (159) (180 mg, 694 µmol), N-
chlorosuccinimide (92.7 mg, 694 µmol) and N-methylindole (89 µL, 91 mg, 
694 µmol, 1.00 equiv.) were dissolved in MeCN (5.0 mL) and stirred at 
70 °C for 19 h. All volatiles were removed in vacuo; the residual red solid 
was dissolved in DCM (5 mL) and washed with sat. aq. NaSbF6 (3.0 mL) 
for 5 min. The organic layer was dried over MgSO4 and concentrated in vacuo. After column 
chromatography (DCM:MeOH), product 215 was obtained as a yellow foam (244 mg, 
390 µmol, 56%). 
1H NMR (300 MHz, CD2Cl2 ppm) δ = 1.47 (d, J = 7.1 Hz, 12H), 2.32 (s, 6H), 3.85 (s, 3H), 5.63 
(s, 2H), 7.26 – 7.38 (m, 2H), 7.41 – 7.46 (m, 2H), 7.59 – 7.64 (m, 1H). 13C NMR (75 MHz, 
CD2Cl2, ppm) δ = 10.9, 21.4, 33.9, 55.2, 92.2, 111.2, 119.1, 122.1, 123.8, 129.7, 130.5, 136.9, 
137.7. IR (neat, cm–1): 2964.1, 2923.6, 2901.4, 1432.9, 1398.1, 1384.6, 1358.6, 1344.1, 
1323.9, 1229.4, 1197.6, 1161.9, 1144.5, 1121.4, 1090.5, 944.9, 759.8, 601.7, 584.3, 530.3. 
HRMS: m/z calcd. for C20H28N3Se+ [M–SbF6]+ = 390.1443; found = 390.1461; m/z calcd. for 






According to GP3, 2-selenoimidazoline 159 (180 mg, 694 µmol, 
1.00 equiv.), N-chlorosuccinimide (92.7 mg, 694 µmol, 1.00 equiv.) and 1-
phenylpyrrole (99.4 mg, 694 µmol, 1.00 equiv.) were dissolved in MeCN 
(5.0 mL) and stirred at 70 °C for 19 h. All volatiles were removed under 
reduced pressure; the yellow solid was dissolved in DCM (7.0 mL) and 
washed with sat. aq. NaSbF6 (7.0 mL) for 5 min. The organic layer was dried over MgSO4 and 
concentrated in vacuo. After column chromatography (DCM:MeOH), product 216 was obtained 
as an yellow solid (212 mg, 332.7 µmol, 48%). 
1H NMR (300 MHz, CD2Cl2 ppm) δ 1.32 (d, J = 7.1 Hz, 12H), 2.29 (s, 6H), 5.02 (hept, J = 7.1 
Hz, 2H), 6.41 (dd, J = 3.8, 3.0 Hz, 1H), 6.74 (dd, J = 3.8, 1.8 Hz, 1H), 7.13 (dd, J = 3.0, 1.7 Hz, 
1H), 7.30 – 7.35 (m, 2H), 7.48 – 7.60 (m, 3H). 13C NMR (75 MHz, CD2Cl2, ppm) δ = 10.8, 21.3, 
55.2, 109.6, 111.9, 123.6, 126.6, 129.0, 129.2, 130.2, 130.8, 139.5. IR (neat, cm–1): 3089.4, 
3032.5, 2961.2, 2903.3, 1767.4, 1747.2, 1605.4, 1509.0, 1438.6, 1404.9, 1383.7, 1333.5, 
1304.6, 1234.2, 1194.7, 1147.4, 1133.0, 1121.4, 1098.3, 1081.9, 914.1, 756.0, 716.4, 709.7, 
618.1, 584.3. HRMS: m/z calcd. for C21H28N3Se [M–SbF6]+ = 402.1443, found = 402.1456; 
calcd. for SbF6– [M]– = 234.8948; found = 234.8954. 
2-{[4-(Dimethylamino)phenyl]selanyl}-1,3-diisopropyl-4,5-dimethyl-1H-imidazol-3-ium 
Hexafluoroantimonate (217): 
According to GP3, 2-selenoimidazoline 159 (427 mg, 1.65 mmol, 
1.00 equiv.), N-chlorosuccinimide (220 mg, 1.65 mmol, 1.00 equiv.) 
and dimethylaniline (209 µL, 200 mg, 1.65 mmol, 1.00 equiv.) were 
dissolved in MeCN (8.0 mL) and stirred at 70 °C for 19 h. All volatiles 
were removed under reduced pressure, the yellow residual solid was 
dissolved in DCM (15 mL) and washed with sat. aq. NaSbF6 (15 mL) for 5 min. The organic 
layer was dried over MgSO4 and concentrated in vacuo. After column chromatography 
(DCM:MeOH), product 217 was obtained as an orange solid (602 mg, 979 µmol, 59%). 
1H NMR (300 MHz, CD2Cl2 ppm) δ = 1.32 (d, J = 7.1 Hz, 12H), 2.36 (s, 6H), 2.96 (s, 6H), 5.47 
(s, 2H), 6.65 (d, J = 8.9 Hz, 2H), 7.34 (d, J = 8.9 Hz, 2H). 13C NMR (101 MHz, CD2Cl2, ppm) δ 
= 10.9, 21.5, 40.4, 55.2, 109.4, 114.0, 130.7, 136.0, 152.1. IR (neat, cm–1): 2984.3, 2942.8, 
2886.9, 2815.6, 1715.4, 1618.9, 1590.0, 1508.1, 1463.7, 1445.4, 1417.4, 1363.4, 1331.6, 




906.4, 814.8, 750.2, 737.6, 710.6, 652.8, 582.4, 570.8, 542.9, 523.6. HRMS: m/z calcd. for 
C19H30N3Se [M–SbF6]+ = 380.1600, found = 380.1595; calcd. for SbF6– [M]– = 234.8948; found 
= 234.8957. 
5.3.2 Synthesis of unsymmetrical selenides 
3-[(4-Methoxyphenyl)selanyl]-1-methyl-1H-indole (218): 
According to GP4, imidazolium salt 215 (225 mg, 360 µmol, 1.00 
equiv.) was dissolved in THF (2.0 mL) and cooled to -78 °C. Under 
stirring, methoxyphenylmagnesium bromide (0.5M in THF, 1.08 mL, 
540 µmol, 1.50 equiv.) was added dropwise to the white suspension, and the obtained yellow 
suspension was allowed to warm up overnight furnishing the orange solution. The reaction 
was quenched with sat. NH4Cl (5 mL), stirred for 5 min and extracted with DCM (3  20 mL). 
The combined organic phases were dried over MgSO4, concentrated in vacuo and purified by 
column chromatography (hexane:DCM) to obtain 218 as a white solid (104.6 mg, 331 µmol, 
92%). 
1H NMR (300 MHz, CD2Cl2 ppm) δ = 3.71 (s, 3H), 3.83 (s, 3H), 6.71 (d, J = 8.8 Hz, 2H), 7.14 
(ddd, J = 8.0, 7.0, 1.1 Hz, 1H), 7.23 – 7.29 (m, 3H), 7.35 (s, 1H), 7.36 – 7.41 (m, 1H), 7.59 (d, 
J = 8.0 Hz, 1H). 13C NMR (101 MHz, CD2Cl2, ppm) δ = 33.5, 55.8, 97.8, 110.2, 115.2, 120.6, 
120.7, 122.8, 124.2, 131.0, 131.9, 135.8, 138.1, 159.1. 77Se NMR (76 MHz, CD2Cl2 ppm) δ = 
196.9. IR (neat, cm–1): 2939.0, 1597.7, 1577.5, 1496.5, 1280.5, 1157.1, 1117.5, 1016.3, 831.2, 
818.6, 810.0, 795.5, 575.6, 518.8. HRMS: m/z calcd. for C16H16NOSe+ [M+H]+ = 318.0392; 
found = 318.0388. 
2-[(4-Methoxyphenyl)selanyl]-1-phenyl-1H-pyrrole (219): 
According to GP4, imidazolium salt 216 (127 mg, 199.3 µmol, 1.00 
equiv.) was dissolved in THF (2.0 mL) and cooled to -78 °C. 
Methoxyphenylmagnesium bromide (0.5M in THF, 600 µL, 
300 µmol, 1.50 equiv.) was added dropwise to the stirred colorless solution, and the obtained 
dark brown solution was allowed to warm up overnight furnishing the yellow solution. The 
reaction was quenched with sat. NH4Cl (5 mL), stirred for 5 min and extracted with DCM (3  
20 mL). The combined organic phases were dried over MgSO4, concentrated in vacuo and 
purified by column chromatography (hexane:DCM) to obtain 219 as a colourless oil (41.5 mg, 
126 µmol, 63%). 




3.6, 1.8 Hz, 1H), 6.72 (d, J = 8.8 Hz, 2H), 7.02 – 7.09 (m, 3H), 7.18 – 7.23 (m, 2H), 7.31 – 7.39 
(m, 3H). 13C NMR (101 MHz, CD2Cl2, ppm) δ 55.8, 110.3, 115.3, 116.4, 120.9, 121.9, 124.0, 
126.7, 127.3, 128.0, 129.1, 130.2, 132.4, 141.0, 159.4. 77Se NMR (76 MHz, CD2Cl2 ppm) δ = 
262.4. IR (neat, cm–1): 3049.9, 2978.5, 2943.8, 2914.9, 1577.5, 1470.5, 1444.4, 1396.2, 
1305.6, 1207.2, 1094.4, 1079.0, 1010.5, 794.5, 776.2, 745.4, 703.9, 610.4. HRMS: m/z calcd. 
for C17H16NOSe+ [M+H]+ = 330.0392; found = 330.0387. 
4-[(4-Methoxyphenyl)selanyl]-N,N-dimethylaniline (220): 
According to GP4, imidazolium salt 217 (215 mg, 349 µmol, 1.00 
equiv.) was dissolved in THF (2.0 mL) and cooled to -78 °C. 
Methoxyphenylmagnesium bromide (0.5M in THF, 2.03 mL, 
1.02 mmol, 2.92 equiv.) was added dropwise to the white suspension, and the obtained light 
yellow suspension was allowed to warm up overnight furnishing the yellow solution. The 
reaction was quenched with sat. NH4Cl (5 mL), stirred for 5 min and extracted with DCM (3  
20 mL). The combined organic phases were dried over MgSO4, concentrated in vacuo and 
purified by column chromatography (hexane:DCM) to obtain 220 as a white solid (87.2 mg, 
284.7 µmol, 82%). 
1H NMR (300 MHz, CDCl3 ppm) δ = 2.95 (s, 6H), 3.77 (s, 3H), 6.64 (d, J = 8.8 Hz, 2H), 6.78 
(d, J = 8.8 Hz, 2H), 7.33 (d, J = 8.8 Hz, 2H), 7.41 (d, J = 8.8 Hz, 2H). 13C NMR (75 MHz, CDCl3, 
ppm) δ = δ 40.5, 55.4, 113.4, 115.0, 116.0, 123.7, 133.3, 135.7, 150.3, 158.9. 77Se NMR (MHz, 
CD2Cl2 ppm) δ = 380.0. IR (neat, cm–1): 2950.6, 2917.8, 2864.7, 1592.9, 1505.2, 1490.7, 
1444.4, 1356.7, 1193.7, 1102.1, 1082.8, 1068.4, 1015.3, 807.1, 529.4. HRMS: m/z calcd. for 
C15H18NOSe+ [M+H]+ = 308.05488; found = 308.0541. 
4-[(3,4-Dihydronaphthalen-1-yl)selanyl]-N,N-dimethylaniline (221): 
According to GP4, imidazolium salt 217 (33 mg, 53.6 µmol, 1.0 equiv.) 
was dissolved in THF (1.0 mL) and cooled to -78 °C. (3,4-
Dihydronaphthalen-1-yl)magnesium bromide (0.4M in THF, 200 µL, 
80 µmol, 1.49 equiv.) was added dropwise to the white suspension, 
and the obtained light yellow suspension was allowed to warm up overnight furnishing the 
yellow solution. The reaction was quenched with sat. NH4Cl (5 mL), stirred for 5 min and 
extracted with DCM (3  20 mL). The combined organic phases were dried over MgSO4, 
concentrated in vacuo and purified by column chromatography (hexane:DCM) to obtain 




1H NMR (300 MHz, CD2Cl2 ppm) δ = 2.27–2.36 (m, 2H), 2.78 (t, J=8.0 Hz, 2H), 2.93 (s, 6H), 
6.20 (t, J=4.7 Hz, 1H), 6.61–6.68 (m, 2H), 7.09–7.20 (m, 3H), 7.35–7.43 (m, 2H), 7.50–7.59 
(m, 1H). 13C NMR (126 MHz, CD2Cl2, ppm) δ = 28.5, 40.7, 113.6, 114.3, 126.3, 126.9, 127.8, 
127.9, 130.8, 133.0, 134.8, 135.8, 136.9, 150.7. 77Se NMR (MHz, CDCl3 ppm) δ = 345.8. IR 
(neat, cm–1): 1587.9, 1503.1, 1480.8, 1446.4, 1424.7, 1358.3, 1315.3, 1277.0, 1260.8, 1228.0, 
1195.6, 1170.2, 1083.5, 1066.3, 1043.2, 1029.5, 1015.7, 953.6, 935.7, 809.3, 779.0, 758.0, 




5.4 Reaction towards the synthesis of imidazole-, benzimidazole-, 
triazole- and benzoxazole-thioether 
5.4.1 Synthesis of imidazole-thioethers  
General protocol GP6 
A dry Schlenk flask was charged with imidazolthione 78 (127 mg, 600 µmol, 1.20 equiv.), N-
chlorosuccinimide (80.1 mg, 600 µmol, 1.20 equiv.) and 1-methyl-2-phenylindole (104 mg, 
500 µmol, 1.00 equiv.). MeCN (6 mL) was added, and the solution was stirred for 10 min at rt. 
and then at the indicated temperature for the indicated time. The orange brown solution was 
allowed to cool down to rt and all volatiles were removed under reduced pressure. The 
obtained orange oil was dissolved in DCM (5 mL) and washed with sat. aq. NaSbF6 solution 
(5 mL) for 4 min. In case of 1,2-DCE as a solvent, the reaction mixture was directly washed 
with aq. NaSbF6 solution without evaporation of DCE. The organic layer was dried over MgSO4 
and concentrated in vacuo. After column chromatography (DCM:MeOH), the 
arylthioimidazolium salt 100 was obtained as a yellow foam. 
N,N-Dimethyl-4-[(1-methyl-1H-imidazol-2-yl)thio]aniline (237), General protocol GP6: 
In a dry Schlenk flask, carbimazole (186 mg, 1.00 mmol, 
1.05 equiv.), N-chlorosuccinimide (133.5 mg, 1.00 mmol, 
1.05 equiv.) and N,N-dimethylaniline (115.4 mg, 121 µL, 952 µmol, 
1.00 equiv.) were dissolved in MeCN (10.0 mL) and stirred at 70 °C 
for 12 h. All volatiles were removed in vacuo; the residual violet oil was dissolved in DCM 
(10 mL) and washed with sat. aq. NaHCO3 (10 mL) for 2 min. The organic layer was dried over 
MgSO4 and concentrated in vacuo. After column chromatography (DCM:MeOH) and 
purification by HPLC (CH3CN:H2O; 40:60, 10 min → 100:0 over 15 min), sulfide 237 was 
obtained as an orange solid (126 mg, 540 µmol, 57%). 
1H NMR (300 MHz, CD3CN) δ = 2.90 (s, 6H) ),  3.63 (s, 3H),  6.64 – 6.72 (m, 2H),  6.95 (d, J 
= 1.3 Hz, 1H),  7.09 (d, J = 1.2 Hz, 1H), 7.17 – 7.24 (m, 2H)ppm. 13C NMR (126 MHz, CD3CN) 
δ = 34.3, 40.5, 111.1, 113.9, 119.1, 124.7, 129.8, 133.3, 151.4 ppm. IR (neat, cm–1): 3111.5, 
3091.6, 2947.0, 2888.7, 2819.2, 1874.7, 1772.3, 1762.0, 1709.8, 1604.6, 1545.0, 1511.1, 
1479.0, 1444.7, 1406.3, 1365.2, 1339.8, 1315.1, 1281.0, 1228.7, 1191.5, 1154.9, 1120.5, 
1096.7, 1080.8, 1059.3, 1041.1, 998.6, 947.7, 931.9, 915.5, 865.3, 804.4, 784.8, 716.6, 683.3, 






According to GP6, carbimazole (186 mg, 1.00 mmol, 1.05 equiv.), N-
chlorosuccinimide (133.5 mg, 1.00 mmol, 1.05 equiv.) and N-
phenylpyrrole (136 mg, 950 µmol, 1.00 equiv.) were dissolved in MeCN 
(10.0 mL) and stirred at 70 °C for 12 h. All volatiles were removed in 
vacuo; the residue yellow oil was dissolved in DCM (10 mL) and washed with sat. aq. NaHCO3 
(10 mL) for 2 min. The organic layer was dried over MgSO4 and concentrated in vacuo. After 
column chromatography (DCM:MeOH), sulfide 231 was obtained as an orange solid (199 mg, 
779 µmol, 82%). 
1H NMR (300 MHz, CD3Cl) δ =  3.27 ppm (s, 3H),  6.29 (dd, J = 3.7, 2.9 Hz, 1H),  6.72 (dd, J 
= 3.7, 1.8 Hz, 1H),  6.77 (d, J = 1.2 Hz, 1H),  6.95 (dd, J = 3.0, 1.8 Hz, 1H),  6.97 (d, J = 1.2 
Hz, 1H),  7.23 – 7.33 (m, 2H), 7.33 – 7.47 (m, 3H). 13C NMR (75 MHz, CD3Cl) δ = 33.3, 109.7, 
118.0, 119.9, 122.4, 127.0, 127.8, 128.8, 129.7, 139.6, 140.5 ppm. IR (neat, cm–1): 3103.3, 
3065.1, 2982.0, 2942.5, 2258.8, 1771.3, 1740.7, 1708.7, 1597.1, 1579.0, 1498.2, 1455.2, 
1435.9, 1410.6, 1390.7, 1366.5, 1340.1, 1318.0, 1277.8, 1241.9, 1206.1, 1184.5, 1145.6, 
1121.6, 1076.5, 1036.3, 1012.7, 1003.9, 985.9, 958.5, 913.5, 878.1, 838.2, 763.1, 724.0, 
694.0, 629.9, 618.5, 606.7, 583.9, 558.6, 530.0, 504.5. ESI-MS: m/z calcd. for C14H14N3S+ 
[M+H]+  = 256.0903; found = 256.0908. 
1-Methyl-3-[(1-methyl-1H-imidazol-2-yl)thio]-1H-indole (233): 
According to GP6, carbimazole (186 mg, 1.00 mmol, 1.05 equiv.), N-
chlorosuccinimide (133.5 mg, 1.00 mmol, 1.05 equiv.) and N-methylindole 
(125 mg, 119 µL, 952 µmol, 1.00 equiv.) were dissolved in MeCN 
(10.0 mL) and stirred for 12 h at 70 °C. All volatiles were removed in vacuo; the residual yellow 
oil was dissolved in DCM (10 mL) and washed with sat. aq. NaHCO3 (10 mL) for 2 min. The 
organic layer was dried over MgSO4 and concentrated in vacuo. After column chromatography 
(DCM:MeOH) and purification by HPLC (CH3CN:H2O; 60:40 → 100:0 over 20 min), sulfide 233 
was obtained as a yellow oil (190 mg, 781 µmol, 82%). 
1H NMR (300 MHz, CD3CN) δ = 3.70 (s, 3H),  3.76 (s, 3H),  6.86 (d, J = 1.3 Hz, 1H),  6.97 (d, 
J = 1.3 Hz, 1H),  7.14 (ddd, J = 8.0, 7.0, 1.1 Hz, 1H),  7.23 (ddd, J = 8.2, 7.0, 1.3 Hz, 1H),  7.34 
– 7.42 (m, 1H),  7.45 (s, 1H), 7.67 – 7.74 (m, 1H). 13C NMR (101 MHz, CD3CN) δ = 33.5, 34.4, 
100.8, 111.1, 120.0, 121.1, 124.1, 129.4, 130.2, 135.2, 138.1, 141.3 ppm. IR (neat, cm–1): 
3110.1, 3091.3, 1710.9, 1648.5, 1610.5, 1575.6, 1556.4, 1508.0, 1481.8, 1454.0, 1412.1, 




1046.7, 1009.6, 970.1, 919.3, 853.0, 825.0, 773.4, 767.3, 751.1, 732.3, 696.8, 689.6, 633.1, 
605.0, 583.6, 574.0, 543.4, 533.8, 502.1. ESI-MS: m/z calcd. for C13H14N3S+ 
[M+H]+ = 244.0903; found = 244.0911. 
1-Methyl-3-[(1-methyl-1H-imidazol-2-yl)thio)-2-phenyl-1H-indole (234): 
According to GP6, carbimazole (186 mg, 1.00 mmol, 1.05 equiv.), N-
chlorosuccinimide (133.5 mg, 1.00 mmol, 1.05 equiv.) and N-methyl-2-
phenylindole (197 mg, 950 µmol, 1.00 equiv.) were dissolved in MeCN 
(10.0 mL) and stirred at 70 °C for 12 h. All volatiles were removed in vacuo; 
the residual yellow oil was dissolved in DCM (10 mL) and washed with sat. 
aq. NaHCO3 (10 mL) for 2 min. The organic layer was dried over MgSO4 and concentrated in 
vacuo. After column chromatography (DCM:MeOH) and purification by HPLC (CH3CN:H2O; 
50:50 → 100:0 over 25 min), sulfide 234 was obtained as a yellow oil (271 mg, 848 µmol, 
89%). 
1H NMR (400 MHz, CD3CN) δ = 3.34 (s, 3H) ),  3.63 (s, 3H),  6.82 (d, J = 1.3 Hz, 1H),  6.90 (d, 
J = 1.3 Hz, 1H),  7.16 (ddd, J = 7.9, 7.0, 1.0 Hz, 1H),  7.27 (ddd, J = 8.3, 7.1, 1.2 Hz, 1H),  7.41 
– 7.44 (m, 1H),  7.50 – 7.60 (m, 5H), 7.72 (dt, J = 7.9, 1.0 Hz, 1H) ppm. 13C NMR (101 MHz, 
CD3CN) δ = 32.2, 33.9, 100.2, 111.2, 120.2, 121.5, 123.7, 129.4, 130.3, 131.5, 132.0, 138.2, 
141.9, 145.6 ppm. IR (neat, cm–1): 3044.5, 2932.3, 2912.1, 1766.5, 1697.5, 1603.9, 1589.1, 
1571.0, 1507.0, 1470.8, 1463.4, 1455.6, 1442.7, 1428.0, 1409.0, 1383.1, 1365.3, 1337.7, 
1314.7, 1275.6, 1239.9, 1220.0, 1157.5, 1132.5, 1122.0, 1108.4, 1075.7, 1055.7, 1039.6, 
1020.6, 1012.0, 981.1, 969.3, 925.1, 913.0, 850.4, 842.1, 832.8, 802.1, 765.9, 745.7, 707.6, 
694.1, 681.7, 632.3, 621.1, 591.8, 577.6, 510.3. ESI-MS: m/z calcd. for C19H18N3S+ 
[M+H]+ = 320.1216; found = 320.1211. 
Ethyl 5,6-Dimethoxy-3-[(1-methyl-1H-imidazol-2-yl)thio]-1H-indole-2-carboxylate (236): 
According to GP6, carbimazole (186 mg, 1.00 mmol, 1.052 equiv.), N-
chlorosuccinimide (133.5 mg, 1.00 mmol, 1.052 equiv.) and ethyl-5,6-
dimethoxy-1H-indole-2-carboxylate (237 mg, 950.8 µmol, 1.00 equiv.) 
were dissolved in MeCN (10.0 mL) and stirred at 70 °C for 12 h. All 
volatiles were removed in vacuo; the residual yellow oil was dissolved in DCM (10 mL) and 
washed with sat. aq. NaHCO3 (10 mL) for 3 min. The organic layer was dried over MgSO4 and 
concentrated in vacuo. After column chromatography (DCM:MeOH) and purification by HPLC 
(CH3CN:H2O; 40:60, 10 min → 100:0 over 15 min), sulfide  236 was obtained yellow solid 




1H NMR (400 MHz, CD2Cl2) δ = 1.11 – 1.66 (m, 3H),  3.59 (t, J = 5.2 Hz, 3H),  3.67 (t, J = 5.1 
Hz, 3H),  3.76 (t, J = 5.2 Hz, 3H),  4.14 – 4.52 (m, 2H),  6.41 (t, J = 5.1 Hz, 1H),  6.67 (t, J = 
5.1 Hz, 1H),  6.96 – 7.23 (m, 2H), 9.85 (s, 1H) ppm. 13C NMR (101 MHz, CD2Cl2) δ = 14.7, 
34.3, 56.3, 61.3, 94.6, 100.9, 110.3, 121.8, 123.6, 124.7, 129.7, 131.9, 140.2, 146.8, 150.8, 
161.1 ppm. IR (neat, cm–1): 3311.4, 3104.6, 2960.1, 2931.4, 2904.3, 2833.0, 1692.7, 1631.5, 
1576.6, 1507.2, 1455.9, 1440.7, 1409.4, 1377.5, 1338.3, 1272.8, 1247.7 1203.6, 1175.0, 
1151.1, 1124.3, 1093.9, 1034.0, 1018.7, 1004.6, 923.0, 863.7, 821.5, 770.6, 734.4, 694.5, 
686.0, 655.3, 625.2, 614.2, 592.6, 564.7, 528.8, 508.1. ESI-MS: m/z calcd. for C17H20N3O4S+ 
[M+H]+ = 362.1169; found = 362.1175. 
1-Methyl-2-[(2,4,6-trimethoxyphenyl)thio]-1H-imidazole (239): 
According to GP6, carbimazole (186 mg, 1.00 mmol, 1.05 equiv.), N-
chlorosuccinimide (133.5 mg, 1.00 mmol, 1.05 equiv.) and 1,3,5-
trimethoxybenzene (160 mg, 951.3 µmol, 1.00 equiv.) were dissolved in 
MeCN (10.0 mL) and stirred at 70 °C for 24 h. All volatiles were removed 
in vacuo; the residual brown oil was dissolved in DCM (10 mL) and washed 
with sat. aq. NaHCO3 (10 mL) for 3 min. The organic layer was dried over 
MgSO4 and concentrated in vacuo. After column chromatography (DCM:MeOH), sulfide 239 
was obtained as a colorless solid (160 mg, 570.7 µmol, 60%). 
1H NMR (400 MHz, CD3CN) δ = 3.68 (s, 3H),  3.75 (s, 6H),  3.80 (s, 3H),  6.22 (s, 2H),  6.81 
(s, 1H), 6.97 (s, 1H) ppm. 13C NMR (101 MHz, CD3CN) δ = 30.4, 34.1, 56.2, 56.9, 92.4, 123.4, 
129.4, 162.3, 163.5 ppm. IR (neat, cm–1): 3121.7, 3101.3, 2975.4, 2944.0, 2839.5, 1772.5, 
1708.3 1581.7, 1505.0, 1452.1, 1434.9, 1411.6, 1369.6, 1334.4, 1278.7, 1230.8, 1207.3, 
1186.6, 1162.1, 1118.3, 1087.7, 1035.1, 951.0, 915.3, 849.9, 809.7, 759.5, 729.8, 718.6, 
681.1, 662.0, 635.3, 584.3, 516.0. ESI-MS: m/z calcd. for C13H17N2O3S+ [M+H]+ = 281.0954; 






According to GP6, carbimazole (186 mg, 1.00 mmol, 1.05 equiv.), 
N-chlorosuccinimide (133.5 mg, 1.00 mmol, 1.05 equiv.) and 
aniline (86 µL, 88.7 mg, 952 µmol, 1.00 equiv.) were dissolved in 
MeCN (10.0 mL) and stirred at 70 °C for 24 h. All volatiles were 
removed in vacuo; the residual red oil was dissolved in DCM (10 mL) and washed with sat. aq. 
NaHCO3 (10 mL) for 3 min. The organic layer was dried over MgSO4 and concentrated in 
vacuo. After column chromatography (DCM:MeOH) and purification by HPLC (CH3CN:H2O; 
40:60, 10 min → 80:20 over 20 min), aniline 238 was obtained as a yellow oil (78.2 mg, 
381 µmol, 40%).  
1H NMR (300 MHz, CD3CN) δ = 3.62 (d, J = 0.7 Hz, 3H) ),  4.28 (s, 2H),  6.54 – 6.62 (m, 2H),  
6.96 (d, J = 1.2 Hz, 1H), 7.05 – 7.14 (m, 3H) ppm. 13C NMR (101 MHz, CD3CN) δ = 34.3, 49.9, 
116.0, 124.7, 129.9, 133.4, 141.0, 149.1 ppm. IR (neat, cm–1): 3228.1, 3169.2, 3088.6, 3026.1, 
2978.7, 2964.2, 2927.0, 1771.1, 1704.6, 1596.5, 1579.1, 1537.7, 1496.9, 1475.1, 1455.0, 
1402.1, 1365.0, 1350.7, 1342.8, 1315.4, 1294.3, 1279.7, 1225.8, 1182.1, 1158.0, 1124.3, 
1095.2, 1057.8, 1011.6, 934.1, 921.0, 841.4, 823.7, 764.0, 734.7, 712.0, 690.9, 685.7, 674.6, 
638.1, 556.0, 527.9. ESI-MS: m/z calcd. For C10H12N3S+ [M+H]+ = 206.0746; found = 
206.0749. 
1-[(1-Methyl-1H-imidazol-2-yl)thio]-5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinoline (235): 
According to GP6, carbimazole (186 mg, 1.00 mmol, 1.05 equiv.), N-
chlorosuccinimide (133.5 mg, 1.00 mmol, 1.05 equiv.) and Lilolidine 
(148 mg, 952 µmol, 1.00 equiv.) were dissolved in MeCN (10.0 mL) and 
stirred at 70 °C for 24 h. All volatiles were removed in vacuo; the 
residual yellow oil was dissolved in DCM (10 mL) and washed with sat. aq. NaHCO3 (10 mL) 
for 3 min. The organic layer was dried over MgSO4 and concentrated in vacuo. After column 
chromatography (DCM:MeOH) and purification by HPLC (CH3CN:H2O; 60:40 → 100:0 over 
20 min), sulfide 235 was obtained as a yellow oil (157 mg, 583 µmol, 61%). 
1H NMR (400 MHz, CD3CN) δ = 2. 10 – 2.20 (m, 2H) ),  2.82 – 2.95 (m, 2H),  3.70 (s, 3H),  
4.06 – 4.15 (m, 2H),  6.85 (d, J = 1.2 Hz, 1H),  6.91 (dd, J = 7.1, 1.0 Hz, 1H),  6.97 (d, J = 1.3 
Hz, 1H),  7.01 (dd, J = 8.0, 7.1 Hz, 1H),  7.43 (dd, J = 8.0, 0.9 Hz, 1H), 7.43 (s, 1H) ppm. 
13C NMR (75 MHz, CD3CN) δ = 23.5, 25.0, 34.4, 45.0, 100.7, 117.3, 120.2, 121.6, 123.8, 
124.1, 127.9, 129.4, 132.4, 135.4, 141.6 ppm. IR (neat, cm–1): 3103.3, 3091.6, 2955.0, 2929.7, 




1309.8, 1281.2, 1248.0, 1180.1, 1165.7, 1121.7, 1083.0, 1067.6, 1033.3, 955.1, 914.0, 831.7, 
777.1, 750.9, 699.9, 685.6, 673.1, 636.3, 601.0, 526.6, 504.1. ESI-MS: m/z calcd. for 
C15H16N3S+ [M+H]+ = 270.1059; found = 270.1061. 
2-[(1H-Pyrrol-2-yl)thio]-3-(ethoxycarbonyl)-1-methyl-1H-imidazol-3-ium Chloride (241): 
According to GP6, carbimazole (186 mg, 1.00 mmol, 1.05 equiv.), N-
chlorosuccinimide (133.5 mg, 1.00 mmol, 1.05 equiv.) and pyrrole 
(63.9 mg, 66.1 µL, 952 µmol, 1.00 equiv.) were dissolved in MeCN 
(10.0 mL) and stirred at 70 °C for 24 h. All volatiles were removed in vacuo; the residual black 
oil was dissolved in DCM (10 mL) and washed with sat. aq. NaHCO3 (10 mL) for 3 min. The 
organic layer was dried over MgSO4 and concentrated in vacuo. After column chromatography 
(DCM:MeOH) and purification by HPLC (CH3CN:H2O; 40:60, 10 min → 80:20 over 20 min), 
sulfide 241 was obtained as a yellow solid (98.8 mg, 343 µmol, 36%).  
1H NMR (300 MHz, CD3CN) δ = 1.37 (td, J = 7.1, 0.8 Hz, 3H) ),  3.64 (d, J = 0.7 Hz, 3H),  4.33 
– 4.47 (m, 2H),  5.36 – 5.46 (m, 1H),  6.15 (td, J = 3.4, 0.8 Hz, 1H),  7.05 (d, J = 1.2 Hz, 1H),  
7.21 (d, J = 1.2 Hz, 1H), 7.26 – 7.36 (m, 1H) ppm. 13C NMR (75 MHz, CD3CN) δ = 14.4, 34.2, 
65.0, 112.9, 114.3, 123.0, 125.6, 130.5, 138.1, 151.2 ppm. IR (neat, cm–1): 3107.1, 2980.3, 
2940.2, 1737.7, 1538.4, 1507.9, 1453.0, 1399.9, 1369.2, 1319.6, 1297.4, 1279.4, 1243.9, 
1208.0, 1192.8, 1161.1, 1147.5, 1121.7, 1093.3, 1054.1, 1014.0, 989.9, 926.5, 914.2, 878.2, 
864.3, 832.0, 792.7, 764.1, 712.2, 696.2, 686.7, 612.9, 592.0, 573.4, 528.3, 504.0. ESI-MS: 
m/z calcd. for C11H14N3O2S+ [M–Cl]+ = 252.0801; found = 252.0804. 
N1-Benzyl-N2,N2-dimethyl-N1-{4-[(1-methyl-1H-imidazol-2-yl)thio]phenyl}ethane-1,2-
diamine (86): 
According to GP6, phenbenzamine hydrochloride 
(145 mg, 500 µmmol, 1.00 equiv.), N-chlorosuccinimide 
(70 mg, 524 µmol, 1.05 equiv.) and carbimazole (98 mg, 
526 µmol, 1.05 equiv.) were dissolved in MeCN (5 mL). 
The yellow solution was stirred at 70 °C for 24 h All volatiles were removed under 
reduced pressure, the residual yellow oil was dissolved in DCM (3 mL) and washed 
with a sat. NaHCO3 solution (5 mL). The precipitate was purified by column 





1H NMR (300 MHz, CD3CN) δ = 2.26 (s, 6H) ),  2.51 (t, J = 7.1 Hz, 2H),  3.51 (t, J = 
7.1 Hz, 2H),  3.62 (s, 3H),  4.52 (s, 2H),  6.59 (d, J = 8.9 Hz, 2H),  6.92 (s, 1H),  7.05 
(s, 1H), 7.12 – 7.32 (m, 7H) ppm. 13C NMR (101 MHz, CDCl3) δ = 33.9, 45.9, 49.5, 
54.7, 56.3, 112.8, 118.1, 123.0, 126.5, 127.0, 128.7, 129.6, 133.0, 138.3, 141.0, 148.2 
ppm. IR (neat, cm–1): 2940.9, 2767.4, 1592.9, 1500.3, 1451.2, 1393.3, 1353.8, 1278.6, 
1237.1, 1196.6, 1148.4, 1119.5, 1097.3, 1077.0, 1040.4, 1027.9, 952.7, 912.2, 808.0, 
728.0, 694.2, 524.5. ESI-MS: m/z calcd. for C21H27N4S+ [M+H]+ = 367.1951, found = 
367.1953. 
 
5.4.2 Synthesis of sulfur-containing precursors 
4-Phenyl-2,4-dihydro-3H-1,2,4-triazole-3-thione (258): 
Compound 258 was synthesized according to the modified protocol of M. 
K. Bharty, N. K. Singh et al.[299] Formyl hydrazine (900.8 mg, 15.0 mmol, 
1.00 equiv.) was dissolved in EtOH (30 mL). Phenyl isocyanate (1.86 mL, 
2.03 g, 17.0 mmol, 1.13 equiv.) was added, and the solution was stirred at 65 °C for 4 h. The 
solid precipitate was washed with H2O (10 mL) and Et2O (10 mL) and dried in vacuo. The 
obtained solid was dissolved in EtOH (30 mL) and NaOH (0.75 g, 18.75 mmol, 1.25 equiv.) 
was added. The resulting solution was stirred at 78 °C for 12 h. After cooling, aq. HCl (1M, 
30 mL, 30 mmol, 2.0 equiv.) was added; the obtained white precipitate was filtered off, washed 
with water, dried in vacuo and finally recrystallized from a mixture of MeOH:CHCl3 (50:50). 
Sulfide 258 was obtained as a white solid (1.263 g, 7.11 mmol, 47%) 
1H NMR (300 MHz, CDCl3) δ = 7.42 – 7.69 (m, 5H),  7.93 (s, 1H), 11.22 (s, 1H)  ppm. 13C NMR 
(101 MHz, CDCl3) δ = 125.7, 129.8, 133.8, 141.0, 167.6 ppm. IR (neat, cm–1): 1556.3, 1498.4, 
1484.9, 1456.0, 1373.1, 1327.7, 1298.8, 1280.5, 1242.9, 1154.2, 1076.1, 940.1, 840.8, 767.5, 
689.4, 675.9, 570.8. ESI-MS: m/z calcd. for C8H8N3S+ [M+H]+ = 178.0433; found = 178.0436. 





Ethyl 2-Thioxobenzo[d]oxazole-3(2H)-carboxylate (250): 
Compound 250 was synthesized using the modified protocol of S. Dove et 
al.[298] 2-Mercaptobenzoxazole (1.50 g, 9.92 mmol, 1.00 equiv.) was 
dissolved in dry THF (15 mL); Et3N (1.51 mL, 1.095 g, 10.82 mmol, 
1.09 equiv.) was added and the solution was cooled to 0 °C. A solution of ethyl chloroformate 
(945 µL, 1.08 g, 9.93 mmol, 1.00 equiv.) in THF (15 mL) was added dropwise, the reaction 
mixture was stirred for an additional 2 h, then allowed to warm up to rt. All volatile were 
removed in vacuo. The residual white precipitate was dissolved and extracted two times with 
EtOAc (2  25 mL). The combined organic phases were washed with H2O (2  15 mL) and 
dried over MgSO4; the solvent was removed under reduced pressure. The obtained crude 
product was purified by column chromatography (DCM:MeOH) affording compound 250 as a 
white solid (1.00 g, 4.48 mmol, 45%). 
1H NMR (400 MHz, CDCl3) δ = 1.53 (t, J = 7.1 Hz, 3H), 4.61 (q, J = 7.2 Hz, 2H), 7.28 – 7.36 
(m, 3H), 7.73 – 7.78 (m, 1H) ppm. 13C NMR (101 MHz, CDCl3) δ = 14.3, 65.3, 110.2, 115.2, 
125.4, 126.0, 129.3, 146.4, 149.9, 177.0 ppm. IR (neat, cm–1): 1775.2, 1306.5, 1271.8, 1238.1, 
1210.1, 1158.0, 1140.7, 1090.5, 1055.8, 1011.5, 934.3, 828.3, 762.7, 749.2, 652.8, 628.7. ESI-
MS: m/z calcd. for C10H10NO3S+ [M+H]+ = 224.0376; found = 224.0380. 
 
Ethyl 3-Methyl-2-thioxo-2,3-dihydro-1H-benzo[d]imidazole-1-carboxylate (251): 
Compound 251 was synthesized employing the modified protocol of S. 
Dove et al.[295] The solution of 1-methyl-1H-benzimidazole-2-thiol 
(492 mg, 3.00 mmol, 1.00 equiv.) in dry THF (5 mL) was cooled to 0 °C. 
Under stirring, NEt3 (806 µl, 585 mg, 5.78 mmol, 1.93 equiv.) was added 
dropwise followed by a solution of ethyl chloroformate (286 µL, 325.6 mg, 
3.00 mmol, 1.00 equiv.) in THF (5 mL). The suspension was allowed to warm up to rt within 
1 h and stirred for an additional 12 h. The reaction was quenched with EtOH (1 mL). After 
removing all volatile compounds in vacuo, the obtained white precipitate was dissolved in 
EtOAc (50 mL); the extract was washed with H2O (15 mL). After drying and concentrating the 
organic phase, the obtained white solid was purified by column chromatography (DCM:MeOH). 
Product 251 was obtained as a white solid (344 mg, 1.46 mmol, 49%, literature: 32%). 
1H NMR (300 MHz, CDCl3) δ = 1.53 (t, J = 7.1 Hz, 3H) ),  3.76 (s, 3H),  4.60 (q, J = 7.1 Hz, 
2H),  7.10 – 7.18 (m, 1H),  7.27 – 7.37 (m, 2H), 7.83 – 7.90, (m, 1H) ppm. 13C NMR (101 MHz, 




(neat, cm–1): 1715.4, 1440.6, 1384.6, 1360.5, 1335.5, 1311.4, 1285.3, 1250.6, 1177.3, 1150.3, 
1091.5, 1019.2, 759.8, 739.6, 557.3. ESI-MS: m/z calcd. for C11H13N2O2S+ 
[M+H]+ = 237.0692; found = 237.0696. 
 
Ethyl 4-Phenyl-5-thioxo-4,5-dihydro-1H-1,2,4-triazole-1-carboxylate (252): 
Compound 252 was synthesized in modified protocol of S. Dove et 
al.[295] The solution of compound 258 (531.7 mg, 3.00 mmol, 
1.00 equiv.) in dry THF (5 mL) was cooled to 0 °C. Under stirring, 
NEt3 (808 µL, 587 mg, 5.8 mmol, 1.93 equiv.) was added dropwise 
followed by a solution of ethyl chloroformate (286 µL, 326 mg, 3.00 mmol, 1.00 equiv.) in THF 
(5 mL). The suspension was allowed to warm up to rt within 1 h and stirred for an additional 
2 h. The reaction was quenched with EtOH (1 mL). After removing the volatiles in vacuo, the 
residual white precipitate was dissolved in EtOAc (50 mL) and washed with H2O (15 mL). The 
organic phase was dried and concentrated under reduced pressure; the obtained white crude 
product was purified by column chromatography (DCM:MeOH) affording 252 as a white solid 
(425 mg, 1.70 mmol, 57%). 
1H NMR (300 MHz, CDCl3) δ = 1.50 (t, J = 7.1 Hz, 3H), 4.58 (q, J = 7.2 Hz, 2H), 7.46 – 7.62 
(m, 5H), 7.90 (s, 1H) ppm. 13C NMR (101 MHz, CDCl3) δ =14.3, 65.3, 126.4, 129.9, 130.1, 
133.7, 140.6, 148.6, 169.2 ppm. IR (neat, cm–1): 1772.3, 1553.4, 1366.3, 1336.4, 1316.2, 
1242.9, 1216.9, 1171.5, 1044.3, 1014.4, 953.6, 892.9, 841.8, 757.9, 741.5, 690.4, 594.9, 
585.3. ESI-MS: m/z calcd. for C11H12N3O2S+ [M+H]+ = 250.0645; found = 250.0651. The 












5.4.3 Synthesis of benzimidazole-, triazole- and benzoxazole-thioethers 
4-(Benzo[d]oxazol-2-ylthio)-N,N-dimethylaniline (259): 
According to GP6, compound 250 (223 mg, 1.00 mmol, 1.05 equiv.) 
and N-chlorosuccinimide (134 mg, 1.00 mmol, 1.00 equiv.) were 
dissolved in MeCN (10 mL). N,N-dimethylaniline (117 μL, 122 mg, 
1.00 mmol, 1.00 equiv.) was added dropwise to the yellow solution. The reaction mixture was 
stirred for 12 h at 70 °C. After cooling, all volatiles were removed under reduced pressure; the 
green oil was dissolved in DCM (3 mL) and washed with a sat. NaHCO3 solution (10 mL), dried 
and evaporated. The residual precipitate was purified by column chromatography 
(DCM:MeOH) and subsequent preparative HPLC (MeCN:H2O; 20:80, 20 min). Sulfide 259 was 
obtained as a white solid (24 mg, 89 µmol, 9%).  
1H NMR (400 MHz, CD3CN) δ =  2.96 (s, 6H) ),  6.71 – 6.80 (m, 2H),  7.19 – 7.28 (m, 2H),  
7.39 – 7.44 (m, 1H), 7.44 – 7.50 (m, 3H) ppm. 13C NMR (126 MHz, CD3CN) δ = 40.4, 110.9, 
113.7, 119.3, 125.1, 125.4, 137.6, 143.0, 152.8, 152.9, 166.4 ppm. IR (neat, cm–1): 1589.1, 
1504.2, 1486.8, 1446.4, 1368.2, 1235.2, 1193.7, 1133.0, 1118.5, 1087.7, 995.1, 948.8, 918.9, 
803.2, 754.0, 738.6, 710.6, 621.0, 529.4. ESI-MS: m/z calcd. for C15H15N2OS+ 
[M+H]+ = 271.0900, found = 271.0892. 
Two signals in the 13C NMR spectrum overlapped each other. 
 
N,N-Dimethyl-4-[(4-phenyl-4H-1,2,4-triazol-3-yl)thio]aniline (261): 
According to GP6, compound 252 (125 mg, 500 µmol, 
1.00 equiv.) and N-chlorosuccinimide (67 mg, 500 µmol, 
1.00 equiv.) were dissolved in MeCN (5 mL). N,N-
Dimethylaniline (63 μL, 60.6 mg, 500 µmol, 1.00 equiv.) was 
added dropwise to the green solution; the reaction mixture was stirred for 24 h at ambient 
temperature, than at 70 °C for another 24 h. After cooling, all volatiles were removed under 
reduced pressure, the obtained blue oil was dissolved in DCM (3 mL) and washed with a sat. 
NaHCO3 solution (5 mL). After drying and evaporation of the solvent, the attempted purification 
of the residual solid by column chromatography (DCM:MeOH) was performed. NMR analysis 
of the crude product indicated the formation of traces of 261. 





According to GP6, compound 251 (118 mg, 500 µmol, 1equiv.) 
and N-chlorosuccinimide (67 mg, 500 µmol, 1.00 equiv.) were 
dissolved in MeCN (5 mL). N,N-dimethylaniline (63 μL, 60.6 mg, 
500 µmol, 1.00 equiv.) was added dropwise to the yellow solution. The reaction mixture was 
stirred at 70 °C for 12 h. After cooling, all volatiles were removed under reduced pressure; the 
obtained green oil was dissolved in DCM (3 mL) and washed with a sat. NaHCO3 solution 
(5 mL). After drying and evaporation of the solvent, the residual solid was purified by column 
chromatography (DCM:MeOH) and subsequent preparative HPLC (MeCN:H2O; 60:40 → 
100:0 over 10 min). Sulfide 260 was obtained as white solid (11 mg, 39 µmol, 8%). 
1H NMR (400 MHz, CDCl3) δ = 2.96 (s, 6H) ),  3.74 (s, 3H),  6.64 – 6.69 (m, 2H),  7.18 – 7.25 
(m, 3H),  7.40 – 7.45 (m, 2H), 7.69 – 7.72 (m, 1H) ppm. 13C NMR (101 MHz, CDCl3) δ = 30.8, 
40.4, 109.0, 113.2, 114.8, 119.6, 122.1, 122.6, 134.7, 136.8, 143.3, 150.8, 151.1 ppm. IR (neat, 
cm–1): 1594.8, 1507.1, 1467.6, 1439.6, 1409.7, 1361.5, 1323.9, 1276.6, 1225.5, 1189.9, 
1093.4, 1063.6, 807.1, 765.6, 756.0, 742.5, 729.9, 680.7, 516.8. ESI-MS: m/z calcd. for 






According to GP6, compound  251 (112 mg, 500 µmol, 1.00 equiv.), 
N-chlorosuccinimide (67 mg, 500 µmol, 1.00 equiv.) and 1-
phenylpyrrole (72 mg, 500 µmol, 1.00 equiv.) were dissolved in 
MeCN (5 mL). The brown reaction mixture was stirred at 70 °C for 
24 h. After cooling, all volatiles were removed under reduced pressure; the obtained brown 
solid was dissolved in DCM (3 mL) and washed with a sat. NaHCO3 solution (5 mL). After 
drying and evaporation of the solvent, the residual solid was purified by column 
chromatography (DCM:MeOH). Unfortunately, 262 was obtained in minor amounts and low 
purity. 
ESI-MS: m/z calcd. for C17H13N2OS+ [M+H]+ = 293.0743, found = 293.0532. 
1-Phenyl-5-[(1-phenyl-1H-pyrrol-2-yl)thio]-1H-1,2,4-triazole (263): 
According to GP6, compound 252 (100 mg, 400 µmol, 1.00 equiv.), N-
chlorosuccinimide (54 mg, 400 µmol, 1.00 equiv.) and 1-phenylpyrrole 
(57.2 mg, 400 µmol, 1.00 equiv.) were dissolved in MeCN (4 mL). The 
brown reaction mixture was stirred at 70 °C for 24 h. After cooling, all 
volatiles were removed under reduced pressure; the obtained brown oil 
was dissolved in DCM (3 mL) and washed with a sat. NaHCO3 solution (4mL). The precipitate 
was purified with column chromatography (DCM:MeOH) and subsequent preparative HPLC 
(MeCN:H2O; 60:40, 7 min → 65:35 over 3 min; 100:0, 2 min). 263 was obtained as a brown 
solid (17 mg, 52 µmol, 13%). 
1H NMR (300 MHz, CD3CN) δ = 6.28 (t, J = 3.0, 1H) ),  6.54 (dd, J = 3.8, 1.8 Hz, 1H),  7.01 
(dd, J = 3.0, 1.8 Hz, 1H),  7.09 – 7.17 m, 2H),  7.27 – 7.50 (m, 8H), 8.18 (s, 1H) ppm. 13C NMR 
(101 MHz, CDCl3) δ = 110.0, 113.0, 121.0, 126.0, 127.0, 127.0, 128.0, 129.0, 130.0, 130.0, 
133.0, 139.0, 145.0 ppm. IR (neat, cm–1): 1595.8, 1497.5, 1435.7, 1417.4, 1392.4, 1319.1, 
1267.0, 1159.0, 1139.7, 1086.7, 1074.2, 1036.6, 1005.7, 760.8, 726.1, 691.4, 656.6, 618.1, 
549.6. ESI-MS: m/z calcd. for C18H15N4S+ [M+H]+ = 319.1012; found = 319.1009. 






5.5 Tosylamide- and 1,3-diketone-derived reagents 
5.5.1 Synthesis of reagents 
2-[(1,3-Diisopropyl-4,5-dimethyl-1,3-dihydro-2H-imidazol-2-ylidene)-λ4-sulfaneylidene]-
1,3-diphenylpropane-1,3-dione (304):  
The information presented below is included for the sake of completeness of data but are not 
discussed in this thesis. 
1,3-Diphenyl-1,3-propanedione (112 mg, 500 µmol, 1.00 equiv.) was 
dissolved in dry MeCN (5.0 mL). DIPEA (261 µL, 194 mg, 1.50 mmol, 3.00 
equiv.) was added dropwise, and the clear solution was stirred for 20 min 
at rt. Dibromide 79 (241 mg, 648 µmol, 1.30 equiv.) was added to the 
solution. After the orange solid was completely dissolved within 5 min, the 
yellow solution was stirred for an additional 2 h. Solvents were removed under reduced 
pressure, the residual yellow oil was dissolved in DCM (4.0 mL) and washed with water 
(20 mL) for 2 min to remove residual ammonium salts. The organic layer was dried over MgSO4 
and concentrated in vacuo. The obtained yellow oil was purified by column chromatography 
(DCM:MeOH) affording product 304 as a light yellow oil (166 mg, 382 µmol, 76%). 
1H NMR (300 MHz, CD2Cl2, ppm) δ = 1.57 (d, J = 7.1 Hz, 12H), 2.30 (s, 6H), 6.00 (q, J = 7.0 
Hz, 2H), 6.87 – 7.01 (m, 6H), 7.14 – 7.23 (m, 4H). 13C NMR (75 MHz, CD2Cl2, ppm) δ =10.7, 
21.0, 49.7, 113.0, 128.9, 129.0, 129.3, 130.0, 130.9, 132.8, 133.9, 136.5, 157.6, 191.7. IR 
(neat, cm–1) = 2916.8, 1589.1, 1487.8, 1400.1, 1376.9, 1321.0, 1291.1, 1180.2, 1134.9, 
1076.1, 1064.5, 1031.7, 815.7, 803.2, 703.9, 649.9, 637.4, 579.5, 519.7. HRMS: m/z calcd. for 
C26H31N2O2S [M+H]+ = 435.2101; found = 435.2108.  
2-[(1,3-Diisopropyl-4,5-dimethyl-1,3-dihydro-2H-imidazol-2-ylidene)-λ4-sulfaneylidene]-
1-phenylbutane-1,3-dione (305):  
The information presented below is included for the sake of completeness of data but are not 
discussed in this thesis. 
1-Phenyl-1,3-butanedione (81.1 mg, 500 µmol, 1.00 equiv.) was dissolved in 
dry MeCN (5.0 mL). DIPEA (261 µL, 194 mg, 1.50 mmol, 3.00 equiv.) was 
dropwise added and the clear solution was stirred for 20 min at rt. Dibromide 
79 (242 mg, 650 µmol, 1.30 equiv.) was added to the solution. After the 
orange solid was completely dissolved within 5 min, the dark pink reaction 




residual pink solid was dissolved in DCM (4.0 mL) and washed with water (20 mL) for 2 min to 
remove residual ammonium salts. The organic layer was dried over MgSO4 and concentrated 
in vacuo. The obtained light violette oil was purified by column chromatography (DCM:MeOH) 
affording product 305 as a light yellow oil (120 mg, 322 µmol, 64%). 
1H NMR (300 MHz, CDCl3, ppm) δ = 1.42 (d, J = 7.1 Hz, 12H), 1.88 (s, 3H), 2.19 (s, 6H), 5.55 
(h, J = 7.0 Hz, 2H), 7.21 – 7.25 (m, 3H), 7.29 – 7.34 (m, 2H). 13C NMR (101 MHz, CDCl3, ppm) 
δ = 10.5, 21.3, 29.8, 52.1, 98.4, 126.5, 127.3, 127.7, 128.4, 144.6, 145.2, 189.8, 190.5. IR 
(neat, cm–1) = 1729.8, 1609.3, 1593.9, 1467.6, 1432.9, 1396.2, 1367.3, 1329.7, 1268.0, 
1168.7, 1146.5, 1096.3, 1066.4, 1032.7, 954.6, 845.6, 798.4, 770.4, 674.0, 601.7, 572.8. 
HRMS: m/z calcd. for C21H28N2NaO2S+ [M+Na]+ = 395.1764; found = 395.1764.  
[(1,3-Diisopropyl-4,5-dimethyl-1H-imidazol-3-ium-2-yl)thio](tosyl)amide (269): 
Dibromide 79 (744 mg, 2.00 mmol, 1.00 equiv.) and p-
toluenesulfonamide (342 mg, 2.00 mmol, 1.00 equiv.) were 
dissolved in dry DCM (20 mL) and cooled to –78 °C. Under 
vigorous stirring, DIPEA (766 µL, 569 mg, 4.40 mmol, 2.20 
equiv.) was added dropwise to the obtained orange gel. The clear colorless reaction mixture 
was stirred for 15 min at –78 `C, then allowed to warm up to rt within 60 min and stirred with 
water (12 mL) for 1 min. The organic phase was subsequently filtered through MgSO4 and all 
volatiles were removed in vacuo. Product 269 was obtained as a white foam (660 mg, 
1.73 mmol, 86%). 
1H NMR (300 MHz, CD2Cl2, ppm) δ = 1.58 (d, J = 7.1 Hz, 12H), 2.32 (s, 6H), 2.38 (s, 3H), 5.58 
(hept, J = 7.0 Hz, 2H), 7.18 – 7.24 (m, 2H), 7.61 – 7.69 (m, 2H). 13C NMR (75 MHz, CD2Cl2, 
ppm) δ = 10.8, 21.6, 21.6, 52.9, 127.4, 127.8, 129.2, 140.8, 143.0. 15N NMR (51 MHz, CD2Cl2, 
ppm) δ = –185.9, –283.4. IR (neat, cm–1) = 2975.6, 1447.3, 1391.4, 1370.2, 1258.3, 1129.1, 
1087.7, 913.1, 813.8, 729.9, 708.7, 644.1, 565.0, 553.5. HRMS: m/z calcd. for C21H28N3O2S2 







The information presented below is included for the sake of completeness of data but are not 
discussed in this thesis. 
Dibromide 79 (186 mg, 500 µmol, 1.00 equiv.) and 
trifluoromethanesulfonamide (75 mg, 500 µmol, 1.00 equiv.) were 
dissolved in dry DCM (5 mL) and cooled to –78 °C. Under vigorous 
stirring, DIPEA (191 µL, 142 mg, 1.10 mmol, 2.20 equiv.) was added dropwise to the obtained 
orange gel. The clear colorless reaction mixture was stirred for 15 min at –78 `C, then allowed 
to warm up to rt within 60 min and stirred with water (12 mL) for 1 min. The organic phase was 
subsequently filtered through MgSO4 and all volatiles were removed in vacuo. Product 306 
was obtained as a white foam (140 mg, 389.5 µmol, 78%). 
1H NMR (300 MHz, CD2Cl2, ppm) δ = 1.59 (d, J = 7.0 Hz, 12H), 2.35 (d, J = 0.6 Hz, 6H), 5.65 
(p, J = 7.0 Hz, 2H). 13C NMR (75 MHz, CD2Cl2, ppm) δ = 10.8, 21.5, 53.5, 115.5, 119.8, 124.2, 
128.5, 128.9, 145.5. 15N NMR (51 MHz, CD2Cl2, ppm) δ = -183.3, -294.3. 19F NMR (282 MHz, 
CD2Cl2, ppm) δ = -77.2. IR (neat, cm–1) = 2991.1, 2252.4, 1449.2, 1376.0, 1294.0, 1208.2, 
1157.1, 1037.5, 973.9, 918.9, 837.0, 753.1, 615.2, 567.0. HRMS: m/z calcd. for 
C12H21N3F3O2S2+ [M+H]+ = 360.1022; found = 360.1018.  
[(1,4-Diisopropyl-1H-1,2,4-triazol-4-ium-5-yl)thio](tosyl)amide (288): 
Brominated 2,4-diisopropyl-1,2,4-triazole-3-thione 287 [5-
(bromothio)-1,4-diisopropyl-1H-1,2,4-triazol-4-ium bromide, 173 mg, 
501 µmol, 1.00 equiv.] and p-toluenesulfonamide (324 mg, 
2.00 mmol, 1.00 equiv.) were dissolved in dry DCM (5 mL) and 
cooled to –78 °C. Under vigorous stirring, DIPEA (200 µL, 149 mg, 1.150 mmol, 2.30 equiv.) 
was added dropwise to the obtained orange gel. The clear colorless reaction mixture was 
stirred for 15 min at –78 `C, then allowed to warm up to rt within 60 min and stirred with water 
(12 mL) for 1 min. The organic phase was subsequently filtered through MgSO4 and all 
volatiles were removed in vacuo. Product 288 was obtained as a white foam (145 mg, 
409 µmol, 82%). 
1H NMR (400 MHz, CD2Cl2, ppm) δ = 1.40 – 1.63 (m, 12H), 2.38 (s, 3H), 5.22 – 5.29 (m, 2H), 
7.09 – 7.34 (m, 2H), 7.65 (d, J = 8.2 Hz, 2H), 8.20 (s, 1H). 13C NMR (126 MHz, CD2Cl2, ppm) 
δ =  21.8, 22.7, 51.8, 54.7, 127.4, 129.3, 141.1, 141.4, 141.6, 155.7. IR (neat, cm–1) = 1524.5, 




1081.9, 1042.3, 1012.4, 902.5, 813.8, 736.7, 667.3, 648.0, 596.9, 567.0, 552.5. HRMS: m/z 
calcd. for C15H23N4O2S2+ [M+H]+ = 355.1257; found = 355.1260.  
5.5.2 Reactivity of reagents 
(4-Methoxyphenyl)(phenyl)methanone (307):  
The information presented below is included for the sake of completeness of data but are not 
discussed in this thesis. 
Sulfaneylidene 304 (80.0 mg, 184 µmol, 1.00 equiv.) was dissolved in dry 
THF (1.5 mL) and cooled to –78 °C. 4-Methoxyphenylmagnesium bromide 
solution (0.50M in THF, 644 µL, 322 µmol, 1.75 equiv.) was added 
dropwise, and the reaction was allowed to warm up to 10 °C over a period of 14 affording the 
yellow solution. The reaction was quenched with sat. NH4Cl (5 mL), stirred for 5 min and 
extracted with DCM (2  20 mL). The combined organic phases were dried over MgSO4, 
concentrated in vacuo and purified by column chromatography (DCM:MeOH) furnishing 
benzophenone 307 as a colorless oil (17.9 mg, 84.3 µmol, 46%).  
1H NMR (300 MHz, CD2Cl2, ppm) δ = 3.89 (s, 3H), 6.95 – 7.03 (m, 2H), 7.44 – 7.53 (m, 2H), 
7.54 – 7.65 (m, 1H), 7.70 – 7.77 (m, 2H), 7.77 – 7.85 (m, 2H). 13C NMR (75 MHz, CD2Cl2, ppm) 
δ =56.1, 114.1, 128.7, 130.1, 130.7, 132.4, 132.9, 138.9, 163.8, 195.6. IR (neat, cm–1) 1646.9, 
1594.8, 1505.2, 1456.0, 1444.4, 1317.1, 1279.5, 1258.3, 1180.2, 1168.7, 1149.4, 1111.8, 
1073.2, 1021.1, 999.9, 954.6, 936.3, 917.0, 841.8, 791.6, 738.6, 693.3, 676.9, 632.5, 597.8, 
564.1, 512.0. HRMS: m/z calcd. for C28H24NaO4+ [2M+Na]+ = 447.1567; found = 447.1563.  
 
1-(4-Methoxyphenyl)ethan-1-one (308):  
The information presented below is included for the sake of completeness of data but are not 
discussed in this thesis. 
Sulfaneylidene 305 (80.0 mg, 214.7 µmol, 1.00 equiv.) was dissolved in dry 
THF (1.5 mL) and cooled to –78 °C. 4-Methoxyphenylmagnesium bromide 
solution (0.50M in THF, 644 µL, 322 µmol, 1.50 equiv.) was added dropwise, and the reaction 
was allowed to warm up to 10 °C over a period of 14 affording the yellow solution. The reaction 
was quenched with sat. NH4Cl (5 mL), stirred for 5 min and extracted with DCM (2  20 mL). 
The combined organic phases were dried over MgSO4, concentrated in vacuo and purified by 
column chromatography (DCM:MeOH) furnishing acetophenone 308 as a colorless oi (17.9 




1H NMR (300 MHz, CDCl3, ppm) δ = 2.56 (s, 3H), 3.87 (s, 3H), 6.93 (d, J = 9.0 Hz, 2H), 7.94 
(d, J = 9.0 Hz, 2H). 13C NMR (75 MHz, CDCl3, ppm) δ =26.5, 55.6, 113.8, 130.7, 163.6, 196.9. 
IR (neat, cm–1) = 1665.2, 1595.8, 1573.6, 1506.1, 1460.8, 1415.5, 1355.7, 1309.4, 1273.8, 
1246.8, 1169.6, 1110.8, 1074.2, 1019.2, 953.6, 829.2, 817.7, 805.1, 590.1, 575.6. HRMS: m/z 
calcd. for C9H10O2+ [M]+ = 150.0675; found = 150.0678.  
N-(Cyclopentylthio)-4-methylbenzenesulfonamide (275): 
Compound 269 (100.0 mg, 262 µmol, 1.00 equiv.) was dissolved in dry 
THF (2.0 mL) and cooled to –35 °C. Cyclopentylmagnesium bromide 
solution (2.00M in THF, 394 µL, 788 µmol, 3.00 equiv.) was added 
dropwise, and the reaction mixture was stirred for 2 d at –35°C, then allowed to warm up to 10 
°C over 2 h furnishing the yellow solution. The reaction was quenched with sat. NH4Cl (5 mL), 
stirred for 5 min and extracted with DCM (2  20 mL). The combined organic phases were 
dried over MgSO4, concentrated in vacuo and purified by column chromatography 
(DCM:MeOH) affording 275 as a colorless oil (27.5 mg, 101 µmol, 39%). 
 
1H NMR (300 MHz, CD2Cl2, ppm) δ = 1.41 – 1.74 (m, 6H), 1.77 – 1.92 (m, 2H), 2.43 (s, 3H), 
3.41 – 3.54 (m, 1H), 5.88 (s, 1H), 7.27 – 7.41 (m, 2H), 7.77 (d, J = 8.3 Hz, 2H). 13C NMR (126 
MHz, CD2Cl2, ppm) δ =21.9, 25.3, 31.0, 50.6, 128.0, 130.1, 137.0, 144.7. IR (neat, cm–1) = 
3268.8, 2957.3, 1596.8, 1445.4, 1363.4, 1291.1, 1155.2, 1088.6, 1020.2, 849.5, 809.0, 660.5, 
559.3, 541.9. HRMS: m/z calcd. for C12H18NO2S2+ [M+H]+ = 272.0773; found = 272.0777.  
N-(Isopropylthio)-4-methylbenzenesulfonamide (281) and 1,3-Diisopropyl-2-
(isopropylthio)-4,5-dimethyl-1H-imidazol-3-ium Chloride (282):  
Compound 269 (71.0 mg, 186 µmol, 1.00 equiv.) was dissolved in 
dry THF (1.0 mL) and cooled to –78 °C. iso-Propylmagnesium 
bromide solution (1.30M in THF, 220 µL, 286 µmol, 1.54 equiv.) was 
added dropwise, and the reaction mixture was allowed to warm up 
rt over 21 h furnishing the red solution. The reaction was quenched 
with sat. NH4Cl (5 mL), stirred for 5 min and extracted with DCM (2 
 20 mL). The combined organic phases were dried over MgSO4, concentrated in vacuo and 
purified by column chromatography (DCM:MeOH) affording products 281 as a colorless oil (4.0 






1H NMR (300 MHz, CD2Cl2, ppm) δ 1.17 (d, J = 6.7 Hz, 6H), 2.43 (s, 3H), 3.18 (hept, J = 6.7 
Hz, 1H), 5.76 (s, 1H), 7.29 – 7.38 (m, 2H), 7.68 – 7.84 (m, 2H). 13C NMR (126 MHz, CD2Cl2, 
ppm) δ =20.5, 21.9, 41.8, 128.0, 130.1, 136.9, 144.7. IR (neat, cm–1) = 1750.1, 1678.7, 1604.5, 
1456.0, 1303.6, 1217.8, 1181.2, 1093.4, 1011.5, 914.1, 838.9, 802.2, 753.1, 702.9, 666.3, 
597.8. HRMS: m/z calcd. for C10H16NO2S2+ [M+H]+ = 246.0617; found 246.0617.  
Product 282: 
1H NMR (300 MHz, CD2Cl2, ppm) δ 1.33 (d, J = 6.7 Hz, 6H), 1.59 (d, J = 7.1 Hz, 12H), 2.43 (s, 
6H), 3.45 (hept, J = 6.7 Hz, 1H), 5.19 – 5.46 (m, 2H). 13C NMR (126 MHz, CD2Cl2, ppm) δ 
=11.3, 21.8, 23.7, 44.8, 131.0, 137.0. IR (neat, cm–1) = 3102.9, 1710.6, 1595.8, 1497.5, 1455.0, 
1433.8, 1409.7, 1392.4, 1319.1, 1277.6, 1206.3, 1155.2, 1134.9, 1119.5, 1075.1, 1035.6, 
1001.8, 957.5, 912.2, 879.4, 760.8, 722.2, 693.3, 636.4, 617.1, 605.5, 558.3. HRMS: m/z 
calcd. for C14H27N2S+ [M]+ = 255.1889; found = 255.1893.  
N-(2,4-Dinitrophenyl)-4-methylbenzenesulfonamide (309):  
The information presented below is included for the sake of completeness of data but are not 
discussed in this thesis. 
 
Compound 269 (95.4 mg, 250 µmol, 1.00 equiv.) was dissolved in dry 
MeCN (5.0 mL). A solution of 1-fluoro-2,4-dinitrobenzene (46.5 mg, 
250 µmol, 1.00 equiv.) in MeCN (2.0 mL) was added dropwise to the 
yellow solution. After stirring the reaction mixture at 70 °C for 16 h, the 
orange solution was concentrated in vacuo and purified by column chromatography 
(DCM:MeOH) to afford 309 as a yellow solid (23.9 mg, 70.8 µmol, 28%).  
1H NMR (400 MHz, CD3CN, ppm) δ = 2.33 – 2.53 (m, 3H), 7.41 (dd, J = 8.6, 0.7 Hz, 2H), 7.84 
– 7.88 (m, 1H), 7.89 – 7.93 (m, 2H), 8.36 (dd, J = 9.3, 2.7 Hz, 1H), 8.89 (d, J = 2.7 Hz, 1H), 
10.07 (s, 1H). 13C NMR (126 MHz, CD2Cl2, ppm) δ =21.9, 25.3, 31.0, 50.6, 128.0, 130.1, 137.0, 
144.7. IR (neat, cm–1) = 2925.5, 1619.9, 1594.8, 1539.9, 1518.7, 1489.7, 1424.2, 1394.3, 
1345.1, 1326.8, 1300.8, 1277.6, 1219.8, 1187.0, 1168.7, 1141.7, 1083.8, 1064.5, 1039.4,  
930.5, 914.1, 885.2, 838.9, 813.8, 763.7, 739.6, 711.6, 702.0, 652.8, 610.4, 588.2, 544.8, 





5.6 Reactions towards the synthesis of aryldisulfides 
The information presented in this Subchapter is included for the sake of completeness of data 
but are not discussed in this thesis. 
5.6.1 Synthesis of cationic tetramethylthiourea salts 
2-[4-(Dimethylamino)phenyl]-1,1,3,3-tetramethylisothiouronium Hexafluoroantimonate 
(310): 
Tetramethylthiourea (159 mg, 1.20 mmol, 1.20 equiv.) and N-
chlorosuccinimide (160 mg, 1.20 mmol, 1.20 equiv.) were dissolved 
in DCE (10 mL). Dimethylaniline (127 µL, 121 mg, 1.00 mmol, 1.00 
equiv.) was added dropwise, and the yellow reaction mixture was 
stirred for 17 h at 70 °C, then cooled to rt and washed with aq. NaSbF6 (7.0 mL) for 5 min. The 
aq. phase was re-extracted with DCM (3  10 mL), the combined organic phases were dried 
over MgSO4 and concentrated in vacuo. After column chromatography (DCM:MeOH), the salt 
310 was obtained as a white solid (268 mg, 549 µmol, 55%). 
1H NMR (300 MHz, CDCl3 ppm) δ = 2.97 (s, 6H), 3.17 (s, 12H), 6.67 (d, J = 9.0 Hz, 2H), 7.23 
(d, J = 9.0 Hz, 2H). 13C NMR (75 MHz, CDCl3, ppm) δ = 40.1, 44.0, 110.6, 113.4, 134.0, 151.4, 
176.7. IR (neat, cm–1): 3451.0, 2896.5, 1589.1, 1512.8, 1440.9, 1397.0, 1362.3, 1253.6, 
1201.8, 1149.5, 1103.4, 826.3, 810.8, 530.7, 507.7. HRMS: m/z calcd. for C13H22N3S+ [M–
SbF6]+ = 252.1529; found = 252.1531; calcd. for SbF6– [M]– = 234.8948; found = 234.8950. 
 
Additional information: 
• To optimize the yield of compound 310, this reaction was repeated several times under 
different conditions varying solvent, temperature and time, as presented in Table 15. 
• If the reaction was done in MeCN as a solvent, the anion exchange was performed in 
a different way: The solution was cooled, and sodium hexafluoroantimonate (776 mg, 
3.0 mmol, 3.0 equiv.) was added. The suspension was stirred for 15 min, and then the 
white solid was filtered off and was washed with DCM (3  10 mL). The solvent was 






Table 15: Screening of conditions for the synthesis of 310. 
Reaction Solvent Temperature [°C] Time [h] Yield [%] 
1 DCE 70 16 12 
2 DCM 30 18 40 
3 MeCN 70 24 67 








Tetramethylthiourea (159 mg, 1.20 mmol, 1.20 equiv.) and N-
chlorosuccinimide (160 mg, 1.20 mmol, 1.20 equiv.) were dissolved in 
MeCN (10 mL). Aniline (90 µL, 93 mg, 1.00 mmol, 1.00 equiv.) was added 
dropwise, and the yellow reaction mixture was stirred at 70 °C for 2 h affording the violet 
solution. The latter was cooled to rt, NaSbF6 (776 mg, 3.00 mmol, 3.00 equiv.) was added, and 
the suspension was stirred for 15 min. The organic layer was filtered off, dried over MgSO4 
and concentrated in vacuo. After column chromatography (DCM:MeOH), product 311 was 
obtained as a red solid (273 mg, 638 mmol, 64%).30 
1H NMR (300 MHz, CD2Cl2 ppm) δ = 2.95 (s, 12H), 6.98 (d, 3 = 8.0 Hz, 2H), 7.23 (t, J = 8.0 
Hz, 1H), 7.41 (t, J = 8.0 Hz, 2H), 7.51 (s, 1 H). 13C NMR (75 MHz, CD2Cl2, ppm) δ = 40.6, 
121.2, 126.4, 130.6, 138.9, 158.9. IR (neat, cm–1): 3356.0, 3161.9, 3070.7, 2948.6, 1770.5, 
1704.3, 1626.8, 1597.1, 1557.1, 1402.9, 1355.0, 1293.6, 1168.7, 848.5, 821.1, 749.3, 653.0, 
640.1, 556.6. HRMS: m/z calcd. for C11H18N3 [M–SbF6]+ = 192.1495; found = 192.1496. 
1,1,3,3-Tetramethyl-2-[4-(methylamino)phenyl]isothiouronium Hexafluoroantimonate 
(312): 
Tetramethylthiourea (159 mg, 1.20 mmol, 1.20 equiv.) and N-
chlorosuccinimide (160 mg, 1.20 mmol, 1.20 equiv.) were dissolved in 
MeCN (10 mL). N-Methylaniline (108 µL, 107 mg, 1.00 mmol, 1.00 
equiv.) was added dropwise, and the yellow reaction mixture was 
stirred for 17 h at 70 °C furnishing the violet solution. The latter was cooled to rt, NaSbF6 (776 






30 It was not possible to separate residual succinimide from the desired product after twofold repetitive column 
chromatography, as indicated by the singlets at 2.70 ppm and at 3.02 ppm in the 1H NMR spectrum as well as 
the signals at 30.1 ppm and 179.0 ppm in the 13C NMR spectrum. The vibration of the carbonyl group is visible at 




layer was filtered of, dried over MgSO4 and concentrated in vacuo. After column 
chromatography (DCM:MeOH), compound 312 was obtained as a yellow oil (268 mg, 565 
µmol, 57%) with 85% purity.31 
1H NMR (300 MHz, CD2Cl2 ppm) δ = 2.84 (d, J = 5.2 Hz, 3 H), 3.16 (s, 12 H), 4.34 (s, 1 H), 
6.66 (d, J = 9.4 Hz, 2 H), 7.19 (d, J = 9.4 Hz, 2 H). 13C NMR (75 MHz, CD2Cl2, ppm) δ = 30.5, 
44.4, 111.0, 114.2, 134.7, 151.9, 178.1. IR (neat, cm–1): 3441.1, 2936.0, 2890.6, 2827.0, 
1593.7, 1509.5, 1401.9, 1390.1, 1329.0, 1258.9, 1111.0, 823.2, 650.7. HRMS: m/z calcd. for 
C12H20N3S+ [M–SbF6]+ = 238.1372; found = 238.1381. 
2-[4-(Benzylamino)phenyl]-1,1,3,3-tetramethylisothiouronium Hexafluoroantimonate 
(313): 
Tetramethylthiourea (159 mg, 1.20 mmol, 1.20 equiv.), N-
chlorosuccinimide (160 mg, 1.20 mmol, 1.20 equiv.) and N-
benzylaniline (183 mg, 1.00 mmol, 1.00 equiv.) were dissolved in 
MeCN (10 mL). The yellow reaction mixture was stirred at 70 °C 
for 19 h. Solvents were removed, and the residue was pre-purified 
by a column chromatography on a short column with DCM as the eluent and a 0–10% gradient 
of MeOH. The obtained product was dissolved in DCM (10 mL) and washed with aq. NaSbF6 
solution (10 mL). After drying and evaporation of the solvent, compound 313 was obtained as 
a yellow solid (128 mg, 233 µmol, 23%). 
1H NMR (300 MHz, CD3CN ppm) δ = 3.08 (s, 12H), 4.36 (bs, 2H), 5.51 (bs, 1H), 6.69 (d, J = 
8.7 Hz, 2H), 7.19 (d, J 
 = 8.7 Hz, 2H), 7.22 – 7.33 (m, 1H), 7.22 – 7.33 (m, 4H). 13C NMR (126 MHz, CD3CN, ppm) δ 
= 44.4, 47.6, 112.4, 114.8, 127.9, 128.1, 129.4, 134.9, 140.0, 151.2, 177.4. IR (neat, cm–1): 











1255.5, 1167.7, 1111.7, 825.1, 752.5, 652.5. HRMS: m/z calcd. for C18H24N3S+ [M–SbF6]+ = 
314.1685; found = 314.1685. 
1,1,3,3-Tetramethyl-2-(1-methyl-1H-indol-3-yl)isothiouronium Hexafluoroantimonate 
(314): 
Tetramethylthiourea (132 mg, 1.00 mmol, 1.20 equiv.) and N-
chlorosuccinimide (134 mg, 1.00 mmol, 1.20 equiv.) were dissolved in 
DCE (8 mL). N-Methylindole (107 µL, 109 mg, 833 µmol, 1.00 equiv.) 
were added, and the yellow solution was stirred for 18 h at 70 °C. The 
dark brown solution was allowed to reach rt and washed with aq. NaSbF6 solution (647 mg, 
2.50 mmol, 3.00 equiv. in 10 mL H2O). The organic layer was dried over MgSO4, concentrated 
in vacuo and the obtained crude product was purified by column chromatography with DCM 
as the eluent and a 0–10% gradient of MeOH. Compound 314 was obtained as a brown solid 
(300 mg, 602 µmol, 72%). 
1H NMR (300 MHz, CD2Cl2, ppm) δ = 3.19 (d, J = 0.9 Hz, 12H), 3.88 (d, J = 0.9 Hz, 3H), 7.25 
– 7.32 (m, 1H), 7.36 (ddt, J = 8.2, 7.0, 1.3 Hz, 1H), 7.42 – 7.50 (m, 2H), 7.56 (s, 1H). 13C NMR 
(75 MHz, CD2Cl2, ppm) δ = 34.0, 44.3, 93.8, 111.4, 118.0, 122.4, 124.0, 128.2, 135.8, 137.8, 
177.9. IR (neat, cm–1): 1686.4, 1591.0, 1506.1, 1467.6, 1445.4, 1399.1, 1368.2, 1294.0, 
1257.4, 1227.5, 1197.6, 1167.7, 1107.9, 1061.6, 944.0, 872.6, 814.8, 649.9, 523.6. HRMS: 
m/z calcd. for C14H20N3S+ [M–SbF6]+ = 262.1372; found =  262.1378. 
1,1,3,3-Tetramethyl-2-(1-methyl-2-phenyl-1H-indol-3-yl)isothiouronium 
hexafluoroantimonate  (315): 
Tetramethylthiourea (159 mg, 1.20 mmol, 1.20 equiv.), N-
chlorosuccinimide (160 mg, 1.20 mmol, 1.20 equiv.) and N-Methyl-2-
phenylindole (207 mg, 1.00 mmol, 1.00 equiv.) were dissolved in DCE 
(10 mL). The yellow solution was stirred at 70 °C for 15 h. The orange 
reaction mixture was allowed to reach rt and washed with a solution of 
NaSbF6 (777 mg, 3.00 mmol, 3.00 equiv.) in H2O (10 mL). The organic 
layer was dried over MgSO4 and concentrated in vacuo. The crude product was purified by 
column chromatography with DCM as the eluent with a 0–10% gradient of MeOH. Compound 
315 was obtained as a white solid (331 mg, 575 µmol, 58%). 
1H NMR (300 MHz, CD2Cl2, ppm) δ = 2.97 (s, 12H), 3.73 (s, 3H), 7.31 – 7.45 (m, 4H), 7.50 – 




111.6, 118.0, 123.0, 124.4, 127.8, 129.3, 129.7, 130.7, 130.8, 137.9, 146.2, 177.9. IR (neat, 
cm–1): 1702.8, 1597.7, 1499.4, 1466.6, 1445.4, 1399.1, 1382.7, 1336.4, 1259.3, 1237.1, 
1205.3, 1165.8, 1134.9, 1104.0, 1080.9, 1057.8, 1023.1, 871.7, 801.3, 761.7, 749.2, 703.9, 
651.8, 574.7, 549.6. HRMS: m/z calcd. for C20H24N3S+ [M–SbF6]+ = 338.1685; found = 
338.1685. 
5.6.2 Synthesis of thiols and disulfides 
4,4'-Disulfanediylbis(N,N-dimethylaniline) (316): 
Compound 310 (195 mg, 399 μmol, 1.00 equiv.) was added to 
a solution of methylamine (9.8M in MeOH, 4.32 mL, 42.30 
mmol, 106 equiv.). The reaction mixture was stirred for 10 min 
at rt until no starting material was detectable by TLC. The solvent was removed in vacuo at 
100–200 mbar. The product was purified by column chromatography with DCM as the eluent 
with a 0–10% gradient of MeOH affording the yellow oily liquid which, according to 1H NMR 
spectrum, was essentially a 1:2.5 mixture of the thiol and the disulfide. Exposing the product 
to air for several days lead to the formation of pure 316 (43.4 mg, 143 µmol, 62%) 
1H NMR (300 MHz, CDCl3 ppm) δ = 2.98 (s, 12H), 6.63 (d, J = 9.0 Hz, 4H), 7.27 (d, J = 9.0 Hz, 
2H), 7.36 (d, J = 9.0 Hz, 2H). 13C NMR (75 MHz, CDCl3, ppm) δ = 40.4, 112.6, 123.5, 134.3, 
150.8. IR (neat, cm–1): 2891.6, 2799.1, 1591.9, 1504.0, 1443.1, 1357.4, 1226.7, 1193.6, 
1168.4, 1094.8, 945.4, 811.5, 521.5. HRMS: m/z calcd. for C16H21N2S2+ [M+H]+ = 305.1141; 
found = 305.1143. 
4-(Methylamino)benzenethiol (317a) and 4,4'-Disulfanediylbis(N-methylaniline) (317b): 
Compound 312 (192 mg, 406 μmol, 1.00 equiv.) was added to a 
solution of methylamine (9.8M in MeOH, 4.50 mL, 44.1 mmol, 
108.6 equiv.). The reaction mixture was stirred for 10 min at rt until 
no starting material was detectable by TLC. The solvent was 
removed in vacuo at 100–200 mbar. The product was purified by 
column chromatography with DCM as the eluent with a 0–10% gradient of MeOH. The thiol 
317a (4.2 mg, 30 μmol, 7.4%) and the disulfide 317b (46.2 mg, 167 μmol, 83%) were isolated 
both as yellow oily liquids. 
Compound 317a: 
1H NMR (300 MHz, CDCl3 ppm) δ = 2.81 (s, 3H), 3.30 (s, 1H), 3.74 (s, 1H), 6.52 (d, J = 8.9 




133.5, 148.6. IR (neat, cm–1): 3408.0, 2932.8, 2888.2, 2810.8, 1591.8, 1498.0, 1316.3, 1291.6, 
1259.7, 1179.9, 1154.9, 1091.5, 1059.0, 812.9, 513.2. HRMS: m/z calcd. for C7H10NS+ [M+H]+ 
= 140.0528; found = 140.0534.  
Compound 317b 
1H NMR (300 MHz, CDCl3 ppm) δ = 2.84 (s, 6H), 3.87 (s, 2H), 6.53 (d, J = 8.9 Hz, 4H), 7.29 
(d, J = 8.9 Hz, 4H). 13C NMR (75 MHz, CDCl3, ppm) δ = 30.6, 112.7, 124.4, 134.6, 149.9. IR 
(neat, cm–1): 3390.1, 3364.0, 2915.4, 2880.5, 2818.0, 1587.8, 1505.8, 1324.3, 1265.4, 1177.5, 
1088.0, 813.0, 521.3. HRMS: m/z calcd. for C14H17N2+S2 [M+H]+ = 277.0828; found = 277.0824. 
4,4'-Disulfanediylbis(N-benzylaniline) (318): 
Compound 313 (132 mg, 240 μmol, 1.00 equiv.) was added 
to the solution of methylamine (9.8M in MeOH, 4.19 mL, 41 
mmol, 170 equiv.). The reaction mixture was stirred for 10 
min at rt until no starting material was detectable by TLC. 
The solvent was removed in vacuo at 100–200 mbar. The 
product was purified by column chromatography with DCM as the eluent with a 0–10% gradient 
of MeOH. The disulfide 318 was isolated as a yellow oily solid (44.1 mg, 103 μmol, 86%). 
1H NMR (300 MHz, CDCl3 ppm) δ = 4.12 (s, 2H), 4.32 (d, J = 4.8 Hz, 4H), 6.55 (d, J = 9.0 Hz, 
4H), 7.19 (d, J = 9.0 Hz, 2H), 7.28 (d, J = 9.0 Hz, 4H), 7.31 – 7.39 (m, 8H). 13C NMR (75 MHz, 
CDCl3, ppm) δ = 48.4, 113.7, 115.0, 127.5, 128.8, 133.4, 134.4, 139.2, 148.7. IR (neat, cm–1): 
3380.3, 3027.0, 2924.7, 2849.4, 1665.9, 1618.9, 1592.8, 1493.0, 1471.1, 1452.7, 1323.2, 
1291.1, 1176.9, 1088.6, 818.8, 734.8, 698.4, 516.6. HRMS: m/z calcd. for C26H24N2NaS2+ 
[M+Na]+ = 451.1273; found = 451.1268. 
1-Phenyl-2-[(1-phenyl-4,5-dihydro-1H-pyrrol-2-yl)disulfaneyl]-1H-pyrrole (319): 
Compound 107a (92.7 mg, 182 μmol, 1.00 equiv.) was added to 
a solution of methylamine (9.8M in MeOH, 2.02 mL, 19.8 mmol, 109 
equiv.). The reaction mixture was stirred for 10 min at rt until no 
starting material was detectable by TLC. The solvent was removed in vacuo at 100–200 mbar. 
The product was purified by column chromatography with DCM as the eluent with a 0–10% 
gradient of MeOH. Compound 319 was isolated as a brown oil (17.4 mg, 49.8 μmol, 55%). 
1H NMR (300 MHz, CD2Cl2 ppm) δ = 2.93 (ddd, J = 0.7, 4.4, 18.3 Hz, 1H), 3.24 (dd, J = 7.8, 




Hz, 1H), 6.31 (dd, J = 2.9, 3.6 Hz, 1H), 6.64 (dd, J = 1.9, 3.8 Hz, 1H), 7.06 (dd, J = 2.1, 3.2 Hz, 
1H), 7.27 – 7.50 (m, 10H). 13C NMR (75 MHz, CDCl3, ppm) δ = 42.8, 52.2, 64.0, 110.0, 122.0, 
125.7, 127.3, 127.4, 128.2, 128.3, 129.5, 129.5, 140.0. IR (neat, cm–1): 3104.6, 3044.4, 2919.8, 
1596.5, 1496.6, 1430.1, 1387.1, 1317.7, 1137.6, 1087.1, 1072.7, 1035.2, 759.5, 721.7, 690.1, 
617.0, 605.7, 557.5. HRMS: m/z calcd. for C20H19N2S2+ [M+H]+ = 351.0984; found = 351.0980. 
 
4,4'-Disulfanediyldianiline (320): 
Compound 131 (100 mg, 185 μmol, 1.00 equiv.) was added to 
a solution of methylamine (9.8M in MeOH, 2.05 mL, 20.1 mmol, 
108.6 equiv.). The red reaction mixture was stirred for 22 h at rt and then the solvent was 
removed in vacuo (100–200 mbar). The product was purified by column chromatography with 
DCM as the eluent with a 0–10% gradient of MeOH. Compound 320 was obtained as a yellow 
solid (1.5 mg, 6.0 μmol, 6.5%). 
1H NMR (300 MHz, CD2Cl2 ppm) δ =3.71 (s, 4H), 6.63 (d, J = 8.8 Hz, 4H), 7.15 (d, J = 8.8 Hz, 
4H). 13C NMR (75 MHz, CD2Cl2, ppm) δ = 116.0, 126.0, 131.3, 145.9. IR (neat, cm–1): 2975.9, 
2393.5, 2817.3, 1591.7, 1506.1, 1489.6, 1446.8, 1360.8, 1195.1, 801.0, 653.1, 527.3. HRMS: 
m/z calcd. for C6H7NS+ [M–C6H6NS+H]+ = 125.0294; found = 125.0291. 
 
9-Methyl-9H-carbazole-3-thiol (321): 
Compound 119 (118 mg, 188 μmol, 1.00 equiv.) was added to a solution of methylamine (9.8M 
in MeOH, 2.09 mL, 21.3 mmol, 100 equiv.). The yellow 
reaction mixture was stirred for 18 h at rt and then the solvent 
was removed in vacuo (100–200 mbar). The product was 
purified by column chromatography with DCM as the eluent 
with a 0–10% gradient of MeOH and obtained as a yellow 
solid. According to 1H NMR spectrum, it consisted from thiol 
321b (7.3 mg, 34.1 μmol, 18%) and disulfide 321a (16.7 mg, 
39.3 μmol, 42%). After exposure of the product to air for one week the ratio 321a:321b did not 
change. Further separation attempts were not successful.  
1H NMR (300 MHz, CD2Cl2, ppm) δ =3.82 (s, 2.7H, A), 3.86 (s, 0.3H, B), 7.21 (td, J = 1.0, 8.1 
Hz, 1H), 7.32 – 7.53 (m, 3H), 7.62 (dd, J = 2.0, 8.4 Hz, 1H), 7.99 (dd, J = 1.0, 7.8 Hz, 1H), 8.10 
(dd, J = 0.7, 1.8 Hz, 0.3H, B), 8.24 (dd, J = 0.7, 1.8 Hz, 0.7H, A). 13C NMR (75 MHz, CD2Cl2, 




(A), 121.6 (B), 122.7 (B), 123.9 (B), 125.0 (A), 126.6 (B), 126.8 (A), 127.4, 128.0 (B), 130.4 
(A), 141.7 (A), 142.0 (A). IR (neat, cm–1): 3048.8, 2924.8, 1586.8, 1474.0, 1456.1, 1420.6, 
1268.0, 1243.8, 1210.1, 797.1, 742.5, 724.2, 597.4, 580.1, 563.6. HRMS of 321a: m/z calcd. 





5.7 Dibenzothiophene studies 
The following information is included for the sake of completeness of data but are not 
discussed in this thesis. 
[5,2':8',5''-Terdibenzo[b,d]thiophene]-5,5''-diium Ditriflate (322):  
A solution of dibenzothiophene sulfoxide (300 mg, 1.50 mmol, 
3.00 equiv.) in dry DCM (15 mL) was cooled to –50°C. Under 
stirring, a solution of triflic anhydride (252 µL, 423 mg, 
1.50 mmol, 3.00 equiv.) in dry DCM (2 mL) was added 
dropwise over 7 min, and the orange suspension was stirred at 
–50°C for 4 h. A solution of 1-(trimethylsilyl)pyrrolidine (262 µL, 215 mg, 1.50 mmol, 
3.00 equiv.) in dry DCN (2.0 mL) was added dropwise over 10 min. The obtained orange 
reaction mixture was allowed to reach –20°C within 60 min and stirred for an additional 17 h 
at this temperature. The white solid was filtered off and washed initially with dry DCM (2.0 mL) 
at –20°C, then with dry Et2O (4  20 mL) and dry pentane (20 mL). The solid was dissolved in 
DCM (20 mL) and washed with water (10 mL). The organic layer was dried over MgSO4 and 
concentrated in vacuo to obtain 322 as a white solid (101.9 mg, 120 µmol, 24%). 
1H NMR (400 MHz, CD2Cl2, ppm) δ = 7.45 (dd, J = 8.7, 2.0 Hz, 2H), 7.74 (td, J = 7.9, 1.1 Hz, 
4H), 8.00 (td, J = 7.7, 1.0 Hz, 4H), 8.10 (d, J = 8.1 Hz, 4H), 8.16 (d, J = 8.7 Hz, 2H), 8.41 (dd, 
J = 7.9, 1.1 Hz, 4H), 8.75 (d, J = 2.0 Hz, 2H). 13C NMR (101 MHz, CD3CN, ppm) δ = 123.3, 
124.8, 126.7, 126.7, 127.7, 128.1, 131.8, 132.0, 134.7, 135.4, 139.6, 147.0. 19F NMR (282 
MHz, CD3CN, ppm) δ = –78.8. IR (neat, cm–1) = 3358.4, 3112.5, 3050.8, 2995.9, 2920.7, 
2867.6, 2854.1, 2826.2, 1928.5, 1893.8, 1644.0, 1598.7, 1537.0, 1517.7, 1478.2, 1457.9, 
1441.5, 1426.1, 1376.0, 1346.1, 1309.4, 1263.1, 1222.6, 1152.3, 1124.3, 1104.0, 1065.5, 
1024.0, 986.4, 944.0, 869.7, 857.2, 805.1, 778.1, 763.7, 740.5, 711.6, 702.0, 661.5, 636.4, 
613.3, 571.8, 552.5, 540.0, 531.3, 516.8. HRMS: m/z calcd. for C36H22S22+ [M–2OTf]2+ = 
275.0436; found = 275.0437.  
1-(5H-Dibenzo[b,d]thiophen-5-ium-5-yl)-4-(dimethylamino)pyridin-1-ium Ditriflate 
(323): 
A solution of dibenzothiophene sulfoxide (300 mg, 1.50 mmol, 
3.00 equiv.) in dry DCM (30 mL) was cooled to –42°C. Under 
stirring, a solution of triflic anhydride (239 µL, 402 mg, 
1.42 mmol, 0.95 equiv.) in dry DCM (2 mL) was added dropwise 




6 h. A solution of DMAP (192 mg, 1.57 mmol, 1.05 equiv.) in dry DCM (7.0 mL) was added 
dropwise over 10 min. The obtained light orange suspension was stirred at –42°C for 15 h. 
The cryostat was switched off, all volatiles were removed under high vacuum over a period of 
2 h and the residual orange solid residue was dried for an additional hour under high vacuum. 
Dry DCM (12 mL) was added, and the suspension was sonicated in an ultrasound bath for 
1 min. The orange solution was filtered off and the residual yellow solid was washed again with 
dry DCM (12 mL). The precipitate was filtered off and dried for 1 h under high vacuum affording 
product 323 (202 mg, 334 µmol, 24%) as a yellow solid. Compound 323 is extremely moisture 
sensitive and was stored at –20°C. 
1H NMR (300 MHz, CD3CN, ppm) δ = 3.27 (s, 6H), 6.91 (d, J = 7.9 Hz, 2H), 7.79 (t, J = 7.8 Hz, 
2H), 7.90 (d, J = 8.1 Hz, 2H), 8.07 (d, J = 7.8 Hz, 2H), 8.33 (t, J = 8.1 Hz, 4H). 13C NMR (101 
MHz, CD3CN, ppm) δ = 42.3, 111.8, 126.6, 130.1, 131.5, 133.7, 139.3, 140.5, 141.6, 158.5. 
19F NMR (282 MHz, CD3CN, ppm) δ = -79.3. IR (neat, cm–1) = 3266.8, 3093.3, 1645.0, 1565.9, 
1444.4, 1403.9, 1270.9, 1214.0, 1171.5, 1147.4, 1059.7, 1025.0, 998.0, 943.0, 863.0, 833.1, 
799.4, 780.1, 758.9, 710.6, 632.5, 587.2, 572.8, 510.1. HRMS: Neither EI-spectrometry, nor 
ESI-spectrometry under anhydrous condition were able to detect the product in gas phase.  
2-(5H-Dibenzo[b,d]thiophen-5-ium-5-yl)-1,3-diisopropyl-4,5-dimethyl-1H-imidazol-3-
ium Ditriflate (324): 
To the yellow stirred suspension of the salt 323 (139 mg, 230 µmol, 
1.00 equiv.) in dry THF (5.0 mL), a solution of 1,3-diisopropyl-4,5-
dimethylimidazol carbene (81) (45.6 mg, 253 µmol, 1.10 equiv.) in dry THF 
(3.0 mL) was added dropwise at –45 °C. The yellow reaction mixture was 
allowed to warm up to –20 °C over a period of 1 h. After stirring for an 
additional 30 min, the obtained white precipitate was filtered off, washed with dry THF (3.0 mL) 
and dried in vacuo. Compound 324 (30.9 mg, 46.6 µmol, 20%) was isolated as a white solid. 
1H NMR (400 MHz, CD3CN, ppm) δ = 0.82 (d, J = 7.0 Hz, 5H), 1.96 (d, J = 7.0 Hz, 5H), 2.39 
(s, 3H), 2.54 (s, 3H), 3.41 (hept, J = 7.0 Hz, 1H), 5.53 (d, J = 7.0 Hz, 1H), 7.79 – 7.98 (m, 2H), 
8.02 – 8.15 (m, 2H), 8.24 (d, J = 8.3 Hz, 2H), 8.46 (d, J = 7.9 Hz, 2H). 13C NMR (101 MHz, 
CD3CN, ppm) δ = 11.3, 12.0, 19.0, 22.9, 54.5, 56.9, 123.7, 126.7, 127.3, 130.3, 133.5, 137.3, 
140.1, 140.1, 140.6. 19F NMR (282 MHz, CD3CN, ppm) δ = –79.3. IR (neat, cm–1) = 1587.1, 
1484.0, 1450.2, 1404.9, 1380.8, 1248.7, 1222.6, 1148.4, 1090.5, 1026.9, 899.6, 799.4, 753.1, 






5-(3,4-Dimethoxyphenyl)-5H-dibenzo[b,d]thiophen-5-ium Triflate (325): 
To the stirred suspension of the salt 323 (25.0 mg, 41.3 µmol, 1.00 equiv.) in 
dry DCM (2.0 mL), a solution of 1,2-dimethoxybenzene (6.9 mg, 49.9 µmol, 
1.2 equiv.) in dry DCM (1.0 mL) was added dropwise at –40 °C. The reaction 
mixture was stirred at –40 °C for 23 h affording the dark blue suspension. The 
latter was allowed to warm up to rt, stirred for an additional 2 h and directly 
purified by column chromatography (DCM:MeOH), affording 325 as light yellow solid (5.0 mg, 
10.6 µmol, 26%). 
1H NMR (400 MHz, CD3CN, ppm) δ = 3.67 (s, 3H), 3.86 (s, 3H), 6.87 (s, 1H), 7.08 (dd, J = 8.8, 
1.8 Hz, 1H), 7.25 (dd, J = 8.8, 2.4 Hz, 1H), 7.67 – 7.77 (m, 2H), 7.94 (t, J = 7.6 Hz, 2H), 8.02 
(d, J = 8.1 Hz, 2H), 8.33 (d, J = 7.6 Hz, 2H). 13C NMR (126 MHz, CD3CN, ppm) δ = 57.0, 57.1, 
112.9, 114.1, 125.5, 126.6, 128.7, 132.6, 133.3, 135.3, 140.1. 19F NMR (282 MHz, CD3CN, 
ppm) δ = -79.4. IR (neat, cm–1) = 2917.8, 2359.5, 1586.2, 1508.1, 1449.2, 1340.3, 1260.3, 
1224.6, 1147.4, 1086.7, 1029.8, 1013.4, 807.1, 756.9, 705.8, 637.4, 572.8, 516.8. HRMS: m/z 
calcd. for C20H17O2S+ [M–OTf]+ = 321.0944; found 321.0949. 
5-(1-Methyl-1H-indol-3-yl)-5H-dibenzo[b,d]thiophen-5-ium Triflate (326): 
To the stirred suspension of the salt 323 (50.0 mg, 82.7 µmol, 1.00 equiv.) in dry 
DCM (2.5 mL), a solution of methylindole (12.7 µL, 13.0 mg, 99.1 µmol, 
1.20 equiv.) in dry DCM (1.0 mL) was added dropwise at – 40 °C. The reaction 
mixture was stirred at this temperature for an additional 23 h affording the white 
suspension. The latter was allowed to warm up to rt, stirred for 2 h more and directly purified 
by column chromatography (DCM:MeOH) affording 326 as a white solid (6.0 mg, 12.9 µmol, 
16%). 
1H NMR (400 MHz, CD3CN, ppm) δ 3.97 (s, 3H), 6.21 (d, J = 8.1 Hz, 1H), 6.90 (t, J = 7.7 Hz, 
1H), 7.29 (t, J = 7.8 Hz, 1H), 7.58 (d, J = 8.4 Hz, 1H), 7.68 (t, J = 7.8 Hz, 2H), 7.87 – 8.00 (m, 
4H), 8.39 (d, J = 7.8 Hz, 2H), 8.48 (s, 1H). 13C NMR (126 MHz, CD3CN, ppm) δ = 35.0, 
113.4, 118.0, 124.2, 125.2, 125.6, 128.2, 132.4, 135.0, 139.8, 143.3 19F NMR (282 MHz, 
CD3CN, ppm) δ = –79.3. IR (neat, cm–1) = 1577.5, 1518.7, 1483.0, 1452.1, 1421.3, 1381.7, 
1261.2, 1223.6, 1157.1, 1132.0, 1055.8, 1029.8, 976.8, 758.9, 744.4, 708.7, 636.4, 594.0, 





1,3-Diisopropyl-4,5-dimethyl-1H-imidazol-3-ium-2-ide (81):  
Carbene 81 was synthesized following a modified protocol of M. S. Sanford et al.[307] 
Potassium (1.49 g, 38.2 mmol, 2,50 equiv.) was placed in a three-neck flask 
and washed with dry pentane (2  10 mL) to remove residual mineral oil. 
Afterwards, dry THF (90 mL) was added followed by 1,3-diisopropyl-4,5-dimethyl-2(3H)-
imidazolethione (78) (3.23 g, 15.2 mmol, 1.00 equiv.). The reaction mixture was vigorously 
stirred at 84 °C for 4 h. The resulting blue suspension was allowed to cool down to rt and 
filtered through a pad of Celite®. All volatiles were removed under reduced pressure and pure 
81 (2.11 g, 11.6 mmol, 77%) was isolated as a white solid, which was kept at –20 °C.  
1H NMR (300 MHz, C6D6, ppm) δ 1.51 (d, J = 6.5 Hz, 12H), 1.73 (s, 6H), 3.95 (hept, J = 6.6 
Hz, 2H).  
Spectral properties were identically to those reported in the literature.[307] 
2-(2-Bromophenyl)pyridine (327): 
327 was synthesized following a modified protocol of A. Togni et al.[308] 
N-Bromosuccinimide (979 mg, 5.50 mmol, 1.10 equiv.) and palladium(II) acetate 
(202 mg, 900 µmol, 16 mol%) were dissolved in dry MeCN (25 mL). A solution of 
2-phenylpyridine (715  µL, 776 mg, 5.00 mmol, 1.00 equiv.) in MeCN (2 mL) was added 
dropwise, and the suspension was stirred at 100°C for 48 h. The orange reaction mixture was 
allowed to reach rt, and the orange solution was filtered off. The residual white solid was 
washed with MeCN (10 mL), and the combined organic phases were dried over MgSO4. All 
volatiles were removed under reduced pressure, and the obtained orange oil was purified by 
column chromatography (cyclohexane:EtOAc). Compound 327 was isolated as a slightly 
yellow oil (737 mg, 3.15 mmol, 63%). 
1H NMR (300 MHz, CDCl3, ppm) δ = 7.22 – 7.34 (m, 2H), 7.41 (td, J = 7.5, 1.2 Hz, 1H), 7.54 
(dd, J = 7.7, 1.8 Hz, 1H), 7.60 (d, J = 7.9 Hz, 1H), 7.68 (dd, J = 8.0, 1.2 Hz, 1H), 7.77 (d, J = 
1.8 Hz, 1H), 8.72 (d, J = 4.9 Hz, 1H). 13C NMR (126 MHz, CDCl3, ppm) δ = 122.6, 124.9, 127.7, 
129.8, 131.6, 133.4, 135.9, 149.6. IR (neat, cm–1) = 1591.0, 1582.3, 1566.9, 1480.1, 1457.0, 
1437.7, 1418.4, 1299.8, 1149.4, 1093.4, 1077.0, 1046.2, 1025.9, 1015.3, 989.3, 789.7, 745.4, 








Compound 327 (520 mg, 2.22 mmol, 1.00 equiv.) was dissolved in dry THF 
(20 mL) and cooled to –78 °C. sec-Buthyllithium (1.4M in THF, 2.38 mL, 
3.33 mmol, 1.50 equiv.) was added dropwise within 5 min. After 25 min, no 327 
was detectable by GC-MS. TMSCl (761 µL, 652 mg, 6.00 mmol, 2.70 equiv.) was added 
dropwise within 5 min. The dark red solution was allowed to warm up to –15°C within 1 h. After 
an additional stirring for 24 h, sat. NH4Cl solution (10 mL) was added to the white suspension. 
The phases were separated, and the aqueous layer was extracted with Et2O (2  20 mL). The 
combined organic phases were dried over MgSO4 and all volatiles were removed under 
reduced pressure. The obtained crude product was purified by column chromatography 
(cyclohexane:EtOAc) to obtain 328 as colorless oil (490 mg, 2.15 mmol, 97%). 
1H NMR (400 MHz, CDCl3 ppm) δ = 0.08 (s, 9H), 7.23 – 7.29 (m, 1H), 7.37 – 7.52 (m, 4H), 
7.69 – 7.77 (m, 2H), 8.64 (ddd, J = 4.9, 1.8, 1.0 Hz, 1H). 13C NMR (101 MHz, CDCl3, ppm) δ = 
1.0, 122.1, 123.1, 127.6, 128.7, 128.9, 135.6, 136.5, 139.5, 147.2, 148.6, 161.5. IR (neat, cm–
1) = 1586.2, 1568.8, 1557.2, 1477.2, 1466.6, 1424.2, 1241.9, 1150.3, 1123.3, 1101.2, 1021.1, 
833.1, 798.4, 767.5, 746.3, 727.0, 680.7, 634.5, 622.9, 615.2, 557.3. HRMS: m/z calcd. for 
C14H18NSi+ [M+H]+ = 228.1203; found 228.1203. 
Note: 
Attempts to perform a Br-Mg exchange using i-PrMgBr (1.30 equiv.) in dry Et2O at –78°C were 








5.8 Crystal structures 
5.8.1 Structure of reagents 
Structure 91 
 
Figure S1: Asymmetric unit of 91.  
CSD code  1843380 
Empirical formula  C31H50Cl4N6O4S2  
Formula weight  776.69  
Temperature/K  100(2) 
Crystal system  triclinic  
Space group  P-1  
a/Å  9.2375(7)  
b/Å  12.5810(12)  
c/Å  16.6226(17)  
α/°  94.204(4)  
β/°  90.453(3)  
γ/°  102.479(3)  
Volume/Å3  1880.6(3)  
Z  2  
ρcalcg/cm3  1.372  
μ/mm-1  0.469  
F(000)  820.0  
Crystal size/mm3  0.284 × 0.177 × 0.05  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  4.284 to 63.122  
Index ranges  -13 ≤ h ≤ 13, -18 ≤ k ≤ 18, 
 -24 ≤ l ≤ 24  
Reflections collected  73341  
Independent reflections  12576 [Rint = 0.0317, 
 Rsigma = 0.0221]  
Data/restraints/parameters  12576/0/436  
Goodness-of-fit on F2  1.038  
Final R indexes [I>=2σ (I)]  R1 = 0.0304, wR2 = 0.0748  
Final R indexes [all data]  R1 = 0.0366, wR2 = 0.0785  







Figure S2: Asymmetric unit of 94. 
 
  
Empirical formula  C11H18BrN3OS  
Formula weight  320.25  
Temperature/K  106(2)  
Crystal system  monoclinic  
Space group  P21  
a/Å  7.4262(2)  
b/Å  11.3331(3)  
c/Å  16.0948(5)  
α/°  90  
β/°  100.078(2)  
γ/°  90  
Volume/Å3  1333.67(7)  
Z  4  
ρcalcg/cm3  1.595  
μ/mm-1  3.228  
F(000)  656.0  
Crystal size/mm3  0.233 × 0.232 × 0.110  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  4.42 to 61.14  
Index ranges  -10 ≤ h ≤ 10, -16 ≤ k ≤ 16, -23 ≤ l ≤ 23  
Reflections collected  42209  
Independent reflections  8187 [Rint = 0.0748, Rsigma = 0.0646]  
Data/restraints/parameters  8187/1/316  
Goodness-of-fit on F2  1.009  
Final R indexes [I>=2σ (I)]  R1 = 0.0342, wR2 = 0.0478  
Final R indexes [all data]  R1 = 0.0582, wR2 = 0.0526  
Largest diff. peak/hole / e Å-3  0.40/-0.48  








Figure S3: Asymmetric unit of 90 containing two MeCN molecules. 




Empirical formula  C23H30BrN5O2S  
Formula weight  520.49  
Temperature/K  104(2)  
Crystal system  orthorhombic  
Space group  Pbca  
a/Å  11.6964(6)  
b/Å  20.2093(10)  
c/Å  20.8590(10)  
α/°  90  
β/°  90  
γ/°  90  
Volume/Å3  4930.6(4)  
Z  8  
ρcalcg/cm3  1.402  
μ/mm-1  1.781  
F(000)  2160.0  
Crystal size/mm3  0.222 × 0.219 × 0.092  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  4.03 to 61.016  
Index ranges  -16 ≤ h ≤ 16, -28 ≤ k ≤ 28, -29 ≤ l ≤ 29  
Reflections collected  279010  
Independent reflections  7531 [Rint = 0.1299, Rsigma = 0.0313]  
Data/restraints/parameters  7531/0/297  
Goodness-of-fit on F2  1.045  
Final R indexes [I>=2σ (I)]  R1 = 0.0351, wR2 = 0.0576  
Final R indexes [all data]  R1 = 0.0593, wR2 = 0.0640  







5.8.2 Structure of backbone derivatives 
Structure 107b 
 
Figure S4: Asymmetric unit of 107b. 
 
  
Empirical formula  C15H20F6N3SSb  
Formula weight  510.15  
Temperature/K  120(2) 
Crystal system  monoclinic  
Space group  P21/n  
a/Å  8.6111(3)  
b/Å  17.8265(7)  
c/Å  12.2312(5)  
α/°  90  
β/°  94.297(2)  
γ/°  90  
Volume/Å3  1872.28(12)  
Z  4  
ρcalcg/cm3  1.810  
μ/mm-1  1.646  
F(000)  1008.0  
Crystal size/mm3  0.2 × 0.1 × 0.05  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  5.266 to 59.998  
Index ranges  -11 ≤ h ≤ 12, -25 ≤ k ≤ 25, -17 ≤ l ≤ 17  
Reflections collected  58949  
Independent reflections  5425 [Rint = 0.0339, Rsigma = 0.0158]  
Data/restraints/parameters  5425/0/239  
Goodness-of-fit on F2  1.074  
Final R indexes [I>=2σ (I)]  R1 = 0.0179, wR2 = 0.0396  
Final R indexes [all data]  R1 = 0.0225, wR2 = 0.0435  








Figure S5: Asymmetric unit of 107a. 
 
  
Empirical formula  C15H20F6N3SSb  
Formula weight  510.15  
Temperature/K  120(2) 
Crystal system  monoclinic  
Space group  P21/c  
a/Å  16.7471(6)  
b/Å  11.4907(4)  
c/Å  20.3725(7)  
α/°  90  
β/°  99.8340(10)  
γ/°  90  
Volume/Å3  3862.8(2)  
Z  8  
ρcalcg/cm3  1.754  
μ/mm-1  1.596  
F(000)  2016.0  
Crystal size/mm3  0.404 × 0.218 × 0.15  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  4.058 to 66.328  
Index ranges  -25 ≤ h ≤ 25, -17 ≤ k ≤ 17, -31 ≤ l ≤ 31  
Reflections collected  198418  
Independent reflections  14734 [Rint = 0.0372, Rsigma = 0.0161]  
Data/restraints/parameters  14734/0/477  
Goodness-of-fit on F2  0.917  
Final R indexes [I>=2σ (I)]  R1 = 0.0273, wR2 = 0.0793  
Final R indexes [all data]  R1 = 0.0391, wR2 = 0.0999  








Figure S6: Asymmetric unit of 310. 
 
  
Empirical formula  C13H22F6N3SSb  
Formula weight  488.14  
Temperature/K  120(2) 
Crystal system  triclinic  
Space group  P-1  
a/Å  8.6347(4)  
b/Å  10.4132(6)  
c/Å  11.7499(6)  
α/°  109.832(2)  
β/°  95.488(2)  
γ/°  109.583(2)  
Volume/Å3  909.85(8)  
Z  2  
ρcalcg/cm3  1.782  
μ/mm-1  1.689  
F(000)  484.0  
Crystal size/mm3  0.146 × 0.121 × 0.095  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  4.522 to 72.904  
Index ranges  -14 ≤ h ≤ 14, -17 ≤ k ≤ 17, -19 ≤ l ≤ 19  
Reflections collected  71029  
Independent reflections  8893 [Rint = 0.0353, Rsigma = 0.0215]  
Data/restraints/parameters  8893/0/223  
Goodness-of-fit on F2  1.354  
Final R indexes [I>=2σ (I)]  R1 = 0.0245, wR2 = 0.0722  
Final R indexes [all data]  R1 = 0.0331, wR2 = 0.0967  









Figure S7: Asymmetric unit of 111. 
 
  
Empirical formula  C22H21F6N2SSb  
Formula weight  581.22  
Temperature/K  100(2) 
Crystal system  monoclinic  
Space group  P21/n  
a/Å  15.2643(5)  
b/Å  9.7130(3)  
c/Å  15.4112(5)  
α/°  90  
β/°  103.5930(10)  
γ/°  90  
Volume/Å3  2220.90(12)  
Z  4  
ρcalcg/cm3  1.738  
μ/mm-1  1.399  
F(000)  1152.0  
Crystal size/mm3  0.304 × 0.304 × 0.056  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  4.998 to 65.172  
Index ranges  -23 ≤ h ≤ 19, -14 ≤ k ≤ 14, -23 ≤ l ≤ 22  
Reflections collected  28007  
Independent reflections  8089 [Rint = 0.0203, Rsigma = 0.0208]  
Data/restraints/parameters  8089/0/292  
Goodness-of-fit on F2  1.035  
Final R indexes [I>=2σ (I)]  R1 = 0.0314, wR2 = 0.0763  
Final R indexes [all data]  R1 = 0.0359, wR2 = 0.0795  








Figure S8: Asymmetric unit of 112. 
 
  
Empirical formula  CHNFSSb  
Formula weight  199.84  
Temperature/K  100(2) 
Crystal system  monoclinic  
Space group  P21/c  
a/Å  12.2043(5)  
b/Å  9.1873(4)  
c/Å  18.8925(10)  
α/°  90  
β/°  105.750(2)  
γ/°  90  
Volume/Å3  2038.78(16)  
Z  19  
ρcalcg/cm3  3.093  
μ/mm-1  6.743  
F(000)  1710.0  
Crystal size/mm3  0.210 × 0.300 × 0.150  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  4.48 to 56.654  
Index ranges  -16 ≤ h ≤ 16, -12 ≤ k ≤ 12, -25 ≤ l ≤ 23  
Reflections collected  36353  
Independent reflections  5079 [Rint = 0.0463, Rsigma = 0.0266]  
Data/restraints/parameters  5079/0/257  
Goodness-of-fit on F2  1.066  
Final R indexes [I>=2σ (I)]  R1 = 0.0217, wR2 = 0.0428  
Final R indexes [all data]  R1 = 0.0307, wR2 = 0.0464  








Figure S9: Asymmetric unit of 104. 
  
Empirical formula  CHNFSSb  
Formula weight  199.84  
Temperature/K  100(2) 
Crystal system  monoclinic  
Space group  P21/c  
a/Å  8.8256(4)  
b/Å  17.4237(7)  
c/Å  11.9860(5)  
α/°  90  
β/°  92.419(2)  
γ/°  90  
Volume/Å3  1841.50(14)  
Z  17  
ρcalcg/cm3  3.063  
μ/mm-1  6.679  
F(000)  1530.0  
Crystal size/mm3  0.454 × 0.297 × 0.21  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  4.128 to 61.092  
Index ranges  -12 ≤ h ≤ 12, -24 ≤ k ≤ 24, -17 ≤ l ≤ 17  
Reflections collected  56424  
Independent reflections  5612 [Rint = 0.0437, Rsigma = 0.0185]  
Data/restraints/parameters  5612/0/237  
Goodness-of-fit on F2  1.089  
Final R indexes [I>=2σ (I)]  R1 = 0.0227, wR2 = 0.0475  
Final R indexes [all data]  R1 = 0.0272, wR2 = 0.0495  








Figure S10: Asymmetric unit of 108. 
The crystal was poorly diffracting and decomposes on the loop over time. Therefore, the completeness 
of the data set is low (90%). Attempts to grow bigger crystals and repeating of the diffraction experiment 
have not been successful.   
  
Empirical formula  CHNFSSb  
Formula weight  199.84  
Temperature/K  100(2) 
Crystal system  triclinic  
Space group  P-1  
a/Å  10.8894(5)  
b/Å  11.1177(4)  
c/Å  22.5424(9)  
α/°  91.8960(10)  
β/°  100.3580(10)  
γ/°  117.1570(10)  
Volume/Å3  2367.90(17)  
Z  22  
ρcalcg/cm3  3.083  
μ/mm-1  6.722  
F(000)  1980.0  
Crystal size/mm3  0.099 × 0.132 × .0.241  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  4.154 to 48.81  
Index ranges  -12 ≤ h ≤ 12, -11 ≤ k ≤ 12, -23 ≤ l ≤ 26  
Reflections collected  12766  
Independent reflections  7014 [Rint = 0.0295, Rsigma = 0.0469]  
Data/restraints/parameters  7014/0/577  
Goodness-of-fit on F2  1.031  
Final R indexes [I>=2σ (I)]  R1 = 0.0330, wR2 = 0.0813  
Final R indexes [all data]  R1 = 0.0408, wR2 = 0.0877  






5.8.3 Structure of arylthioimidazolium salts 
Structure 113 
 
Figure S11: Asymmetric unit of 113. 
The pyrrole ring in one of the two molecules disordered about two positions. They were refined with 
distance restraints and restraints for the anisotropic displacement parameters. The occupancy of the 
minor position including N3A was refined to 0.46525. 
CSD code  1842214  
Empirical formula  C15H23F6N3SSb  
Formula weight  513.17  
Temperature/K  100(2) 
Crystal system  triclinic  
Space group  P-1  
a/Å  10.6342(8)  
b/Å  13.9433(11)  
c/Å  15.3612(12)  
α/°  80.585(3)  
β/°  69.903(3)  
γ/°  67.620(3)  
Volume/Å3  1976.5(3)  
Z  4  
ρcalcg/cm3  1.725  
μ/mm-1  1.560  
F(000)  1020.0  
Crystal size/mm3  0.458 × 0.218 × 0.118  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data 
collection/°  
5.964 to 56  
Index ranges  -12 ≤ h ≤ 14, -17 ≤ k ≤ 18, 0 ≤ l ≤ 20  
Reflections collected  9134  
Independent reflections  9134 [Rsigma = 0.0418]  
Data/restraints/parameters  9134/20/495  
Goodness-of-fit on F2  1.061  
Final R indexes [I>=2σ (I)]  R1 = 0.0454, wR2 = 0.1160  
Final R indexes [all data]  R1 = 0.0470, wR2 = 0.1174  






Figure S12: Asymmetric unit of 114 including a molecule dichloromethane. 
 
CSD code  1842208 
Empirical formula  C21H30ClF6N3SSb  
Formula weight  627.74  
Temperature/K  100(2) 
Crystal system  triclinic  
Space group  P-1  
a/Å  8.6895(7)  
b/Å  10.6326(8)  
c/Å  14.2624(12)  
α/°  103.338(3)  
β/°  102.901(3)  
γ/°  92.570(3)  
Volume/Å3  1243.36(17)  
Z  2  
ρcalcg/cm3  1.677  
μ/mm-1  1.361  
F(000)  630.0  
Crystal size/mm3  0.448 × 0.32 × 0.028  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  4.346 to 59.198  
Index ranges  -12 ≤ h ≤ 12, -14 ≤ k ≤ 14, -19 ≤ l ≤ 19  
Reflections collected  42400  
Independent reflections  6985 [Rint = 0.0206, Rsigma = 0.0146]  
Data/restraints/parameters  6985/0/305  
Goodness-of-fit on F2  1.058  
Final R indexes [I>=2σ (I)]  R1 = 0.0291, wR2 = 0.0808  
Final R indexes [all data]  R1 = 0.0298, wR2 = 0.0815  







Figure S13: Asymmetric unit of 99. 
 
  
Empirical formula  C21H29F6N3SSb  
Formula weight  591.28  
Temperature/K  100. 
Crystal system  monoclinic  
Space group  P21/n  
a/Å  10.4709(4)  
b/Å  22.2447(7)  
c/Å  10.8000(4)  
α/°  90  
β/°  99.9630(10)  
γ/°  90  
Volume/Å3  2477.62(15)  
Z  4  
ρcalcg/cm3  1.585  
μ/mm-1  1.256  
F(000)  1188.0  
Crystal size/mm3  ? × ? × ?  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  5.004 to 59.28  
Index ranges  -14 ≤ h ≤ 13, -26 ≤ k ≤ 29, -14 ≤ l ≤ 14  
Reflections collected  16803  
Independent reflections  5563 [Rint = 0.0381, Rsigma = 0.0393]  
Data/restraints/parameters  5563/0/295  
Goodness-of-fit on F2  1.210  
Final R indexes [I>=2σ (I)]  R1 = 0.0279, wR2 = 0.0791  
Final R indexes [all data]  R1 = 0.0375, wR2 = 0.1069  








Figure S14: Asymmetric unit of 100. 
 
CSD code  1842198 
Empirical formula  C26H32F6N3SSb  
Formula weight  654.35 
Temperature/K  100(2) 
Crystal system  orthorhombic 
Space group  P n a 21 
a/Å  16.992(3) 
b/Å  14.219(2)   
c/Å  22.529(3) 
α/°  90 
β/°  90 
γ/°  90 
Volume/Å3  5443.4(14) 
Z  8  
ρcalcg/cm3  1.597 
μ/mm-1  1.152  
F(000)  2640 
Crystal size/mm3  0.19 × 0.100 × 0.060 
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  3.106 to 28.283 
Index ranges  -22 ≤ h ≤ 22, -18 ≤ k ≤ 18, -30 ≤ l ≤ 30  
Reflections collected  121075 
Independent reflections  13511 [Rint = 0.1455; Rsigma = 0.0807 ]  
Data/restraints/parameters  13511/1/682  
Goodness-of-fit on F2  1.058  
Final R indexes [I>=2σ (I)]  R1 = 0.0434, wR2 = 0.0913  
Final R indexes [all data]  R1 = 0.0564, wR2 = 0.0973  








Figure S15: Asymmetric unit of 115. 
Both molecules in the asymmetric unit of 115 exhibited hydrogen bonds between the OH/NH and the 
flour atom of the anion. For clarity, the interaction is only shown once in Figure S15. The hydrogen bond 
between F7 and O2 leads to an elongation of the Sb2-F7 which results in a bond length of 1.8846(7)Å. 
In case of Sb2-F8, elongated by the NH, the bond length is 1.8923(7)Å. Both bonds are significant longer 
than the average axial Sb-F bonds of both anions (1.8718[7]Å). 
 
CSD code  1842205 
Empirical formula  C20H28F6N3OSSb  
Formula weight  594.26  
Temperature/K  100(2) 
Crystal system  triclinic  
Space group  P-1  
a/Å  11.3916(4)  
b/Å  12.0591(5)  
c/Å  18.7226(7)  
α/°  79.9640(10)  
β/°  77.9580(10)  
γ/°  70.4490(10)  
Volume/Å3  2355.08(16)  
Z  4  
ρcalcg/cm3  1.676  
μ/mm-1  1.325  
F(000)  1192.0  
Crystal size/mm3  0.279 × 0.272 × 0.169  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  4.382 to 63.022  
Index ranges  -15 ≤ h ≤ 16, -17 ≤ k ≤ 17, -27 ≤ l ≤ 27  
Reflections collected  38257  
Independent reflections  15617 [Rint = 0.0144, Rsigma = 0.0178]  
Data/restraints/parameters  15617/4/601  
Goodness-of-fit on F2  1.063  
Final R indexes [I>=2σ (I)]  R1 = 0.0177, wR2 = 0.0439  
Final R indexes [all data]  R1 = 0.0192, wR2 = 0.0447  







Figure S16: Asymmetric unit of 117 containing two dichloromethane molecules. 
117 shows hydrogen bond interaction between the COOH (O1) and the chloride (Cl1). The distance 
between O1 and Cl1 is 2.97575(13)Å. 
 
CSD code  1842207 
Empirical formula  C23H32Cl3N3O4S  
Formula weight  552.92  
Temperature/K  100(2) 
Crystal system  monoclinic  
Space group  C2/c  
a/Å  18.565(4)  
b/Å  24.465(5)  
c/Å  12.017(3)  
α/°  90  
β/°  101.886(6)  
γ/°  90  
Volume/Å3  5341.1(19)  
Z  8  
ρcalcg/cm3  1.375  
μ/mm-1  0.455  
F(000)  2320.0  
Crystal size/mm3  0.135 × 0.068 × 0.022  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  4.484 to 59.236  
Index ranges  -25 ≤ h ≤ 25, -34 ≤ k ≤ 34, -15 ≤ l ≤ 16  
Reflections collected  41385  
Independent reflections  7530 [Rint = 0.0378, Rsigma = 0.0284]  
Data/restraints/parameters  7530/0/322  
Goodness-of-fit on F2  1.055  
Final R indexes [I>=2σ (I)]  R1 = 0.0355, wR2 = 0.0838  
Final R indexes [all data]  R1 = 0.0466, wR2 = 0.0901  








Figure S17: Asymmetric unit of 118. 
The ethyl residue attached to O1 is disordered resulting in big ADPs of the carbon atoms. The hydrogen 
bond between N1 and F3 results in N1-F3 distance of 2.939 Å as well as in an elongation of the Sb1-
F3-bond (1.879(3)Å) compared to the average of the other Sb-F-bonds (1.867Å). The disorder of the 
isopropyl group attached to N2 was disordered about two positions. They were refined with distance 
restraints and restraints for the anisotropic displacement parameters. The occupancy of the minor 
position refined to 0.447(15). Due to disordered solvent molecule contribution to the calculated structure 
factors. PLATON SQUEEZE[309] was used to take this observation into account. The intensity of the 
highest unassigned peak decreased from 5.9 e Å-3 to 3.1 e Å-3.  
 
CSD code  1742205 
Empirical formula  C24H34F6N3O4SSb  
Formula weight  696.35  
Temperature/K  100(2) 
Crystal system  orthorhombic  
Space group  Pnma  
a/Å  8.3908(15)  
b/Å  25.698(4)  
c/Å  27.710(4)  
α/°  90  
β/°  90  
γ/°  90  
Volume/Å3  5975.1(17)  
Z  8  
ρcalcg/cm3  1.548  
μ/mm-1  1.064  
F(000)  2816.0  
Crystal size/mm3  0.2 × 0.067 × 0.064  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  4.324 to 59.28  
Index ranges  -11 ≤ h ≤ 11, -35 ≤ k ≤ 34, -38 ≤ l ≤ 38  
Reflections collected  42615  
Independent reflections  8592 [Rint = 0.0386, Rsigma = 0.0315]  
Data/restraints/parameters  
Goodness-of-fit on F2  
8592/1/394  
1.180  
Final R indexes [I>=2σ (I)]  R1 = 0.0704, wR2 = 0.1503  
Final R indexes [all data]  R1 = 0.0829, wR2 = 0.1557  







Figure S18: Asymmetric unit of 129 including one molecule dichloromethane. 
 
CSD code  1842200 
Empirical formula  C20H32Cl2F6N3SSb  
Formula weight  653.19  
Temperature/K  100(2) 
Crystal system  monoclinic  
Space group  P21/c  
a/Å  8.5286(3)  
b/Å  10.6320(5)  
c/Å  28.8881(13)  
α/°  90  
β/°  93.371(2)  
γ/°  90  
Volume/Å3  2614.93(19)  
Z  4  
ρcalcg/cm3  1.659  
μ/mm-1  1.396  
F(000)  1312.0  
Crystal size/mm3  0.281 × 0.186 × 0.062  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  4.76 to 60  
Index ranges  -10 ≤ h ≤ 11, -12 ≤ k ≤ 14, -40 ≤ l ≤ 35  
Reflections collected  18803  
Independent reflections  7580 [Rint = 0.0331, Rsigma = 0.0436]  
Data/restraints/parameters  7580/0/306  
Goodness-of-fit on F2  1.269  
Final R indexes [I>=2σ (I)]  R1 = 0.0494, wR2 = 0.0952  
Final R indexes [all data]  R1 = 0.0616, wR2 = 0.1001  








Figure S19: Asymmetric unit of 123 including one molecule dichloromethane. 
 
CSD code  1842199 
Empirical formula  C28H35Cl2F6N2O2S2Sb  
Formula weight  802.35  
Temperature/K  150(2)  
Crystal system  monoclinic  
Space group  P21/c  
a/Å  9.7036(11)  
b/Å  26.893(3)  
c/Å  12.5997(13)  
α/°  90  
β/°  93.073(4)  
γ/°  90  
Volume/Å3  3283.2(6)  
Z  4  
ρcalcg/cm3  1.623  
μ/mm-1  1.194  
F(000)  1616.0  
Crystal size/mm3  0.299 × 0.220 × .0.174  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  4.434 to 63.192  
Index ranges  -14 ≤ h ≤ 14, -39 ≤ k ≤ 39, -18 ≤ l ≤ 15  
Reflections collected  164305  
Independent reflections  10998 [Rint = 0.0355, Rsigma = 0.0156]  
Data/restraints/parameters  10998/0/396  
Goodness-of-fit on F2  1.062  
Final R indexes [I>=2σ (I)]  R1 = 0.0318, wR2 = 0.0749  
Final R indexes [all data]  R1 = 0.0401, wR2 = 0.0806  







Figure S20: Asymmetric unit of 130. 
 
CSD code  1842204 
Empirical formula  C18H27F6N3SSb  
Formula weight  553.23  
Temperature/K  100(2) 
Crystal system  monoclinic  
Space group  P21/n  
a/Å  8.4731(6)  
b/Å  12.5408(6)  
c/Å  21.0842(15)  
α/°  90  
β/°  92.469(2)  
γ/°  90  
Volume/Å3  2238.3(2)  
Z  4  
ρcalcg/cm3  1.642  
μ/mm-1  1.384  
F(000)  1108.0  
Crystal size/mm3  0.202 × 0.197 × 0.096  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  5.05 to 59.13  
Index ranges  -11 ≤ h ≤ 11, -17 ≤ k ≤ 17, -29 ≤ l ≤ 29  
Reflections collected  34568  
Independent reflections  6272 [Rint = 0.0256, Rsigma = 0.0191]  
Data/restraints/parameters  6272/0/269  
Goodness-of-fit on F2  1.276  
Final R indexes [I>=2σ (I)]  R1 = 0.0525, wR2 = 0.1074  
Final R indexes [all data]  R1 = 0.0545, wR2 = 0.1083  








Figure S21: Asymmetric unit of 116. 
 
CSD code  1842213 
Empirical formula  C22H30F6N3SSb  
Formula weight  604.30  
Temperature/K  100(2) 
Crystal system  monoclinic  
Space group  P21/n  
a/Å  8.3461(2)  
b/Å  12.7053(4)  
c/Å  22.9335(7)  
α/°  90  
β/°  90.1370(10)  
γ/°  90  
Volume/Å3  2431.85(12)  
Z  4  
ρcalcg/cm3  1.651  
μ/mm-1  1.282  
F(000)  1216.0  
Crystal size/mm3  0.291 × 0.169 × 0.096  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  5.19 to 70.092  
Index ranges  -13 ≤ h ≤ 13, -20 ≤ k ≤ 20, -37 ≤ l ≤ 37  
Reflections collected  47413  
Independent reflections  10652 [Rint = 0.0166, Rsigma = 0.0138]  
Data/restraints/parameters  10652/0/305  
Goodness-of-fit on F2  1.055  
Final R indexes [I>=2σ (I)]  R1 = 0.0187, wR2 = 0.0474  
Final R indexes [all data]  R1 = 0.0195, wR2 = 0.0479  








Figure S22: Asymmetric unit of 134. 
The methyl-aniline substituent is disordered about two positions. They were refined with distance 
restraints and restraints for the anisotropic displacement parameters. The occupancy of the minor 
position including N3B was refined to 0.24085 
  
Empirical formula  C18H28F6N3SSb  
Formula weight  554.24  
Temperature/K  100(2) 
Crystal system  monoclinic  
Space group  P21/n  
a/Å  8.5751(3)  
b/Å  11.8860(5)  
c/Å  21.7274(8)  
α/°  90  
β/°  92.4020(10)  
γ/°  90  
Volume/Å3  2212.59(15)  
Z  4  
ρcalcg/cm3  1.664  
μ/mm-1  1.400  
F(000)  1112.0  
Crystal size/mm3  0.534 × 0.487 × 0.249  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  5.038 to 61.076  
Index ranges  -12 ≤ h ≤ 11, -16 ≤ k ≤ 16, -29 ≤ l ≤ 31  
Reflections collected  50462  
Independent reflections  6723 [Rint = 0.0237, Rsigma = 0.0150]  
Data/restraints/parameters  6723/99/354  
Goodness-of-fit on F2  1.128  
Final R indexes [I>=2σ (I)]  R1 = 0.0224, wR2 = 0.0521  
Final R indexes [all data]  R1 = 0.0228, wR2 = 0.0524  







Figure S23: Asymmetric unit of 329. 
Due to the low scattering properties of the obtained crystal the Rint is high. It was not possible to measure 
the same crystal a second time with longer exposure times. One of the SbF6 anion is disordered by 
rotation of the F7-F8 axis. The overlapping anions were refined and restraints for the anisotropic 
displacement parameters. The occupancy of the minor position was refined to 0.13156 (F10, F12, F14, 
F16.) 
  
Empirical formula  C21H28F6N3SSb  
Formula weight  590.27  
Temperature/K  100(2) 
Crystal system  monoclinic  
Space group  P21/n  
a/Å  13.2399(8)  
b/Å  27.0374(15)  
c/Å  13.7406(8)  
α/°  90  
β/°  100.178(2)  
γ/°  90  
Volume/Å3  4841.4(5)  
Z  8  
ρcalcg/cm3  1.620  
μ/mm-1  1.285  
F(000)  2368.0  
Crystal size/mm3  0.222 × 0.214 × 0.064  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  4.26 to 52.824  
Index ranges  -16 ≤ h ≤ 16, -33 ≤ k ≤ 33, -17 ≤ l ≤ 17  
Reflections collected  125907  
Independent reflections  9920 [Rint = 0.1615, Rsigma = 0.0612]  
Data/restraints/parameters  9920/67/626  
Goodness-of-fit on F2  1.041  
Final R indexes [I>=2σ (I)]  R1 = 0.0524, wR2 = 0.0930  
Final R indexes [all data]  R1 = 0.0890, wR2 = 0.1089  






Figure S24: Asymmetric unit of 99. 
  
Empirical formula  C21H28F6N3SSb  
Formula weight  590.27  
Temperature/K  100(2) 
Crystal system  monoclinic  
Space group  P21/n  
a/Å  10.4709(4)  
b/Å  22.2447(7)  
c/Å  10.8000(4)  
α/°  90  
β/°  99.9630(10)  
γ/°  90  
Volume/Å3  2477.62(15)  
Z  4  
ρcalcg/cm3  1.582  
μ/mm-1  1.256  
F(000)  1184.0  
Crystal size/mm3  0.385 × 0.342 × 0.116  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  4.244 to 80.636  
Index ranges  -19 ≤ h ≤ 19, -40 ≤ k ≤ 40, -19 ≤ l ≤ 19  
Reflections collected  151537  
Independent reflections  15581 [Rint = 0.0333, Rsigma = 0.0165]  
Data/restraints/parameters  15581/0/295  
Goodness-of-fit on F2  1.031  
Final R indexes [I>=2σ (I)]  R1 = 0.0249, wR2 = 0.0579  
Final R indexes [all data]  R1 = 0.0302, wR2 = 0.0611  








Figure S25: Asymmetric unit of 138. 
Due to a phase transition of the crystal at lower temperatures data collection had to be carried out at an 
elevated temperature of 200 K causing increased thermal movement. 
  
Empirical formula  CNOFS2SbH0.13  
Formula weight  247.02  
Temperature/K  200(2) 
Crystal system  triclinic  
Space group  P-1  
a/Å  8.0772(3)  
b/Å  9.5091(3)  
c/Å  17.2074(7)  
α/°  80.5930(10)  
β/°  84.2550(10)  
γ/°  82.0220(10)  
Volume/Å3  1287.19(8)  
Z  8  
ρcalcg/cm3  2.549  
μ/mm-1  4.847  
F(000)  905.0  
Crystal size/mm3  0.256 × 0.174 × 0.12  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  4.376 to 61.104  
Index ranges  -11 ≤ h ≤ 11, -13 ≤ k ≤ 13, -24 ≤ l ≤ 24  
Reflections collected  137499  
Independent reflections  7879 [Rint = 0.0253, Rsigma = 0.0126]  
Data/restraints/parameters  7879/0/307  
Goodness-of-fit on F2  1.177  
Final R indexes [I>=2σ (I)]  R1 = 0.0403, wR2 = 0.1237  
Final R indexes [all data]  R1 = 0.0465, wR2 = 0.1416  







Figure S26: Asymmetric unit of 132. 
One hexafluoroantimonate anion is disordered about two positions. It is refined with distance restraints. 
The occupancy of the minor position (F9B to F12B) is refined to 0.49162. 
 
  
Empirical formula  C24H32F6N3SSb  
Formula weight  630.33  
Temperature/K  100(2) 
Crystal system  triclinic  
Space group  P-1  
a/Å  8.8424(4)  
b/Å  11.2732(8)  
c/Å  27.7533(19)  
α/°  79.465(2)  
β/°  84.329(2)  
γ/°  89.118(2)  
Volume/Å3  2706.6(3)  
Z  4  
ρcalcg/cm3  1.547  
μ/mm-1  1.155  
F(000)  1272.0  
Crystal size/mm3  0.43 × 0.2 × 0.076  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  4.214 to 62.898  
Index ranges  -12 ≤ h ≤ 12, -16 ≤ k ≤ 16, -40 ≤ l ≤ 40  
Reflections collected  92745  
Independent reflections  17894 [Rint = 0.0397, Rsigma = 0.0304]  
Data/restraints/parameters  17894/119/687  
Goodness-of-fit on F2  1.036  
Final R indexes [I>=2σ (I)]  R1 = 0.0353, wR2 = 0.0816  
Final R indexes [all data]  R1 = 0.0398, wR2 = 0.0844  






Figure S27: Asymmetric unit of 136-SP. 
 
One of the two SbF6 anions is disordered about two positions. It is refined with distance restraints and 
some of the anisotropic displacement parameters are constrained to be the same. The occupancy of 
the minor position refined to 0.185. The enclosed dichloromethane is disordered about two positions. 
The occupancy of the minor position refined to 0.498(18). A bridged hydrogen bond between N4 and 






Empirical formula  C26H40Cl2F12N4SSb2  
Formula weight  983.08  
Temperature/K  100(2) 
Crystal system  orthorhombic  
Space group  Pbca  
a/Å  17.5297(10)  
b/Å  13.1456(6)  
c/Å  31.3247(18)  
α/°  90  
β/°  90  
γ/°  90  
Volume/Å3  7218.4(7)  
Z  8  
ρcalcg/cm3  1.809  
μ/mm-1  1.790  
F(000)  3872.0  
Crystal size/mm3  0.601 × 0.266 × 0.076  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  4.648 to 59.224  
Index ranges  -24 ≤ h ≤ 20, -18 ≤ k ≤ 16, -41 ≤ l ≤ 43  
Reflections collected  56715  
Independent reflections  10102 [Rint = 0.0300, Rsigma = 0.0219]  
Data/restraints/parameters  10102/121/521  
Goodness-of-fit on F2  1.033  
Final R indexes [I>=2σ (I)]  R1 = 0.0375, wR2 = 0.0818  
Final R indexes [all data]  R1 = 0.0441, wR2 = 0.0854  








Figure S28: Asymmetric unit of 136. 
 
One of the two SbF6 anions is disordered about two positions. The occupancy of the minor position 
refined to 0.185. The enclosed dichloromethane is disordered about two positions. The occupancy of 
the minor position refined to 0.46695. A bridged hydrogen bond between N1 and N2 is observable. 136 







Empirical formula  C25H38F12N4SSb2  
Formula weight  898.15  
Temperature/K  100(2) 
Crystal system  orthorhombic  
Space group  Pca21  
a/Å  17.2749(8)  
b/Å  7.9258(3)  
c/Å  24.4029(11)  
α/°  90  
β/°  90  
γ/°  90  
Volume/Å3  3341.2(3)  
Z  4  
ρcalcg/cm3  1.785  
μ/mm-1  1.769  
F(000)  1768.0  
Crystal size/mm3  0.511 × 0.311 × 0.256  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  4.716 to 59.23  
Index ranges  -23 ≤ h ≤ 23, -10 ≤ k ≤ 9, -32 ≤ l ≤ 33  
Reflections collected  52887  
Independent reflections  9307 [Rint = 0.0213, Rsigma = 0.0156]  
Data/restraints/parameters  9307/1/445  
Goodness-of-fit on F2  1.035  
Final R indexes [I>=2σ (I)]  R1 = 0.0238, wR2 = 0.0601  
Final R indexes [all data]  R1 = 0.0243, wR2 = 0.0605  
Largest diff. peak/hole / e Å-3  1.15/-0.68  






5.8.4 Structure of thioethers 
Structure of 170 
 
Figure S29: Asymmetric unit of 170. 
 
 
CSD code  1842212 
Empirical formula  C17H12N2S2  
Formula weight  308.41  
Temperature/K  100(2) 
Crystal system  monoclinic  
Space group  P21/n  
a/Å  12.9549(12)  
b/Å  5.7904(6)  
c/Å  19.3714(18)  
α/°  90  
β/°  97.300(4)  
γ/°  90  
Volume/Å3  1441.3(2)  
Z  4  
ρcalcg/cm3  1.421  
μ/mm-1  0.362  
F(000)  640.0  
Crystal size/mm3  0.293 × 0.21 × 0.035  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  6.342 to 61.012  
Index ranges  -18 ≤ h ≤ 16, -8 ≤ k ≤ 8, -27 ≤ l ≤ 27  
Reflections collected  26393  
Independent reflections  4386 [Rint = 0.0204, Rsigma = 0.0150]  
Data/restraints/parameters  4386/0/190  
Goodness-of-fit on F2  1.059  
Final R indexes [I>=2σ (I)]  R1 = 0.0268, wR2 = 0.0726  
Final R indexes [all data]  R1 = 0.0282, wR2 = 0.0738  








Figure S30: Asymmetric unit of 87with one highly disordered dichloromethane molecule. 
The dichloromethane molecule was disordered about two positions. The occupancy of the minor position 
refined to 0.084(3). 
 
CSD code  1842203 
Empirical formula  C35H32Cl2N2O8S2  
Formula weight  743.64  
Temperature/K  100(2) 
Crystal system  triclinic  
Space group  P-1  
a/Å  11.0578(8)  
b/Å  11.8434(9)  
c/Å  13.5784(8)  
α/°  87.855(2)  
β/°  81.169(3)  
γ/°  71.873(2)  
Volume/Å3  1669.9(2)  
Z  2  
ρcalcg/cm3  1.479  
μ/mm-1  0.376  
F(000)  772.0  
Crystal size/mm3  0.394 × 0.158 × 0.054  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  4.438 to 59.202  
Index ranges  -15 ≤ h ≤ 15, -16 ≤ k ≤ 16, -18 ≤ l ≤ 18  
Reflections collected  52316  
Independent reflections  9391 [Rint = 0.0202, Rsigma = 0.0165]  
Data/restraints/parameters  9391/21/478  
Goodness-of-fit on F2  1.033  
Final R indexes [I>=2σ (I)]  R1 = 0.0285, wR2 = 0.0751  
Final R indexes [all data]  R1 = 0.0299, wR2 = 0.0761  







Figure S31: Asymmetric unit of 168. 
The phenyl rings of the 1-phenylpyrrole are disordered about two positions. They were refined with a 
fitted hexagon as free rotating group (C24B[C23,C22B,C21B,C20,C25B]) and restraints for the 
anisotropic displacement parameters. The occupancy of the minor position was refined to 0.068(3). 
 
CSD code  1842201 
Empirical formula  C25H19NOS  
Formula weight  381.47  
Temperature/K  100(2) 
Crystal system  monoclinic  
Space group  P21  
a/Å  5.9190(8)  
b/Å  7.7752(8)  
c/Å  21.527(2)  
α/°  90  
β/°  95.175(5)  
γ/°  90  
Volume/Å3  986.6(2)  
Z  2  
ρcalcg/cm3  1.284  
μ/mm-1  0.179  
F(000)  400.0  
Crystal size/mm3  0.37 × 0.325 × 0.052  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  5.574 to 63.09  
Index ranges  -8 ≤ h ≤ 8, -11 ≤ k ≤ 11, -31 ≤ l ≤ 31  
Reflections collected  38446  
Independent reflections  6609 [Rint = 0.0260, Rsigma = 0.0194]  
Data/restraints/parameters  6609/1/255  
Goodness-of-fit on F2  1.070  
Final R indexes [I>=2σ (I)]  R1 = 0.0314, wR2 = 0.0840  
Final R indexes [all data]  R1 = 0.0331, wR2 = 0.0855  
Largest diff. peak/hole / e Å-3  0.33/-0.21  








Figure S32: Asymmetric unit of 163. 
The completeness of the dataset is low (88%) due to very low scattering abilities of the crystal especially 
at higher angles when each frame was recorded with a frame time of 100s. 
 
CSD code  1842209 
Empirical formula  C17H12N2S  
Formula weight  276.35  
Temperature/K  100(2) 
Crystal system  monoclinic  
Space group  P21/n  
a/Å  14.139(3)  
b/Å  6.0096(12)  
c/Å  16.475(4)  
α/°  90  
β/°  90.480(6)  
γ/°  90  
Volume/Å3  1399.8(5)  
Z  4  
ρcalcg/cm3  1.311  
μ/mm-1  0.221  
F(000)  576.0  
Crystal size/mm3  0.256 × 0.085 × 0.035  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  4.946 to 53.996  
Index ranges  -18 ≤ h ≤ 17, -7 ≤ k ≤ 5, -21 ≤ l ≤ 21  
Reflections collected  5768  
Independent reflections  2666 [Rint = 0.0348, Rsigma = 0.0556]  
Data/restraints/parameters  2666/0/181  
Goodness-of-fit on F2  1.013  
Final R indexes [I>=2σ (I)]  R1 = 0.0458, wR2 = 0.1068  
Final R indexes [all data]  R1 = 0.0722, wR2 = 0.1196  








Figure S33: Asymmetric unit of 162. 
 
CSD code  1842211 
Empirical formula  C16H12FNS  
Formula weight  269.33  
Temperature/K  100(2) 
Crystal system  triclinic  
Space group  P-1  
a/Å  9.0400(6)  
b/Å  9.3397(7)  
c/Å  9.4356(5)  
α/°  112.285(2)  
β/°  101.900(2)  
γ/°  106.502(2)  
Volume/Å3  661.07(8)  
Z  2  
ρcalcg/cm3  1.353  
μ/mm-1  0.240  
F(000)  280.0  
Crystal size/mm3  0.317 × 0.304 × 0.224  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  4.988 to 61.05  
Index ranges  -12 ≤ h ≤ 12, -13 ≤ k ≤ 13, -13 ≤ l ≤ 13  
Reflections collected  20832  
Independent reflections  4030 [Rint = 0.0195, Rsigma = 0.0153]  
Data/restraints/parameters  4030/0/172  
Goodness-of-fit on F2  1.033  
Final R indexes [I>=2σ (I)]  R1 = 0.0312, wR2 = 0.0830  
Final R indexes [all data]  R1 = 0.0328, wR2 = 0.0844  






5.8.5 Structure of aryltriazolium salts 
Structure 210 
 
Figure S34: Asymmetric unit of 210. 
  
Empirical formula  C18H23F6N4SSb  
Formula weight  563.21  
Temperature/K  100(2) 
Crystal system  tetragonal  
Space group  P41  
a/Å  8.5569(4)  
b/Å  8.5569(4)  
c/Å  30.0518(13)  
α/°  90  
β/°  90  
γ/°  90  
Volume/Å3  2200.4(2)  
Z  4  
ρcalcg/cm3  1.700  
μ/mm-1  1.411  
F(000)  1120.0  
Crystal size/mm3  0.448 × 0.399 × 0.064  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  4.76 to 59.16  
Index ranges  -11 ≤ h ≤ 11, -11 ≤ k ≤ 11, -41 ≤ l ≤ 41  
Reflections collected  21863  
Independent reflections  6160 [Rint = 0.0386, Rsigma = 0.0368]  
Data/restraints/parameters  6160/1/275  
Goodness-of-fit on F2  1.090  
Final R indexes [I>=2σ (I)]  R1 = 0.0194, wR2 = 0.0459  
Final R indexes [all data]  R1 = 0.0197, wR2 = 0.0461  
Largest diff. peak/hole / e Å-3  0.27/-0.49  









Figure S35: Asymmetric unit of 300. 
The hydrogen bond between N4 and F4 results in N4-F4 distance of 2.860 Å as well as in an elongation 
of the Sb1-F4-bond (1.888(1)Å) compared to the average of the other Sb-F-bonds (1.864Å). 
 
  
Empirical formula  C21H29F6N4O4SSb  
Formula weight  669.29  
Temperature/K  100(2)  
Crystal system  monoclinic  
Space group  P21/c  
a/Å  10.9060(9)  
b/Å  11.8738(12)  
c/Å  20.949(2)  
α/°  90  
β/°  99.768(3)  
γ/°  90  
Volume/Å3  2673.5(4)  
Z  4  
ρcalcg/cm3  1.663  
μ/mm-1  1.186  
F(000)  1344.0  
Crystal size/mm3  0.288 × 0.059 × 0.048  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  4.986 to 63.098  
Index ranges  -16 ≤ h ≤ 15, -17 ≤ k ≤ 17, -30 ≤ l ≤ 30  
Reflections collected  54251  
Independent reflections  8930 [Rint = 0.0234, Rsigma = 0.0162]  
Data/restraints/parameters  8930/1/344  
Goodness-of-fit on F2  1.145  
Final R indexes [I>=2σ (I)]  R1 = 0.0249, wR2 = 0.0562  
Final R indexes [all data]  R1 = 0.0275, wR2 = 0.0573  




5.8.6 Additional structures 
Structure 301 
 
Figure S36: Asymmetric unit of 301. 
 
CSD code  1843380 
Empirical formula  C17H25BrO  
Formula weight  325.28  
Temperature/K  99.99  
Crystal system  orthorhombic  
Space group  P212121  
a/Å  6.3330(2)  
b/Å  7.9935(3)  
c/Å  31.5153(12)  
α/°  90  
β/°  90  
γ/°  90  
Volume/Å3  1595.39(10)  
Z  4  
ρcalcg/cm3  1.354  
μ/mm-1  2.568  
F(000)  680.0  
Crystal size/mm3  0.483 × 0.445 × 0.25  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  5.17 to 65.17  
Index ranges  -9 ≤ h ≤ 9, -12 ≤ k ≤ 12, -47 ≤ l ≤ 46  
Reflections collected  21580  
Independent reflections  5807 [Rint = 0.0233, Rsigma = 0.0222]  
Data/restraints/parameters  5807/0/175  
Goodness-of-fit on F2  1.050  
Final R indexes [I>=2σ (I)]  R1 = 0.0230, wR2 = 0.0516  
Final R indexes [all data]  R1 = 0.0255, wR2 = 0.0524  
Largest diff. peak/hole / e Å-3  0.34/-0.39  








Figure S37: Two asymmetric unit of 330 generated by symmetry element [2-X,1-Y,1-Z]. 
 
  
Empirical formula  C34H26N2O6S2  
Formula weight  622.69  
Temperature/K  100(2) 
Crystal system  monoclinic  
Space group  P21/c  
a/Å  6.0491(3)  
b/Å  19.1171(9)  
c/Å  12.1059(5)  
α/°  90  
β/°  99.251(2)  
γ/°  90  
Volume/Å3  1381.73(11)  
Z  2  
ρcalcg/cm3  1.497  
μ/mm-1  0.247  
F(000)  648.0  
Crystal size/mm3  ? × ? × ?  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  5.458 to 54.276  
Index ranges  -7 ≤ h ≤ 7, -24 ≤ k ≤ 24, -15 ≤ l ≤ 15  
Reflections collected  40746  
Independent reflections  3064 [Rint = 0.0337, Rsigma = 0.0148]  
Data/restraints/parameters  3064/0/201  
Goodness-of-fit on F2  1.083  
Final R indexes [I>=2σ (I)]  R1 = 0.0347, wR2 = 0.0816  
Final R indexes [all data]  R1 = 0.0385, wR2 = 0.0836  







5.8.7 Structure of arylselenoimidazolium salts 
Structure 217 
 
Figure S38: Asymmetric unit of 217 containing one dichloromethane molecule. 
 
CSD code  1844013 
Empirical formula  C20H32Cl2F6N3SbSe  
Formula weight  700.09  
Temperature/K  150(2)  
Crystal system  orthorhombic  
Space group  P212121  
a/Å  9.2925(4)  
b/Å  10.8514(5)  
c/Å  27.7046(13)  
α/°  90  
β/°  90  
γ/°  90  
Volume/Å3  2793.6(2)  
Z  4  
ρcalcg/cm3  1.665  
μ/mm-1  2.535  
F(000)  1384.0  
Crystal size/mm3  0.643 × 0.456 × 0.088  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  4.032 to 59.32  
Index ranges  -12 ≤ h ≤ 12, -14 ≤ k ≤ 15, -38 ≤ l ≤ 38  
Reflections collected  52383  
Independent reflections  7868 [Rint = 0.0374, Rsigma = 0.0248]  
Data/restraints/parameters  7868/0/307  
Goodness-of-fit on F2  1.065  
Final R indexes [I>=2σ (I)]  R1 = 0.0346, wR2 = 0.0975  
Final R indexes [all data]  R1 = 0.0365, wR2 = 0.0989  
Largest diff. peak/hole / e Å-3  0.81/-0.93  






5.8.8 Structure of imidazolthioether 
Structure 232 
 
Figure S39: Asymmetric unit of 232 containing one molecule dichloromethane. 
 
232 crystalized as a twin. The interaction of the positive polarized sulfur atom and the nearest chloride 
anion result in an average distance between S-Cl  is 3.084Å. [Summe(v.-d.-Waals):3.55Å][296]. 
  
Empirical formula  C34H44Cl5N9O12S3  
Formula weight  1044.21  
Temperature/K  100(2) 
Crystal system  triclinic  
Space group  P-1  
a/Å  11.205(3)  
b/Å  14.007(3)  
c/Å  16.650(3)  
α/°  67.291(5)  
β/°  89.525(7)  
γ/°  71.495(7)  
Volume/Å3  2266.5(8)  
Z  2  
ρcalcg/cm3  1.530  
μ/mm-1  0.527  
F(000)  1080.0  
Crystal size/mm3  0.317 × 0.188 × 0.058  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  4.404 to 57.296  
Index ranges  -15 ≤ h ≤ 15, -17 ≤ k ≤ 18, 0 ≤ l ≤ 22  
Reflections collected  11527  
Independent reflections  11527 [Rint = ?, Rsigma = 0.0213]  
Data/restraints/parameters  11527/0/575  
Goodness-of-fit on F2  1.060  
Final R indexes [I>=2σ (I)]  R1 = 0.0307, wR2 = 0.0739  
Final R indexes [all data]  R1 = 0.0343, wR2 = 0.0761  







Figure S40: Asymmetric unit of 237. 
 
  
Empirical formula  C12H15N3S  
Formula weight  233.33  
Temperature/K  100(2)  
Crystal system  monoclinic  
Space group  P21/c  
a/Å  13.6491(10)  
b/Å  7.4013(5)  
c/Å  11.4104(6)  
α/°  90  
β/°  92.807(3)  
γ/°  90  
Volume/Å3  1151.31(13)  
Z  4  
ρcalcg/cm3  1.346  
μ/mm-1  0.256  
F(000)  496.0  
Crystal size/mm3  0.396 × 0.255 × 0.088  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  5.976 to 59.172  
Index ranges  -18 ≤ h ≤ 18, -10 ≤ k ≤ 10, -15 ≤ l ≤ 14  
Reflections collected  24847  
Independent reflections  3198 [Rint = 0.0226, Rsigma = 0.0134]  
Data/restraints/parameters  3198/0/148  
Goodness-of-fit on F2  1.041  
Final R indexes [I>=2σ (I)]  R1 = 0.0292, wR2 = 0.0789  
Final R indexes [all data]  R1 = 0.0314, wR2 = 0.0810  








Figure S41: Asymmetric unit of 235. 
 
  
Empirical formula  C15H15N3S  
Formula weight  269.36  
Temperature/K  100(2) 
Crystal system  monoclinic  
Space group  P21/c  
a/Å  11.5161(16)  
b/Å  9.7152(15)  
c/Å  11.8038(14)  
α/°  90  
β/°  102.249(5)  
γ/°  90  
Volume/Å3  1290.6(3)  
Z  4  
ρcalcg/cm3  1.386  
μ/mm-1  0.239  
F(000)  568.0  
Crystal size/mm3  0.476 × 0.42 × 0.108  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  5.482 to 59.204  
Index ranges  -15 ≤ h ≤ 15, -13 ≤ k ≤ 13, -16 ≤ l ≤ 15  
Reflections collected  17877  
Independent reflections  3590 [Rint = 0.0284, Rsigma = 0.0214]  
Data/restraints/parameters  3590/0/173  
Goodness-of-fit on F2  1.039  
Final R indexes [I>=2σ (I)]  R1 = 0.0311, wR2 = 0.0787  
Final R indexes [all data]  R1 = 0.0346, wR2 = 0.0817  





Structure 234 NHS 
 
Figure S42: Asymmetric unit of 234 NHS. 
 
  
Empirical formula  C23H22N4O2S  
Formula weight  418.50  
Temperature/K  100(2) 
Crystal system  monoclinic  
Space group  P21/c  
a/Å  13.7652(14)  
b/Å  8.3479(7)  
c/Å  17.6642(18)  
α/°  90  
β/°  97.550(3)  
γ/°  90  
Volume/Å3  2012.2(3)  
Z  4  
ρcalcg/cm3  1.381  
μ/mm-1  0.190  
F(000)  880.0  
Crystal size/mm3  0.667 × 0.345 × 0.254  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  4.652 to 61.06  
Index ranges  -19 ≤ h ≤ 19, -11 ≤ k ≤ 11, -24 ≤ l ≤ 25  
Reflections collected  51129  
Independent reflections  6120 [Rint = 0.0249, Rsigma = 0.0154]  
Data/restraints/parameters  6120/0/276  
Goodness-of-fit on F2  1.065  
Final R indexes [I>=2σ (I)]  R1 = 0.0338, wR2 = 0.0928  
Final R indexes [all data]  R1 = 0.0355, wR2 = 0.0942  








Figure S43: Asymmetric unit of 239. 
 
  
Empirical formula  C13H16N2O3S  
Formula weight  280.34  
Temperature/K  100(2) 
Crystal system  triclinic  
Space group  P-1  
a/Å  7.9206(5)  
b/Å  12.8647(8)  
c/Å  14.0093(8)  
α/°  69.954(2)  
β/°  88.577(2)  
γ/°  82.141(2)  
Volume/Å3  1328.05(14)  
Z  4  
ρcalcg/cm3  1.402  
μ/mm-1  0.249  
F(000)  592.0  
Crystal size/mm3  0.406 × 0.269 × 0.231  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  5.194 to 57.46  
Index ranges  -10 ≤ h ≤ 10, -17 ≤ k ≤ 17, -18 ≤ l ≤ 18  
Reflections collected  44288  
Independent reflections  6864 [Rint = 0.0190, Rsigma = 0.0133]  
Data/restraints/parameters  6864/0/351  
Goodness-of-fit on F2  1.043  
Final R indexes [I>=2σ (I)]  R1 = 0.0267, wR2 = 0.0724  
Final R indexes [all data]  R1 = 0.0277, wR2 = 0.0732  








Figure S44: Asymmetric unit of 233. 
 
  
Empirical formula  C13H13N3S  
Formula weight  243.32  
Temperature/K  100  
Crystal system  monoclinic  
Space group  P21/c  
a/Å  10.9446(3)  
b/Å  10.4950(3)  
c/Å  11.1756(3)  
α/°  90  
β/°  114.0750(10)  
γ/°  90  
Volume/Å3  1172.01(6)  
Z  4  
ρcalcg/cm3  1.379  
μ/mm-1  0.255  
F(000)  512.0  
Crystal size/mm3  0.337 × 0.283 × 0.102  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  5.63 to 61.052  
Index ranges  -15 ≤ h ≤ 15, -14 ≤ k ≤ 15, -15 ≤ l ≤ 15  
Reflections collected  41743  
Independent reflections  3572 [Rint = 0.0199, Rsigma = 0.0114]  
Data/restraints/parameters  3572/0/156  
Goodness-of-fit on F2  1.058  
Final R indexes [I>=2σ (I)]  R1 = 0.0287, wR2 = 0.0757  
Final R indexes [all data]  R1 = 0.0297, wR2 = 0.0765  






5.8.9 Structure of other heterocyclic backbones 
Structure 258 
 
Figure S45: Asymmetric unit of 258. 
258 forms hydrogen bond bridged dimers in the solid state between N1H and S2 which is accessible 
by the symmetry operation [-1+X,3/2-Y,1/2+Z]. 
  
Empirical formula  C8H7N3S  
Formula weight  177.23  
Temperature/K  100(2)  
Crystal system  monoclinic  
Space group  P21/c  
a/Å  6.0142(6)  
b/Å  14.1041(11)  
c/Å  10.1918(8)  
α/°  90  
β/°  98.841(3)  
γ/°  90  
Volume/Å3  854.25(13)  
Z  4  
ρcalcg/cm3  1.378  
μ/mm-1  0.322  
F(000)  368.0  
Crystal size/mm3  0.277 × 0.084 × 0.073  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  4.97 to 52.778  
Index ranges  -7 ≤ h ≤ 7, -15 ≤ k ≤ 17, -12 ≤ l ≤ 12  
Reflections collected  5371  
Independent reflections  1717 [Rint = 0.0701, Rsigma = 0.0705]  
Data/restraints/parameters  1717/0/137  
Goodness-of-fit on F2  1.091  
Final R indexes [I>=2σ (I)]  R1 = 0.0478, wR2 = 0.0854  
Final R indexes [all data]  R1 = 0.0724, wR2 = 0.0979  




5.8.10 Structure of tetramethylthiourea adducts 
The following structures are included for the sake of completeness of data but are not 
discussed in this thesis. 
Structure 315 
 
Figure S46: Asymmetric unit of 315. 
 
  
Empirical formula  C20H24F6N3SSb  
Formula weight  574.23  
Temperature/K  100(2)  
Crystal system  monoclinic  
Space group  P21/n  
a/Å  10.9954(4)  
b/Å  15.1752(5)  
c/Å  14.1479(5)  
α/°  90  
β/°  107.5950(10)  
γ/°  90  
Volume/Å3  2250.24(14)  
Z  4  
ρcalcg/cm3  1.695  
μ/mm-1  1.380  
F(000)  1144.0  
Crystal size/mm3  0.155 × 0.087 × 0.073  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  4.724 to 61.164  
Index ranges  -15 ≤ h ≤ 15, -21 ≤ k ≤ 21, -20 ≤ l ≤ 20  
Reflections collected  94108  
Independent reflections  6920 [Rint = 0.0318, Rsigma = 0.0132]  
Data/restraints/parameters  6920/0/285  
Goodness-of-fit on F2  0.746  
Final R indexes [I>=2σ (I)]  R1 = 0.0191, wR2 = 0.0777  
Final R indexes [all data]  R1 = 0.0228, wR2 = 0.0844  




5.8.11 Struture of further reagents and products 
Structure 269 
 
Figure S47: Asymmetric unit of 269 containing two dichloromethane molecules. 
The distance of N1 and the C19 of the nearest dichloromethane molecule of 3.075Å indicates N-HC 
interactions of the switterionic compound 269 and the dichloromethane.  Both dichloromethane 
molecules are disordered about  two  positions.  They are refined with some restrained anisotropic 
displacement parameters. The occupancies of the minor positions are refined to 0.08997 (Cl12B) and 






Empirical formula  C20H31Cl4N3O2S2  
Formula weight  551.40  
Temperature/K  100(2)  
Crystal system  triclinic  
Space group  P-1  
a/Å  9.8104(5)  
b/Å  10.3280(6)  
c/Å  14.4043(8)  
α/°  101.815(2)  
β/°  106.662(2)  
γ/°  94.336(2)  
Volume/Å3  1354.46(13)  
Z  2  
ρcalcg/cm3  1.352  
μ/mm-1  0.613  
F(000)  576.0  
Crystal size/mm3  0.418 × 0.236 × 0.161  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  4.466 to 63.11  
Index ranges  -14 ≤ h ≤ 14, -15 ≤ k ≤ 15, -21 ≤ l ≤ 21  
Reflections collected  49416  
Independent reflections  9042 [Rint = 0.0230, Rsigma = 0.0198]  
Data/restraints/parameters  9042/24/307  
Goodness-of-fit on F2  1.033  
Final R indexes [I>=2σ (I)]  R1 = 0.0304, wR2 = 0.0818  
Final R indexes [all data]  R1 = 0.0322, wR2 = 0.0831  








Figure S 48: Asymmetric unit of 275. 
 
  
Empirical formula  C12H17NO2S2  
Formula weight  271.38  
Temperature/K  100(2)  
Crystal system  monoclinic  
Space group  P21/n  
a/Å  5.0837(10)  
b/Å  19.708(4)  
c/Å  13.403(2)  
α/°  90  
β/°  100.063(5)  
γ/°  90  
Volume/Å3  1322.2(4)  
Z  4  
ρcalcg/cm3  1.363  
μ/mm-1  0.392  
F(000)  576.0  
Crystal size/mm3  0.413 × 0.066 × 0.038  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  5.16 to 63.006  
Index ranges  -7 ≤ h ≤ 7, -28 ≤ k ≤ 28, -19 ≤ l ≤ 17  
Reflections collected  29571  
Independent reflections  4394 [Rint = 0.0256, Rsigma = 0.0167]  
Data/restraints/parameters  4394/0/159  
Goodness-of-fit on F2  1.058  
Final R indexes [I>=2σ (I)]  R1 = 0.0278, wR2 = 0.0761  
Final R indexes [all data]  R1 = 0.0311, wR2 = 0.0784  








Figure S49: Asymmetric unit of 306 after symmetry operation [+X,1/2-Y,+Z]. 
306 lays on a mirror plane located through S1, S2 and S4. The TfN-group is disordered about two 
positions over the mirror plane. 
 
  
Empirical formula  C12H20F3N3O2S2  
Formula weight  359.43  
Temperature/K  100(2)  
Crystal system  orthorhombic  
Space group  Pnma  
a/Å  21.4772(9)  
b/Å  15.1570(8)  
c/Å  9.9949(5)  
α/°  90  
β/°  90  
γ/°  90  
Volume/Å3  3253.6(3)  
Z  8  
ρcalcg/cm3  1.468  
μ/mm-1  0.367  
F(000)  1504.0  
Crystal size/mm3  0.432 × 0.134 × 0.104  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  4.494 to 61.024  
Index ranges  -30 ≤ h ≤ 30, -21 ≤ k ≤ 21, -14 ≤ l ≤ 14  
Reflections collected  54470  
Independent reflections  5118 [Rint = 0.0377, Rsigma = 0.0176]  
Data/restraints/parameters  5118/0/271  
Goodness-of-fit on F2  1.045  
Final R indexes [I>=2σ (I)]  R1 = 0.0491, wR2 = 0.1129  
Final R indexes [all data]  R1 = 0.0589, wR2 = 0.1204  








Figure S50: Asymmetric unit of 309. 
The hydrogen bond between N1 and O3 results in N1-O3 distance of 2.599 Å. 
  
Empirical formula  C13H11N3O6S  
Formula weight  337.31  
Temperature/K  100(2) 
Crystal system  monoclinic  
Space group  P21/c  
a/Å  7.9828(15)  
b/Å  16.640(3)  
c/Å  10.691(3)  
α/°  90  
β/°  98.939(12)  
γ/°  90  
Volume/Å3  1402.9(5)  
Z  4  
ρcalcg/cm3  1.597  
μ/mm-1  0.269  
F(000)  696.0  
Crystal size/mm3  0.268 × 0.072 × 0.036  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  5.166 to 57.388  
Index ranges  -10 ≤ h ≤ 10, -22 ≤ k ≤ 22, -14 ≤ l ≤ 12  
Reflections collected  20454  
Independent reflections  3618 [Rint = 0.0308, Rsigma = 0.0218]  
Data/restraints/parameters  3618/0/212  
Goodness-of-fit on F2  1.055  
Final R indexes [I>=2σ (I)]  R1 = 0.0326, wR2 = 0.0787  
Final R indexes [all data]  R1 = 0.0373, wR2 = 0.0814  










5.8.12 Studies of dibenzothiophene-based structure 
The following structures are included for the sake of completeness of data but are not 
discussed in this thesis. 
Structure 323 
 
Figure S51: Asymmetric unit of 323 containing four dichloromethane molecules. Two dichloromethane molecules 
are emitted for clarity.  
Two of the four dichloromethane molecules in the asymmetric unit are disordered about two positions. 
and are emitted in Figure S51. They are is refined with distance restraints and some of the anisotropic 






Empirical formula  C23H22.01Cl4.01F6N2O6S3  
Formula weight  774.68  
Temperature/K  100(2) 
Crystal system  triclinic  
Space group  P-1  
a/Å  12.4396(18)  
b/Å  16.799(2)  
c/Å  17.184(3)  
α/°  103.843(6)  
β/°  102.712(5)  
γ/°  106.394(7)  
Volume/Å3  3181.5(8)  
Z  4  
ρcalcg/cm3  1.617  
μ/mm-1  0.646  
F(000)  1569.0  
Crystal size/mm3  0.735 × 0.141 × 0.1  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  4.824 to 61.104  
Index ranges  -15 ≤ h ≤ 17, -24 ≤ k ≤ 22, -24 ≤ l ≤ 24  
Reflections collected  64517  
Independent reflections  19403 [Rint = 0.0264, Rsigma = 0.0281]  
Data/restraints/parameters  19403/49/874  
Goodness-of-fit on F2  1.025  
Final R indexes [I>=2σ (I)]  R1 = 0.0403, wR2 = 0.1062  
Final R indexes [all data]  R1 = 0.0487, wR2 = 0.1117  



















Synthesis of backbones and reagents 
1H NMR (300 MHz, CDCl3) 78 
 











1H NMR (300 MHz, CD2Cl2) 91 
 





1H NMR (300 MHz, CD2Cl2) 93 
 





1H NMR (300 MHz, CD2Cl2) 295  
 





1H NMR (300 MHz, CD3CN) 92  
 





1H NMR (300 MHz, CDCl3) 94  
 





1H NMR (300 MHz, CDCl3) 90 
 





1H NMR (400 MHz, CD2Cl2) 296  
 











Screening of different backbones 
1H NMR (400 MHz, CD2Cl2) 111  
 





1H NMR (300 MHz, CD2Cl2) 108 
 





1H NMR (300 MHz, CD2Cl2) 104 
 





1H NMR (300 MHz, CD2Cl2) 109 
 





1H NMR (300 MHz, CD2Cl2) 103 
 





1H NMR (300 MHz, CD2Cl2) 107a 
 





Synthesis of arylthiazolium salts 
1H NMR (300 MHz, CD2Cl2) 113 
 





1H NMR (300 MHz, CD2Cl2) 99 
 





1H NMR (300 MHz, CD2Cl2) 114 
 





1H NMR (400 MHz, CD2Cl2) 100 
 





1H NMR (600 MHz, CD2Cl2) 115 
 





1H NMR (400 MHz, CD2Cl2) 117 
 





1H NMR (400 MHz, CD2Cl2) 118 
 





1H NMR (300 MHz, CD2Cl2) 116 
 





1H NMR (300 MHz, CD2Cl2) 122 
 





1H NMR (300 MHz, CD2Cl2) 123 
 





1H NMR (300 MHz, CD2Cl2) 129  
 





1H NMR (300 MHz, CD2Cl2) 119 
 





1H NMR (300 MHz, CD2Cl2) 132 
 





1H NMR (300 MHz, CD2Cl2) 131 
 





1H NMR (300 MHz, CD2Cl2) 130 
 





1H NMR (300 MHz, CD2Cl2) 137 
 





1H NMR (300 MHz, CD2Cl2) 136 
 






1H NMR (400 MHz, CD2Cl2) 138 
 





1H NMR (300 MHz, CD3CN) 201 
 










1H NMR (300 MHz, CD2Cl2) 299 
 





1H NMR (400 MHz, CD2Cl2) 151 
 





Synthesis of aryltriazolium salts 
1H NMR (400 MHz, CD2Cl2) 300  
 





1H NMR (400 MHz, CD2Cl2) 105  
 





1H NMR (400 MHz, CD2Cl2) 211 
 





Synthesis of ansymmetrical sulfides 
1H NMR (400 MHz, CDCl3) 301 
 





1H NMR (400 MHz, CDCl3) 302 
 






1H NMR (600 MHz, CDCl3) 303 
 





1H NMR (300 MHz, CDCl3) 161 
 





1H NMR (300 MHz, CDCl3) 162 
 











1H NMR (300 MHz, CDCl3) 163 
 





1H NMR (600 MHz, CDCl3) 164 
 





1H NMR (400 MHz, CDCl3) 165   
 





1H NMR (600 MHz, CD2Cl2) 167 
 





1H NMR (300 MHz, CDCl3) 169 
 





1H NMR (600 MHz, CDCl3) 166 
 





1H NMR (600 MHz, CDCl3) 168 
 





1H NMR (300 MHz, CD3CN) 170 
 





1H NMR (300 MHz, CDCl3) 172 
 






1H NMR (300 MHz, CDCl3) 171 
 





1H NMR (400 MHz, CDCl3) 157 
 





1H NMR (600 MHz, CD3CN) 175 
 





1H NMR (400 MHz, CD2Cl2) 87 
 





1H NMR (300 MHz, CD2Cl2) 176 
 





1H NMR (400 MHz, CDCl3) 186 
 





1H NMR (300 MHz, CDCl3) 190 
 





1H NMR (300 MHz, CDCl3) 179 
 











1H NMR (300 MHz, CDCl3) 160 
 





1H NMR (300 MHz, CDCl3) 187 
 





1H NMR (400 MHz, CDCl3) 184 
 





1H NMR (300 MHz, CDCl3) 191 
 





1H NMR (600 MHz, CDCl3) 192 
 






1H NMR (300 MHz, CD2Cl2) 193 
 





1H NMR (300 MHz, CDCl3) 195 
 





1H NMR (400 MHz, CDCl3) 196 
 





1H NMR (300 MHz, CD2Cl2) 197 
 





1H NMR (400 MHz, CDCl3) 198 
 





1H NMR (300 MHz, CDCl3) 182 
 












1H NMR (300 MHz, CDCl3) 182 
 






1H NMR (300 MHz, CDCl3) 200 
 





1H NMR (400 MHz, CDCl3) 194 
 





1H NMR (400 MHz, CDCl3) 173 
 





1H NMR (300 MHz, CD2Cl2) 184 
 





1H NMR (300 MHz, CDCl3) 88 
 





  1H NMR (400 MHz, CDCl3) 86 
 






Synthesis of arylselenoimidazolium salts 
 





1H NMR (300 MHz, CD2Cl2) 215 
 






1H NMR (300 MHz, CD2Cl2) 216 
 





1H NMR (300 MHz, CD2Cl2) 217 
 






Synthesis of unsymmetrical selenides 
1H NMR (300 MHz, CD2Cl2) 218 
 











1H NMR (300 MHz, CD2Cl2) 219 
 










1H NMR (300 MHz, CDCl3) 220 
 











1H NMR (300 MHz, CD2Cl2) 221 
 











Synthesis of imidazole thioether 
1H NMR (400 MHz, CDCl3) 231 
 





1H NMR (400 MHz, CD3CN) 237 
 






1H NMR (400 MHz, CD3CN) 233 
 





1H NMR (400 MHz, CD3CN) 234 
 






1H NMR (400 MHz, CD2Cl2) 236 
 






1H NMR (400 MHz, CD3CN) 240 
 





1H NMR (400 MHz, CD3CN) 239 
 





1H NMR (400 MHz, CD3CN) 238 
 





1H NMR (400 MHz, CD3CN) 235 
 





1H NMR (400 MHz, CD3CN) 241 
 





Synthesis of sulfur containing precursors 
1H NMR (300 MHz, CDCl3) 258 
  





1H NMR (400 MHz, CDCl3) 250 
 





1H NMR (300 MHz, CDCl3) 251 
 






1H NMR (300 MHz, CDCl3) 252 
 





Synthesis of benzimidazole-, triazole and oxazole-thioethers 
1H NMR (400 MHz, CD3CN) 259 
 





1H NMR (400 MHz, CDCl3) 260  
 





  1H NMR (400 MHz, CD3CN) 263 
 





Synthesis of tetramethyl thiourea salts 
1H NMR (300 MHz, CDCl3) 310 
 





1H NMR (300 MHz, CD2Cl2) 311 
 





1H NMR (300 MHz, CD2Cl2) 312 
 





1H NMR (300 MHz, CD3CN) 313 
 





1H NMR (300 MHz, CD2Cl2) 107a 
 





1H NMR (300 MHz, CD2Cl2) 314 
 





1H NMR (300 MHz, CD2Cl2) 315 
 
13C NMR (75 MHz, CD2Cl2) 315 




Synthesis of thiols and disulfides 
1H NMR (300 MHz, CDCl3) 316 
 






1H NMR (300 MHz, CDCl3) 317a 
 





1H NMR (300 MHz, CD2Cl2) 317b 
 





1H NMR (300 MHz, CDCl3) 318 
 





1H NMR (300 MHz, CD2Cl2) 319 
 





1H NMR (300 MHz, CD2Cl2) 320 
 





1H NMR (300 MHz, CD2Cl2) 321 
 






1H NMR (400 MHz, CD3CN) 304 
 











1H NMR (300 MHz, CD3CN) 323 
 





19F NMR (282 MHz CD3CN) 323 




1H NMR (400 MHz, CD3CN) 324 
 
13C NMR (126 MHz, CD3CN) 324 




19F NMR (282 MHz CD3CN) 324 
 





NOESY 1H-1H-NMR (400 MHz, CD3CN) 324 




1H NMR (400 MHz, CD2Cl2) 325 
 












1H NMR (300 MHz, CD3CN) 326 
 

















1H NMR (400 MHz, CDCl3) 327 
 





1H NMR (400 MHz, CD2Cl2) 328 
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